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Abstract 
As the production of new chiral products such as drugs continually increases, the 
currently available CSPs (chiral stationary phases) are not guarantees to provide 
adequate enantioseparation for new products. With the increased demand from drug 
regulatory agencies for drug manufacturers to provide safety data by way of 
enantiomeric purity, there is a need for the development of more chiral selectors for 
application in GC/ or LC stationary phases for the analysis of chiral drug products.  
Given that GC is one of the preferred methods of chiral analysis recommended by drug 
regulatory agencies, it is important to have a range of GC stationary phases which 
possess diverse physical and chemical properties to allow researchers to conduct not only 
routine chiral analysis but provide a selection of stationary phases with the appropriate 
properties required to conduct specialised enantioselective analysis experiments. 
Ionic liquids have been identified as good candidates for application as stationary phases 
in GC. Their negligible vapour pressure, good thermal stability, multiple solvation 
interaction and their tuneable physical and chemical properties make them ideal 
candidates for application in the design of new stationary phases. 
In this work the design, synthesis, and testing of novel chiral ionic liquids (ILs), for 
enantioselective capability in GC stationary phases is presented. First, new chiral cis- and 
trans-2,4,5-triphenylimidazolinium ILs are synthesised as well as their achiral 2,4,5-
triphenylimidazolium IL counter parts. Following which the asymmetrical N-derivatisation 
of trans-2,4,5-triphenylimidazoline with various amino acids is described, yielding new 
2,4,5-triphenylimidazolines, which upon alkylation with an alkylhalide served as 
precursors for the synthesis of novel chiral ILs. In addition to these 2,4,5-
triphenylimidazoline bases ILs, we describe the synthesis of new asymmetrical chiral 
imidazolinium ILs with various side groups from simple amino acids. This method proved 
to be quite versatile, permitting the incorporation of various functional groups at 
positions 2, 3, 4, and 5 on the imidazoline moiety, allowing for the production of a wide 
range of imidazolinium ILs with tunable physical and chemical properties.  
In addition to the imidazoline based ILs, new ionic cyclodextins (CD) were synthesised 
from per-6-iodo-2,3-hydroxy-β-CD, per-6-iodo-2,3-O-acetyl-β-CD, per-6-iodo-2,3-O-
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acetyl-γ-CD to afford various per-6-imidazolium-2,3-hydroxy-β-CD iodide, per-6- 
imidazolium-2,3-O-acetyl-β-CD iodide, and per-6-imidazolium-2,3-O-acetyl-γ-CD iodide 
as well as their pyridium ionic CD counterparts. 
A selection of these chiral ILs were incorporated into capillary columns as chiral selectors 
diluted in OV-1701, by static coating and evaluated their effect on phase polarity and 
their enantioselective capabilities. Despite the addition of IL to the relatively non-polar 
OV-1701 phase the resultant mixed phases remained relatively non-polar while 
displaying markedly altered retention behaviours for various analytes. 
A good example of the need for a wider selection of chiral stationary phases which 
possess a variety of chemical properties for specialized applications was illustrated in the 
study we conducted with chiral oximes which undergo dynamic molecular interconversion 
between their E & Z isomeric forms during the chromatographic elution process on wax 
stationary phases. The study was conducted on wax column coupled to a chiral column to 
allow the sequential examination of the interconversion process and chiral resolution. It 
would be ideal to examine the interconversion process and enantiomer resolution 
simultaneously, however, this would be achievable on a stationary phase capable of both 
chiral oxime resolution while simultaneously inducing the interconversion. Nonetheless, a 
column with such as phase is not currently available on the market, illustrating the need 
for the development of new chiral stationary phases (CSPs) for both routine and 
specialised enantioselective analysis. 
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“The universe is asymmetric and I am persuaded that life, as it is known to us, 
is a direct result of the asymmetry of the universe or of its indirect consequences. 
The universe is asymmetric.” 
 
Louis Pasteur 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
1 Chapter 1 
General introduction 
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1.1 The mystery of chirality  
1.1.1 Introduction to chirality 
One of the most remarkable facts in biology is that the biomolecular chirality, be it in a 
virus, in a bacterium, or in a human brain cell, is everywhere the same. All cells contain 
DNA in the form of a right-handed double helix, all proteins 
consist of L- amino acids, and carbohydrates are derived from 
D-sugars, where  ‘L’ stands for laevum, meaning ‘left in latin and 
‘D’ signifies dextrum, ‘right. These very complex molecules that 
make up a living organism, such as DNA, RNA, proteins, and 
sugars, are thus all chiral. RNA contains the carbohydrate moiety D-ribose, and DNA D-2-
deoxyribose. Life on earth is based on enantiomeric biomolecules. On the other hand, left 
handed DNA do not occur naturally in nature. While D-amino acids and L-sugars only 
occur in trace amounts in nature.1 This remarkable selectivity is called biological 
homochirality. And it is this phenomenon that drives research into chiral molecules in the 
world of synthetic chemistry. 
 
From the chemical standpoint, a chiral molecule and its enantiomer should, under 
identical external conditions have exactly the same energy. In a thermodynamic 
equilibrium with their surroundings, both enantiomers would consequently have the same 
probability of existing. However, from a particle physics aspect, it must be taken into 
  
“Life on earth is 
based on 
enantiomeric 
biomolecules.” 
  
account the elementary particle interactions called parity violating weak forces, whereby 
it has been suggested that there must exist a very small energy difference favouring one 
chiral form with respect to the other, resulting in the observed biological homochirality.    
 
Pasteur postulated that the peculiar selectivity of living processes for one or the other of 
enantiomeric forms of the same molecule might be the manifestation of asymmetric 
forces of the environment acting upon the living organism during the synthesis of 
protoplasmic constituents.2,3 As we know on the Earth, the biological systems are based 
on D-sugars and L-amino acids rather than L-sugars and D-amino acid.4 
 
Figure 1.1: A- and B-DNA in the form of a right-handed double helix.   
 
1.1.2 The discovery of natural optical activity 
In a chiral medium, the plane of polarization of linear polarized light is rotated. This 
phenomenon is called natural optical rotation or natural optical activity. The angle of 
rotation is specific for the molecular property of the medium. In enantiomeric medium 
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under the same conditions, the angle of rotation is exactly opposite for each emantiomer. 
This very fundamental effect was discovered by two French scientists in the early 19th 
century.5  
 
In 1811 Francois Arago noticed optical rotation in slabs of α-quartz. The observation that 
optical activity not only is a property of a particular crystals, but that it occurs in liquids, 
for instance, in sugar solutions, was demonstrated four years later by Jean-Baptiste Biot. 
The angle of rotation is measured with a polarimeter.  
 
Figure 1.2: Portrait of Louis Pasteur6 
Arago’s and Biot’s discovery in the early 19th 
century stimulated much research into the optical 
properties of matter. An important breakthrough 
for the future development of chemistry was 
achieved in 1848 by Louis Pasteur. He 
investigated solutions of sodium ammonium 
tartarate that were indifferent to polarized light 
(not optically active). Letting the solutes 
crystallize, Pasteur discovered that the crystals 
turned out to be hemihedral, indicating that they 
were chiral. Some crystals turned out to be hemihedral to the right, others hemihedral to 
the left, showing the presence of both enantiomorphous forms. Selectively redissolving 
the right handed crystals, Pasteur found the new solutions rotated the plane of linearly 
polarized light to one side, while the solution made from left handed crystals rotated the 
plane of linearly polarized light to the other. The original, optically inactive solutions were 
racemic, containing equal amounts of both enantiomers of the compound, achieving the 
first resolution of a racemic mixture into its chiral components. Pasteur was fortunate 
enough to have found the perfect sample molecules. However, racemic solutions often 
  
form racemic crystals,7 and the resolution of the enantiomers has to be carried out by 
other procedures. 
 
1.1.3 Enantioselective separation of racemic mixture into isolated 
enantiomers. 
If one is as fortunate as Pasteur was with the tartaric salt, and the racemic mixture 
crystallizes forming distinguishable chiral, enantiomorphous crystals, one may separate 
the crystals by inspection to obtain the molecular enantiomers. Unfortunately, many 
racemic solutions under laboratory conditions form racemic crystals.7 Furthermore, if 
chiral crystals indeed are formed, the procedure of manually selecting these crystals 
enantioselectively is tedious and does not lend itself well to separations on a large scale.  
 
One method of resolution relies on selective absorption to an external chiral medium by 
chiral chromatography. The chromatographic material (stationary phase) must be 
chemically inert, yet contain numerous, asymmetrically configured polar groups. 
Carbohydrates polymers such as cellulose or cyclodextrin, or macromolecules like chiral 
crown ethers, lend themselves well to this purpose.  
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(a) 
 
(b) 
 
 
Figure 1.3: Sodium ammonium tartrate salt crystals; (a) an illustration of the left and 
right handed salt crystals,6 (b) large crystals formed by seeding method (Left, (–)-
enantiomer; right, (+)-enantiomer).8  
 
  
1.2 Chirality in drug design and development 
1.2.1 Introduction 
Chiral drugs are a group of drug substances that contain one or more stereogenic 
centers. More than one half of marketed drugs are chiral.9 It has been well established 
that the opposite enantiomer of a chiral drug often differs significantly in its 
pharmacological, toxicological, pharmacodynamic, pharmacokinetic properties.10,11,12,13 
Therefore from the points of view of safety and efficacy, the pure enantiomer is preferred 
over the racemate in many marketed dosage forms. However, chiral drugs are often 
synthesized in the racemic form, and it is frequently costly to resolve the racemic 
mixture into the pure enantiomers. The decision whether to market the racemate or the 
enantiomer of a chiral drug is mainly based on pharmacology, toxicology, and economics. 
From a pharmaceutical perspective, the physical properties of both the racemate and the 
enantiomer need to be characterized in detail in order to develop a safe, effective and 
reliable formulation, no matter whether the racemate or the enantiomer is chosen as the 
marketed form. 
 
1.2.2 Drug Stereochemistry 
1.2.2.1 Stereoselectivity in Drug Action.  
Stereoselectivity in drug action has been known since the early years of the last 
century,14 but apart from a relatively few instances, it was not understood and hence 
overlooked between the 1950s and the early 1970s, a time period stamped as the golden 
age of drug discovery and development. As a result of this neglect, by the late 1980s 25 
% of the products available in a survey of 1675 drugs were racemic.15 However, over the 
last 15 to 20 years there has been a change in safety regulations with respect to chiral 
pharmaceuticals. This change has catalysed medicinal chemistry research advances in 
methodology associated with the stereoselective synthesis and stereospecific analysis of 
chiral drug molecules, coupled together with an increased appreciation of the potential 
for significant differences in biological properties of the enantiomers of chiral drugs 
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administered as racemates. As a consequence of the advances in technology and 
increasing safety concerns,16 drug chirality has become the highest priority for both the 
regulatory agencies and the pharmaceutical industry,17 driving a move toward the 
development of single stereoisomer products.9,17,18 
 
1.2.2.2 Biological Discrimination of Stereoisomers 
The differential biological activity of stereoisomers is a long known phenomenon that was 
not previously understood. In 1858, Pasteur demonstrated that the mold Penicillium 
glaucum metabolized (+)-tartrate more rapidly than the (-)-enantiomer.19 This was 
followed in 1886 by Piutti’s observation that (+) asparagine had a sweet taste whereas 
the (-)-enantiomer was insipid (Figure 1.4). Following Puitti’s report, Pasteur made the 
remark that ‘‘the nervous tissue might itself be dissymmetric,’’ an observation regarded 
as the first mention of stereoselectivity of a receptor.19 These differences in taste have 
been established for other amino acids where by the D-isomers are sweet while the L-
isomers are either bitter or tasteless. 
 
H2N
OH
O
O
NH2
NH2
HO
O
O
NH2
D-Asparagine L-Asparagine
(sweet) (insipid)
HO
OH
O
OOH
OH
D-(-)-Tartaric acid
OH
HO
O
O OH
OH
L-(+)-Tartaric acid
 
Figure 1.4: (+/-) of tartrate and asparagine 
 
The α,β-unsaturated terpenoid ketones (R)- and (S)-carvone were isolated and shown to 
have odors of spearmint and caraway, respectively (Figure 1.5).20-22 Similarly, the related 
terpine enantiomers (R)- and (S)-limonene have odors of orange and turpentine 
respectively.20 This physiological sensivity to chirality is nicely demonstrated by the 
olfactory sense.   
 
  
CH3
CH3
H2C
R-(+)-Limonene S-(-)-Limonene
H3C
H3C
CH2
CH3
CH3
H2C
O
S-(+)-Carvone R-(-)-Carvone
H3C
H3C
CH2
O
(Turpentine)(Orange) (Spearmint)(Caraway)  
Figure 1.5: (R) and (S) enantiomers of Limonene, and Carvone along with their 
distinctive odours.  
 
The interaction between a drug and a receptor is associated with bonding interactions 
between the functionalities in the drug and complementary sites on the receptor, the 
three-dimensional spatial arrangement of such functionalities being of considerable 
significance. It was postulated by Easson and Stedman23 that the differences in activity 
arise as a result of differential binding of the pair of enantiomers to a common site, 
resulting in a difference in the fit of the enantiomers to the receptor and, the total energy 
of the interaction. 
 
 
Figure 1.6: Receptor-substrate binding complex 
 
Chiral recognition is a fundamental molecular phenomenon. Chiral recognition models 
continue to be a matter of considerable interest, not only with respect to biological 
activity but also with molecular recognition phenomena in chemistry and particularly the 
separation sciences.24-27  
 
Substrate 
Receptor 
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1.2.2.3 Eudismic Ratio and Enantiomeric Purity 
The differential pharmacodynamic activities of drug stereoisomers are described as being 
either the eutomer or distomer. The enantiomer with the greater affinity, or activity, is 
termed the eutomer, whereas that with the lower affinity or activity is the distomer. The 
eudismic ratio (ratio of affinities or activities, of eutomer to distomer) refers to a single 
activity of a drug and it is important to recognize that for a dual action drug the eutomer 
for one activity may be the distomer for the other.  
 
Determination of the eudismic ratio is dependent on the stereochemical purity of the 
material under examination. This is particularly true in the case for the less active 
enantiomer, and as the eudismic ratio increases, the significance of trace quantities of 
the eutomer as an impurity of the distomer also increases. Enantiomeric purity is 
frequently not reported in the pharmacological literature, and when presented, is 
presented in terms of optical rotation, particularly in the older literature, which is not a 
sensitive technique at levels of enantiomeric contamination of a few per cent. Even if 
values of the specific rotation of a given analyte are known, then experimental factors 
such as temperature, solvent, and wavelength need to be reproduced to ensure that 
accurate and comparable data is obtained.17 An example of the significance of 
stereochemical purity may be illustrated by a consideration of the activity of the selective 
β2-adrenoceptor agonist Formoterol (Figure 1.7).
28  This compound contains two 
stereogenic centers in its structure, and therefore four stereoisomers are possible. Initial 
investigations indicated that the β2-agonist activity resided in the R,R stereoisomer with a 
ranking order of potency of R,R > R,S > S,S >> S,R. Subsequent investigations reported 
much greater differences, the eudismic ratio R,R/S,S increasing from 50 to 850 when the 
impurity of the eutomer in the distomer decreased from approximately 1.5 % to <0.1 %. 
And, the increased stereoisomeric purity resulted in an altered ranking order of potency 
ratio to R,R>>>R,S > S,R >> S,S.29  
 
  
Having seen examples of the effect of enantiomeric impurities in determining eudismic 
ratios we can see the importance of the continuous development of stereospecific 
analytical methodologies in the separation sciences, such as gas chromatography. With 
these developments in analytical methodology, it should be considered unacceptable to 
present pharmacological data on enantiomers without quoting their stereochemical 
purity. 
 
Formoterol
OHCHN
HO
OH
H
N
CH3
O
CH3
*
*
 
Figure 1.7: Formoterol 
 
1.2.2.4 Pharmacodynamic complexities 
There are relatively few examples of drugs in which the pharmacodynamic activity is 
restricted to a single stereoisomer, and its enantiomer being totally devoid of activity. 
Similarly, there are few examples where the required beneficial activity resides in a 
single stereoisomer and the adverse effects, or toxicity, reside in its enantiomer. 
Instances are also known where the activity of a pair of enantiomers differs sufficiently 
that both are marketed with different therapeutic indications. It is obvious that the 
evaluation of the activity of a racemate does not provide a clear indication of the 
properties of the drug and it is essential to separate the enantiomers to evaluate the 
pharmacodynamic activities of each stereoisomer.  
 
1.2.3 Drug Metabolism and toxicology  
1.2.3.1  Thalidomide and related teratogenic agents 
A compound frequently cited, as an example where the use of a single stereoisomer 
would have prevented a tragedy, is the teratogenic hypnotic sedative agent, thalidomide 
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(Figure 1.8). An investigation in the late 1970s reported that following administration of 
the individual enantiomers to mice, both enantiomers possessed hypnotic activity, 
whereas the teratogenic activity resided solely in the S-enantiomer.30 However, studies in 
a more sensitive test species, New Zealand White rabbits, indicated that both 
enantiomers, and the racemate, were teratogenic,31 while further research found the 
drug to readily undergo racemization in biological media.32-34 These findings indicated 
that even if the single R-enantiomer had been commercially available in the early 1960s, 
patients would still have been exposed to both enantiomers of the drug as a result of its 
racemization. Thalidomide is therefore not a particularly useful example to cite in support 
of single stereoisomer products. But rather an example of the great need for 
chromatographic separation technologies that allow the investigation of the effects of not 
only the individual enantiomers but rather the analysis of metabolite enantiomeric 
compositions as well. In seeing this demand we strive to advance research into 
developing new chiral stationary phases to make such analysis possible by providing a 
new range of separation media, in the way of ionic liquids, with chiral selective 
properties.  
 
N
O
O
NH
O
O
Thalidomide
*
 
Figure 1.8: Chemical structure of Thalidomide  
 
Creating Chiral Molecular Environments in Synthesis and Separation 
The enantioselective biochemical synthesis of enantiopure products as produced in nature 
is an ideality that is rarely achieved in reality in the laboratory. The necessity to obtain 
and deliver enantiomerically pure pharmaceuticals and chemicals has produced an 
enormous growth in fields such as asymmetric synthesis, asymmetric catalysis, and in 
separation science. In asymmetric catalysis or in enantiomeric discrimination there are a 
  
limited number of generic or key activation modes that are important in understanding 
the interactions of catalysts or chiral selectors with their substrates or analytes. For 
example in the enantioselective bromocycloetherification of olefins 1, the combination of 
an achiral Lewis base (LB) and a chiral Bronsted acid (BA*) are the key activators that 
afford reasonable product enantioselectivities in the cyclization of Z or E configured 5-
arylpentenols to tetrahydrofuran derivatives. The chiral complex formed by the hydrogen 
bonding of the BINOL-related chiral phosphoric acid catalyst to the Br+ electrophile and 
to the hydroxyl group of the pentenol, reacted with the alkene nucleophile and facilitated 
the enantioselective bromoetherification to give the anti-Markovnikov 5-exo chiral ether 
cyclization products as outlined in Figure 1.9. 
 
Ar OH Ar
Br
O
Ar
Br
O
or
NBS [1.2 equiv]
LB = Ph3P = S [0.05 equiv]
HBA* = (S)-TRIP [0.05 equiv]
PhMe, 0 oC, 12-14 h
N
O
O
BrLB
H
BA*
LB, succinimide Ar
O
Br
HBA
*
HBA*
BA* Br
91:9 er, 77% yield
Ar= (Z)-C6H5
93:7 er, 77% yield
Ar= (E)-C6H5
 
Figure 1.9: Enantioselective synthesis of arylbromomethyl tetrahydrofurans 
 
The consequent task of product enantiomeric analysis is quite challenging because of the 
small differences in reactivity or binding energies between the enantiomers. The analysis 
and determination of enantiomeric composition and concentration of the products mainly 
relies on separation-based techniques such as gas chromatography, high-performance 
liquid chromatography and capillary electrophoresis. 
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1.3 Chiral analysis techniques 
1.3.1 Enantioseparation by Gas Chromatography 
Although pharmacologists have long been aware of the pharmacological 
enantioselectivity of drug action, pharmacokineticists became focused on the possibility 
of stereoselectivity in drug disposition only in the past 25 years. Part of this delayed 
response was caused by limitations in analytical chemistry. With the early development 
of gas chromatography and high performance liquid chromatography, significant inroads 
into quantitative determination of xenobiotics in biological specimens were made, 
(Xenobiotics being substances such as antibiotics used in a species in which they are not 
naturally produced). A variety of methods based on chromatographic techniques such as 
Supercritical Fluid Chromatography (SFC), Thin Layer Chromatography (TLC) have been 
developed during the past three decades, and more recently, Capillary Electrophoresis 
(CE), Capillary Electrochromatography (CEC) and Countercurrent Chromatography (CCC) 
have also been shown to be useful techniques for the purpose of separating enantiomers. 
 
 Analytical separation of enantiomers can be achieved by the use of two quantitative 
chemistry approaches, to facilitate the physical separation of enantiomers.35 One 
approach involves molecular modification of the enantiomers by derivatization with an 
enantiopure reagent. In so doing, the enantiomers are converted to diastereomers, which 
possess different physicochemical properties and which can then be separated using 
conventional chromatography. The second method involves changing the molecular 
environment to interact with the enantiomers during the separation procedure. This is 
facilitated by use of special chromatographic columns which consist of chiral materials 
that confer a three dimensional structure to the stationary phase. These stationary 
phases consist of enantiopure compounds bonded or coated onto the chromatography 
column. As the racemic mixture passes through such a column, the enantiomers interact 
differently with the stationary phase resulting in separation. These columns have become 
increasingly popular over the past decade as their reliability and durability have 
improved.  
  
 
1.3.2 Chiral stationary phases for Gas Chromatography 
1.3.2.1 Introduction 
The heart of gas chromatography resides in the column which contains the stationary 
phase. The stationary phase functions as the separation medium. For chiral analysis, 
chiral stationary phases (CSPs) are used to separate enantiomers. Today, the most 
popular columns are open tubular capillary columns made of fused silica with the 
stationary liquid phase coated on the inside surface of the capillary wall as shown in 
Figure 1.10. 
 
 
Figure 1.10: An illustration of an open tubular capillary columns made of fused silica 
with the stationary liquid phase coated on the inside surface of the capillary wall. 
 
Chiral stationary phases use chiral selectors to partition the enantiomers (the mechanism 
associated with enantiomer resolution is discussed in detail in Section 1.3.2.2). The 
selector is either attached to or mixed with the stationary phase, to produce a chiral 
stationary phase (CSP). The enantiomers are introduced in the mobile phase and move 
at slightly different speeds according to their binding constants with the chiral selector as 
NN
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NN
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they partition between the mobile phase and the CSP. It is the culmination of these 
interaction mechanisms which is known as enantiomeric resolution. And these 
interactions vary according to the molecular structure of both the chiral selector and the 
ligand (or analyte).  
 
1.3.2.2 Chiral recognition mechanisms  
1.3.2.2.1 Three-point interaction model 
The key step in chiral recognition is the formation of non-covalent diastereoisomeric 
complexes between the enantiomers and a chiral selector. Molecular recognition results 
from the differences in Gibbs free energy between the two diastereoisomeric 
enantiomer–selector complexes. Naturally biologists were the first to be interested in the 
chiral recognition mechanisms. While working on quantitative structure–activity 
relationships, Easson and Stedman, in 1933, proposed that a minimum of three points of 
attachment were needed between a asymmetric drug and its target to elicit the different 
physiological activities observed.36 Fifteen years later, another biologist, Ogston used the 
three-point model in his work on chiral enzymatic reactions.37 And Dalgliesh followed by 
adapting the same model to TLC.38 The model explains the differential binding of the two 
enantiomers to a chiral three-point site on the selector (Figure 1.11). 
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Figure 1.11: Easson-Stedman Model of drug-receptor interaction or 3-point interaction 
model, the above stereoisomer represents 3 points of interaction simultaneously, while 
the other enantiomer is only capable of 2-points of interaction simultaneously, 
irrespective of orientation to the binding site. 
 
The original three-point model only involved attraction interactions at all three points. 
From a separations point of view, repulsion and attraction forces are considered 
opposites. However, from a stereochemical aspect, repulsion is considered as productive 
an interaction as attraction. For example, two of the interactions can be repulsive if the 
third interaction is strong enough to promote the formation of at least one of the two 
possible diastereoisomeric selector–ligand complexes.39 The key points in the three-point 
interaction model are that at least three simultaneous interactions are required and that 
they should occur with three different substituents attached to the stereogenic center. 
Although widely accepted, the model has been challenged.40,41 Additional 
investigations,42,43 resulted in the conclusion that the Easson–Stedman hypothesis only 
holds for sites of direct action.42,43 
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Sokolov and Zefirov44 developed the Ogston enzyme in which they described a ‘‘rocking 
tetrahedron’’ model. In this model, enantioselectivity is examined in dynamic terms 
rather than the static terms.45,46 In the rocking tetrahedron model the substrate binds to 
the enzyme via two interactions and has conformational flexibility. The two enantiotopic 
groups (A and A*, Figure 1.12) occupy overlapping but identical volumes, and the 
enantioselectivity of the enzymatic transformation is dependent on the orientation and 
interaction between the active site and the “volume”. If the interaction is at right angles 
to the plane of the substrate (from point X, Figure 1.12, then enantioselectivity is not 
observed, whereas if the interaction is in the plane (e.g., from point Y), the process is 
potentially highly enantioselective, or enantiospecific. Thus in compounds with ‘‘small’’ 
highly flexible enantiotopic functionalities, minimal stereoselectivity would be observed. 
In contrast, if the enantiotopic groups are large bulky substituents, which are 
conformationally less flexible, then greater selectivity, tending towards specificity, is 
expected.44 
B C
B'             C'
A*A
Y        Highly
enantiospecific
            No 
enantiospecificity
X
 
Figure 1.12: “Rocking tetrahedron” model 
 
Chiral recognition models continue to be a matter of considerable interest, not only with 
respect to biological activity but also with recognition phenomena in chemistry and 
particularly the separation sciences. The rocking tetrahedron concept has been expanded 
to a conformationally driven chiral recognition mechanism by Booth et al.,41 in terms of 
  
chromatographic recognition.47 They proposed a four stage chiral recognition process. 
The initial step involving the formation of a selectand–selector complex (tethering), 
followed by a conformational change of the complex in order to optimize the molecular 
interactions, complex activation via additional interactions and finally an expression of 
molecular fit, that is,  chiral recognition.41 They proposed that this general process 
describes enantiomeric discrimination for all cases of chiral selection. In recent years 
there has been extensive discussion as to the minimal requirements for chiral 
recognition. Current consensus appears to be that a diastereomeric intermediate must be 
involved, and that interactions between eight centers (and hence a four-point 
attachment) are required.26  
1.3.2.2.2 Intermolecular forces involved in enantiomer-selector complexation 
interactions. 
Table 1.1 lists a range of intermolecular forces that can exist between two enantiomers 
and a chiral selector in the stationary phase. Coulomb force are the strongest interaction, 
this is well illustrated by the high cohesion of salts. The hydrogen bond interactions are 
also very strong forces, they occur between a positively polarized hydrogen atom of a 
hydroxyl or amine group and a negatively polarized oxygen or nitrogen atom. Steric 
hindrance is another strong force which result from the intrinsic room needed per atom 
or group of atoms; they are repulsive in action and very strong at very short range. π–π 
interactions are observed when π-electron molecular assemblies, mainly aromatic rings, 
interact with each other. The π–π interactions involved in chiral recognition mechanisms 
are most often attractive; a π-accepting group of the enantiomer interacts with a π-
donating group of the selector, or vice versa. Ion–dipole, dipole–dipole, and dipole–
induced-dipole interactions occur with molecules that have a dipole moment. The 
strongest force being ion–dipole interactions which involve the attractive coulomb force 
from the ion and the partial charge from the dipolar molecule. The weakest interactions 
are dipole-induced dipole forces which occur between a permanent dipolar molecule and 
a dipole induced by the electric field. The weakest intermolecular forces are London 
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dispersion forces. They are responsible for hydrophobic effects and for entropy driven 
forces that cause oil to separate from water. 
 
Table 1.1: Characteristics of molecular interactions. 
Type of 
interaction Strength Direction Range 
 
Coulomb or 
electric 
Very strong 
Attractive or 
repulsive 
Medium (1/d2) 
Hydrogen bond Very strong Attractive Long 
Steric hinderance Very strong Repulsive Very short 
π-π Strong 
Attractive (donor or 
acceptor) or 
repulsive 
Medium 
Ion-dipole Strong Attractive Short  
Dipole-dipole Intermediate Attractive Short (1/d3) 
Dipole-induced 
dipole 
Weak Attractive Very short (1/d6)  
London dispersion 
or Van der Waals 
Very weak Attractive Very short(1/d6) 
 
1.3.2.2.3 Designing chiral selectors. 
Chiral selectors can be separated into two subgroups, synthetic chiral selectors and the 
natural chiral selectors. The ability to synthesise various chiral selectors permit 
researches to study interaction mechanisms (Table 1.2) and consequently design a chiral 
selector that will interact preferentially with one enantiomeric form than with its mirror 
image. Chiral selectors derived by natural routes are based on the fact that the living 
world contains numerous chiral molecules which can function as chiral selectors and are 
  
produced as pure enantiomers. Once a natural product is chosen for application as a 
chiral selector, the natural chiral selector is tested with its natural chiral target(s) and 
many other enantiomers, to derive information pertaining to the molecular interactions 
involved, and the data used to postulate the mechanisms involved in chiral recognition. 
However, neither of these classes of selectors are 100 % synthetic or natural. These 
chiral selectors are actually semisynthetic; because many synthetic selectors are based 
on a natural product and many natural selectors are chemically modified to enhance their 
initial properties (Table 1.2).  
 
Most information on chiral recognition mechanisms is obtained by measuring the binding 
energy of the two chiral selector–enantiomer complexes. Multiple selector–ligand 
association–dissociation reactions occur in the CSP as the analytes partition between the 
mobile phase and the stationary phase. The enantiomers introduced into the mobile 
phase move at slightly different speeds through the mobile phase according to the sum 
of their binding constants with the chiral selector in the stationary phase. The retention 
time (or migration times) of the enantiomers provide their binding constants. 
 
Researchers can observe the thermodynamics of chiral reaction mechanisms by varying 
study temperatures.48 The thermodynamic parameters, binding constant, and enthalpy or 
entropy changes correspond to the ligand–chiral selector association.  
 
1.3.2.3 Chiral Stationary Phases  
1.3.2.3.1 A brief historical perspective of chiral GC and ILs stationary phases 
• 1959 Barber et al., describe the first separation by GC using ILs (molten salts).49 
• 1966 Gil-Av, Feibush and Sigler reported the first direct enantioseparation of a 
derivatised α-amino acids by GC on a CSP containing the involitile α-amino acid 
derivative N-trifluoroacetyl-L-isoleucine lauryl ester.50,51 Organic ILs of the type currently 
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used today were used as GC stationary phases by Gordon et al. in 1966, however, little 
was known of their general properties.52 
• 1977 Frank, Nicholson and Bayer developed Chirasil-L-Val, by bonding a valine 
diamine chiral selector to a copolymer consisting of carboxy-alkymethylsiloxane and 
dimethylsiloxane, officially combining the desirable properties of silicone (renowned for 
producing high resolution and efficiencies) and the  enantioselectivity of the chiral 
selector.53 The result was a thermally stable, non-volatile, enantioselective chiral 
polysiloxane-valine diamide CSP.53 Schurig provides an excellent account of the historical 
development, optimization and utilization of GC analysis of derivatized α-amino acids on 
CSP.51 
• 1980s Cyclodextrins [CDs] and derivatives considered the most versatile and efficient 
chiral selectors for the enantiomeric separation54-56 of volatile and thermally stable 
compounds. 
• 1980-1990s The unique properties of ionic liquids plus their solubilizing properties 
were shown to be beneficial for GC57  and many other areas of separation technology. 
• 2000-12 Various chiral materials such as: ionic liquids, polymeric ionic liquids, ionic-
CDs, chiral metal organic frameworks are under investigation as CSPs. 
 
The chemical asymmetric synthesis impetus is driven by the established science that 
individual enantiomers of chiral compounds exhibit unique biological, pharmacological 
and physical responses. In achiral media, enantiomers show identical physical and 
chemical properties, so scientists have developed and utilized natural and synthetic chiral 
materials and compounds to facilitate enantiomer separation. Table 1.2 lists the classes 
of chiral selectors used in chiral stationary phases, the mechanism involved in 
enantiomer resolution and the primary intermolecular interaction involved in the 
enantiomeric-complexation mechanism.   
 
 
  
Table 1.2: Chiral selectors and their mechanisms of interaction. 
 
Class of 
Selector Chiral Selectors 
 
Mechanism 
Primary 
interactions 
 
Synthetic selectors 
 
Ligand 
exchange 
Amino acid chiral selectors and 
their derivatives.58,59 Metal ions 
Cu(II), Co(II), Cd(II), Ni(II), 
Zn(II).59 
 
Diasteromeric 
selector-metal 
ion-analyte 
complexation 
Coulomb or 
ion-dipole 
Molecular 
imprinted 
polymers 
(MIPs) 
Amino acids,60 amino acid 
derivatives,61,62 peptides,63 
carboxylic acids,62 β-blockers,64,65 
cinchona alkaloids,66,67 NSAIDs,68,69 
and benzodiazepines.70 
Key and lock 
association 
Selective 
shape 
interaction 
with imprint 
 
Chiral crown 
ethers 
Derivatized forms of 
polyoxyethylene crown-6.71 
Inclusion 
complex, steric 
and 
hydrophobic 
 
Ion-dipole 
Polymers 
Polyacrylamide and 
Poly(methylacrylamide),72 
Poly(trphenylmethylmethacrylate)73 
Diastereomeric 
selector-
analyte 
complex 
Hydrogen 
bond 
Natural selectors 
 
Proteins 
 
Bovine serum albumin (BSA),74 
Human serum albumin (HSA),75 
Ovomucoid from chicken egg 
white,76 
Trypsin77 and α-Chymotrypsin78 
Lysozyme79 and Pepsin80 
Cellobiohydrolases81,82 
Multiple 
binding sites 
Variable 
Polysaccharides 
Cyclodextrin, Cellulose,32,33 
chitosan,34,83 chitin,84 amylose and 
amylopectin85,86 
Insertion into 
helical 
structures, 
plus individual 
chiral 
carbohydrate 
monomers 
Hydrogen 
bond, 
dipolar, or 
steric 
 
Cyclodextrins 
(CDs) 
Most common derivatives are 
methylated, acetylated, 
carboxymethylated and 
hydroxypropylated CDs 
 
Inclusion 
complexation 
Hydrogen 
bond 
 
Macrocyclic 
glycopeptides 
Vancomycin,87 teicoplanin,88 
Ristocetin A,89 and Avoparcin90 
Thiostrepton87 and Rifamycin B87 
 
Multiple 
binding sites 
Variable 
 
Cinchona 
alkaloids 
 
Ionic Quinidine, and  Quinine N-
derivatives91 
Ion pairing Coulombs 
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1.3.2.3.2 Innovative chiral stationary phases for GC. 
A snapshot of some innovative chiral stationary phases that are currently utilized or 
under investigation is presented in Figure 1.14. 
 
Figure 1.13: An outline of the innovative CSPs currently utilised and/or being 
investigated for GC enantiomeric analysis. 
 
Chiral metal-organic frameworks 
A novel application of chiral metal organic frameworks (MOFs) as GC stationary phases 
has been reported to produce excellent enantiomer recognition ability towards a mixture 
of aldehydes, ketones, organic acids, amino acids, alcohols.92 Crystal structure analysis 
revealed that the stationary phase possesses a 3-dimensional left-handed helical chiral 
channel framework with a 2.5 nm screw pitch, with the formula [(Cu(sala))n] (H2sala=N-
(2-hydroxybenzyl)-L-alanine.92 The chiral recognition mechanism for the MOFs phase is 
reported to depend on surface interactions, primarily steric fit between the chiral 
framework and  conformation of the analyte.92 Dispersion forces, dipole-dipole, and 
hydrogen bonding interactions are also said to play a role in the chiral recognition 
mechanism.92 Besides their excellent chiral recognition ability, these new types of GC 
CSP have many positive attributes which make them ideal candidates for application in 
  
GC phases such as selective adsorption, high porosity, and high thermal and chemical 
stability.92 Further studies are being under taken to exploit inherently chiral natural 
products to create function helical metal organic frameworks from γ-CD co-ordinated to 
alkaline metal cations.93-95 α-Cyclodextrin MOFs are also being developed with Rb+ ions to 
afford left handed helical crystals with pores running through the structure.96 The α-CD 
rings in the CD metal-coordinated frameworks are co-ordinated to Rb+ cations, with each 
Rb+ ion binding to the α-1-4-D-glucose units on either the primary or secondary face via 
C2, C3, C6, and ring oxygen atoms.96 
 
Amino acid derivatives 
There is one popular non-cyclodextrin based CSP that is widely used, Chirasil-Val (Figure 
1.15), supplied by Agilent Technologies (Santa Clara, California, USA). This phase was 
based on the work of E. Bayer's group,53 it is one of the earliest commercially available 
CSPs, and yet it is still the most popular for the separation of D/L amino acids.51,56 
Chirasil-Val is prepared by covalently bonding L-Valine-tert-butylamine units to a 
polysiloxane backbone.51 Although it is a versatile phase it has limited capabilities in 
other areas.  
Si O Si O
CH3CH3
CH3 n
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H
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CH3 O CH3
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Figure 1.14: Chirasil-Val phase available in the D or L enantiomeric form. 
 
In order to overcome some of the limitations of Chirasil-Val, particularly its inadequate 
separation of Proline, a new diamide chiral polymethysiloxane phase based on (S)-(-)-t-
leucine-(S)-1-(-)-(α-naphthyl)-ethylamide was synthesised and applied to the separation 
of N-pivaloyl derivatised amino acids.55 This phase was shown to produced baseline 
separation of  most proteinogenic amino acid N-pivaloyl derivatives, including Proline, but 
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was found to be unsuccessful at separating multi-functional amino acids such as, Asp, 
Glu, Orn, Lys and Trp.55 The same research group also introduced another Chirasil-Type 
CSP based on (S)-(-)-t-leucine-(S)-(-)-1-phenylethylamide for the separation of warfarin 
enantiomers following conversion to O-perfluoroacyl derivative.55 Another Chirasil-Type 
GC phase known as Chirasil-Calix was prepared by covalently bonding resorcinarenes, 
which contain L-valine-tert-butylamide moieties, to a dimethylpolysiloxane.55 However, 
this phase did not display any improvement in enantioselectivity when compared with 
chirasil-Val. 
 
ChDA is a co-polymeric (1R-trans)-N,N’-1,2-cyclohexylene-bis-benzamide 
oligodimethylsiloxane (ChDA) developed for investigation as a new chiral stationary 
phase for GC.55 This phase exhibited high enantioselectivity for a broad spectrum of 
chiral molecules, however, it was limited to an operating temperature range of 110-260 
˚C. Such a high minimum operating temperature is disadvantageous to enantiomer 
resolution, because enantiomer resolution is known to take place at low temperatures 
(the lower the elution temperature, the greater selectivity differences observed between 
enantiomers). In addition this phase only showed high efficiencies at temperature above 
150 ˚C, which is higher than the temperatures at which enantioresolution typically takes 
place.  
 
Metal chelates 
The design and synthesis of a diverse series of novel chiral metal-containing ionic liquids 
(CMILs) was reported by Song et al.,97 and used as chiral cocatalysts in the 
enantioselective cycloaddition of CO2 to epoxides. These novel chiral salts consist of 
natural amino acid anions and crown ether-chelated alkali metal (potassium/ sodium) 
cations.97 They are reported to have melting points below than 200 ˚C and thermal 
stabilities ranging from 138 ˚C up to 222 ˚C.97 Application of these novel CMIL as GC 
stationary phases has not been reported and may prove to be potentially applicable to 
enantiomeric separation of chiral analytes such as amino acids. 
  
 
Cyclodextrins  
Separation techniques like HPLC employ a wide variety of stationary phases (such as 
crown ethers, macrocyclic antibiotics and proteins, among others), whereas cyclodextrins 
are ubiquitous to capillary GC. Cyclodextrins (CDs) are small cyclic polysaccharides that 
form a cone-shaped cavity with six, seven, or eight glucopyranose units known as α-, β-, 
and γ-CD, respectively. The interior is a hydropobic cavity consisting of ether groups, 
while the outer rim of the cavity are lined with the polar hydroxyl groups making it 
hydrophilic. Inclusion complexation is the driving interaction in chiral recognition by CDs. 
Derivatization of these hydroxyl groups produced a wide variety of CDs with adjusted 
polarities and functionalities that can separate a broad spectrum of enantiomers.98,99,100 
Several CD derivatives have been developed showing improved enantioselectivity in 
many cases and are available commercially (see Table 3.1).101,102,103,104,105 In addition to 
inclusion complexation, hydrogen-bondings, π–π interactions, hydrophobic interactions 
and steric repulsion are assumed to be responsible for chiral recognition. 
 
The two most popular CD chiral selectors employed in enantioselective GC are the 2,3-di-
O-methyl-6-tert-butyldimethylsilyl-β-CD and the 2,6-di-O-pentyl-3-trifluoroacetyl-γ-CD.56 
2,3-di-O-methyl-6-O-tert-butyldimethylsilyl-β-CD being the leading commercial CD 
derivative in the field from an application standpoint, and has largely replaced the 
straight 2-3-6-tri-O-methyl version.56 The tert-butyl group in the 6-position has little 
effect on chiral selectivity but provides improved solubility of the CD in the different 
polysiloxane carriers which are used. This chiral selector has been shown to provide ~60 
% of all chiral separations possible on capillary GC phases.56 The maximum operating 
temperature of this phase is usually the highest of all the CD phases at 220–230 ˚C 
isothermal, and is extended to 250 ˚C when using temperature programing.55  
 
The 2,6-di-O-pentyl-3-trifluoroacetyl-γ-CD phase is produced by Sigma-Aldrich/Supelco 
(Bellefonte, Pennsylvania, USA).56 The mechanism for this phase is a surface dipole–
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dipole interaction and as a result covers a broader area using the γ-CD as opposed to the 
β-CD.56 This phase is highly selective for oxygen-containing analytes, separating not only 
the widest variety of enantiomers, but also the greatest number within certain classes. 
Its main limitations are that its sensitivity to moisture and its isothermal upper 
temperature limit of 180 ˚C.55,56 
 
The mechanisms of separation of CD based stationary phases fall into two basic 
categories: surface interactions vs. inclusion complexation.56 Certain CD derivatives 
involve largely surface interactions, being more efficient and with higher capacity, while 
other CDs involve the inclusion complexation phenomena typically associated with 
cyclodextrins. Because the internal cavity of a cyclodextrin molecule tends to be more 
hydrophobic than its exterior, most nonpolar molecules (or molecules with nonpolar 
moieties) prefer to reside in the cyclodextrin cavity.55,56 This inclusion phenomenon in 
capillary GC is associated with the type and number of derivatives linked to the 3-
position hydroxyl as opposed to the 2-position of the glucose units that make up the CD 
structure.56 When more polar groups are placed in the 3-hydroxyl position of the CD 
glucose unit, chiral interaction does not appear to involve the inclusion phenomena.55 
These types of CSPs typically have higher efficiency, faster separations and capacities as 
high as 10–50 times greater than those relying on the inclusion phenomena.56 
 
Thermodynamic relationships106 and sample loading studies are used in the 
determination of the dominant chiral recognition mechanism. Enantiomers that have 
large H˚ and S˚ values also have low loading capacities, which is suggestive that 
inclusion complexes are involved in the enantioselective mechanism.56 Enantiomers that 
have smaller H˚ and S˚ values also have higher sample loading capacities, which is 
indicative that inclusion complexes play a less dominant, or negligible, role in the 
enantioselective mechanism.56 The involvement of surface interactions in chiral 
recognition mechanisms can be determined by observing the peak efficiencies of the 
enantiomers. It has been observed that peak efficiencies are much higher for those CD 
  
derivatives that involve surface interaction mechanisms as opposed to an inclusion 
mechanism.56 
 
A complete understanding of the chiral recognition mechanism, would allow researchers 
to predict which selector would best separate the enantiomers of chiral compounds. 
However, given that a comprehensive understanding of the chiral recognition mechanism 
has not yet been realized, there is a need for the development of a wide range of chiral 
selectors to permit the separation of a wide variety of chiral compounds.  This is the 
driving force behind research into the development of new classes of chiral selectors, 
such as ionic liquid selectors for application in stationary phases. Here in we discuss the 
properties of ionic liquids, their various applications, but most importantly, their 
application in Gas Chromatography, as well as the properties which make ILs good 
candidates for application in stationary phases. 
1.4 Ionic liquids 
Ionic liquids are defined as salts with melting points below 100 ˚C. Although the first 
observation of an ionic liquid occurred in 1914, it was the development of modern ionic 
liquids that really accelerated research in this area during the last decade. 
 
NN RR
Imidazolium IL
NHN
Alkylation
Step 1 Cl
Imidazole
NN RR
Imidazolium IL
Anion metathesis
Step 2 BF4
 
Figure 1.15: Typical IL synthesis reaction scheme. 
 
The more conventional ionic liquids are generally prepared in a two-step procedure from 
the corresponding amines in Figure 1.16. Alkylation leads to quaternization of the 
heteroatom and then anion metathesis can be performed if desired. Because they need 
to be prepared, RTILs are less environmentally friendly in this respect than many other 
alternative solvents. However, they are perfect solvents for many applications.  
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Figure 1.16: Various types of ILs cation and counter anions. 
1.4.1 Ionic liquids and their properties. 
Ionic liquids (ILs) can be composed from a large number of cations and anions. 
Knowledge of the physical properties of ILs is important for evaluating and selecting ILs 
for each application as well as process design. More recently, ILs have become very 
popular as potential solvents for industrial applications in different disciplines of science 
and environment. Although ILs have various fields of application our focus is on the 
synthesis of new chiral ionic liquids (CILs) for application in the field of analytical 
chemistry, more specifically in GC stationary phases. Indeed, because each IL has its 
own unique properties, it is possible to design an IL, to suit particular applications. We 
have taken advantage of this property of tunablility to design chiral ILs for application as 
chiral selectors in GC stationary phases. 
 
  
1.4.1.1 Effects of the structure on physical properties. 
The physical–chemical properties of ILs depend on the nature and size of both their 
cation and anion constituents. Their application in science and industries is merited 
because ILs have some unique properties, such as a negligible vapour pressure, good 
thermal stability, tunable viscosity and miscibility with water, inorganic and organic 
substances, a wide electrochemical window, high conductivity, high heat capacity and 
solvents available to control reactions. Despite their wide range of polarity and hydrogen-
bonding ability, these new solvents are liquid from -93 ˚C (glass transition) to ~327 ˚C. 
 
Possible choices of cation and anion allow the formation of numerous ILs. The most 
popular well-known classes of ILs are: imidazolium, pyridinium, pyrrolidinium quaternary 
ammonium, and tetra alkylphosphonium ILs. Of these, the most used in experimental 
laboratory work worldwide are undoubtedly 1,3-dialkylimidazolium salts, primarily due to 
their attractive and easy-tailored physical properties. 
 
By changing the cation or anion, their solvent properties can differ considerably from one 
another as well as from traditional molecular solvents. Two different ILs that have 
essentially identical polarity ratings or descriptors can produce very different results 
when used as solvents for organic reactions, gas–liquid chromatography (GLC), or 
extraction. ILs with additional functional groups are capable of having additional 
interactions with other solvents or dissolved molecules. Due to the diversity of their 
structure and functionalities, they are capable of most types of interactions such as 
dispersive, π–π, n–π, hydrogen bonding, dipolar, and ionic/charge–charge interactions.  
 
The viscosity of ILs is determined by van der Waals forces and hydrogen bonded 
structures. Electrostatic forces and the shift of charge at the anion may also play an 
important role. For the same cation (N-butyl-N-methylimidazolium), the viscosities for 
typical anions decrease in the order: [I]− > [PF6]
− > [BF4]
− > [TfO]− > [CF3CO2]
− > 
[Tf2N]
−. For a series of 1-alkyl-3-methylimidazolium cations with [PF6]
− and [BF4]
− 
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anions, increasing the alkyl chain length from butyl to octyl increases the hydrophobicity 
and the viscosity of the IL, while densities and surface tension values decrease.107  This 
results from the stronger Van der Waals forces between cations, leading to an increase in 
the energy required for molecular motion.107   
 
1.4.1.2 Melting point, glass transition, and thermal stability. 
Ionic liquids have been defined as having melting points below 100 ˚C and most of them 
are liquid at room temperature. Both, the cation and anion influence the melting points of 
ILs. The size and symmetry of the cation have a significant impact on the melting points 
of ILs. Generally, increasing the size of the anion and having an asymmetric substitution 
pattern leads to a decrease in the melting point. For the short chain alkyl substituents in 
1,3-dialkylimidazolium salts, an increase in the alkyl chain decreases the melting 
temperature. The melting points of imidazolium salts also increase with the degree of 
chains branching.108 
 
Popular ILs are thermally stable up to around ~427 ˚C.109 Thermal stability is limited by 
the same factors that contribute to the melting temperature.109 Usually, the difference in 
the decomposition temperature between particular salts with different cations is rather 
insignificant.109  Branching of the alkyl chain, as with the melting temperature, decreases 
the thermal stability of imidazolium ILs.110 
 
1.4.2  Various applications for ionic liquids. 
Ionic liquids (ILs) are solvents that have captured the interest of academia and industry. 
As a result ILs are currently being introduced into a number of industrial processes 
worldwide. The widespread interest in ILs has drawn scientists from all disciplines to 
study ILs resulting in the increase in knowledge and understanding of these unique 
solvents in the last decade. Because the properties (melting point, density, viscosity) and 
behaviour of the ILs can be adjusted to suit an individual processes, they can truly be 
  
described as designer solvents. Thus, ILs have found applications in various processes 
including biological application as immunotoxins, protein renaturation and crystallization 
studies,111-116 biocatalysts,117 and as potentially useful antimicrobials.118,119 They have 
even found applications in bacterial endospore detection.120 Polymer membrane fuel cells 
are considered to be one of the most promising clean energy sources since they do not 
generate toxic gases and other hazardous compounds.121,122 Ionic liquids are also used in 
explosive formulations for use as propellants or explosives.123-125,126 They also have 
applications as Lubricants.127  
 
1.4.3 Applications in organic synthesis 
A wide range of ILs usually containing imidazolium cations have been used as the 
solvents and catalysts for a number of different organic reactions. There are major 
potential benefits in using ILs as solvents and catalysts for organic reactions. The main 
driving force for their use is the environmental advantage of using the relatively benign 
ILs to replace organic solvents and what are usually highly acidic catalysts.  
 
The main application of these ILs is as catalysts in reactions that require a Lewis or 
Brønsted acidic catalyst or, more rarely, a basic catalyst.128-136 These ILs are typically 
easy and cheap to produce, can be easily recycled and reused, usually involve simple 
reaction processes, and often only produce one byproduct, water. In comparison, most 
traditional methods for these organic reactions involve large amounts of acidic waste, 
waste molecular solvents, and either waste catalyst or expensive and time-consuming 
catalyst-recycling procedures. The driving force behind the use of ILs in this field has 
been to find “greener” alternatives; hence, high conversions, high selectivities, and the 
ability to reuse the IL are important. No additional catalysts were required, and 
compared to conventional methods, yields were higher, the reaction times were shorter, 
less hazardous solvents were used, there were milder conditions, and the ILs could be 
reused.137,138 
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In addition to the reactions listed in Table 1.3 Beckmann Rearrangement,139 
Condensation reactions137-145, Isomerization146, Ether Cleavage,147 Chlorination,148 
Nitration149 and Friedel-Craft alkylation150-152 reactions have also been reported to have 
also been successfully conducted using ILs as both catalysts and solvents.  
 
More recently copper- and phosphine-free Sonogashira coupling reactions in 
biodegradable ionic liquids derived from nicotinic acid were reported by Harjani et 
al.153,154 Of particular interest was 3-(n-butoxycarbonyl)-methylpyridinium 
bis(trifluoromethanesulfonyl)imide which proved to be biodegraded within 7 days of 
treatment with waste water organism.153 A number of typical 1,3-dialkylimidazolium 
based ILs have proven to be resilient to biodegradation, however, it was demonstrated 
that when an ester functionality was built into the imidazolium salt sidechain the 
resulting ILs biodegrade within 28 days.155,156  
In addition to the presumed environmental advantage of using relatively benign ILs to 
replace organic solvents and the use of catalysts, this characteristic of biodegradability 
156-158 bodes well for the application of ILs as “greener” reaction solvents/catalysts in 
organic synthesis.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1.3: A list of organic reactions which use ILs as either solvents or catalyst. 
Reaction Mechanism Application 
Diels-Alder 
Reaction159 
R
2
R
1
HH
R
1
R
2R
1
R
2
endo exo
 
solvents and 
catalysts 
Henry 
Reaction160 
NO2
R
2
R
3
O
catalyst
R
1
O2N OH
R
2
R
3
 
catalysts 
 
Direct-Aldol 
condensation 
Reaction161 
R
2
R
1
O
R
2
R
1
OO
X
H
O
X
IL (30mol%)
 
basic catalyst 
Mannich 
Reaction161 
RCHO R
1
NH2 R
3
R
2
O
R
3
R
2
O
catalyst
R
HN
R
1
 
solvents and 
catalysts 
 
Fischer 
Esterification 
150,162-165 
R
1
COOH R
2
OH
R
1
O
R
2
O
 
solvents and 
catalysts 
Dehydration of 
Fructose166 
CH2OH
CH2OH
OH
OH
H
O
H
H
HO
O
CHOHOH2C
H
 
solvents and 
catalysts 
Biginelli 
Reaction 167,168 O O
H2N NH2
X
R
1
CHO
N
H
NHO
R
3
X
R
1
R
2
 
solvents and 
catalysts 
(Z)-to(E)-
Alkene 
Isomerisation146 
 
HH
COOCH3H3COOC
COOCH3H
HH3COOC  
solvents and 
catalysts 
 
There are strong expectations for the use of ILs to increase in laboratory and industrial 
applications, as replacements for many organic solvents which are currently in used. In 
addition to their environmental benefits, non-volatile, re-usable and biodegradable), ILs 
also have a major advantage over conventional molecular solvents in the number of 
potential combinations of cations and anions that could be produced and, hence, the 
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ability of ILs to be designed for specific applications, one of which is as stationary phases 
in analytical chemistry.169 
 
1.4.4 Application of ionic liquids as stationary phases in Gas 
Chromatography. 
1.4.4.1 Introduction 
ILs possess many unique physicochemical and solvation properties that can be varied 
and tuned for specific applications. It is this tunability that makes these ILs so desirable 
for a large variety of applications. In addition, most ILs possess negligible vapor pressure 
and high thermal stability, producing few volatile organic compounds. Because of their 
unique solvation properties ILs have been employed as replacements of traditional 
solvents.170,171 Furthermore, IL-based solvent systems typically exhibit enhanced reaction 
kinetics resulting in the efficient use of time and energy.171 The potential for producing 
unique task-specific ILs can be achieved by the simple modification of the cation and 
anion structure.172,173 The resulting ILs can be used to carry out designated applications 
or to serve a functional purpose in a method or device.  
 
1.4.4.2 Chromatographic relationship between the structure and properties of 
ionic liquid as stationary phases for gas chromatographic separations. 
In the field of gas chromatography (GC), new stationary phases that exhibit unique 
separation selectivity, high efficiency, and high thermal stability are in high demand 
and are particularly sought after. These properties have allowed ILs to function as 
stationary phases which are described as possessing unique dual-nature retention 
selectivity providing highly selective separations. Figure 1.18 is a good illustration of 
the “dual-nature” retention behaviour of IL stationary phases as described by 
Armstrong et al.57 The Figure 1.18 illustrates the comparison of the retention 
behaviour of 8 analytes on an IL phase (Figure 1.18 B) and a commercial phase 
(Figure 1.18 A) of identical dimensions and similar polarities, under identical 
  
conditions.57 It was shown that non-acidic or basic nonpolar analytes, separated on 
the ionic liquid stationary phases in much the same manner as on non-polar 
commercial stationary phase.57 However, polar analytes (Figure 1.18 B: compounds 
4, 5, and 7) are strongly retained by the ionic liquid stationary phases.57 
 
In addition to providing highly selective separations, there are a multitude of other 
desired characteristics that a gas chromatographic stationary phase should possess. 
These properties include high viscosity, low surface tension allowing for wetting of 
the fused silica capillary wall, and low vapour pressure at elevated temperatures. 
This section primarily describes the desired characteristics of ILs namely viscosity, 
thermal stability, and surface tension which largely dictate the quality and integrity 
of the stationary phase coating.  
 
 
Figure 1.17:57 A comparative analysis of the separation of 8 compounds on an ionic 
liquid phase [BuMIm][PF6] (B) versus a commercial DB-5 phase (A). The columns were of 
identical dimensions (15 m × 0.25-mm i.d.), under identical conditions, and similar 
polarity. The test compounds are:  1) butyl acetate; 2) n-heptanol, 3) p-dichlorobenzene, 
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4) o-cresol, 5) 2,5-dimethylphenol, 6) n-dodecane, 7) 4-chloroaniline, and 8) n-
tridecane.57 
 
Poole and coworkers evaluated liquid organic salts as stationary phases in GLC in the 
early 1980s.174-177 Ethylpyridinium bromide was used to separate various organic 
compounds containing large dipoles or functional groups capable of hydrogen bonding. 
Ethylpyridinium bromide has a melting point of 110 ˚C, below this melting point, this 
stationary phase exhibited poor efficiency and peak asymmetry.177 However, due to the 
tunability of ILs, the temperature range of the molten salts was expanded by the design 
of new classes of RTIL stationary phases such as tetra-n-hexylammonium benzoate, 1-
methyl-3-ethylimidazolium chloride, tri-n-butylbenzylphosphonium chloride, and tetra-n-
butylammonium tetrafluoroboroate.174  
     
1.4.4.2.1 Thermal stability characteristics of ionic liquids 
One of the most chromatographically impotant physical properties possessed by many 
ILs is their high thermal stabilities. In GLC, the thermal stability of the stationary phase 
is one of the most important considerations as it governs the onset of column bleed and 
ultimately dictates the lifespan of the stationary phase.178  
 
For ILs based on the 1,3-dialkyl imidazolium cation, it was found that the thermal 
stability can be increased by incorporating large, bulky cations paired with triflate 
anions179 as shown in Figure 1.19, IL structures A and B. Not only did these bulkier ILs 
exhibiting higher thermal stabilities, but also demonstrated improved separation 
selectivity for solutes containing nonbonding and π-electrons as well as hydrogen bond 
basic character. This was likely due to the ability of the electron-rich phenyl ring in IL B 
being able to interact strongly via π−π interactions with aromatic solutes, whereas the 
phenyl ring in IL A is insulated from the imidazolium ring by the methylene group, 
slightly decreasing its propensity for π−π interactions. This is an excellent demonstration 
of the tunability of ILs for enhanced thermal stability while also producing two stationary 
  
phases that exhibit quite unique selectivities. It has also been observed that the thermal 
stability of geminal dicationic ILs is considerably higher than their monocationic 
analogs.180  
NN NN
OCH3
TfOTfO
BA  
Figure 1.18: Bulky imidazolium cations paired with a triflate anion. 
 
1.4.4.2.2 Development of highly viscous stationary phases 
Ideal stationary phases in GC possess high viscosities as well as exhibit small changes in 
viscosity with large ranges in temperature. ILs possessing the highest viscosities typically 
contain halide anions that exhibit superior hydrogen bond coordinating behavior. 
However, despite having high viscosities, these ILs tend to exhibit lower thermal 
stabilities and tenaciously retain analytes capable of hydrogen bonding.  
 
1.4.4.2.3 IL surface tension and wall-coated open tubular columns 
To perform gas chromatographic separations in wall coated open tubular (WCOT) 
capillary columns, it is essential that the stationary phase be evenly coated as a thin film 
on the wall of the capillary column. It is imperative that the stationary phase retains an 
even film over the surface of the capillary column without forming droplets, neither 
during the coating process or chromatographic separation when the oven temperature is 
increased. The surface tension of the IL is crucial in forming a thin and homogeneous 
coated layer.   
 
1.4.4.2.4 Anion and cation effects on chromatographic selectivity 
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Selectivity is one of the most important characteristics of any chromatographic stationary 
phase. Typically, GLC stationary phases are classified in terms of their polarity, in order 
to achieve separation the polarity of the employed stationary phase should closely match 
that of the analytes being separated. ILs can give rise a multitude of different solvation 
interactions that result in unique interactions with the solute molecules. However, an 
evaluation of imidazolium-based ILs with different combinations of cations and anions 
revealed that the anion contributes the most to the unique selectivity exhibited by the IL 
stationary phase.179  
 
1.4.4.3 Application of ionic liquids as chiral stationary phase solvents 
Two approaches have been employed to incorporate ILs as new stationary phases for 
chiral GLC. One method involves coating a pure chiral IL as the stationary phase in WCOT 
GLC.181 The second approach, involves dissolving chiral selectors such as cyclodextrins in 
an achiral IL and the mixture coated onto the wall of the capillary column.182 Both 
approaches can separate a variety of different analytes, but the observed 
enantioselectivities and efficiencies do not rival those observed with commercially 
available chiral stationary phases (CSPs). The first application of a chiral IL as a CSP was 
first demonatrated by Armstrong, Welton, and coworkers.181 The chiral ILs evaluated 
were based on the N,N-dimethylephedrinium cation paired with the 
bis[trifluorormethylsulfonyl]amide anion [Tf2N]- (Figure 1.20).  
 
CH3
OH
N
(+)-(1S,2S)
H3C CH3
(+)-(1S,2R)
CH3
OH
N
H3C CH3
CH3
OH
N
H3C
CH3
(-)-(1R,2S)
CH3 CH3 CH3
Tf2N Tf2NTf2N
 
Figure 1.19: (1S,2R)-(+)-N,N-dimethylephedrinium, (1R,2S)-(-)-N,N-
dimethylephedrinium, (1S,2S)-(+)-N,N-dimethylephedrinium with 
bis[trifluoromethylsulfonyl]amide anion. 
 
  
These IL CSPs were enantioselective for four classes of chiral analytes: alcohols 
(including diols), sulfoxides, epoxides, and acetylated amines (Figure 1.21). And when 
the opposite enantiomer of the chiral IL was employed as the stationary phase the 
elution order of the chiral analytes could be reversed.181 
 
 
 
Figure 1.20:181  Enantiomeric separation of sec-phenethyl alcohol, 1-phenyl-1-butanol, 
and trans-1,2-cyclohexanediol on a (1S,2R)-(+)-N,N-dimethylephedrinium 
bis(trifluoromethane sulfon)imidate ionic liquid stationary phase.  
 
As mentioned earlier, the chiral selector can also be dissolved in the IL solvent and be 
subsequently coated on the capillary wall.182 Using this approach, the achiral [N-butyl-N-
methylimidazolium] Cl− IL was used to dissolve permethylated β-cyclodextrin (PM-βCD) 
and dimethylated β-cyclodextrin (DM-βCD). The chromatographic separations obtained 
from these two columns were compared to two commercially available CSPs based on 
PM-βCD and DM-βCD dissolved in polydimethylsiloxane. From a set of 64 chiral molecules 
separated by the commercial PM-βCD column, only 21 of the molecules were 
enantioresolved by the IL-based PM-βCD column. Likewise, from a collection of 80 
analytes separated by the DM-βCD column, only 16 analytes could be separated on the 
IL-based DM-βCD column.182 A considerable enhancement in the separation efficiency of 
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the IL-based CSPs was observed. The enhancement in separation efficiency, coupled to 
the loss of enantioselectivity for most separations, suggested to be the result of the 
imidazolium cation occupying the cavity of the cyclodextrin preventing the analyte–
cyclodextrin inclusion complexation that is crucial for chiral recognition.182-183 
 
1.4.4.4 Binary mixtures of ionic liquids as high-selectivity stationary phases  
Although IL-based stationary phases exhibit unique selectivity compared to many non-
ionic stationary phases, it is not always possible to completely resolve all analytes in 
complex mixtures during the separation. As a result stationary phases consisting of a 
mixture of ILs have been used in GLC to achieve selectivities that is not achievable with 
neat IL stationary phases.184 A complex mixture of alcohols (both cyclic and aliphatic) 
and analytes with aromatic functionality were subjected to separation on a stationary 
phase consisting of neat N-butyl-N-methylimidazolium [Tf2N]
− IL.184 This stationary 
phase, though selective for most of the molecules, exhibited poor resolution.184 Columns 
were prepared consisting of a mixture of different percentages of the ILs N-butyl-N-
methylimidazolium [Cl]− and N-butyl-N-methylimidazolium [Tf2N]
− (Figure 1.22). 
Through tuning the composition of the stationary phase mixture, the separation 
selectivity and resolution of most analytes were varied. It was observed that the 
hydrogen bond basicity increased linearly as the concentration of chloride anion (in the 
form of N-butyl-N-methylimidazolium Cl−) was increased.184 It was found that the 
retention factors of short-chained alcohols increased by as much as 1100 % on the 
column containing the highest percentage of chloride anion compared to the neat N-
butyl-N-methylimidazolium [Tf2N]
−.184 Most alcohols exhibited a reversal of elution order 
as the stationary phase hydrogen bond basicity increased.184 By utilizing stationary 
phases based on IL mixtures it has been demonstrated that the separation selectivity, 
resolution, and elution order of analytes can be tuned systematically,184 adding another 
parameter in the design aspect to ILs based stationary phases for gas chromatographic 
separations. 
 
  
NN NN
Tf2NCl  
Figure 1.21: N-butyl-N-methylimidazolium [Cl]− and [Tf2N]
− ionic liquids 
 
1.4.4.5 Polymeric ionic liquid stationary phases for high-temperature 
separations. 
Although ILs possess a variety of favourable properties rendering them excellent 
candidates for application as stationary phases, their most significant drawback lies with 
their drop in viscosity with increasing temperature. This characteristic results in an 
increased propensity for flowing of the IL within the capillary, producing pooling of the IL 
and irregular coating and film thickness throughout the column. These factors often have 
detrimental effects on retention time reproducibility as well as separation efficiency. 
 
In an attempt to combat the problem of IL on column flow during separation at increased 
temperature a method of immobilizing the IL onto the capillary column was devised.185 
This method involved on-column polymerisation of mono- and di-cations vinyl-
substituted imidazolium cations (Figure 1.23) with a free-radical initiator 
(azobisisobutyronitrile, AIBN) in dichloromethane. This mixture was coated onto the wall 
of the capillary column by the static coating method and the capillary was sealed at both 
ends and heated to initiate polymerization.185 Three types of polymerised stationary 
phases were produced with this method, linear polymerised, partially crosslinked and 
fully crosslinked stationary phases. 
 
NN
NTf2
NN
NTf2
N N
NTf2
(b)(a)  
Figure 1.22: Mono- and di-cations vinyl-substituted imidazolium ILs; (a) 1-vinyl-3-
hexylimidazolium and (b) 1,9-di-(3-vinylimidazolium)nonane bis-(trifluoromethane 
sulfonyl)imidate. 
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The formation of a linear IL polymer stationary phase was performed by the free radical 
polymerization of monocationic monomers. These stationary phases exhibited the lowest 
thermal stability, producing significant column bleed and dramatic decreases of efficiency 
above 300 ˚C.185 Partially crosslinked stationary phases were synthesized by 
polymerizing a blend of monocationic and dicationic crosslinking monomers. Using this 
approach, the stationary phase consisting of an equal ratio of mono- and dicationic ILs 
exhibited the best thermal stability up to ~280 ˚C.185 The third stationary phases 
consisted of a completely crosslinked IL polymer formed by the polymerization of geminal 
dicationic IL monomers.185  This matrix exhibited high stability and enhanced efficiencies 
at separation temperatures over 350 ˚C.185 It was shown that mono-cationic IL matrixes 
were best suited for low-temperature analysis, whereas the partially crosslinked and fully 
crosslinked stationary phases exhibited higher thermal stabilities, thus, were ideal for 
moderate (100–280 ˚C) and high (200–380 ˚C) temperature gas chromatographic 
separations, respectively (as illustrated in Figure 1.24).185 In addition it was found that 
the solvation interaction parameters of the polymerized IL stationary phases were largely 
unchanged compared to their monomeric IL analogs.185 Further work into the 
development of IL polymeric stationary phases has continued,186 including the 
development of racemic 2-(1H-imidazol-1-yl)cyclohexanol based polymeric phase which 
exhibited good thermal stabilities (240–300 ˚C), very high efficiencies (3120–
4200 plates/m) and excellent selectivity.187 This is one of the very few chiral IL GC 
stationary phases reported, however, only a racemic form of the stationary phases was 
reported to have been synthesised and so no enantiomeric separations were reported. 
 
  
 
 
Figure 1.23: 185 Separation of C6-C24 fatty acid methyl esters on a partially cross-linked 
ionic liquid stationary phase. Conditions: 100 ˚C, hold for 2 mins, 15 ˚C/min to 260 ˚C. 
 
Despite the increased interest in the development on IL stationary phases for application 
in GC analysis and the increasing availability of IL stationary phases on the market, there 
are very few examples of chiral ionic liquid GC stationary phases in the literature and 
none are commercially available. This is in part due to the very large number of achiral 
ionic liquids being developed and comparatively few chiral ionic liquids.  In addition, the 
most common (and effective) chiral selecting agents used in chiral GC stationary phases 
are cyclodextrins based chiral selecting agent. A great deal of research has gone into the 
development of various CD derivatives for application as chiral selecting agents and 
much less effort into the development of new chiral selectors. In this study we endeavour 
to design and synthesise noval chiral ionic liquids and test them for enantiomer resolving 
capabilities.  
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1.5 The aim and scope of this research 
The various properties exhibited by ILs make them ideal stationary phases in GLC. ILs 
exhibit a unique dual-nature selectivity that allows them to separate polar molecules like 
a polar stationary phase and nonpolar molecules like a nonpolar stationary phase. In 
addition, the combination of cations and anions can be tuned to add further selectivity for 
more complex separations. Viscosity, thermal stability, and surface tension are vital 
properties that dictate the quality and integrity of the stationary phase coating and are 
additional characteristics that can be controlled when custom designing and synthesizing 
ILs. IL-based stationary phases also hold great promise in GC mass spectrometry where 
the dual-nature selectivity of the stationary phase eliminates the need for frequent 
changing of columns. 
 
Several simultaneous interactions are required to discriminate between enantiomers; the 
diasteroisomeric selector–ligand complexations required for chiral discrimination involve 
a combination of interactions. Chapter 2 describes the synthesis of new imidazole based 
chiral ionic liquids with various functional groups designed to be able to promote a 
variety of molecular interactions.  
 
In chapter 3 the new chiral IL are incorporated into OV-1701 polysiloxane stationary 
phases as chiral resolving agents and tested for enantionselective capability by gas 
chromatography. In these studies we look at the thermal stability of the CILs which 
impacts a columns maximum operation temperature, the ability of the various functional 
groups on the CILs to form diastereoisomeric selector–ligand complexation interactions 
between enantiomers and also study the dynamic interconversion process of chiral 
oximes on polysiloxane chiral stationary phases and achiral polyethylene glycol stationary 
phases.  
 
The aim of this work is to endeavour to assess whether these new classes of ILs can be 
used as chiral resolving agents in common achiral stationary phases such as polysiloxane 
  
gums. In doing so we strive to develop a new class of IL chiral stationary phases that can 
be used to tackle the chemists’ problem of assessing the enantiomeric purity of new 
synthetic products, as well as, provide an extra avenue for pharmaceutical industries and 
the like, to be able separate and assess enantiomers and provide the data required by 
regulatory agencies with respect to chiral drugs.   
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2 Chapter 2  
 The synthesis of novel ionic liquids for application as chiral selecting agents 
 
 
 
 
 
 
 
 
 
 
 
 
  
2.1 Synthesis of simple imidazole and pyridine based ionic liquids 
2.1.1 Introduction 
The first reported application of ionic salts, previously known as molten salts, as GC 
stationary phases was by Barber et al in 1959.1 In 1982 1-alkyl-3-methylimidazolium 
cation based room temperature ionic liquids were first reported by Wilkes et al.2 paving 
the way for the development of air and moisture stable ionic liquids (ILs) which could be 
used for a wider range of applications. Common organic ILs consist of an asymmetrically 
substituted nitrogen containing cation such as imidazoles or pyridines with a counter 
anion such as a halide ion, PF6
-, BF4
- or Tf2O
- anion. The wide range of anion and cation 
combinations which can be coupled, allows for the synthesis of various room temperature 
ionic liquids (RTILs) with customized physical and chemical properties suited to specific 
applications.   
 
More recently, imidazole based room temperature ionic liquids have been employed as 
stationary phases in gas chromatography. Ionic liquids have been shown to possess 
separation capabilities by Anderson et al.3 who stated they had “dual nature” retention 
capabilities. That is, ionic liquid stationary phases can separate both polar molecules as 
do polar stationary phases and nonpolar molecules as do nonpolar stationary phases, on 
the one phase.  In 2004 Ding et al.4 reported the first enantiomeric separations using 
imidazole based chiral ionic liquid stationary phases in gas chromatography. The utility of 
imidazole based ionic liquids as GC stationary phases has stimulated the development of 
new imidazole based ionic liquids. Because the physical and chemical properties of ionic 
liquids can be tuned by altering the structure and functional groups of the cation and 
anion, they make ideal candidates for application in the development of new stationary 
phases with a wide range of tunable physical and chemical properties for application in 
analytical chemistry separations.  
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Moreover, a few chiral imidazolinium salts have recently been reported as chiral ionic 
liquids.5,6 However, examples of chiral ionic liquids remain few compared to achiral ionic 
liquids.7,8 This research was undertaken to contribute to the development of new chiral 
ionic liquids. Some simple methods for the synthesis of imidazole based ionic liquids, and 
some new chiral ionic liquids are presented. 
 
2.1.2 Results and Discussion 
Imidazolium ionic liquids 
Ionic liquids were synthesised from the 1H-imidazole dissolved in anhydrous DMF. To this 
solution was added excess alkylhalide and heated for ~6 hrs at 90 ˚C under a nitrogen 
atmosphere. The solution was concentrated under negative pressure and the remaining 
residues of DMF and alkyhalide were removed by kugelrohr bulb-to-bulb distillation to 
afford N,N-dialkylimidazolium ionic liquids (reaction shown in Figure 2.1). Using this 
method the simple room temperature ionic liquids 1-3 were synthesized as depicted in 
Figure 2.2.  
NN
RR
X
NHN
DMF/alkyhalide
90
o
C, 6hrs  
Figure 2.1: Typical reaction scheme for the synthesis of N,N-dialkylimidazolium ILs. 1 
molar equivalent of imidazole with excess alkylhalide in DMF heated to 90 ˚C for 6 hrs 
affords dialkylimidazolium halide. 
 
  
NN NN
NN
NN
Cl
Br
I
Imidazole 1 (97%)
2 (98%)
 3 (99%)
OH
O
HN
O
N
NCl
4 (quantitative)
OH
O
HN
O
N
NI
5 (quantitative)  
Figure 2.2: Imidazolium ILs 1-3 were synthesised by heating 1-H-imidazole with the 
alkylhalides ethyliodide, benzylchloride and n-bromobutane in DMF at 90 ˚C for 6 hrs 
under nitrogen. ILs 4-5 were synthesised from either N-benzoylhistidine or N-
acetylhistidine by heating with benzylchloride or ethyliodide, repectively, in DMF at 90 ˚C 
for 6 hrs.  
 
These ILs are achiral, however, using the same method novel chiral imidazolium ILs were 
synthesised from (L)-N-benzoylhistidine (44) and (L)-N-acetylhistidine by alkylating with 
benzylchloride and ethyliodide, respectively. By heating N-benzoylhistidine (44) or (L)-N-
acetylhistidine with either benzylchloride or ethyliodide at 90 ˚C for 6 hrs, 4 and 5 are 
afforded in quantitative yield (Figure 2.2 and 2.3). DMF is removed by rotary evaporation 
and the product further purified by recystallisation. These chiral ILs are ideal for 
application as chiral selecting agents. 
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OH
O
HN
O
N
NClOH
O
HN
O
H
N
N
BzCl/ DMF
Heat 90oC
44 4  
Figure 2.3: Synthesis of histidine derived ionic liquid 4. Reflux (L)-N-benzoylhistidine 
with benzyl chloride in anhydrous DMF at 90 ˚C for 6 hrs. 
 
Chiral epoxides are also very useful compounds for producing chiral imidazoles which can 
then be used for the synthesis of chiral ionic liquids. Epoxides are simply cyclic ethers, 
but because of their cyclic structure, the strain from their three-membered ring structure 
gives them unique chemical reactivity when compared to open chain ethers. Unlike linear 
ethers, epoxide can be cleaved by both base as well as by acid. Whereas the ether 
oxygen is normally a poor leaving group in an SN2 reaction, epoxides react with imidazole 
at elevated temperatures. 
Glas and Thiel9 reported a facile, high yield synthesis of a chiral imidazole derived from 
(R)-styrene epoxide under microwave conditions. Following this procedure, irradiating a 
1:1 mixture of imidazole and (+/-)-styrene epoxide for 3 minutes at 360 W afforded (+/-
)-2-(1-imidazolyl)-1-phenylethanol (6), the pure product was precipitated upon addition 
of ethyl acetate in 77 % yield (Figure 2.4).  
NN
OHNN
MW irradiation
O
(+/-)-2-(1-Imidazolyl)-1-phenylethanol
*
6
 
Figure 2.4: Microwave irradiation of a 1:1 mixture of of imidazole and (R)-styrene 
epoxide at 360 W for 3 mins, affords (1R)-2-(1-imidazolyl)-1-phenylethanol (6). 
 
  
Base-catalysed epoxide ring opening is a typical SN2 reaction in which attack by the 
nucleophile takes place at the least hindered epoxide carbon. The basic nitrogen on the 
imidazole acts as the nucleophile attacking the least hindered carbon on the three-
membered ring. Given that styrene epoxide has primary and secondary carbons, 
nucleophilic attack takes place at the primary carbon via SN2 mechanism producing a 
single isomeric product. 
NN
OH
 90
o
C/ 6 hrs
7-10
RX/ DMFNN
OH
6
R
X
 
Figure 2.5: Alkylation of (+/-)-2-(1-Imidazolyl)-1-phenylethanol (6) to afford ILs 7-10.  
 
(+/-)-2-(1-Imidazolyl)-1-phenylethanol was then alkylated with the alkylhalides 
ethyliodide, bromobutane, benzylchloride, and allylbromide to afford the corresponding 
new imidazolium salts 7-10 (Figure 2.5 & 2.6) in quantitative yields with melting points 
ranging from RTIL-125 ˚C.  
NN
OH
NN
OH
NN
OH
I
Br ClNN
OH
NN
OH
Br
7 (97%)
8 (97%)
9 (98%)
10 (83%)
*
*
*
*
*
6 (77%)
 
Figure 2.6: Racemic ionic liquids synthesised from (+/-)-2-(1-imidazolyl)-1-
phenylethanol. 
 64 
 
  
 
 
 
Figure 2.7: 13C-NMR spectrum of IL 9 in CDCl3. (iii) DEPT135 spectrum of carbon atoms 
which are bonded to hydrogen atoms (CH and CH3 positive, CH2 negative), (ii) DEPT90 
showing only CH carbons and, (i) 13C-NMR spectra showing CH, CH2, CH3, and quaternary 
carbons. 
 
 
NN
OH
Br
15
1
2
3
45
6
7
8
9
10
11
12
13
14
10
  
Table 2.1: Imidazolium IL melting points (mp) and yields. 
 
Compound Mp ˚C Yield % 
1 RTIL 97 
2 RTIL 78 
3 RTIL 99 
4 RTIL Q 
5 RTIL Q 
6 141-142 77 
7 124-125 92 
8 72-74 97 
9 RTIL 98 
10 120-122 83 
   Q= quantitative yield. 
Pyridinium ILs 
Pyridine also undergoes SN2 alkylation with an alkylhalide, due to its basic sp
2 hybridised 
lone-pair electrons. Refluxing neat pyridine-4-carboxaldehyde with excess alkylhalide, 
such as ethyliodide or benzylchloride, forms N-alkylpyridinium halide ILs (Figure 2.8). 
The excess alkyhalide can be removed to give pure 11-12 in quantitative yields.  
N
H O
N
H O
RX
Reflux
R
X
11-12  
Figure 2.8: Formation of pyridinium ILs . 
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Given the ease with which pyridines can be alkylated, the possiblilty of manipulating the 
physical and chemical properties of poly-4-vinylpyridine (4-PVP) polymers by alkylating 
the pyridine pendant groups to form poly-4-vinylpyridinium ILs was explored. Being a 
polymer the solubility of 4-PVP is limited to acetic acid, t-butanol, DMF, DMSO, lower 
alcohols and water at low pH. In converting the pyridine pendant groups into ionic liquids 
we endeavoured to expand the solubility of these polymers in less polar organic solvents, 
because their insolubility rendered them difficult to use in many applications including 
their application as GC stationary phases.  
 
N
CH2CH CH2CH CH2CH
N
CHCH2
x y z
N N N
CH2CH CH2CH CH2CHx y z
(a) (b)  
Figure 2.9: Polyvinyl pyridines (a) poly(4-vinylpyridine) (4-PVP) and (b) poly(4-
vinylpyridine) 2% crosslinked with divinylbenzene (4-PVP-XL). 
 
Alkylation of the PVP’s was conducted under the same conditions as the imidazolium ILs, 
in DMF with the alklyhalides ethyliodide, 1-bromobutane or benzylchloride with a longer 
reaction time of 24 hrs owing to the lower solubility of the PVP’s. The resultant PVP ILs 
(13-15 and 16-18) were synthesised in good yields (Figure 2.11), however, the 
solubility of these IL polymers in nonpolar solvents was not significantly increased by N-
alkylation. With the knowledge that anion metathesis can increase the solubility of ILs, 
anion metathesis was applied to these ionic polymers unsuccessfully. The ionic polymers 
remained insoluble in most organic solvents thus anion exchange did not take place. Due 
to their insolublilty in less polar common organic solvents their incorporation into GC 
stationary phases is not possible. Further investigation into appropriate solvent systems 
for anion exchange metathesis may yield ionic PVP polymers with improved solubility. 
Perhaps ionic liquids themselves could be used to dissolve PVP based ionic polymers. 
Generally the crosslinked PVP’s were less soluble than the non-crosslinked PVP’s. Thus 
  
employing a non-crosslinked 4-PVP of smaller molecular mass than ~60,000 perhaps, for 
synthesising ionic PVP polymers is recommended and worthwhile investigating. Such 
ionic polymers may be soluble enough in less polar solvents such as DCM to permit their 
investigation as novel GC stationary phases.   
 
Alkyl halide
N N N
CH2CH CH2CH CH2CHx y z
DMF 90oC 6hr N N N
CH2CH CH2CH CH2CHx y z
R R R
X X X
 
Figure 2.10: Alkylation of 4-PVP with the alkylhalides ethyliodide, bromobutane, and 
benzylchloride. 
 
Thermogravometric analysis of 4-PVP ILs 
In order to evaluate the thermal stability of the 4-PVP ILs, thermogravimetric analysis 
tests were carried out. Thermogravimetric analysis scans were obtained on a Mettler 
thermogravimmeteric balance at a heating rate of 20 ˚C/min from 50 to 800 ˚C under an 
inert nitrogen atmosphere flowing at 20 mL/min, switching to air at 600 ˚C. As can be 
seen in Figure 2.12 (A) compounds 13-15 begin to show weight loss indicative of 
decomposition at 233 ˚C, 200 ˚C, and 208 ˚C, respectively, compared to the 
underivatised 4-PVP which begins to decompose at 320 ˚C.  
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N
CHCH2
x y z
N N N
CH2CH CH2CH CH2CHx y z
N N N
CH2CH CH2CH CH2CHx y z
N N N
CH2CH CH2CH CH2CHx y z
I I I
Br Br Br
Cl Cl Cl
N
CH2CH CH2CH CH2CH
N
CHCH2
x y z
N
CH2CH CH2CH CH2CH
N
CHCH2
x y z
Cl
I
Br
13 16
14 17
15  18  
Figure 2.11: The poly-(4-vinylpyridinium halide) ionic liquids synthesised. 
 
Underivatised 2 % crosslinked 4-PVP begins to decompose at 341 ˚C, while its derivative 
ILs 16-18 began decomposing at 245 ˚C, 203 ˚C, and 227 ˚C, respectively (Figure 2.12 
B). It can be seen that the thermal stabilities of the ionic 4-PVP were significantly 
reduced by the dervatisation process. It was observed that the N-benzyl derivative 
produced the least thermally stable ILs while N-ethyl derivatives showed the greatest 
stability out of the 3 derivatives synthesised for both the 2 % cross-linked and non-
crosslinked polymers. Despite the reduced thermal stability these ionic PVPs are stable at 
high enough temperatures to be functional as stationary phases. Although these ionic 
PVP may not be novel compounds, their application as GC stationary phases would be 
novel and make an interesting study which could pave the way for the application of 
chiral ionic polymers derived from chiral polymers such as chitosan, for example.    
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  
A 
 
B) 
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Figure 2.12: A) TGA analysis of PVP ILs, 14, 15, and 13 compared to non cross-linked 
poly(4-vinylpyridine) (4-PVP). B) TGA analysis of 4-PVP-XL ILs, 17, 18, and 16 
compared with 2 % cross-linked poly(4-vinylpyridine) (4-PVP-XL). 
 
2.1.3 Conclusion 
Simple methods for the synthesis of achiral and chiral imidazolium ionic liquids as well as 
their dicationic imidazolium analogues were presented. The possiblilty of manipulating 
the physical and chemical properties of poly-4-vinylpyridine polymers by converting the 
pyridine pendant goups into pyridinium salts were also explored for the purpose of 
improving the solubility of the polymers which would permit their application in GC 
stationary phases. However, no significant changes in solubility were observed, and the 
TGA analysis of the ionic PVPs were found to have lower thermal stability than their 
precursors. Although their lowered thermal stabilities do not diminish their usefulness in 
stationary phases, their limited solubility impedes their ability to be incorporated into GC 
capillary columns as stationary phases, which is the focus of our research. The potential 
use of ILs to solubilize ionic PVP polymers has never been explored and should be 
investigated as a possible solution to overcoming the problem of insolubility. These 
investigations into the synthesis of ionic polymers pave the way for future work to 
prepare highly soluble ionic PVP polymers as well as chiral ionic carbohydrate based 
polymers which would be highly desirable for application as chiral resolving agents in 
separation media such as GC stationary phases.  
 
 
 
 
 
 
  
2.1.4 Experimental 
2.1.4.1 Reagents 
DMF, ethyl acetate, ethyl iodide, 1,2-diiodoethane, benzylchloride, 1-bromobutane, (R)- 
and (+/-)-styrene epoxide, imidazole, N-methylimidazole, N-benzylimidazole, N-
Butylimidazole, N-acetyl-L-histidine monohydrate, (L)-N-benzoylhistidine, poly-4-
vinylpyridine (4-PVP), poly-4-vinylpyridine 2 % cross-linked with divinylbenzene (4-PVP-
XL), and pyridine-4-carboxaldehyde were all purchased from Sigma Aldrich. 
 
2.1.4.2 Instruments 
DMF was removed by bulb-bulb distillation using a Buchi Kugelrohr (manufactured in 
Switzerland). Melting points were measured with a Gillkhenhamp Melting Point apparatus 
(manufactured England). NMR spectra analysis was conducted on a Bruker 300 
spectrometer. All NMR structure elucidation was done from 1H-NMR, 13C-NMR, DEPT135, 
DEPT90, HSQCGP, and HH-COSYGPSW experiments. Mass spectroscopy data were 
obtained by Electro-spray ionization (model) in positive ion mode (in 1:1 acetonitile/ 
H2O). Thermogravimetric analysis (TGA) was conducted on a Perkin-Elmer TGA-7 
instrument. The scan was obtained at 20 ˚C/min under an inert nitrogen atmosphere 
flowing at 20 mL/min from ambient temperature to 800 ˚C switching to air at 600 ˚C. 
The thermostabilities of the ILs were determined on a Mettler thermogravimmeteric 
balance at a heating rate of 10 ˚C/min.  
 
2.1.4.3 Synthesis 
Genaral N-alkylation procedure: 
To a stirring solution of imidazole in dry DMF under nitrogen was added an alkyl halide 
and heated for 6hr at 90 ˚C under a nitrogen atmosphere. The solution was concentrated 
by rotary evaporation at 80 ˚C and the remaining residues of DMF were removed by 
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bulb-to-bulb distillation using a kugelrohr. Further purification was carried out either by 
flash chromatography or recrystallization from ethyl acetate and hexane.   
Imidazoles 
N,N’-Diethylimidazolium iodide 1 
1 was synthesised following the general alkylation procedure from 3.0 g (44.08 mM) 
imidazole and excess ethyl iodide (7.8 mL) in 7mL of DMF to afford 1 as a dark brown 
ionic liquid; yield: 10.8 g (97 %): RTIL; 1H-NMR (300 MHz DMSO-d6) δ= 9.23-9.08 (m, 
1H,-NCHN-), 7.80-7.67 (m, 2H, -NCH), 4.20 (dq, 3JH,H = 7.5 Hz, 4H, -CH2), 1.41 (t, 
3JH,H 
=7.5 Hz, 6H, -CH3); 
13C-NMR (75MHz, DMSO-d6) δ = 135.2, 134.9, 122.0, 121.6, 120.1, 
119.4, 44.2CH2), 43.8(CH2), 15.9(CH3), 15.7(CH3); ESI-MS: calcd m/z = 125.19 (M
+), found 
m/z = 125.1 (M+). 
 
N,N’-Dibenzylimidazolium chloride 2 
2 was synthesised following the general alkylation procedure from 3.0 g (44.08 mM) 
imidazole and  excess benzyl chloride (11.2 mL) in 7 mL of DMF to afford 2 as a a brown 
glass; yield: 9.77 g (78 %): RTIL; 1H-NMR (300 MHz, DMSO-d6) δ= 9.49 (s, 1H, -NCHN-
), 7.86 (s, 2H, -NCH), 7.50-7.36 (m, 10H, Ar-H), 5.47 (s, 4H, -CH2); 
13C-NMR (75MHz, 
DMSO-d6) δ= 136.2q, 129.0, 128.9, 128.8 ,128.6, 128.4, 128.2, 122.8, 41.7(CH2); ESI-
MS: calcd m/z = 249.33 (M+), found m/z = 249.1 (M+). 
 
N,N’-Dibutylimidazolium bromide 3 
3 was synthesised from 3 g (44.08 mM) of imidazole following the general alkylation 
procedure using excess n-bromobutane (10.45 mL) in 7 mL of DMF to afford 3 as a light 
brown RTIL; yield: 11.4 g (99 %): RTIL; 1H-NMR (300 MHz, CDCl3) δ= 8.5 (m, 1H, -
NCHN-), 6.30-6.71 (m, 2H, -NCH), 3.57-3.47 (m, 4H, -NCH2-), 1.03 (m, 4H, -NCH2CH2-), 
0.45 (m, 4H, -CH2CH3). 0.02 (m, 6H, -CH2CH3); 
13C-NMR (75MHz, CDCl3) δ= 135.2, 
134.0, 132.9, 122.1, 121.5, 119.33, 118.6, 49.0(CH2), 48.8(CH2), 31.5(CH2), 31.4(CH2), 
18.7(CH2), 12.9(CH3); ESI-MS: calcd m/z = 181.30 (M
+), found m/z = 181.1 (M+). 
  
 
5-(2-Benzoylamino-2-carboxy-ethyl)-1,3-dibenzyl-imidazolium chloride  4 
4 was synthesised from 44 (3 g, 11.57 mM) following the general alkylation procedure 
using excess benzyl chloride (4.2 mL) in 7 mL of DMF with K2CO3. Following the removal 
of DMF by bulb-bulb distillation the crude product was dissolved in methanol leaving 
K2CO3 as a white precipitate. The solution was filtered and the methanol removed by 
evaporation to afford 4 as a brown glass in quantitative yield: 5.7 g: RTIL; 1H-NMR (300 
MHz, DMSO-d6) δ = 9.67 (s, 1H, -OH), 9.05 (d, JH,H = 7.8 Hz, 1H, -CHIm), 7.86 (d, 
3JH,H= 7.5 Hz, 4H, Ar-H), 7.74-7.08 (m, 12H, Ar-H/-CHIm), 5.60 (s, 2H, -CH2), 5.45 (s, 
2H, -CH2), 4.71 (m, 1H, -CH), 3.21 (m, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 
171.9q, 170.2q, 166.6q, 166.4q, 142.6q, 136.6, 135.7q, 134.8q, 134.0q, 133.9q, 133.6q, 
133.2, 132.2q, 131.5q, 131.4, 131.0, 130.2, 129.22q, 129.0, 128.8, 128.6, 128.6, 128.6, 
128.5, 128.3, 128.3, 128.1, 128.0, 127.8, 127.7, 127.5, 127.4, 127.2, 126.5, 126.4, 
120.8, 51.9(CH2), 51.10, 49.7(CH2), 25.2(CH2); ESI-MS: calcd m/z = 443.54 (M
+), found m/z 
= 440.3 
 
5-(2-Acetylamino-2-carboxy-ethyl)-1,3-diethyl-imidazolium iodide 5 
5 was synthesised from N-acetyl-L-histidine monohydrate (2 g, 10.14 mM) following the 
general alkylation procedure using ethyl iodide in 7 mL of DMF with K2CO3. Following the 
removal of DMF by bulb-bulb distillation the crude product was dissolved in methanol 
leaving K2CO3 as a white precipitate. The solution was filtered and the methanol removed 
by evaporation  to afford 5 as a dark brown glass in quantitative yield: 3.9 g: (RTIL); 
1H-
NMR (300 MHz, D2O) δ= 7.35 (s, 1H, -NCHN-), 4.48 (m, 
3JH,H =4.7 Hz, 1H, -CH2CH), 
4.38 (s, 1H), 4.21 (dq, 3JH,H =7.4 Hz, 4H, -CH2CH3), 3.34-3.01 (m, 
3JH,H =4.7 Hz, 2H, -
CH2CH-), 2.03 (s, 3H, -CH3), 1.5 (dt, 
3JH,H =7.4 Hz, 6H, -CH2CH3); 
13C-NMR (75MHz, 
D2O) δ= 176.7q, 173.7q, 131.4q, 119.8, 53.4, 49.2, 44.9(CH2), 42.2(CH2), 26.2(CH2), 
22.2(CH3), 14.8(CH3), 14.4(CH3); ESI-MS: calcd m/z = 257.33 (M
+), found m/z = 257.1. 
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Microwave reaction: 
Styrene epoxides 
(1R)- or (+/-)-2-(1-Imidazolyl)-1-phenylethanol  6 
A 1:1 mixture of imidazole (0. 51 g) and styrene epoxide (838 µL) was irradiated for 3 
minutes in a microwave oven at 360 W. To the oily crude product was added ethyl 
acetate to afford 2-(1-imidazolyl)-1-phenylethanol 6 as a white crystalline precipitate. 
The precicpitate was filtered and air dried: 1.1 g (77 %): mp 141-142 ˚C; 1H-NMR (300 
MHz, DMSO-d6) δ= 7.46 (s, 1H,-NCHN-), 7.37-7.21 (m, 5H, Ar-H), 7.06 (s, -CHIm), 
6.82(s, 1H, -CHIm), 5.70 (s, 1H, -OH), 4.82 (dd, JH,H =7.7, 4.1 Hz, 1H, -CH2CH-), 4.17-
3.99 (m, 2H, -CH2CH-); 
13C-NMR (75 MHz, DMSO-d6) δ= 142.5q, 137.6, 127.9, 127.6, 
127.2, 125.9, 119.9, 79.3, 78.8, 78.4, 72.1, 53.7(CH2); ESI-MS: calcd m/z = 189.23 
(M+H+), found m/z = 189.1 (M+H+). 
 
(+/-) 2-(N-Ethyl-imidazolium iodide)-1-phenylethanol  7 
IL 7 was synthesised from the racemic imidazole 6 (0.5 g) following the general 
alkylation procedure using 260 µL of ethyl iodide in 3 mL of DMF to afford 7 as a dark 
brown glass/RTIL at 97 % yield (0.89 g) : mp 124-125 ˚C; 1H-NMR (300 MHz, 
CDCl3/DMSO –d6) δ = 9.21 (s, 1H, -NCHN-), 7.53 (s, 2H, -NCHIm, 7.41-7.22 (m, 5H, Ar-
H), 5.01 (dd, JH,H =7.9, 2.8 Hz, 1H, -CH2CH-), 4.48 (dd, JH,H =13.7. 2.8 Hz, 1H, -CH2CH-
), 4.22 (m, 3JH,H =14.4, 7.5 Hz, 3H, -CH2CH-(1H) & -CH2CH3 (2H)), 1.47 (t, 
3JH,H =7.5 Hz, 
3H, -CH3); 
13C-NMR (75MHz, CDCl3/DMSO-d6) δ= 145.3q, 141.0, 133.4, 133.0, 130.8, 
128.5, 126.2, 75.9, 61.2(CH2), 49.8(CH2), 20.4(CH3); ESI-MS: calcd m/z = 217.29 (M
+), 
found m/z = 217.1. 
 
(+/-) 2-(N-Benzyl-imidazolium chloride)-1-phenylethanol 8 
8 was synthesised synthesised from the racemic imidazole 6 (0.5 g) following the general 
alkylation procedure using 370 µL of benzyl chloride in 3 mL of DMF to afford 6 as a light 
brown glass at 97 % yield (0.81 g) : mp 72-74 ˚C; 1H-NMR (300 MHz, CDCl3) δ = 9.80 
  
(s, 1H, -NCHN-), 7.41-7.16 (m, 11H, Ar-H), 7.06 (s, 1H,-NCHIm), 5.79 (s, 1H, -OH), 5.29 
(s, 2H, -CH2), 5.20 (dd, JH,H = 4.9, 2.5 Hz, 1H, -CH2CH-), 4.65 (dd, JH,H =13.9, 2.5 Hz, 
1H, -CH2CH-), 4.36 (m, 
3JH,H =13.9, 1H, -CH2CH); 
13C-NMR (75MHz, CDCl3) δ = 140.4q, 
137.0, 132.9q, 129.4, 128.8, 128.6, 127.9, 126.1, 123.7, 120.8, 71.0, 56.8(CH2), 
53.3(CH2); ESI-MS: calcd m/z = 279.36 (M
+), found m/z = 279.2. 
 
(+/-) 2-(N-Butyl-imidazolium bromide)-1-phenylethanol 9 
9 was synthesised synthesised from the racemic imidazole 6 (0.5 g) following the 
general alkylation procedure using butyl bromide in 3 mL DMF to afford 9 as a brown 
glass in good yield: 0.85 g (98 %): (RTIL); 1H-NMR (300 MHz, CDCl3) δ = 9.53 (s, 1H), 
7.44-7.19 (m, 7H, Ar-H/2xHIm), 5.23 (dd, JH,H =7.1, 2.8 Hz, 1H, , -CH2CH-), 4.72 (dd, 
JH,H =13.8, 2.9 Hz, 1H, -CH2CH-), 4.42 (dd, 
3JH,H =13.7, 7.2, 2H, -CH2CH-), 4.41 (s, -
OH), 4.10 (t, 3JH,H =7.3 Hz, 2H, -NCH2CH2-), 1.76 (dt, 
3JH,H =15.1, 7.5 Hz, 2H, -
CH2CH2CH3), 1.25 (dq, 
3JH,H =14.6, 7.3 Hz, 2H, -CH2CH3), 0.89 (t, 
3JH,H = 7.3 Hz, 3H, -
CH3); 
13C-NMR (75MHz, CDCl3) δ = 139.8q, 136.6, 128.6, 128.0, 126.1, 123.67, 121.0, 
70.9, 56.6(CH2), 49.8(CH2), 31.8(CH2), 19.4(CH2), 13.4(CH3); ESI-MS: calcd m/z = 245.34 (M
+), 
found m/z = 245.2. 
 
(+/-) 2-(N-Allyl-imidazolium iodide)-1-phenylethanol 10 
IL 10 was synthesised synthesised from the racemic imidazole 6 (0.35 g)  following the 
general alkylation procedure using allybromide in 3 mL of DMF to afford 10 as a brown/ 
grey solid in good yield: 0.47 g (83 %): mp 120-122 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ 
= 9.25 (s, 1H, -CH), 7.83 (s, 1H, -CH), 7.76 (s, 1H, -CH), 7.52 – 7.22 (m, 5H, Ar-H), 
6.03 (ddt, JH,H = 16.1, 10.3, 5.9 Hz, 1H, =CH), 5.29 (ddd, JH,H = 18.3, 13.7, 1.2 Hz, 2H, 
=CH2), 5.01 (dd, JH,H = 8.4, 2.8 Hz, 1H, -CH), 4.90 (d, JH,H = 5.8 Hz, 2H, -CH2), 4.38 
(ddd, JH,H = 22.2, 13.6, 5.9 Hz, 2H, -CH2) ; 
13C-NMR (75MHz, DMSO-d6) δ = 
13C-NMR (75 
MHz, DMSO-d6) δ = 141.1q, 136.5, 131.8, 131.7, 129.0, 128.2, 127.7, 126.9, 126.0, 
123.3, 122.6, 121.9, 120.3(CH2), 120.0(CH2), 70.4, 55.7(CH2), 50.9(CH2), 50.7(CH2); ESI-MS: 
calcd m/z = 229.30 (M+), found m/z = 229.1. 
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1-Ethyl-4-formyl-pyridinium iodide 11 
RTIL 11 was synthesised from pyridine-4-carboxaldehyde (2.64 mL) by alkylating with 
excess ethyliodide (3 mL) in DCM and heating to 50-60 ˚C for 24 hrs. The DCM and 
excess alkyhalide was removed by evaporation to afford 11 in quatitative yield as a RTIL; 
1H-NMR (300 MHz, DMSO-d6) δ= 10.22 (s, 1H, O=CH), 9.35 (d, 
3JH,H = 6.6 Hz, 2H, Ar-
H), 8.50 (d, 3JH,H = 6.2 Hz, 2H, Ar-H), 4.84–4.56 (dq, 
3JH,H =7.3 Hz, 2H, -CH2), 1.54 (dt, 
3JH,H = 7.3, 5.9 Hz, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ= 190.0, 161.4q, 146.4, 
144.4, 126.4, 124.9, 87.5, 57.0(CH2), 55.9(CH2), 16.2(CH3); ESI-MS: calcd m/z = 136.17 
(M+), found m/z = 136.0 (M+). 
 
1-Benzyl-4-formyl-pyridinium chloride  12   
RTIL 12 was synthesised from pyridine-4-carboxaldehyde (4.4 mL) by alkylating with 
excess benzylchloride (10.8 mL) in DCM and heating to 50-60 ˚C for 24 hrs. The DCM 
and excess alkylhalide was removed by evaporation to afford 12 in quatitative yield as a 
RTIL; 1H-NMR (300 MHz, DMSO-d6) δ= 9.37 (d, 
3JH,H = 6.9 Hz, 2H, Ar-H), 8.48 (d, 
3JH,H = 
6.7 Hz, 2H, Ar-H), 7.61-7.36 (m, 5H, Ar-H), 5.96 (s, 2H, -CH2); 
13C-NMR (75 MHz, 
DMSO-d6) δ = 168.6q, 151.3, 139.2q, 134.5, 134.2, 132.9, 53.8(CH2); ESI-MS: calcd m/z 
= 198.24 (M+), found m/z = 198.1 (M+). 
 
Poly-(4-vinylpyridine) 
N-Ethyl-(4-Polyvinylpyridinium iodide) 13 
Ionic salt 13 was synthesised from 0.5 g of 4-PVP following the general alkylation 
procedure using excess ethyl iodide (500 μL) in 2 mL DMF. However, instead of removing 
the DMF by bulb-bulb distillation, the product was precipitated by addition of acetone to 
afford  13 as a a fluorescent yellow/green solid in ~72 % yield (w/w) (0.74 g): mp >350 
˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 8.88 (b, Ar-H), 7.96 (b, Ar-H), 4.56 (b, -CH2), 
  
3.38 (b, -CH), 1.59(b, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 162.3q, 144.2, 126.8, 
55.8(CH2), 34.4(CH), 15.8(CH3).  
 
N-Benzyl-(4-polyvinylpyridinium chloride) 14 
Ionic salt 14 was synthesised from 0.5 g of 4-PVP following the general alkylation 
procedure using excess benzyl chloride (658 μL) in 2 mL DMF. However, instead of 
removing the DMF by bulb-bulb distillation, the product was precipitated by addition of 
acetone product was precipitated by addition of acetone to afford 14 as a brown solid in 
~66 % yield (w/w) (0.61 g): mp >350 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 9.40 (b, Ar-
H), 8.59 (b, Ar-H), 7.74 (b, Ar-H), 7.42 (b, Ar-H), 6.07 (CH2), 3.66 (CH); 
13C-NMR (75 
MHz, DMSO -d6) δ = 163.6q, 144.5, 134.3q, 129.1, 62.1(CH2), 34.0(CH).  
 
N-Butyl-(4-polyvinylpyridinium bromide) 15 
Ionic salt 15 was synthesised from 0.5 g of 4-PVP following the general alkylation 
procedure using excess n-bromobutane (615 μL) in 2 mL DMF. However, instead of 
removing the DMF by bulb-bulb distillation, the product was precipitated by addition of 
acetone product was precipitated by addition of acetone to afford 15 as a purple solid 
which turned brown upon exposure to air in ~64 % yield (w/w) (0.61 g): mp >250 ˚C; 
1H-NMR (300 MHz, DMSO- d6) δ = 9.10 (b, Ar-H), 8.42 (b, Ar-H), 8.05 (b, Ar-H), 4.62 
(b, -CH2), 3.46 (b, -CH), 1.94 (b, -CH2), 1.31 (b, -CH2), 0.90 (b,CH3); 
13C-NMR (75 MHz, 
DMSO-d6) δ 1= 63.0q, 144.5, 127.0, 59.6(CH2), 34.2(CH), 32.3(CH2), 18.9CH2), 13.4(CH3).  
 
N-Ethyl-(4-polyvinylpyridinium iodide) 2 % cross-linked 16 
Ionic salt 16 was synthesised from 1.0 g of 2% cross-linked 4-PVP following the general 
alkylation procedure using excess ethyl iodide (μL) in 10 mL DMF.  However, instead of 
removing the DMF by bulb-bulb distillation, the product was precipitated by addition of 
acetone to afford 16 as a brown glass; yield: 1.7 g (~81 %): mp >350 ˚C; FT-IR (KBr); 
3121, 3038, 2975, 2934, 1970, 1841, 1715, 1640, 1601, 1570, and 1516 cm-1. 
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N-Benzyl-(4-polyvinylpyridinium chloride) 2 % cross-linked 17 
Ionic salt 17 was synthesised from 0.5 g of 2 % cross-linked 4-PVP following the general 
alkylation procedure using excess benzyl chloride (657 μL) in 2 mL DMF. However, 
instead of removing the DMF by bulb-bulb distillation, the product was precipitated by 
addition of acetone to afford 17 as a brown solid in ~77 % yield (w/w) (0.71 g): mp 
>350 ˚C; FT-IR (KBr); 3120, 3040, 2701, 2410, 2106, 1984, 1842, 1638, 1569, 1515 
cm-1. 
 
N-Butyl-(4-polyvinylpyridinium bromide) 2 % cross-linked 18 
Ionic salt 18 was synthesised from 0.5 g of 2% cross-linked 4-PVP following the general 
alkylation procedure using excess n-bromobutane (615 μL) in 2 mL DMF. However, 
instead of removing the DMF by bulb-bulb distillation, the product was precipitated by 
addition of acetone to afford 18 as a solid in ~68 % yield (w/w) (0.65 g): mp >350 ˚C; 
FT-IR (KBr) 3121, 3012, 2961, 2937, 2874, 2744, 2619, 2059, 1866, 1640, 1570, 1516 
cm-1.  
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2.2 Synthesis of 2,4,5-triphenylimidazolinium ionic liquids 
2.2.1 Introduction 
The synthesis of enantiomerically pure compounds is an important and an intensely 
pursued undertaking in organic chemistry.10 This increasing need for pure enantiomers is 
coupled with an increasing awareness of the differences in molecular interaction between 
living organisms and two enantiomeric substances which result from the chirality of 
receptors, enzymes and other functionalities sited in living organisms. Chemical and 
pharmaceutical companies are obligated to demonstrate and investigate the differences 
in activity of the stereoisomers of racemic drugs and other bioactive compounds for 
environmental and commercial reasons.11 This need to analyse and investigate the 
individual enantiomers of a widening array of chiral compounds has lead to an increase in 
demand for a wider range of chiral selectors for analysis and/or separation of chiral 
compounds. The demand can in part be met by enantioselective gas chromatography 
(GC) and the design of new chiral selecting agents for utilisation in stationary phases in 
order to separate enantiomers.  
NHN
NH2H2N NH2H2N
trans-(+/-)- 2,4,5-triphenyl
imidazoline
SS RR
Stilbenediamine
3 steps
 
Figure 2.13: 3 step ring opening of trans-2,4,5-triphenylimidazoline to produce (R,R) 
and (S,S) enantiomers of stilbenediamine. 1) DCC, DCM. -20 ˚C to r.t, 5 hrs. 2) HCl, 
H2O, THF, reflux 2 hrs. 3) HBr, AcOH, reflux 24 hrs.
12 
  
  
On the other hand, the design of catalysts which provide high stereoselectivity in 
reactions is an emerging field of modern organic chemistry. For this purpose, researchers 
are carrying out extensive studies to discover new complex forming ligands which can be 
easily modified.13 From this point of view, 1,2-ethylenediamine derivatives have 
generated considerable interest. The enantiomers of these diamines have been employed 
for stereoselective synthesis in various reactions. Enantiopure C2-symmetrical 1,2-
diphenylethane-1,2-diamines (stilbenediamine Figure 2.13), (1S,2S) and (1R,2R), and 
their N-modified derivatives have been widely incorporated into diverse reagents for 
highly asymmetric dihydroxylation,14 allylation,15 propargylation16 and aldol17 reactions. 
Moreover, they have been used as ligands in important catalytic asymmetric processes 
such as ruthenium-catalysed hydrogenation of ketones,18-20 manganese-catalysed 
epoxidation of alkenes,21,22 aluminium-catalysed Diels–Alder reactions23,24 and 
magnesium-catalysed merged enolisation-aminations.25  However, the range of vicinal 
diamines is presently limited to 1,2-diphenyl-ethylene-1,2-diamine (stilbenediamine 
Figure 2.13) and their derivatives. Since a general method for the synthesis of vicinal 
diamines is lacking.  
 
The utility of the (R,R) and (S,S) enantiomers of stilbendiamine in asymmetric synthesis 
has stimulated the development of a number of new processes for their preparation.26 As 
the resolution of racemic (+/-)-stilbenediamine can be carried out efficiently to produce 
the two pure enantiomers,26-29 the principal need is for a very simple and economical 
synthesis of the racemic stilbenediamine. The most effective process by which these 
diamines can be produced is via the synthesis of amarine and iso-amarine (cis- and 
trans-2,4,5-triphenylimidazoline). Extensive research has gone into devising methods for 
the synthesis of cis- and trans-2,4,5-triarylimidazolines from which 1,2-diaryl-ethylene-
1,2-diamines can be derived via ring opening of the imidazolines to produce derivatives 
of vicinal diamines (Figure 2.13). However, we have foreseen the potential to exploit 
these chiral imidazolines for the synthesis of new chiral imidazoline ionic liquids. 
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Very few chiral imidazolinium ionic liquids have been reported.5,6 Examples of this 
emerging class of chiral imidazoline based ionic liquids remain scarce compared to other 
types of chiral ionic liquids.7,8 Here, the synthesis of new chiral 2,4,5-triphenylimidazoline 
based ionic salts from trans 2,4,5-triphenyimidazoline (iso-amarine) and their potential 
application as chiral selecting agents was investigated.  
 
2.2.2 Results and Discussion: 
trans (+/-)-2,4,5-Triphenyimidazoline (iso-amarine) captured our interest because of it’s 
inherent stereochemistry, it has two chiral centers and is synthesised as a racemic 
mixture consisting of (RR) and (SS) enantiomers. From these enantiomers there is the 
potential for application in the synthesis of new enantiomerically pure chiral ionic salts. 
The iso-amarine was synthesised from benzaldehyde, the enantiomers isolated, and 
ultimately utilised in the synthesis of new chiral trans (4R5R)-2,4,5-
triphenyimidazolinium ionic liquids. As well as the synthesis of 2,4,5-triphenylimidazole 
based ionic salt analogues of the 2,4,5-triphenylimidazolines.  
 
Hydrobenzamide (1,3,5-triphenyl-2,4-diazapentadiene) 19 
Research began with the synthesis of 1,3,5-triphenyl-2,4-diazapentadiene 
(hydrobenzamide 19, see Figure 2.16), from readily available benzaldehyde. 
Hydrobenzamide is an important intermediate because the two imidazolines (20 and 21) 
and imidazole 22, the precursors required to synthesise ionic salts, can be directly 
synthesised from hydrobenzamide in a one-step reaction by varying the reaction 
conditions and in the case of 20 and 21 with high stereo-specificity. The versatility of 
hydrobenzamide and the high stereospecificity with which it can be converted to 20 and 
21 makes it a highly desirable starting material from which to synthesis the desired 
imidazolines and imidazoles.  
 
There are various methods for synthesising amarine from hydrobenzamide, but the 
simplest and cleanest method was described by Williams and Bailar27 whereby 
  
hydrobenzamide 19 is converted to amarine in high yields. Hydrobenzamide was 
synthesised by the addition of distilled benzaldehyde to excess liquid ammonia at -78 ˚C, 
and the solution allowed to warm to room temperature.27 When the mixture was left to 
stand at room temperature the ammonia evaporated leaving the product as a white 
crystalline solid which was used without further purification. However, if required, 19 can 
be further purified by recrystallisation from cyclohexane to afford the purified crystalline 
product in 89 % yield.  
 
Amarine (cis-2,4,5-triphenylimidazoline) 20 
As shown in Figure 2.16, amarine was prepared by cyclising 19 either with a strong base 
or under thermal conditions. Under thermal conditions amarine was prepared by heating 
neat hydrobenzamide between 90-120 ˚C in a kugelrohr under negative pressure (10-2 
Torr) for 4-6 hrs.30 The resultant product was obtained in high yield (98 %) in a very 
pure state and could be used without further purification for synthesising iso-amarine. 
Treatment of hydrobenzamide with a strong base such as n-butyllithium or potassium-t-
butoxide (t-BuOK) afforded amarine in excellent yields (Table 2.2). 
Base catalysed cyclisation of hydrobenzamide with 0.4 N potassium-t-butoxide in t-
butanol at 60 ˚C for 1 hour led to immediate conversion to amarine, with isomerization 
occurring with a very high degree of stereospecificity to give exclusively the less stable 
isomer amarine via an anionic intermediate.31 The stereospecific formation of 2,4,5-
triphenylimidazolines occurs via an electrolytic pericyclic ring closure which involves the 
cyclisation of the conjugated polyene hydrobenzamide via a 2,4-diazapentadienyl anion. 
The intermediacy of a carbanion was suggested by the observation of a deep blue colour 
upon treatment of hydrobenzamide in tetrahydrofuran with 0.4M n-butyllithium at -78 
˚C.31 Upon warming to room temperature the blue colour faded to a light yellow 
appearance. 
 
The anionic intermediate shown in Figure 2.14 accounts for the interconversion between 
amarine and iso-amarine.31 Although multiple geometries are available for the anionic 
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intermediate, the most stable geometry required for cyclization is a U-shape.32-34 
Conrotatory cyclization (maintaining an axis of symmetry) of this ionic intermediate leads 
to iso-amarine while the disrotatory motion (plane of symmetry) produces amarine.  
N N
Ar
Ar Ar  
Figure 2.14: Anion intermediate U-shape 
 
Pericyclic reactions occur by a concerted process in which all bonding changes occur 
simultaneously in a single step. For bond formation to take place, the outermost π-bond 
must rotate so that favourable bonding interaction is achieved, a positive lobe with a 
positive lobe, or a negative lobe with a negative lobe. If two lobes of like signs are on the 
same side of the molecule, the two orbitals rotate in the opposite directions. This kind of 
motion is referred to as disrotatory. Conversely, if lobes of like sign are on opposite sides 
of the molecule, both orbitals rotate in the same direction, either clockwise or counter 
clockwise by controtatory motion. 
 
Simple orbital symmetry considerations lead to the prediction that a disrotatory process 
is preferred for the ground electronic state of the carbanion. Thus orbital symmetry 
control in the cyclization of the U-shaped anion is consistent with the observed dominant 
formation of the less stable amarine.31 Orbital symmetry further predicts that a planar π, 
π* state would preferentially produce iso-amarine by conrotatory motion.31 
 
N N
Ar
Ar Ar
N NH
Ar
Ar Ar
N N
Ar
Ar Ar
Disrotatory Conrotatory
(+/-)- amarine (+/-)- iso-amarine
 
Figure 2.15: Pericyclic ring closure cyclisation mechanism. 
 
 
  
Iso-amarine (trans-2,4,5-triphenylimidazoline) 21  
In addition, to being prepared from hydrobenzamide 19, iso-amarine 21 can also be 
prepared from isomerisation of its meso isoform amarine 20 as illustrated in Figure 2.16 
(a). By changing the reaction conditions (basic or thermal) one can obtain either the cis 
or trans isomer as shown in Figure 2.16. Under basic conditions amarine is isomerised 
into iso-amarine (Figure 2.16 (b)) by deprotonation by a strong base (such as t-BuOK in 
t-BuOH or NaOH in diethylene glycol) forming a delocalised benzylic anion intermediate, 
which then cyclises by a conrotatory pericyclic ring closure to give trans-2,4,5-
triphenylimidazoline as a racemic mixture of SS and RR enantiomers. Isomerisation can 
be accomplished by boiling cis-2,4,5-triphenylimidazoline in a solution of sodium 
hydroxide, water, and diethylene glycol at 155 ˚C for 45 minutes during which a sodium 
salt of iso-amarine precipitates forming a thick slurry (Figure 2.16 (d)). The slurry was 
allowed to cool then treated with glacial acetic acid dissolving most of the product. 95 % 
Ethanol was then added and the solution was heated under reflux. Then allowed to cool 
and neutralised with excess concentrated ammonia to afford the product as a tan 
crystalline precipitate in 62 % yield. Alternatively, iso-amarine can be synthesised 
directly from Hydrobenzamide by heating at 60 ˚C with t-BuOK in THF for 2 hrs in 88 % 
yield (Figure 2.16 (c)).35  
 
Iso-amarine was also prepared from hydrobenzamide 19 on a smaller scale by 
microwave irradiation of 19 at 500 W with 1.0 molar equivalent of t-BuOK in t-BuOH for 
5 minutes produced iso-marine 21, and amarine 20 was produced upon irradiation for 2 
minutes, thereby drastically reducing the reaction times required by conventional heating 
from 6 hours to just minutes.36 
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Figure 2.16: Synthesis of hydrobenzamide 19 from benzaldehyde in liquid ammonia, 
and the cyclisation to 2,4,5-triphenylimidazolines 20 and 21. a) Benzaldehyde in excess 
liquid ammonia at -78 ˚C, b) kugelrohr 120 ˚C for 6 hrs at 10-2 Torr, c) t-BuOK in 
anhydrous THF at 60 ˚C 2 hrs, d) Diethylene glycol H2O/NaOH at 155 ˚C for 45 mins, e) 
Swern oxidation, and f) Kugelrohr 140-160 ˚C for 5 hrs at 10-2 Torr. 
 
Without a doubt the quickest method of preparing amarine and iso-amarine in small scale 
is by microwave irradiation. This method has proved to be quick, 2 minutes for amarine 
and 5 minutes for iso-amarine, highly stereospecific and affords the products in good 
yield (67 %). 
However, the most effective and efficient method of preparing amarine and iso-amarine 
on large scales is via conventional heating under basic conditions. Although the reaction 
times take 1-6 hours, the product is formed in high yield with high stereospecificity. The 
thermal cyclisation of 19 was also found to be a very clean and efficient method of 
synthesising amarine on larger scales. With microwave irradiation the cis:trans product 
  
ratio can vary with scale up of the reaction, understandably due to the very short time in 
which the reactions are run. Isomerisation of cis to trans is dependant on the base used 
for the cyclisation, the reaction temperature, and, for microwave irradiation, the reaction 
time. 
 
Product characterisation 
2,4,5-triphenylimidazolines have been studied extensively with respect to structure 
elucidation.27  The cis- and trans- isomers can be readily identified from their C4 and C5 
proton 1H NMR signals. The proton signals from C4 and C5 differ for the cis- and trans-
isomers whereby the cis-2,4,5-triphenylimidazoline proton signal is downfield shifted at δ 
5.31 ppm compared to trans-2,4,5-triphenyimidazoline at δ 4.79 ppm, in addition their 
C4 and C5 13C-NMR chemical shift are δ 70.60 ppm and δ 74.62 ppm, respectively. The 
determined configuration of the imidazoline isomers from NMR spectrum were validated 
by the observed differences in their melting point temperatures, which is higher for the 
trans-isomer (202 ˚C) compared to cis-isomer (129-130 ˚C), which is consistant with the 
literature (198-201 ˚C and 128-131 ˚C, respectively).27  
 
Once the target compound (+/-) iso-amarine was synthesised, the next challenge was to 
isolate the individual enantiomers (RR) and (SS). The most desirable way for obtaining 
enantiomerically pure substances is by the enantioselective synthesis. However, this is 
not always feasible as was the case with iso-amarine. Fractional crystallization is an 
efficient and practical method for obtaining optically pure compounds from a 
conglomerate mixture of chiral compounds. Diastereomeric crystallization is a classic 
method and also the most widely applied for resolving racemic compounds. Acidic or 
basic racemates such as carboxylic acids and amines, are most applicable for this method 
as they readily react with an optically active amine or carboxylic acid counterpart to 
afford a pair of diastereomeric salts. Here, (S)-Mandelic acid was used as the enantiopure 
resolving agent.  
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Figure 2.17: Fractional cystallization: a) Reflux (+/-) iso-amarine and (S)-mandelic acid 
in iso-propanol for 1 hr. b) Cool to 0 ˚C for crystallization and salt isolation. c) Treat with 
1N aqueous NaOH to remove mandelic acid. 
  
When racemic iso-amarine 21 was refluxed with (S)-mandelic acid, a pair of 
diastereomeric salt derivatives formed (Figure 2.17). These diastereoisomers differ in 
their chemical and physical properties, therefore, the diastereomeric salt crystals could 
be separated by fractional crystallization and their respective iso-amarine enantiomers 
were recovered by decomposing by treatment with an aqueous solution of NaOH. 
 
Imidazoline ionic salts 
Once the SS and RR enantiomers of iso-amarine were isolated, they were then 
transformed into ionic salts by alkylation with an alkyl halide. Under a nitrogen 
atmosphere to a stirring solution of imidazoline in dry DMF was added excess alkyl halide 
and heated for 6 hrs at 90 ˚C. The resulting solution was concentrated in vacuo. The 
remaining residues of DMF were removed by bulb-to-bulb distillation using a kugelrohr 
apparatus to afford the ionic salt as a glass and further purified by re-crystallisation from 
ethyl acetate and n-hexane to afford a white crystalline salt.  
 
Table 2.2: Melting points and yields of the imidazolines synthesized and their ionic salts.  
Compounds* mp ˚C Yield % 
20 129-132 98a  
23 202-204 91 
24 228-233 74 
25 144-46 83 
21 202 88 
26 78-80 98 
27 190-3 85 
28 79-81 92 
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a Thermal cyclization reaction at 120 ˚C under vacuum in a kugelrohr. *Refer to Figure 
2.21 for their chemical structures. 
 
NN
(RR)- 26-28
X
NHN
RX/ DMF
 90
o
C 6hrs
(RR)-21
RR
 
Figure 2.18: Alkylation reaction, heat imidazoline with excess alkyhalide in DMF at 90 
˚C for 6 hrs. 
 
From the resonance structures (Figure 2.19) of 2,4,5-triphenylimidazoline the imine 
nitrogen acts as an electron withdrawing group (EWG) by resonance effect through the π-
bond delocalisation, stabilising the resultant anionic nitrogen thus, increasing the basicity 
of the amine making it a stronger nucleophile. 
NH
C
NNH
C
N NH
C
N NH
C
N
 
Figure 2.19: Resonance structures of (R,R)-2,4,5-triphenylimidazoline 21. 
 
Substituents with electron-withdrawing resonance effect on a benzene ring have the 
general structure illustrated in Figure 2.20 with a more electronegative Z atom attached 
to a less electronegative Y atom.  
Y
Z 
  
  
Figure 2.20: General structure of substituent with electron-withdrawing group attached 
to a benzene ring. 
 
As a consequence the nitrogen acts as an EWG by resonance effects, when one 
equivalence of alkylhalide is used in the alkylation reaction a mixture of di- and mono-
alkylated imidazolines are formed. The reaction proceeds to the di-alkylated product due 
to the increased resonance/nucleophilicity of both N atoms. The mono-substituted 
product can be isolated by chromatography separation from the mixture but in relatively 
low yield. As a result of the low yield the mono-substituted product was not isolated and 
only the N,N’-dialkyl-2,4,5-triphenylimidazolinium ionic salts were synthesised (Figure 
2.21).  
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26 (95%) 27 (85%) 28 (92%)
29 (84%) 30 (78%) 31 (75%)
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Figure 2.21: Ionic compounds synthesised from alkylation of the 2,4,5-
triphenylimidazoline 20 and 21, and lophine 22. (* synthesised with t-BuOK in 
anhydrous THF at 60 ˚C 2 hrs) 
 
NMR analysis of cis N,N’-diethyl-2,4,5-triphenylimidazolinium iodide ionic liquid 23 
reveals a symmetrical structure (Figure 2.22). The NMR spectrum in the aliphatic region 
can be explained if the methylene (CH2) protons are diastereotopic (that is chemically 
and magnetically non-equivalent) due to the two chiral carbons in the imidazoline ring. 
Geminal coupling of protons on a saturated carbon having different chemical shifts 
commonly occurs in a chiral molecule with a tetrahedral stereocenter adjacent to a 
methylene group. The geminal protons are labeled Ha and Hb and have chemical shifts of 
δ 3.15 ppm and δ 3.37 ppm appearing as sextets (Fiure 2.22). These protons split each 
other into doublets which are then split by methyl CH3 protons into quartets with 
coupling constants 14.4 Hz and 7.3 Hz. The larger coupling constant is typical of geminal 
coupling and the small split typical of vicinal coupling. The sextet observed is actually 2 
overlapping quartets while the methyl group is a triplet with a coupling constant of 7.3 
Hz. 
 
The structure of N,N’-diethyl-2,4,5-triphenylimidazolinium iodide 23 is more accurately 
depicted as a resonance form, in which each of the nitrogens in the imidazoline moiety 
share half the positive charge making the molecule symmetrical. This symmetry is 
observed through the chemical shift equivalences observed for both ethyl groups in both 
the 13C- and 1H-NMR spectra, as well as the single peak observed for both the C4 and C5 
methine carbons at δ 67.6.  
  
 
 
Figure 2.22: NMR spectrum of cis-(+/-)-N,N-diethyl-2,4,5-triphenylimidazolinium iodide 
23 in CDCl3. iv) 
1H-NMR spectra with an expansion of the apparent sextets (which are 
actually overlapping double quartets), i) 13C-NMR spectra showing DEPT135 (iii) and 
DEPT90 (ii) experiments. 
  
This is confirmed by HH-COSY in which methylene Ha and Hb protons are correlated to 
one another as well as to the methyl protons of the ethyl substituent (Figure 2.23).  
N N
I
R S
CH3H3C
HbHa
HH
HaHb
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Figure 2.23: 2D NMR spectra of cis N,N-diethyl-2,4,5-triphenylimidazolinium iodide in 
CDCl3. Determination of HH connectivity by HH-COSYGPSW analysis. 
 
These chiral ionic salts have a symmetrical structure, thus to reduce this symmetry a 
more selective method for the differential substitution of the two amines was employed. 
As it has proved to be a challenge to selectively alkylate the secondary amine on 2,4,5-
triphenylimidazolines without alkylating the tertiary (imine) amine, an alternative method 
of differential substitution of amine using a more selective method typically employed for 
forming peptide bonds was adopted.  
 
N-acyl-N’-alkyl-trans-2,4,5-triphenylimidazolines 
A very useful method of forming peptide or other amide bonds was reported by Sheenan 
and Hess in 1955.37 The two components, one containing a free carboxyl function and the 
other a free amino group, couple directly and rapidly in high yield on treatment with 
  
N,N'-dicyclohexylcarbodiimide at room temperature. DCC is a highly selective 
dehydrating coupling agent and this remarkable selectivity is attested to by the 
successful use of carbobenzoxyserine as an acylating moiety without the need to protect 
its hydroxyl group. In addition, no racemization has been detected when employing DCC 
as the coupling agent with optically active amino acids. This is also advantageous when 
using enantiomerically purified iso-amarine as the starting material as this would permit 
the differential substitution of the amine without racemisation of iso-amarine taking place 
during the reaction. 
 
This method was used for the enantiomeric separation of trans-(+/-)-2,4,5-
triphenylimidazoline by forming diastereoisomers with enantiomerically pure (S)-amino 
acids as illustrated in Figure 2.24.12 Not only was this method used for the separation of 
the (RRS)-32b and (SSS)-32a diastereoisomers of trans-2,4,5-triphenylimidazoline, but, 
it was also applied as a tool for asymmetrically derivatising the enantiomerically purified 
trans-(4R,5R)-2,4,5-triphenylimidazoline permitting the synthesis of a wide variety of 
novel imidazolines with various mono-N-substituents to be synthesised from one isomer 
of iso-amarine (Figure 2.26). These compounds are not only desirable for the synthesis 
of new asymmetrically substituted trans-(4R,5R)-2,4,5-triphenylimidazolinium ionic salts, 
but, they may also possess potential applications as imidazoline-based drugs for various 
therapeutic targets.38 
 
To a solution of (+/-)-trans 2,4,5-triarylimidazoline and N-acyl amino acid (or any 
carboxylic acids) in DCM at -78 ˚C under nitrogen was added N,N'-
dicyclohexylcarbodiimide (DCC). The reaction mixture was allowed to warm to room 
temperature and left to react for 5 hours. During which the carbodiimide precipitated out 
of solution as a white solid which was then removed by filtration. The filtrate was 
collected and DCM was removed under reduced pressure to afford the crude product as a 
solid mixture of imidazoline diastereoisomers at 96 % yield. The diastereoisomers were 
isolated by column chromatography (46 % yield). 
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Figure 2.24: Selective acylation of the secondary amine of iso-amarine. DCC mediated 
acylation reaction with an N-acetylphenylalanine to form the diastereoisomers 32a and 
32b plus N,N’-dicyclohexylurea, which were isolated by flash chromatography. 
 
Figure 2.25 illustrates how dicyclohexylcarbodiimide was used to convert the carboxylic 
acid from an amino acid into a reactive acylating agent which could then undergo 
nucleophilic acyl substitution with amines. The carboxylic acid from the amino acid first 
adds to one of the double bonds of the carbodiimide to give O-acylisourea which is a very 
reactive acylating agent resembling carboxylic acid anhydrides. Then the nucleophilic 
amine from the imidazoline attacks at the carboxyl carbon on the O-acylisourea yielding 
a tetrahedral intermediate. The intermediate then dissociates to an amide losing N,N’-
dicyclohexylurea as a co-product. The co-product, N,N'-dicyclohexylurea, has a very low 
solubility in most organic or aqueous solvents, and is easily separated by precipitation. 
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Figure 2.25: Reaction mechanism for the nucleophilic acyl substitution with trans (+/-)-
2,4,5-triphenylimidazoline. 
 
Using this method it was possible to couple the carboxylic acids of N-acetylphenylalanine, 
N-benzoylhistidine derivatives, and (S)-mandelic acid to trans-(4R,5R)-2,4,5-
triphenylimidazoline. Glutamic acid having two carboxylic acid groups allowed for the 
coupling of 2 imidazolines to the one amino acid to afford the bis-2,4,5-
triphenylimidazoline 39 (Figure 2.27).  
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Figure 2.26: Compounds synthesised by DCC mediated coupling. 
 
The tertiary amines of the mono-N-substituted trans-2,4,5-triphenylimidazolines were 
then alkylated with an alkylhalide by refluxing in DMF at 90 ˚C to afford differentially 
substituted trans-2,4,5-triphenylimidazoline ionic salts. 
 
  
NN
(SRR)-37b 97%
NHAc
O
NN
(RRSRR)-39 96%
NHBz
O
N
O
N
NN
(SRR)-38 88%
NHBz
O
N
N
Cl
* *
*
NN
(SRR-SRR)-40 81%
NHBz
O
N
N Cl*N N
NHBz
O
N
N *Cl
I
I
I I
I
I
NN
(SSS)-37a 97%
NHAc
O
*
I
 
Figure 2.27: Differentially substituted trans-2,4,5-triphenylimidazoline ionic salts. 
 
Following the successful synthesis of chiral cis- and trans-2,4,5-triphenylimidazoline 
based ionic salts we endeavoured to synthesise their achiral imidazole based ionic liquid 
analogues from lophine (2,4,5-triphenylimidazole). These achiral analogues would be 
particularly interesting for studying the effect of the chiral centres if these novel 
imidazolines are found to possess potential applications as imidazoline-based drugs for 
therapeutic targets. 
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Lophine 
Lophine (2,4,5-triphenylimidazole) was synthesised from amarine by Swern oxidation 
(Figure 2.28) or under thermal conditions.30 The overall transformation that takes place 
in the formation of lophine is an oxidation of the imidazoline ring [elimination of 2 H 
atoms]. However, given that H is not a good leaving group, either the C or N of cis-2,4,5-
triphenylimidazoline must have an attached H replaced by a leaving group before an 
elimination reaction can take place. Given that the N of the imidazoline is nucleophilic 
under basic conditions, the elimination reaction can take place first by attachment of a 
leaving group to N of the imidazoline, and then proceeds to a retro-hetero-ene 
elimination reaction.   
N
H
N
Ph
Ph
Ph
Oxalyl chloride
  DMSO/Et3N
-78
o
C/ 24hrs
N
H
N
Ph
Ph
Ph
20
DCM
22  
Figure 2.28: A scheme for the synthesis of Lophine by Swern oxidation and the 
resultant side products. 
 
When 2,4,5-triphenylimidazoline is treated with a reaction mixture derived from oxalyl 
chloride, DMSO, and triethylamine (Et3N), it is oxidized. And it is important to note that 
the order of addition of these reagents is critical. The role of oxalyl chloride is to activate 
the DMSO. Activation of DMSO with oxalyl chloride produces an unstable chlorosulfonium 
salt intermediate (an electrophile) which ultimately becomes a leaving group when 
attached to the imidazoline N.  
 
First oxalyl chloride was added to DMSO at -60 ˚C. DMSO is nucleophilic on the oxygen 
and reacts with the electophilic oxalyl chloride by addition-elimination displacing a 
chloride (Figure 2.29).  
  
H3C
S
H3C
O
Cl
O
Cl
O H3C
S
H3C
O
Cl
O
Cl
O H3C
S
H3C
O
O
Cl
O
Cl
CH3
S
CH3
Cl
Cl
C
O
O
C
O
chlorosulfonium salt
unstable above 
       -60oC
 
Figure 2.29: Addition-elimination reaction of DMSO with oxalyl chloride to form the 
dimethylchlorosulfonium chloride intermediate plus CO2 and CO gases. 
 
The sulfur now having a good leaving group is attacked by the eliminated Cl-, displacing 
the oxalate, which decomposes to give off CO2, CO and produces 
dimethylchlorosulfonium chloride, in which the sulfur is a good electrophile. Then 2,4,5-
triphenylimidazoline and Et3N were added, and the reaction mixture was allowed to warm 
to room temperature. The imidazoline N-H is deprotonated by Et3N and the resultant 
nucleophilic N anion attacks the sulfur on dimethylchlorosulfonium chloride, displacing 
the chloride forming a sulfonium ion intermediate (Figure 2.30).  
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Figure 2.30: The nucleophilic attack by the imidazoline N anion on the electrophilic 
dimethylchlorosulfonium chloride to form the bis-sulfonium salt intermediate. 
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Now there’s a good leaving group attached to the nitrogen of the imidazoline, so 
elimination ensues. In the currently accepted mechanism, the elimination ensues by a 
retro-hetero-ene reaction (Figure 2.31). 
 
Retro-hetero-ene reaction is a subclass of an ene reaction, one of four major classes of 
pericyclic reactions. Retro-hetero-ene reactions are used in some elimination procedures, 
which occurs through a concerted retro-ene mechanism. These reactions are driven by 
the gain in entropy, by charge neutralisation and sometimes by cleavage of a weak σ-
bond (eg N-S) in favour of a C=C π-bond. All retro-hetero-ene reactions involve a 1,2-
dipole such as a sulphur ylide, whereby the CH3 attached to sulphur is deprotonated by 
Et3N to give a sulphur ylide. Ylides are neutral dipolar molecules that have two oppositely 
charges atoms directly bonded to each other, each with an octet of electrons. The 
electron distribution of the ylide is highly polarised toward the carbon making the carbon 
electron rich. The carbon has much of the character of a carbanion and acts as a 
nucleophile toward the H in the imidazoline ring. The nucleophilic carbon attacks the 
imidazoline ring proton creating a five membered ring transition state. The ensuing 
reaction result in the formation of a new C=N and the decomposition of the sulphur ylide 
by cleavage of the N-S σ-bond releasing 2 molecules of dimethylsulfide (Me2S). 
 
The tertiary nitrogen also acts as a nucleophile, which also attacks the 
dimethylchlorosulfonium chloride displacing the chloride forming the second sulfonium 
ion intermediate (Figure 2.31). Elimination ensues via the retro-hetero-ene reaction, to 
afford the imidazole product lophine in 74 % yield (mp 272-273 ˚C) and Me2S, CO2, CO, 
and Et3NH
+Cl- as side products. 
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Figure 2.31: Retro-hetero-ene elimination reaction mechanism. 
 
Lophine can also be synthesised under thermal conditions from amarine by heated to 160 
˚C for 6 hrs under negative pressure (0.01-0.05 mbar) to afford lophine as the 
dehydrogenation product,30 as well as via various methods by microwave irradiation.39-43 
Lophine was then alkylated with excess alkylhalide by refluxing in DMF at 130-140 ˚C to 
afford the N,N-dialkyl-2,4,5-triphenylimidazolium ionic liquids 29-31 (Figure 2.21) in 75-
84 % yields.  
 
2.2.3 Conclusion 
The synthesis of new 2,4,5-triphenylimidazoline based ionic salts from cis- (20) and 
trans-(+/-)-2,4,5-triphenyimidazoline (21) have been prepared and the individual (RR) 
and (SS) enantiomers of trans-2,4,5-triphenyimidazoline 21 separated by fractional 
crystallisation with (S)-mandelic acid. From the enantiomerically purified (4R,5R)-2,4,5-
triphenylimidazoline 21, (4R,5R)-N,N’-dialkyl-2,4,5-triphenylimidazolinium halide ionic 
liquids were synthesised by alkylation with alkyl halides. The reaction proceeded to the 
N,N’-diakylated rather than the monoalkylated product due to the increased 
nucleophilicity of the tertiary amine. 
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To overcome the problem of imidazoline N,N’-dialkylation DCC mediated peptide bond 
formation method was used for differentially derivatising the trans-(+/-)-2,4,5-
triphenyimidazoline 21 nitrogens with the amino acid N-acetylphenylalanine followed by 
the separation and isolation of the resultant (RRS)-32b and (SSS)-32a diastereoisomers. 
This method was applied both as a tool for selective derivation as well as a means for the 
formation of diastereoisomers from trans-(+/-)-2,4,5-triphenyimidazoline 21 which can 
be isolated by column chromatography. Using this method a large variety of imidazolines 
were synthesised, compounds which may also possess potential applications as 
imidazoline-based drugs for various therapeutic targets. The chiral ionic salts 
subsequently synthesised from these imidazolines hold potential for application in 
biological, chemical, or industrial settings. Their potential application as chiral selecting 
agents for GC station phases will be explored in chapter 3.  
 
 
 
 
 
 
 
 
  
 
2.2.4 Experimental 
2.2.4.1 Reagents:  
N-Benzoyl-(L)-histidine, N-acetyl-(L)-phenylalanine, ammonia (gas),  concentrated 
aqueous ammonia, benzaldehyde, benzyl chloride, n-bromobutane, cyclohexane, 
diethylene glycol, dicyclohexylcarbodiimide (DCC), DCM, DMF, 95 % ethanol, ethyl 
acetate, ethyl iodide, glacial acetic acid, n-hexane, iso-propanol, (S)-(+)-mandelic acid, 
methanol, MgSO4, Na2CO3, oxalyl chloride, potassium-t-butoxide, sodium hydroxide, THF, 
and triethylamine. All chemicals were purchased from Sigma Aldrich. 
 
2.2.4.2 Instruments 
Ionic salts were characterised by NMR, ESI-MS, and melting point. 1H and 13C-NMR data 
were recorded on a Bruker 300 spectrometer and the chemical shift values were recorded 
in ppm. All NMR structure elucidation was done from 1H-NMR, 13C-NMR, DEPT135, 
DEPT90, HSQCGP, and HH-COSYGPSW experiments. Mass spectroscopy data were 
obtained by Electro spray ionization (model) in positive ion mode (in 1:1 acetonitile/ 
H2O). Melting points were measured with a Gillkhenhamp Melting point apparatus 
(manufactures in England) and are uncorrected.  
 
2.2.4.3 Synthesis: 
Synthesis of N,N’-di(phenylmethylidene)phenylmethane (Hydrobenzamide) 19 
Hydrobenzamide 19 was prepared by the procedure as outline by Williams and Bailar.27  
Distilled benzaldehyde (10 g, 0.094 M) was added to an excess amount of liquefied 
ammonia at -78 ˚C. The solution was stirred and allowed to warm to room temperature. 
The mixture was allowed to stand until the ammonia evaporated, and the crude product 
was purified by recrystalization from cyclohexane to afford 19 as a white crystalline solid 
in good yield: 8.9 g (95 %): mp 97-100 ˚C; 1H-NMR (300 MHz, CDCl3-d) δ= 8.64 (s, 2H, 
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N=CH), 7.90 (m, 4H, Ar-H), 7.65 (d, 2H, Ar-H), 7.60-7.33 (m, 9H, Ar-H), 6.72 (s, 1H, 
N=CH=N); 13C-NMR (75MHz, CDCl3-d) δ = 160.8, 141.9q, 136.1q, 131.1, 129.8, 128.0, 
127.9, 127.4, 92.7; ESI-MS: calcd m/z = 299.39 (M+H+), found m/z = 299.2 (M+H+).  
 
Synthesis of cis-2,4,5-triphenylimidazoline (amarine) 20 
Following the Chou et al.30 procedure, hydrobenzamide (5 g, 16.76 mM) was cyclised to 
form 20 in a bulb-to-bulb distillation chamber by heating at 120 ˚C for 5 hrs at a 
constant pressure of 10-2 Torr to afford a yellow glass which was used in further reactions 
without further purification  in good yield: 4.9 g (98 %): mp 129-132 ˚C; 1H-NMR (300 
MHz, CDCl3-d) δ= 7.87 (d, 2H, Ar-H) , 7.48-6.81 (m, 13H, Ar-H), 5.31(s, 2H, NCH); 
13C-
NMR (75MHz, CDCl3-d) δ= 164.7q, 138.8q, 131.3, 129.7q, 128.8, 128.7, 128.4, 127.7, 
127.5, 127.4, 126.9, 70.6; ESI-MS: calcd m/z = 299.39 (M+H+), found m/z = 299.2 
(M+H+). 
 
Synthesis of (+/-) trans-2,4,5-triphenylimidazoline (iso-amarine) 21 
Racemic iso-amarine was prepared following the procedure as reported by Williams and 
Bailar.27  A stirred solution of amarine (11.6 g, 0.039 M), diethylene glycol (7.9 mL), 
water (15 mL) and 2.5 g of sodium hydroxide was boiled in a beaker until temperatures 
reached 155 ˚C. The temperature was maintained at 155 ˚C for 45 minutes, during 
which time the sodium salt of iso-amarine precipitated and the solution becames a thick 
slurry. The slurry was allowed to cool, followed by treatment with glacial acetic acid (5.7 
g). When most of the product had dissolved, 95 % ethanol (25 mL) was added and the 
solution heated to boiling. After cooling, the solution was neutralized with excess 
concentrated aqueous ammonia. Iso-amarine precipitated slowly as a mass of light tan 
crystals, which was filtered and washed with cold 95 % ethanol to afford 21 in 62 % 
yield. 
Alternatively, iso-amarine was prepared by a modified procedure of Lozinskaya et al.35 in 
which hydrobenzamide (5 g, 16.76 mM) was dissolved in anhydrous THF (50 mL) and the 
solution placed under nitrogen. Potassium-t-butoxide (1.5 g, 13 mM) was added to the 
  
vigorously stirring solution, resulting in an intense blue colour change. The mixture was 
heated to 60 ˚C for 24 hrs and the reaction stopped by the addition of a triple excess of 
cold water. The product was extracted with ethyl acetate dried with MgSO4, and filtered. 
The solvent was removed under negative pressure to afford 21 as a white solid in good 
yield: 4.4 g (88 %): mp 202 ˚C; 1H-NMR (300 MHz, CDCl3) δ= 7.89-7.82 (m,
 JH,H = 8.29, 
6.97, 1.32 Hz, 2H, Ar-H), 7.46-7.14 (m, JH,H = 8.29, 6.97, 1.32, 13H, Ar-H), 4.79 (s, 2H, 
NCH); 13C-NMR (75MHz, CDCl3) δ = 163.3q, 143.1q, 131.4, 129.3q, 128.8, 128.7, 127.68, 
127.6, 126.6, 74.6; ESI-MS: calcd m/z = 299.39 (M+H+), found m/z = 299.2 (M+H+). 
 
Genaral N-alkylation procedure  
To a stirring solution of imidazoline in dry DMF under nitrogen was added an alkyl halide 
and heated for 6 hrs at 90 ˚C. The solution was concentrated by heating at 80 ˚C under 
negative pressure. The remaining residues of DMF were removed by bulb-to-bulb 
distillation using a kugelrohr. Further purification was carried out by recrystalisation from 
ethyl acetate and n-hexane. 
 
 
cis N,N’-diethyl-2,4,5-triphenylimidazolinium iodide 23 
23 was synthesised following the general alkylation procedure from amarine 20 (8.47 g) 
using 2.1 molar equivalent of ethyl iodide (4.8 mL) in 20 mL of DMF to afford 23 as a 
solid; yield: 12.46 g (91 %): mp 202-204 ˚C; 1H-NMR (300 MHz, CDCl3-d) δ=  8.25 (s, 
1H, Ar-H), 7.71 (s, 4H, Ar-H), 7.14-6.97 (m, 10H, Ar-H), 6.45 (s, 2H, N=CH ), 3.37 (dq, 
3JHH = 14.37, 7.27 Hz, 2H, -CH2), 3.15 (dq, 
3JHH =14.37, 7.27 Hz, 2H, -CH2), 7.17 (t, 
3JHH 
=7.27 Hz, 6H, -CH3); 
13C-NMR (75MHz, CDCl3-d) δ= 167.7q, 132.9, 131.5q, 130.4, 
130.0, 129.0, 128.8, 128.6, 128.3, 127.5, 122.8q, 67.9, 41.9(CH2), CH3 13.3(CH3); ESI-MS: 
calcd m/z = 355.50 (M+), found m/z = 355.3 (M+). 
 
cis N,N’-dibenzyl-2,4,5-triphenylimidazolium chloride [nnDBTPICl] 24 
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24 was synthesised from 20 (5.0 g, 16.76 mM) following the general alkylation 
procedure using 2.1 molar equivalence of  benzyl chloride (4.05 mL) in 20 mL DMF to 
afford 24 as a solid; yield: 1.28 g (74 %): mp 228-233 ˚C: 1H-NMR (300 MHz, CDCl3) 
δ= 8.16 (m, 2H, Ar-H), 7.63 (m, 4H, Ar-H), 7.41-6.73 (m, 19H, Ar-H), 5.20 (s, 2H, -
NCH), 4.58 (d, 3JHH =15.2 Hz, 2H, -CH2), 4.34 (d, 
3JHH =15.2 Hz, 2H, -CH2); 
13C-NMR 
(75MHz, CDCl3) δ= 168.0q, 133.7q, 133.0, 132.7q,130.1, 130.0, 129.7, 129.5, 129.0q, 
128.9, 128.8, 128.6, 128.5, 128.4, 122.5q, 73.1, 51.0(CH2); ESI-MS: calcd m/z = 479.63 
(M+), found m/z = 479.4 (M+). 
 
cis N,N’-dibutyl-2,4,5-triphenylimidazolinium bromide [nnDBTPIBr] 25 
25 was synthesised  from 20 (5.0 g, 16.76 mM) following the general alkylation 
procedure using n-bromobutane (3.98 mL, 2.2 eq.) in 20 mL of DMF to afford 25 as a 
white solid in good yield: 6.84 g (83 %): mp 144-146 ˚C: 1H-NMR (300 MHz, DMSO-d6) 
δ = 8.25 (s, 2H, Ar-H), 8.04-7.11 (m, 13H, Ar-H), 6.18 (s, 2H), 3.19 (dt, 3JHH = 15.2, 
7.5 Hz, 2H, -NCH2), 2.98 (dt, 
3JHH = 14.1, 6.4 Hz, 2H, -NCH2), 1.42 (m, 4H, -
CH2CH2CH3), 1.05 (sxt, 
3JHH = 7.2 Hz, 4H, -CH2CH3), 0.61 (t, 
3JHH = 7.2 Hz, 6H, -CH3); 
13C-NMR (75 MHz, DMSO) δ = 167.3q, 134.8q, 131.7q, 130.8, 129.5, 129.0, 129.0, 
128.9, 128.7q, 128.6, 128.5, 128.4, 128.1, 127.9, 127.6, 122.5q, 66.9, 45.3(CH2), 
28.4(CH2), 18.9(CH2), 13.2 (CH3); ESI-MS: calcd m/z = 411.60 (M
+), found m/z = 411.3 
(M+). 
 
Entantiomeric purification of iso-amarine 
(4R,5R)-2,4,5-triphenylimidazoline [(R,R)-iso-amarine] 21 
The procedure used for the preparation of 21 is a modification of the method of Braddock 
et al.44 Racemic iso-amarine (4.1 g, 0.014 M) and (S)-(+)-mandelic acid (2.1 g, 0.014 M) 
were dissolved in 30 ml of refluxing iso-propanol and allowed to reflux for 1 hr. After 1 
hr, heating was stopped and the flask was left in oil to slowly cool to room temperature 
with gentle stirring. After 16 hrs at room temperature the solution was place on ice and 
cooled to 0 ˚C and stirred for a further 4 hrs. White crystals formed which were filtered, 
  
collected and dried under vacuum, and the filtrate containing a crude mixture of 
diastereoisomer salts (SRR)-21a/(SSS)-21b was collected for isolation of the (S,S)-iso-
amarine enantiomer. The product was recrystalised from iso-propanol to afford the 1:1 
(S)-(+)-mandelic acid: (R,R)-iso-amarine diastereomeric salt 21a as white a crystalline 
solid. 1H-NMR (300 MHz, DMSO-d6 /CDCl3-d) δ = 8.11 (d, JHH = 8.3 Hz, 2H, Ar-H), 7.59 
(t, 3JHH = 7.4 Hz, 1H, Ar-H), 7.44 (t, 
3JHH = 7.6 Hz, 2H, Ar-H), 7.38-7.33 (m, 6H, Ar-H), 
7.25-7.22 (m, 6H, Ar-H), 7.14-7.05 (m, 3H, Ar-H), 5.01 (s, 2H, -NCHIm), 4.64 (s, 1H, -
CH(mandelic.a)); 
13C-NMR (75 MHz, CDCl3-d) δ = 181.1q, 168.9q, 147.3q, 144.8q, 138.7, 
133.0, 134.88, 133.5, 132.6, 131.5, 131.3, 128.6q, 78.8, 75.4. 
The salt was suspended in DCM and 1N NaOH (aq) was added and the bi-phasic mixture 
was stirred rapidly until all of the crystals dissolved. The organic layer containing the iso-
amarine was collected and the aqueous layer was re-extracted with DCM. The organic 
layer was combined, washed with water and dried over MgSO4. The solution was filtered 
and concentrated to afford (R,R)-iso-amarine 21 as a white crystalline solid; yield: 1.84 
g (90 %): mp 202 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ= 8.01 (d, JHH = 7.8 Hz, 2H) , 
7.53-7.43 (m, 3H, Ar-H), 7.37-7.24 (m, 10H, Ar-H), 4.76 (s, 2H, -NCH-); ESI-MS: calcd 
m/z = 299.38 (M+H+), found m/z = 299.2 (M+H+). 
(S,S)-iso-amarine 21 was isolated from the filtrate collected containing the crude 
mixture of diastereoisomeric salts (RRS)-21a/(SSS)-21b.  The filtrated was 
concentrated under negative pressure to give a light yellow solid. The diastereoisomeric 
mixture was purified by flash column chromatography (ethyl acetate: methanol, gradient 
elution 4:0 to 3:1) to yield pure diastereoisomer (SSS)-21b. The salt was suspended in 
DCM and 1M NaOH was added and the bi-phasic mixture was stirred rapidly until the 
solid dissolved. The organic layer containing the iso-amarine was collected and the 
aqueous layer was re-extracted with DCM. The organic layer was combined, washed with 
water and dried over MgSO4. The solution was filtered and concentrated to afford (S,S)-
iso-amarine 21 as a white crystalline solid; 62 % yield (1.28 g). Spectral data and 
melting point comparable with (R,R)-isomer and (+/-)-iso-amarine 21 enantiomer. 
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(4R,5R)-N,N’-diethyl-2,4,5-triphenylimidazolinium iodide [nnDiEtTrPhlineI] 26 
Ionic salt 26 was synthesised from (S,S)-iso-amarine 21 (0.4 g, 1.34 mM) following the 
general alkylation procedure using 280 μL (2.6 eq.) of ethyl iodide in DMF (3 mL) to 
afford 26 as a solid in vey good yield: 0.64 g (98 %): mp 78-80 ˚C: 1H-NMR (300 MHz, 
DMSO-d6) δ = 8.02-7.99 (m, 2H, Ar-H), 7.81-7.47 (m, 13H, Ar-H), 5.42 (s, 2H, -NCH), 
3.25 (dq, 3JHH = 14.5, 7.2 Hz, 2H, -CH2), 2.99 (dq, 
3JHH =14.3, 7.1 Hz, 2H, -CH2), 0.91 
(t, 3JHH = 7.2 Hz  3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 165.7q, 135.7q, 133.0, 
130.9, 129.8, 129.7, 129.4, 129.1, 128.9, 128.5, 128.2, 127.1, 122.2q, 70.9, 41.2(CH2), 
12.7(CH3).; ESI-MS: calcd m/z = 355.50  (M
+), found m/z = 355.3 (M+). 
 
(4R,5R)-N,N’-dibenzyl-2,4,5-triphenylimidazolinium chloride [nnDiBnTrPhlineCl] 27 
27 was synthesised from 0.4 g (1.34 mM) of (S,S)-21 following the general alkylation 
procedure using 2.5 molar equivalence (390 μL) of benzyl chloride in  3 mL of DMF to 
afford 27 as a solid; yield 0.59 g (85 %): mp 190-193 ˚C: 1H-NMR (300 MHz, CDCl3-d) δ 
= 8.67 (d, 3JHH =7.6 Hz, 2H, Ar-H), 8.12-8.10 (s, 2H, Ar-H), 7.75 (s, 4H, Ar-H), 7.60-
6.76 (m, 17H, Ar-H), 5.05, 4.64 (d, 3JHH = 15.2 Hz, 2H), 4.25 (d, 
3JHH = 15.0 Hz, 2H); 
13C-NMR (75 MHz, CDCl3-d) δ 164.1q, 139.2q, 134.5q, 134.0q, 133.7, 132.0q, 130.5, 
130.3, 129.8, 129.2, 129.1, 128.6, 128.4, 128.2, 127.8, 126.2, 121.9q, 72.2, 50.7(CH2); 
ESI MS: calcd m/z = 479.63 (M+), found m/z = 479.4 (M+);. 
 
(4R,5R)-N,N’-dibutyl-2,4,5-triphenylimidazolinium bromide [nnDiBuTrPhlineBr] 28 
28 was synthesised from  0.4 g (1.34 mM) of (S,S)-21 following the general alkylation 
procedure using 2.2 molar equivalence of n-bromo butane (319 μL) in DMF (3 mL) to 
afford 28 as a solid; yield: 0.61 g (92 %): mp 79-81 ˚C; 1H-NMR (300 MHz, CDCl3-d) δ 
= 8.57 (d, 3JHH = 8.0 Hz, 2H, Ar-H), 7.89-6.93 (m, 13H, Ar-H), 5.05, 3.29 (m, 
3JHH =7.6 
Hz, 1H, -NCH2), 3.17 (m, 
3JHH = 7.1 Hz, 1H, -NCH2), 1.52-1.17 (m, 
3JHH = 7.6, 7.0 Hz, 
2H-CH2CH2CH3), 1.12-0.85 (m, 
3JHH = 7.3, 7.0 Hz, 2H, -CH2CH3), 0.64 (t, 
3JHH = 7.3 Hz, 
1H, -CH3);
 13C-NMR (75 MHz, CDCl3-d) δ = 164.1q, 138.8q, 134.3, 133.4, 130.5, 130.4, 
  
130.24, 130.0, 129.2, 129.1, 128.8, 128.5, 128.0, 126.3, 121.4q, 68.6, 46.5(CH2), 
29.4(CH2), 19.5(CH2), 13.2(CH3); ESI-MS: calcd m/z = 411.60 (M
+), found m/z = 411.3 (M+). 
 
Synthesis of 2,4,5-triphenylimidazole (Lophine) 22 
Lophine was sythesised from cis-amarine by Swern oxidation following the procedure 
described by Chou et al.30 To a stirred solution of oxalyl chloride (2.77, 1.6 eq.) in 49.4 
mL DCM at -78 ˚C was added 3.6 mL (3.2 eq.) DMSO in DCM (24.7 mL) dropwise over 5 
minutes. After 10 minutes, cis-amarine (4.0 g 0.0134 M) in DCM (25 mL) was added 
dropwise over 10 minutes, followed by triethylamine (9.5 mL) dropwise over 10 mintues. 
The mixture was stirred and allowed to gradually warm to room temperature overnight. 
The organic phase was washed with brine and dried over MgSO4. The organic phase was 
then filtered and concentrated under negative pressure to afford a crude product, which 
was further purified by flash chromatography using 2:1 n-hexane: ethyl acetate to afford 
22 as a yellow solid; 2.95 g (74 %): mp 272-273 ˚C; 1H-NMR (300 MHz, CDCl3-d/DMSO-
d6) 7.89 (m, 2H, Ar-H), 7.37-7.25 (m, 4H, Ar-H), 7.22-6.94 (m, 9H, Ar-H); 
13C-NMR 
(75MHz, CDCl3-d/DMSO-d6) 150.8q, 137.2q, 134.2, 133.5, 133.4, 133.2, 133.0, 132.2q, 
130.7; ESI-MS: calcd m/z = 297.37 (M+H+), found m/z = 297.2 (M+H+). 
 
N,N’-Diethyl-2,4,5-triphenylimidazolium iodide [DETPzole I] 29 
29 was synthesised from 22 (0.4 g, 1.34 mM) following the general alkylation procedure 
using ethyl iodide (130 μL, 2.2 eq.) in DMF (3 mL) to afford a 29 as a solid; yield: 0.54 g 
(84 %): mp 174 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 8.10 (d, 
3JHH = 7.2 Hz, 2H, Ar-H), 
7.78 (m, 2H, Ar-H), 7.61-7.31(m, 13H, Ar-H), 3.84 (q, 4H, 3JHH = 7.1 Hz, -CH2), 0.95 (t, 
3JHH = 7.1 Hz, 6H, -CH3); 
13C-NMR (75MHz, DMSO-d6) δ= 145.3q, 142.8q, 132.5, 132.2q, 
130.9, 130.9, 130.7, 130.1, 129.7, 129.2, 129.0, 128.9, 128.8, 128.8, 128.5, 128.2, 
127.9, 127.5, 126.4, 125.7q, 125.5, 122.2q, 41.8(CH2), 14.8(CH3); ESI-MS: calcd m/z = 
353.48 (M+), found m/z = 353.3 (M+).  
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N,N’-Dibenzyl-2,4,5-triphenylimidazolium chloride [DBnTPzole Cl] 30 
30 was synthesised from 22 (0.4 g, 1.34 mM) following the general alkylation procedure 
using 342 μL (2.2 eq.) of benzyl chloride in DMF (3 mL) to afford 30 as a solid in good 
yield: 0.54 g (78 %): mp 93 ˚C: 1H-NMR (300 MHz, CDCl3-d) δ = 8.19-8.08 (m, 2H, Ar-
H), 7.68-7.16 (m, 23H, Ar-H), 5.24 (s, 2H, -CH2), 5.06 (s, 2H, -CH2); 
13C-NMR (75 MHz, 
CDCl3-d) δ = 153.2q, 144.2q, 133.3, 132.6, 131.6, 131.4, 131.0, 129.5, 129.7, 129.0, 
128.8, 128.7, 128.2, 127.6q, 127.0, 126.3q, 126.0, 122.7q, 48.0(CH2); ESI-MS: calcd m/z 
= 477.62 (M+), found m/z = 477.4 (M+).  
 
N,N’-Dibutyl-2,4,5-triphenylimidazolium bromide [DBuTPzole Br] 31 
31 was synthesised from 22 (0.4 g, 1.34 mM) following the general alkylation procedure 
using n-bromo butane (321 μL, 2.2 eq.) in DMF (3 mL) to afford 31 as a solid; yield: 0.5 
g (75 %): 1H-NMR (300 MHz, CDCl3-d) δ =  8.37 (m, 2H, Ar-H), 7.61-7.04 (m, 13H, Ar-
H), 3.11 (m, 4H, -NCH2CH2), 1.27 (qui, 
3JHH = 7.9, 7.4 Hz , 2H, -CH2CH2CH3), 0.91 (sxt,
 
3JHH = 7.5, 7.4 Hz , 4H, -CH2CH3), 0.47(t, 
3JHH =7.5 Hz, 6H, -CH3); 
 13C-NMR (75 MHz, 
CDCl3-d) δ = 144.4q, 132.6q, 131.8, 131.3, 130.9, 129.5, 129.2, 129.1, 128.8, 128.7, 
128.5, 128.4, 128.2, 127.6, 127.2, 126.4q, 122.5q, 48.1(CH2), 31.5(CH2), 19.3(CH2), 
13.1(CH3); ESI-MS: calcd m/z = 409.59 (M
+), found m/z = 409.4 (M+).  
 
DCC mediated coupling of amino acids to trans 2,4,5-triphenylimidazoline 
N-[1-Benzyl-2-oxo-2-(2,4,5-triphenyl-4,5-dihydro-imidazol-1-yl)-ethyl]-acetamide 32a 
and 32b. 
To a stirring solution of (+/-)-iso-amarine 21 (1.0 g, 3.35 mM) and an amino acid (in 
this case (S)-N-acetylphenyalanine (0.83 g, 1.2 eq.) in DCM (11 mL) at -78 ˚C under 
nitrogen was added 0.69 g (1.2 eq.) of Dicyclohexylcarbodiimide (DCC). The reaction 
mixture was allowed to react at room temperature for 5 hrs during which N,N'-
dicyclohexylurea precipitated out of solution as a white solid. The mixture was filtered 
and the filtrate concentrated by rotary evaporation to afford 32 at 96 % yield (1.56 g) as 
  
a mixture of 32a (SSS) and 32b (SRR). 1H-NMR (300 MHz, CDCl3-d) δ = 8.38 (s, 2H, Ar-
H), 7.76-6.69 (m, 18H, Ar-H), 5.23 (s, 2H, 2x(-CH)), 4.72 (m, 1H, -CH), 4.38 (m, 1H, -
CH), 3.23 – 3.07 (m, 2H, -CH2), 3.00 (m, 2H, -CH2), 2.02 (s, 3H, -CH3), 1.84 (s, 3H, -
CH3); 
13C-NMR (75 MHz, CDCl3-d) δ = 173.8q, 170.7q, 135.9q, 135.1q, 133.7q, 129.5, 
129.4, 128.6, 128.5, 128.0, 127.3, 127.1, 65.9, 65.3, 53.5, 37.1(CH2), 36.9(CH2), 23.0(CH3), 
15.0(CH3). The two diasteroisomers were isolated by flash chromatography with Ethyl 
acetate and methanol at 3:1. 32a (SSS) was isolated at 46 % yield (0.75 g), Rf =0.8, 
mp 75-77 ˚C; ESI-MS: calcd m/z = 488.60 (M+H+), found m/z = 488.4 (M+H+). 32b 
(SRR) was isolated at 44 % yield (0.72 g), Rf =0.38, mp 132-138 ˚C; ESI-MS: calcd m/z 
= 488.60 (M+H+), found m/z = 488.4 (M+H+).                  
 
N-(1-Benzyl-2-imidazol-1-yl-2-oxo-ethyl)-acetamide 33 
33 was synthesised from imidazole (0.1 g, 1.47 mM) by DCC mediated coupling with of 
DCC (0.3g, 1.2 eq.) and the N-acetyl-(L)-phenylalanine  (0.37g, 1.2 eq.) in DCM (3 mL) 
to afford 33 as a solid in good yield: 0.32 g (85 %): mp 88-90 ˚C: 1H-NMR (300 MHz, 
CDCl3-d) δ = 8.38 (s, 1H, CHIm), 7.22 (m, 7H, Ar-H/CHIm), 4.72 (dd, 1H, -CH), 4.38 (m,  
2H, -CH), 3.25–2.89 (m, 4H, -CH2), 2.02 (s, 3H, -CH3), 1.84 (s, 3H, -CH3); 
13C-NMR (75 
MHz, CDCl3-d) δ = 178.0q, 169.8q, 168.9q, 163.0q, 136.4, 135.2q, 134.4q, 131.5, 129.5, 
129.2, 128.9, 128.5, 127.7, 127.2, 116.1, 66.0, 53.3, 38.8(CH2), 36.9(CH2), 23.0(CH3), 
15.1(CH3); ESI-MS: calcd m/z = 258.30 (M+H
+), found m/z = 258.1 (M+H+).  
 
2-Hydroxy-2-phenyl-1-(2,4,5-triphenyl-4,5-dihydro-imidazol-1-yl)-ethanone 34 
34 was synthesised from a 0.39 g (1.307 mM) mixture of (RR)-21 and (SS)-21  (with an 
excess of the SS enantiomer) by DCC mediated coupling using 0.35 g of DCC and (S)-
mandelic acid (0.26 g, 1.3 eq.) to afford 34 as a white solid in good yield: 0.43 g (76 
%): mp 160 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 8.05 (m, 2H, Ar-H), 7.92 (s, 1H, Ar-
H), 7.57-7.28 (m, 17H, Ar-H), 4.89 (s, 1H, -CH), 4.69 (s, 1H, -CH), 3.42 (s, 1H, -CH); 
13C-NMR (75 MHz, DMSO-d6) δ = 162.3q, 156.7q, 144.4q, 144.1q, 130.6, 130.2q, 128.6, 
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128.4, 128.3, 127.5, 127.3, 126.9, 126.7, 126.2, 79.5, 69.2, 54.7; ESI-MS: calcd m/z = 
433.52 (M+), found m/z = 433.2 (M+).  
 
1,3-Dibenzyl-5-[2-benzylamino-3-oxo-3-(2,4,5-triphenyl-4,5-dihydro-imidazol-1-yl)-
propyl]-3H-imidazol-1-ium; chloride 35. 
35 was synthesised from 0.28 g (0.938 mM) of (SS)-21  by DCC mediated coupling with 
0.53 g (1.2 eq.) of the N-benzoyl-(L)-histidine derived IL 4 to afford 35 as an solid; 72 
% yield (0.50 g): mp 64-66 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 9.55 (s, 1H, -OH), 
8.23-6.97 (m, 32H, Ar-H/-CHIm), 5.57 (m, 2H, -CH2), 5.43 (m, 2H, -CH2), 4.74 (s, 1H, -
CH), 4.51 (s, 1H, -CH), 3.59 (m, 1H, -CH), 3.07 (m, 2H, -CH2); 
13C-NMR (75 MHz, 
DMSO-d6) δ = 167.9q, 165.8q, 163.1q, 156.9q, 154.4q, 141.2q, 140.6q, 139.7q, 134.7q, 
134.2q, 133.9q, 133.2, 133.0, 131.6q, 131.2, 130.2, 129.2, 129.0, 128.8, 128.5, 128.40, 
128.3, 128.3, 128.1, 128.1, 128.0q, 127.7, 127.5, 127.3, 126.9, 126.7, 126.4, 125.7q, 
66.9, 62.8, 51.9(CH2), 51.0, 49.6(CH2), 25.3(CH2); ESI-MS: calcd m/z = 720.88 (M
+), and 
360.95 (M+H)2+, found m/z = 720.6 (M+) and 360.8 (M+H)2+.  
 
N-[4-Oxo-1-(2,4,5-triphenyl-4,5-dihydro-imidazole-1-carbonyl)-4-(2,4,5-triphenyl-4,5-
dihydro-imidazol-1-yl)-butyl]-benzamide 36 
36 was synthesised from 0.4 g (0.37 mM) of (SS)-21 by DCC mediated coupling with 
0.17 g (0.5 eq.) of N-benzoyl-L-glutamic acid using 0.4 g (1.4 eq.) of DCC to afford 36 
as a white crystalline solid; yield: 0.4 g (53 %): 1H-NMR (300 MHz, CDCl3-d) δ = 8.41 (d, 
3JH,H = 7.7 Hz, 1H, Ar-H), 7.66 (d, 
3JH,H = 8.1 Hz, 1H, Ar-H), 7.51-6.94 (m, 33H, Ar-H), 
5.28 (s, 1H, -CH), 5.12 (s, 1H, -CH), 5.07 (s, 1H, -CH), 4.91 (s, 1H, -CH), 4.03 (m, 1H, -
CH), 1.70 (m, 2H, -CH2), 1.47 (m, 2H, -CH2); 
13C-NMR (75 MHz, CDCl3-d) δ = 170.2q, 
169.3q, 168.5q, 168.0q, 162.4q, 159.6q, 155.6q, 152.4q, 140.0q, 138.6q, 137.0q, 135.1q, 
134.0q, 132.9, 132.7q, 130.9q, 129.8, 129.2q, 128.8, 128.2, 127.7, 127.5, 127.4, 127.3, 
127.3, 127.2q, 127.2, 127.0, 126.7, 126.6, 126.3, 126.3, 126.2, 126.1, 125.7, 125.2, 
124.8, 124.4, 124.2, 123.7, 119.9, 76.3, 70.5, 67.2, 55.2, 51.5(CH2), 51.3, 50.4, 35.9(CH2) 
ESI-MS: calcd m/z = 407.0 (M+H)2+, found m/z = 406.7 (M+H)2+.  
  
  
3-(2-Acetylamino-3-phenyl-propionyl)-1-ethyl-2,4,5-triphenyl-4,5-dihydro-3H-
imidazolin-1-ium; iodide 37a (SSS) and 37b (SRR). 
37a (SSS) and 37b (SRR) were synthesised from 0.2 g (0.410 mM) of 32a and 32b, 
respectively, following the general alkylation procedure using excess ethyl iodide (100 
μL, 3 eq.) in 3 mL DMF to afford the 37a (SSS) and 37b (SRR), respectively, in good 
yields: 37a (SSS); yield: 0.26 g (97 %): RTIL: 1H-NMR (300 MHz, DMSO-d6) δ = 8.09-
7.16 (m, 20H, Ar-H), 5.35 (s, 2H, -CH), 4.37 (m, 1H, -CH), 3.34 (q, 3JH,H = 7.3 Hz, 2H, -
CH2), 3.25 – 2.95 (m, 2H, -CH2), 1.93 (s, 3H, -CH3), 1.16 (t, 
3JH,H = 7.3 Hz, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.5q, 169.5q, 163.8q, 138.0q, 135.0, 129.5, 129.4, 
129.1, 129.1, 129.0, 128.9, 128.2, 127.3, 121.9q, 68.9, 53.7, 41.8(CH2), 36.6(CH2), 
22.3(CH3), 8.1(CH3).; ESI-MS: calcd m/z = 516.65 (M
+). found m/z = 516.5 (M+). 37b 
(SRR); yield: 0.26 g (97 %): mp 92-97 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 7.74 (m, 
20H, Ar-H), 5.37 (s, 2H, -CH), 4.42 (dd, JH,H = 14.0, 8.3 Hz, 1H, -CH), 3.34 (q, 
3JH,H = 
7.3 Hz, 2H, -CH2), 3.00–2.81 (m, 2H, -CH2), 1.77 (s, 3H, -CH3), 1.19 (t, 
3JH,H = 7.3 Hz , 
3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.6q, 169.5q, 163.8q, 138.1q, 137.1q, 
135.0, 129.5, 129.4, 129.2, 129.1, 129.0, 128.9, 128.2, 127.3, 126.5, 121.9q, 68.9, 
63.8(CH2), 53.7, 36.6(CH2), 22.3(CH3), 8.0(CH3) ; ESI-MS: calcd m/z = 516.65 (M
+), found 
m/z = 516.5 (M+).  
 
1,3-Dibenzyl-5-[2-benzylamino-3-(3-ethyl-2,4,5-triphenyl-4,5-dihydro-imidazolin-1-ium; 
iodide)-3-oxo-propyl]-3-H-imidazol-1-ium; chloride 38 
38 was synthesised following the general alkylation procedure from 35 (0.26 g 0.35 mM) 
and excess ethyl iodide in 3 mL DMF to afford 38 as a dark oil; yield: 0.28 g (88 %): 
dark oil: 1H-NMR (300 MHz, DMSO-d6) δ = 8.33-7.93 (m, 2H, Ar-H), 7.87-7.19 (m, 30H, 
Ar-H), 5.37 (s, 1H, -CH), 4.43 (m, 1H, -CH), 4.10 (q, 3JH,H = 7.3 Hz, 2H, -CH2), 3.36 (m, 
2H, -CH2), 2.97 (s, 4H, -CH2), 2.77 (s, 3H, -CH3), 1.18 (t, 
3JH,H = 7.3 Hz, 3H, -CH3); 
13C-
NMR (75 MHz, DMSO-d6) δ = 171.6q, 169.4q, 163.8q, 138.2q, 135.0, 129.5, 129.4, 129.2, 
129.1, 129.0, 128.9, 128.2, 127.2, 127.0q, 126.5, 121.9q, 68.9, 57.9(CH2), 53.7, 51.8(CH2), 
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41.7(CH2), 36.6(CH2), 9.4(CH3), 7.9(CH3); ESI-MS: calcd m/z = 374.97 (M
2+), found m/z = 
374.7 (M+).  
 
N-[1-(3-Ethyl-2,4,5-triphenyl-4,5-dihydro-imidazolium-1-carbonyl)-4-(3-ethyl-2,4,5-
triphenyl-4,5-dihydro-imidazol-1-yl)-4-oxo-butyl]-acetamide 39 
39 was synthesised following the general alkylation procedure from 0.17 g (0.227 mM) 
of 36 and excess ethyl iodide (500 μL) in 3 mL DMF to afford 36 as a solid in good yield: 
0.23 g (96 %): mp 72-74 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 8.20-7.38 (m, 35H, Ar-
H), 5.42 (s, 1H, -CH), 5.38 (s, 1H, -CH), 5.35 (s, 1H, -CH), 5.32 (s, 1H, -CH), 3.89 (q, 
JHH = 7.2 Hz, 1H, -CH), 3.50 (td, JHH = 14.5, 7.2 Hz, 1H, -CH2), 3.26 (td, JHH = 14.7, 7.3 
Hz, 1H, -CH2), 3.11 (dt, JHH = 21.1, 6.8 Hz, 1H, -CH2), 3.00 (dt, JHH = 20.2, 6.3 Hz, 1H-
CH2) 1.80 (m, 1H, -CH2), 1.73 (m, 1H, -CH2), 1.60 (m, 1H, -CH2), 1.30 (m, 1H, -CH2), 
1.24 (d, JHH = 7.5 Hz, 1H, -CH2), 0.94 (t, 
3JHH = 7.2 Hz, 6H, -CH3); 
13C-NMR (75 MHz, 
DMSO-d6) δ = 166.4q, 165.8q, 165.7q, 165.3q, 163.8q, 143.0q, 140.6q, 138.4q, 138.0q, 
136.5q, 135.8q, 135.0, 134.8q, 133.5, 133.0, 132.6, 130.9q, 130.9, 130.6, 130.1, 129.8, 
129.7, 129.6, 129.4, 129.4, 129.2, 129.1, 129.0, 128.9, 128.5, 128.2, 128.2, 128.1, 
127.9, 127.2q, 127.2, 127.0, 126.8, 125.7q, 122.9q, 122.2q, 122.1q, 72.7, 70.9, 69.1, 
67.4, 48.3, 41.8(CH2), 41.2(CH2), 40.8(CH2), 32.4(CH2), 25.2(CH2), 24.9(CH2), 14.7(CH3), 12.7(CH3), 
12.6(CH3); ESI-MS: calcd m/z = 435.05 (M
2+), found m/z = 434.8 (M2+).  
 
2-Benzylamino-1-[3-(2-(3-[2-benzylamino-3-(1,3-dibenzyl-1H-imidazol-4-yl)-propionyl]-
2,4,5-triphenyl-4,5-dihydro-3H-imidazol-1-yl)-ethyl)-2,4,5-triphenyl-4,5-dihydro-
imidazol-1-yl]-3-(1,3-dibenzyl-1H-imidazol-4-yl)-propan-1-one 40 
40 was synthesised following the general alkylation procedure from 35 (0.18 g, 0.24 
mM) using 0.5 molar equivalents of 1,2-diiodoethane  (0.034 g) in 3 mL of DMF to afford 
40 as a solid in good yield: 0.17 g (81 %): dark oil: 1H-NMR (300 MHz, DMSO-d6) δ = 
8.17-7.12 (m, 64H, Ar-H/ CHIm), 5.51 (m, 4H, -CH2), 5.43 (m, 4H, -CH2), 4.64 (s, 1H, -
CH), 4.40 (s, 1H, -CH), 3.39 (m, 4H, -CH2), 3.33 (m, 1H, -CH), 3.12 (m, 4H, -CH2),
 13C-
NMR (75 MHz, DMSO-d6) δ = 170.1, 163.8, 138.0, 135.0, 132.9, 131.0, 129.5, 129.4, 
  
129.1, 129.1, 128.9, 128.9, 128.4, 128.2, 128.0, 127.8, 127.3, 121.7, 68.9, 55.3, 
51.9(CH2), 49.3, 49.2, 30.3(CH2), 28.6(CH2), 24.7(CH2), 24.5(CH2), 23.8CH2), 23.6(CH2); ESI-MS: 
calcd m/z = 367.45 (M4+), found m/z = 367.3 (M4+). 
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2.3 Synthesis of amino acid derived imidazolinium ionic liquids 
2.3.1 Introduction 
The synthesis and use of imidazolines has expanded dramatically in the past decade, 
driven both by their increased applications in catalysis and especially by the development 
of imidazoline-based drugs for various therapeutic targets. Human imidazoline binding 
sites (IBS) have been identified, and the nature of these receptor subtypes and their 
preferred ligands have been explored in detail.45 Imidazoline drugs are now in 
development for a remarkable array of disease states including oncology,46 depression 
and neuroprotection,47 hypertension,48 inflammation,49 and analgesia50. 
 
An example of their biological activity is well illustrated by the unique anti-cancer 
properties of syn-imidazolines (nutlins)51 and anti-imidazolines (SP-4-84).52 The syn-
imidazolines were found to be inhibitors of MDM2, a protein that negatively regulates the 
activity of the pro-apoptotic transcription factor p53 (Figure 2.32).51 The anti-imidazoline 
SP-4-84, on the other hand, was found to be a drastic enhancer of the chemotherapeutic 
efficacy of anti-cancer agents and modulator of the anti-apoptotic NF-κB signaling 
pathway.52  
 
High-throughput screening has identified 2,4,4-triphenyimidazoline (Figure 2.32) and 
several of its derivatives to be potent neuropeptide Y Y5 (NPY Y5) receptor agonists.53 
Neuropeptide Y (NPY) is thought to play a major role in the physiological control of 
energy homeostasis.53 Pharmaceutical data suggests that the NPY Y5 receptor is involved 
in feeding regulation.53 Administration of Y5 antagonists suppresses Y5 agonist-induced 
food intake and diet-induced body weight gain.54,55 Hence, Y5 antagonists have been 
targeted by pharmaceutical companies as potential anti-obesity drugs.56,57 
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In addition to their diverse biological activity,38,58-62 imidazolines have been utilized as 
building blocks for biologically interesting scaffolds63,64 and recently attracted 
considerable interest as ligands for asymmetric catalysis.65-69 
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Figure 2.32: syn-imidazolines (nutlins), anti-imidazolines (SP-4-84) and 2,4,4-
triphenylimidazoline. 
 
The stereochemical diversity of these heterocyclic molecules presents novel territory not 
only in terms of their biological applications, but hold potential for application as chiral 
selecting agents in analytical chemistry. Given that these imidazoline molecules have 
stereogenic centers, it was anticipated that their ionic salt analogues may hold great 
potential as chiral selecting agents for gas chromatographic separations. Approaches to 
the efficient synthesis of imidazolinium ionic liquids from simple amino acids, with diverse 
functionalities, was the focus of this research investigation.  
 
2.3.2 Results and Discussion 
Synthesis of N-benzoyl amino acids: 
The  synthesis of imidazolines begins with the N-Acylation of simple and readily available 
amino acids following the procedure outlined by Steiger,70 which was first introduced by 
Baum.71,72 It is important to note that the choice of acetylating agent used at this stage, 
is a major determining factor on the stereoisomeric composition of imidazoline product 
later on in the reaction scheme (Figure 2.36).  
  
 
N-Acylamino acids are most conveniently prepared by the action of an acid chloride upon 
amino acids in aqueous solution in the presence of a base, generally sodium hydroxide. 
Using this method, large quantities of N-acyl amino acids can be prepared efficiently in 
high yields. The amino acids used can be either as a pure enantiomer or a racemic mix 
as this enantiomeric purity of the amino acid will not affect the stereoisomeric 
composition of the imidazolines produced.  
 
Following the procedure as outlined by Steiger,70 an ice cold aqueous solution containing 
one mole of amino acid and one mole of sodium hydroxide was treated with one mole of 
an acid chloride and one mole of sodium hydroxide while vigorously stirring and shaking 
the reaction mixture: 
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Figure 2.33: Amino acid acylation reaction. Amino acids 41-45 have a phenyl group at 
R1 while compounds 45-49 have a benzyl at R1 with R2 being either methyl, phenyl, 
methylindole, and 4-methylimidazole from the sidechains of their respective amino acids 
alanine, phenylalanine, tryptophan, and histidine. 
 
Benzoyl chloride (Figure 2.34) was used as an acylating agent, however, phenylacetyl 
chloride was also utilized to produce N-benzoylamino acids 41-45 and N-
phenylacetylamino acids 46-49, respectively: 
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Figure 2.34: Amino acid benzoylation reaction.  
 
It’s important to note that enough sodium hydroxide must be used to neutralize the 
hydrochloric acid liberated in the reaction, to maintain the sodium salt of the benzoyl 
compound in solution until the reaction is complete, and to destroy any excess of benzoyl 
chloride. An additional amount of sodium hydroxide may be required to prevent the 
premature precipitation of unreacted amino acids. Failure to do so results in reduced 
yields. 
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Figure 2.35: Treatment of the sodium salt of the benzoyl compound with 1 mole 
hydrochloric acid yield N-benzoylamino acids as a precipitate. 
 
The reaction was complete when the reaction mixture had a clear yellow appearance and 
no oil droplets remained at the bottom of the flask. Upon completion, the reaction 
mixture was treated with one mole of hydrochloric acid to precipitate the N-benzoyl 
amino acid. To convert all the unreacted amino acid into the hydrochloride a further 
quantity of hydrochloric acid was added, giving yields of purified benzoyl derivatives as 
high as, 95 % (see Table 2.3). These N-benzoyl amino acids were then used to 
synthesise enantiomerically pure oxazolones.  
 
 
  
Table 2.3: N-Benzoyl and N-phenylacetyl amino acids. 
N-Acyl amino 
acids R1 R2 Stereoisomer 
Mp 
(˚C) 
Yield 
(%) 
41 phenyl methyl L 94-7 95 
42 phenyl phenyl DL 
157-
61 
74 
43 Phenyl 
3-methyl-1H-
indole 
DL 180-4 84 
44 Phenyl 
4-methyl-1H-
imidazole 
L 
179-
82 
92 
45 phenyl Propionic acid L 114-6 86 
46 phenylacetyl methyl L 86-89 65 
47 phenylacetyl phenyl DL 
109-
12 
62 
48 phenylacetyl 
3-methyl-1H-
indole 
DL 146-8 83 
49 phenylacetyl 
4-methyl-1H-
imidazole 
L oil 89 
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Figure 2.36:  The synthesis of imidazolinium ILs 65-77 from N-benzoyl and N-
phenylacetyl amino acids (41-48), where R1= phenyl or benzyl, R2= methyl, phenyl, 
indole or imidazole, R3= phenyl or pyridine R4= ethyl or benzyl, and Xˉ= iodide or 
chloride anion, via oxazolones 50-55. 
 
Synthesis of oxazolones  
Oxazolones are commonly synthesized under mild conditions by reacting N-acylated 
amino acid derivatives with dehydrating reagents. These dehydrating reagents usually 
consist of activated anhydrides or carbodiimides.73 Enantiomerically pure oxazolones 
were prepared from different N-benzoyl- and N-phenylacetyl-amino acids via an EDCI-
mediated dehydration reaction in high yields74-76 using soluble N-ethyl,N’-(γ-
dimethylaminopropyl)-carbodiimide hydrochloride (EDCI) in DCM at 0 ˚C followed by 
removal of urea and any starting material by washing with water and aqueous sodium 
hydrogen carbonate. 
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Figure 2.37: Mechanism for the synthesis of oxazolones from derivatised amino acids. 
 
The solution of N-acylated amino acid and N-ethyl,N’-(γ-dimethylaminopropyl)-
carbodiimide hydrochloride in DCM was allowed to react for 1 hour for racemic amino 
acids and 15 minutes for enantiomerically pure amino acids at 0 ˚C. The carbodiimide 
converts the carboxylic acid into a reactive acylating agent by deprotonating the hydroxyl 
group, as shown in Figure 2.37, which in turn attacks the nucleophilic carbon on the 
carbodiimide to give an O-acylisourea intermediate. The remaining imide abstracts the 
proton on the amino acid amine resulting in the formation of an enolate ion. The enolate 
ion then attacks the carbonyl carbon to yielding a cyclised tetrahedral intermediate. The 
tetrahedral intermediate dissociates losing N-ethyl,N’-(γ-dimethylaminopropyl)-urea as a 
co-product which is highly soluble in water, and is easily removed by washing with water 
as well as any unreacted amino acids. The oxazolones are unstable compounds which 
decompose at room temperature, thus all work up must be done at 0 ˚C and the pure 
oxazolone stored at -20 ˚C. The very short reaction time and the ease of the work up to 
produce enantiomerically pure oxazlones, combined with the high yields produced make 
this procedure highly effective and desirable for synthesising oxazolones. 
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Table 2.4: The yields and properties of the oxazolones synthesised. 
Oxazolones R1 R2 Mp (˚C) Yield (%) 
50 phenyl Methyl oil 67 
51 Phenyl Phenyl oil 87 
52 phenyl 
3-methyl-
1H-indole 
solid 90 
53 phenyacetyl Methyl oil 79 
54 phenyacetyl Phenyl oil 93 
55 phenyacetyl 
3-methyl-
1H-indole 
solid 91 
 
The enantiomeric purity of the oxazolones results from kinetic resolution which occurred 
during the process of the reaction. Classic kinetic resolution is defined as a process by 
which the two enantiomers of a racemate are transformed to their isomeric product at 
different rates. If the kinetic resolution is efficient, one of the enantiomers of the racemic 
mixture is transformed to the desired product while the other is recovered unchanged. 
SR
SS
fast
slow
PR
PS
racemisation
SR
SS
fast
slow
PR
PS
Dynamic Kinetic ResolutionClassic Kinetic Resolution
 
Figure 2.38: Classic kinetic resolution and dynamic kinetic resolution S= substrate, P= 
product. 
  
Classical kinetic resolution has led to the development of the dynamic kinetic resolution 
principal, which combines the resolution step of classic kinetic resolution, with an in situ 
equilibration or racemisation of the chiral substrate. In such a process, one can in 
principle obtain a quantitative yield of one of the enantiomers.  
Dynamic kinetic resolution allows for the selective synthesis of an enantiomer when the 
reaction takes place, along with the creation of a new stereogenic center. The reaction 
proceeds preferentially with one of the two enantiomers of the racemate forming an 
irreversible product. At the same time, the unreactive enantiomer undergoes 
epimerization to the more reactive enantiomer allowing for the complete conversion of 
the racemate to the desired stereoisomer. 
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Figure 2.39: Racemisation of oxazolones 
Under conditions which are not conducive for the racemisation of the product all of the 
substrate is converted into a single isomeric product. Typically, racemisation of a 
substrate can take place chemically, enzymatically, or even spontaneously. In the case of 
this EDCI-mediated dehydration reaction racemisation occurs spontaneously yielding a 
single enantiomer of oxazolone as the product. And because these oxazolones racemise 
very slowly in solvents such as chloroform and DCM the pure oxazolones were obtained 
before racemisation took place. 
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Figure 2.40: The Oxazolone products derived from the amino acids: alanine, 
phenylalanine, and tryptophan. 
 
The oxazolone ring system contains numerous reactive sites allowing for a wide variety 
of transformations (Figure 2.39). The use of Lewis acids with the oxazolones results in 
the formation of either the 1,3-dipole (also known as a münchnone) or the reactive 
ketene intermediate (Figure 2.41), each yielding the possibility of synthesizing novel 
heterocyclic compounds, such as imidazolines, via cycloaddition reactions.77 
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Figure 2.41: Lewis acid mediated formation of a münchnone 1,3-dipole intermediate. 
 
Synthesis of imidazolines 
Imidazolines can be synthesised from oxazolones via a silicon mediated 1,3-dipolar 
cycloaddition with imines.78 Imidazolines can be produced via a one-pot reaction of an 
imine and an in situ Lewis acid-generated münchnone.78 The münchnone and imine are 
allowed to react at slightly elevated temperatures to give imidazoline products.78 1,3-
Dipolar cycloaddition reactions with oxazolones provide a general route for the syntheses 
of heterocyclic compound such pyrroles, pyrrolines, imidazoles and imidazolines with 
various functionalities attached to their heterocyclic scaffolds.79-81  
 
It was discovered that alkenes disubstituted with aryl and acyl groups react with 
münchnones to afford pyrrolines.82 Similar to pyrroline synthesis, imidazolines can be 
synthesised via the reaction of oxazolones with a variety of imines in the presence of the 
lewis acid chlorotrimethylsilane (TMSCl). 1,3-dipolar cycloaddition is promoted when the 
oxazolone is in its münchnone form, wherein it acts as a dipole and reacts with 
dipolarophiles such as imines. The TMSCl promotes the cycloaddition reaction of 
oxazolones and imines to afford the imidazolines. 
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Synthesis of amino acid derived imidazolines: 78  
To synthesize the imidazolines a solution of aldehyde and benzylamine in dry DCM was 
refluxed under a nitrogen atmosphere for 2 hrs to permit the formation of the imine. To 
this solution was added the oxazolone followed by TMSCl to promote the formation of the 
münchnone, then refluxed at 40 ˚C for 6-10 hrs under a nitrogen atmosphere. Because 
oxazolones epimerize readily under mild reaction conditions the münchnone and imine 
were only allowed to react at slightly elevated temperatures. The mixture was left to 
react at room temperature overnight to afford the imidazoline. The DCM was removed by 
rotatary evaporation and the product isolated by flash chromatography. This method 
permits the production of imidazolines with a wide range of substituents at R1, R2, R3 and 
R4 in very good yields (Table 2.5). 
 
Given that these imidazolines were intended for application as chiral selecting agents, 
there was a need to produce imidazolines with high stereoselectivity. As a result it was 
determined to prepare (4S,5S) anti-imidazolines, because (4S,5S) anti-imidazolines 
could be prepared with high stereoselectivity via this trimethylsilyl chloride mediated 1,3-
dipolar cycloaddition reaction (Figure 2.42). The high diastereoselectivity of the 
trimethylsilyl chloride mediated 1,3-dipolar cycloaddition reaction is substrate controlled, 
thus varying the substrates at R1, R2, and R3 enables influence over the formation of 
either syn- or anti-imidazolines.78,83,84 
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Figure 2.42: Proposed mechanism for the synthesis of anti-imidazolines from 1,3-dipolar 
cycloaddition of imines to oxazolones. 
 
Reaction mechanism 
It has been shown that when R1 is phenyl the anti diastereoisomer is exclusively formed, 
regardless of the nature of R2, R3, or R4. 78,84 This observation indicates that R1 controls 
the branch point of the stereochemical diversity. This is why the acylating agent used in 
the preparation of the N-acylamino acids was of significant importance as mentioned 
earlier, as this determines the R1 substituent and consequently the stereoisomeric 
product. In the case of 2-phenylimidazolines where R1 is a phenyl group, the high 
diastereoselectivity was attributed to a (1,3) strain in the azlactone dipole, which 
prevents co-planarity of Ph, TMS, and R2 groups (Figure 2.42). To prevent steric 
interaction between the bulky silyl group of the azlactone and the R3 group of the imine, 
the endo approach of the imine was favoured resulting in the anti-isomer as the sole 
product.78 
 
Reducing the resonance stabilization of the carbocation in the dipole by changing the 
electronic nature of the R1 substituent, has been shown to significantly change the 
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diastereoselectivity of the reaction.83 Replacement of the R1 phenyl group with a benzyl 
or a methyl moiety has been shown to significantly erode the stereoselectivity.83 When R1 
was methyl and R2 methyl, benzyl, or isopropyl a mixture of diastereisomers were 
obtained.83 However, when R1 was an alkyl substituent the syn-imidazolines were 
obtained with high diastereoselectivity as the major or sole products only when the R2 
substituent is an aryl group.83 
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Figure 2.43:  Imidazolines 56-58 and their respective ILs 65-70, synthesised from N-
phenyl amino acids. 
 
Figure 2.43 shows the imidazolines synthesised with a phenyl group at R1 and R3, while 
various functional groups at R2 were inherited from the side groups of amino acids 
utilised in the synthesis of the oxazolones.  The amino acids utilised were alanine, 
  
phenylalanine, and tryptophan which gave a methyl, benzyl, or and indole side groups, 
respectively. Having a phenyl at R1 gave the desired (4S,5S) anti-imidazoline products 
56-58 as the major product with greater than 95 % ee by NMR analysis. From these 
imidazolines ionic liquids 65-70 were synthesised by alkylating the sp2 hybridised 
tertiary amine imidazolines with the alkyl halides iodoethane or benzyl chloride. These 
compounds are novel chiral ionic liquids with greater than 95 % ee of the (4S,5S) anti 
stereoisomer. These chiral ionic liquids hold potential for application as chiral selecting 
agents not only in GC stationary phases but also for chiral NMR analysis. 
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Figure 2.44: Imidazolines 59-61 and their respective ionic liquids 71-75 synthesised 
from N-phenylacetyl amino acids. 
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Imidazolines 59-61 were also synthesised with a benzyl group at R1 and phenyl at R3 
(Figure 2.44). Similarly imidazolines 62-64 had a benzyl group at R1 but pyridine at R3. 
These imidazolines were alkylated to form the ionic salts (71-75) from their imidazolines 
59-61 and the di-cationic salts 76-77 from their imidazoline 62 (Figure 2.45). However, 
having a benzyl group at R1 eroded the stereoselectivity otherwise favoured by a phenyl 
substituent resulting in imidazoline products with a mixture of the syn and anti 
diastereoisomers.  
 
Table 2.5: Imidazolines 56-64 yields and properties. 
Imidazolines 
no. R1 R2 R3 Yield (%) 
56 phenyl Methyl phenyl 46 
57 Phenyl Phenyl Phenyl 51 
58 Phenyl Indole Phenyl 63 
59 phenylacetyl Methyl phenyl 97 
60 Phenylacetyl Phenyl phenyl 83 
61 Phenylacetyl Indole phenyl 96 
62 Phenylacetyl Methyl pyridine 100 
63 Phenylacetyl Phenyl pyridine 94 
64 phenylacetyl Indole pyridine 80 
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Figure 2.45: Imidazolines 62-64, and the di-cationic liquids 76-77 synthesised from 
imidazoline 62. 
  
2.3.3 Conclusion 
An efficient method for synthesising imidazolines which permit the addition of a variety of 
functional groups to the imidazoline scaffold, with a high level of diasteroselectivity, has 
been employed for the development of novel chiral ionic salts. These chiral ionic salts 
may hold future potential for a variety of applications including application as chiral 
selective agents in analytical separation techniques such as gas chromatography. A 
selection of ionic salts derived from the (4S,5S) anti-imidazolines were incorporated into 
GC stationary phases and tested for enantioselective capabilities and these results are 
discussed in Section 3.2.  
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2.3.4 Experimental 
2.3.4.1 Reagents:  
Alanine, phenylalanine, tryptophan, N-histidine monohydrate, NaOH, benzoyl chloride, 
Phenylacetylchloride, conc. HCl, N-(3-dimethylaminopropyl)-N’-ethyl-carbodiimide 
hydrochloride, DCM, Na2CO3, MgSO4, chlorotrimethylsilane, Benzylamine, Benzaldehyde, 
and pyridine-4-carboxaldehyde. All chemicals were purchased from Sigma Aldrich. 
 
2.3.4.2 Instruments 
Residual DMF was removed from the ionic salts by bulb-bulb distillation using a Buchi 
Kugelrohr (manufactured in Germany). Ionic salts were characterised by NMR, ESI-MS, 
and melting point. 1H and 13C-NMR data were recorded on a Bruker 300 spectrometer 
and the chemical shift values were recorded in ppm. All NMR structure elucidation was 
done from 1H-NMR, 13C-NMR, DEPT135, DEPT90, HSQCGP, and HH-COSYGPSW 
experiments. Mass spectroscopy data were obtained by Electro spray ionization (model) 
in positive ion mode, (in 1:1 acetonitrile/ H2O). Melting points were measured with a 
Gillkhenhamp Melting point apparatus (manufactures in England) and are uncorrected.  
 
2.3.4.3 Synthesis 
N-acylation of amino acids: general procedure 
One mole of amino acid in 1000 mL of 1N sodium hydroxide was stirred rapidly at 0 ˚C 
until a clear solution is obtained. To the solution was added 116 mL (1 N) of benzoyl 
chloride dropwise. The solution was stopper and shaken vigorously until the solution was 
completely mixed. The pH was monitored and an additional solution of 6N NaOH was 
added to maintain an alkaline pH. In reactions of more than one mole of amino acid, 
alkali of a higher concentration, 6N sodium hydroxide was used to dissolve the amino 
acid provided that the sodium salt of the benzoyl compound was sufficiently soluble at 0 
  
˚C to remain in solution. The reaction is complete when the reaction mixture has a clear 
yellow appearance and no oil droplets remain in the solution. The clear solution was 
made strongly acid to Congo red to precipitate the crude product by the slow addition of 
conc. hydrochloric acid with continuous stirring and cooling in ice/ water. The suspension 
was filtered and the crystals washed with ice-cold water. The product was dried in a 
vacuum desiccator over phosphorus pentoxide and sodium hydroxide, to remove any 
hydrochloric acid retained by the wet crystals.  
 
2-Benzoylamino-proprionic acid (N-Benzoyl-alanine) 41  
L-Alanine (4 g, 44.9 mM) in 100mL of water was acylated following the general N-
acylation procedure using 10 mL of a 6N sodium hydroxide solution and 6.31 mL (1 eq.) 
of benzoyl chloride. The pH was monitored and an additional solution of 6N sodium 
hydroxide was added to maintain an alkaline pH. The product was precipitated by 
acidifying to congo red with conc. hydrochloric acid to afford 41 in good yield: 8.26 g (95 
%): mp 94-97 ˚C; 1H-NMR (300 MHz, CDCl3-d/DMSO-d6): δ= 9.77 (s, 1H, -OH), 6.88-
6.72 (m, 3JH,H=14.1, 7.7, 7.2, 6.8 Hz, 5H, Ar-H), 3.92 (m, 
3JH,H=14.1, 7.7, 6.8 Hz, 1H, -
NCH), 0.84-0.80 (d, 3JH,H=7.2 Hz, 3H, -CH3); 
13C-NMR (75MHz, CDCl3-d/DMSO-d6): δ= 
179.6q, 171.9q, 138.6q, 137.5, 136.3, 134.4, 133.1, 132.2, 53.3, 22.5(CH3); ESI-MS: calcd 
m/z = 194.21 (M+H)+, found m/z = 194.0 (M+H)+. 
 
2-Benzoylamino-3-phenylproprionic acid (N-Benzoyl-phenyalainine) 42  
DL-Phenylalanine (3.74 g, 22.6 mM) in 200 mL of water was acylated following the 
general N-acylation procedure using 40 mL of a 6N sodium hydroxide solution and 2.63 
mL (1 eq.) of benzoyl chloride. The pH was monitored and an additional 6N solution 
sodium hydroxide was added to maintain an alkaline pH. The product was precipitated by 
acidifying to cong red with conc. hydrochloric acid to afford 42 in good yield: 5.1 g (74 
%): mp 160-164 ˚C; 1H-NMR (300 MHz, CDCl3-d/DMSO-d6): δ = 7.56 (s, 1H, -OH), 
7.45-6.62 (m, 9H, Ar-H), 4.25 (m, 1H, -NCH), 2.76-2.56 (m, 2H, -CHCH2); 
13C-NMR 
(75MHz, CDCl3-d/DMSO-d6): δ= 178.3q, 172.9q, 171.9q, 142.5q, 139.0q, 137.5, 136.3, 
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135.8q, 134.4, 134.1, 133.1, 133.1, 132.3, 131.4, 59.0, 41.8(CH2); ESI MS: calcd m/z = 
270.30 (M+H)+, found m/z = 270.1 (M+H)+. 
 
2-Benzoylamino-3-(1H-indol-3-yl)-proprionic acid (N-Benzoyl-tryptophan) 43  
DL-Typtophan (4 g, 19.0 mM) in 200 mL of water was acylated following the general N-
acylation procedure using 40 mL of a 6N sodium hydroxide solution 2.3 mL (1 eq.) of 
benzoyl chloride. The pH was monitored and an additional 6N solution of sodium 
hydroxide was added to maintain an alkaline pH. The product was precipitated by 
acidifying to congo red with conc. hydrochloric acid to afford 43 in good yield: 4.9 g (84 
%): mp 174-178 ˚C; 1H-NMR (300 MHz, CDCl3-d/DMSO-d6): δ = 9.82 (s, 1H, -OH), 
7.27-6.41 (m, 3JH,H = 15.1, 14.3, 7.0 Hz, 10H, Ar-H), 4.34 (d, 
3JH,H= 7.0 Hz, 1H, -NCH), 
2.84 (m, JH,H = 15.1, 14.3 Hz, 2H, -CHCH2); 
13C-NMR (75MHz, CDCl3-d/DMSO-d6): 
δ=178.7q, 173.0q, 171.8q, 141.2q, 139.0q, 137.5, 136.2, 135.8, 134.4, 133.1, 132.4q, 
132.2, 128.4, 126.1, 123.6, 123.3, 116.4, 114.8q, 58.5, 32.0(CH2); ESI-MS: calcd m/z = 
309.34 (M+H)+, found m/z = 309.2 (M+H)+. 
 
2-Benzoylamino-3-(1H-imidazol-4-yl)-proprionic acid (N-Benzoyl-histidine) 44  
L-Histidine-monohydrate (4 g, 28.7 mM) in 50 mL of water was acylated following the 
general N-acylation procedure using 20 mL of a 6N sodium hydroxide solution and 2.4 
mL (1 eq.) of benzoyl chloride. The pH was monitored and an additional solution of 6N 
sodium hydroxide was added to maintain an alkaline pH. The product was precipitated by 
the acidifying to congo red with conc. hydrochloric acid to afford 44 in good yield: 6.2 g 
(92 %): mp 179-184 ˚C; 1H-NMR (300 MHz, D2O): δ = 8.44 (s, 1H, -OH), 7.52 (d, 
3JH,H 
= 7.5 Hz, 2H, Ar-H), 7.42 (m, 3JH,H = 14.9, 7.5, 7.2 Hz, 1H, Ar-H), 7.33-7.28 (m, 
3JH,H= 
14.9, 7.2 Hz, 3H, Ar-H/Im), 7.14 (s, 1H, -CHim), 4.77 (m, 
3JH,H= 9.2, 5.3 Hz, 1H, -NCH), 
3.32-3.24 (m, JH,H=14.9, 9.2, 5.3 Hz, 2H, -CHCH2); 
13C-NMR (75MHz, D2O): δ= 173.4q, 
170.4q, 134.1q, 133.3, 132.5, 132.4q, 128.8q, 128.7, 127.1, 126.4q, 118.2, 117.1, 52.1, 
26.0(CH2), 25.0(CH2); ESI-MS: calcd m/z = 260.27 (M+H)
+, found m/z = 259.9 (M+H)+. 
 
  
2-Benzoylamino-pentanedioic acid (N-Benzoyl-glutamic acid) 45  
L-Glutamic acid (4.0 g, 27.2 mM) in 200 mL of water was acylated following the general 
N-acylation procedure using 40 mL of a 6N sodium hydroxide solution 3.2 mL (1 eq.) of 
benzoyl chloride. The pH was monitored and an additional solution of 6N sodium 
hydroxide was added to maintain an alkaline pH. The product was precipitated by 
acidifying to congo red with conc. hydrochloric acid to afford 45 in good yield: 5.9 g (86 
%): mp 114-116 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 8.67 (b, 2H, -OH), 8.06–7.86 (m, 
2H, Ar-H), 7.73–7.54 (m, 1H, Ar-H), 7.54–7.40 (m, 2H, Ar-H), 4.54–4.37 (m, 1H, -CH), 
2.39 (t, 3JH,H = 7.4 Hz, 2H,-CH2), 2.24–1.93 (m, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) 
δ = 173.9q, 173.4q, 166.6q, 131.3, 130.5q, 128.8, 127.4, 52.0, 30.4(CH2), 25.9(CH2); ESI-
MS: calcd m/z = 252.24 (M+H)+, found m/z = 524.1 (M+H)+. 
 
2-Phenylacetylamino-proprionic acid (N-Phenylacetyl-alanine) 46  
L-Alanine (4.0 g, 44.9 mM) in 50 mL of water was acylated following the general N-
acylation procedure using 5.7 mL of a 6N sodium hydroxide solution 5.95 mL (1 eq.) of 
phenyl-acetylchloride. The pH was monitored and an additional solution of a 6N solution 
of sodium hydroxide was added to maintain an alkaline pH. The product was precipitated 
acidifying to congo red with conc. hydrochloric acid to afford 46 in good yield: 6.1 g (65 
%): mp 84-92 ˚C; 1H-NMR (300 MHz, CDCl3-d/DMSO-d6): δ= 7.42 (s,
 1H, -OH), 6.75-
6.73 (m, 5H, Ar-H), 3.83 (m, 1H, -NCH), 2.99 (s, 2H, -CH2), 0.81 (d, 3H, -CH3); 
13C-NMR 
(75MHz, CDCl3-d/DMSO-d6): δ= 179.4q, 175.5q, 140.8q, 134.0, 133.2, 131.4, 52.8, 
47.4(CH2), ch3 22.6(CH3); ESI-MS: calcd m/z = 208.23 (M
+), found m/z = 208.1 (M+). 
 
3-Phenyl-2-phenylacetylamino-proprionic acid (N-Phenylacetyl-phenylalanine) 47  
DL-Phenylalanine (4 g, 24.2 mM) in 50 mL of water was acylated following the general N-
acylation procedure using 5.7 mL of a 6N sodium hydroxide solution 3.0 mL (1 eq.) of 
phenyl-acetyl chloride. The pH was monitored and an additional solution of 6N sodium 
hydroxide was added to maintain an alkaline pH. The product was precipitated by 
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acidifying to congo red with conc. hydrochloric acid to afford 47 in good yield: 4.3 g (62 
%): mp 109-112 ˚C; 1H-NMR (300 MHz, CDCl3-d/DMSO-d6): δ= 7.5-7.11 (m, 8H, Ar-H), 
6.93 (s, 1H, Ar-H), s5.86 (s, 1H, Ar-H), 4.82 (m, 1H, -NCH), 3.56 (d, 2H, -CH2), 3.08 (m, 
2H, -CHCH2); 
13C-NMR (75MHz, CDCl3-d/DMSO-d6): δ= 173.0q, 170.7q, 136.1q, 134.7q, 
129.3, 129.3, 128.8, 128.4, 128.3, 127.1, 126.7, 53.0, 43.4(CH2), 37.2(CH2); ESI-MS: 
calcd m/z = 284.33 (M+), found m/z = 284.1 (M+). 
 
3-(1H-indol-3-yl)-2-phenylacetylamino-proprionic acid (N-Phenylacetyl-tryptophan) 48  
DL-Typtophan (4 g, 19.6 mM) in 50 mL of water was acylated following the general N-
acylation procedure using 5.7 mL of a 6N sodium hydroxide solution 2.6 mL (1 eq.) of 
phenyl-acetyl chloride. The pH was monitored and an additional solution of 6N sodium 
hydroxide was added to maintain an alkaline pH. The product was precipitated by 
acidifying to congo red with conc. hydrochloric acid to afford 48 in good yield: 5.2 g (83 
%): mp 146-148 ˚C; 1H-NMR (300 MHz, CDCl3-d): δ=7.23-7.10 (m, 9H, Ar-H), 6.91(s, 
1H, Ar-HIndol), 6.55 (s, 1H, -OH), 4.74-4.68 (dd, JH,H= 13.3, 5.7 Hz , 1H, -NCH), 3.45 (s, 
2H, -CH2), 3.09-2.91 (m, 2H, -CHCH2); 
13C-NMR (75MHz, CDCl3-d/DMSO-d6): δ=178.4q, 
175.4q, 141.1q, 139.9q, 134.1, 133.3, 133.2, 132.5q, 131.6, 128.3, 126.1, 123.7, 123.3, 
116.22, 114.2q, 57.9, 47.9(CH2), 32.1(CH2); ESI-MS: calcd m/z = 323.37 (M
+), found m/z = 
323.2 (M+). 
 
3-(1H-Imidazol-4-yl)-2-phenylacetylamino-propionic acid (N-Phenylacetyl-histidine) 49  
L-Histidine-monohydrate (4 g, 20.9 mM) in 50 mL of water was acylated following the 
general N-acylation procedure using 5.7 mL of a 6N sodium hydroxide solution 2.8 mL (1 
eq.) of phenyl-acetyl chloride. The pH was monitored and an additional solution of 6N 
sodium hydroxide was added to maintain an alkaline pH. The product was precipitated by 
acidifying to congo red with conc. hydrochloric acid to afford 49 in good yield: 5.1 g (89 
%): RTIL; 1H-NMR (300 MHz, DMSO-d6) δ = 9.00 (s, 1H, -OH), 8.80 (d, JH,H = 7.5 Hz, 
1H, -CHIm), 7.50-7.14 (m, 6H, Ar-H/-CHIm), 4.53 (m, 1H, -CH), 3.45 (s, 2H,-CH2), 3.10 
(m, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 172.6q, 172.0q, 171.0q, 170.6q, 170.4q, 
  
169.4, 136.0q, 135.9q, 134.9q, 133.9, 133.3, 129.3, 128.9, 128.3, 128.2, 128.1, 127.09, 
126.5, 126.3, 117.9, 117.0, 116.8, 52.2, 51.3, 51.1, 41.9(CH2), 40.7(CH2), 25.9(CH2), 
25.08(CH2); ESI-MS: calcd m/z = 274.30 (M+H)
+, found m/z = 273.9 (M+H)+. 
 
Synthesis of oxazolones: general procedure 
A solution of N-acylated amino acid and N-ethyl,N’-(γ-dimethylaminopropyl)-carbodiimide 
hydrochloride in DCM were stirred at 0 ˚C for 1 hour for racemic amino acids and 15 
minutes for enantiomerically pure amino acids.  The solution was washed successively 
with ice water, followed by an ice cold aqueous solution of sodium hydrogen carbonate, 
and finally ice water. The DCM solution was then dried over magnesium sulphate, 
filtered, and DCM removed by rotary evaporation to give a pure oxazolone as an oil or 
crystals. 
 
4-Methyl-2-phenyl-4H-oxazol-5-one 50  
50 was synthesised following the general procedure for the synthesis of oxazolones using 
41 (3.0 g, 15.5 mM) in  155 mL of DCM and 2.98 g (1 eq.) of DCC to afford 50 as an oil 
in good yield: 1.8 g (67 %): 1H-NMR (300 MHz, CDCl3-d): δ= 8.07 (d, 
3JH,H= 8.3 Hz, Ar-
Hresonance), 7.90 (d, 
3JH,H= 8.1 Hz, 2H, Ar-H), 7.56-7.36 (m, JH,H= 8.1, 7.3, 6.2, 1.3 Hz, 
3H, Ar-H), 4.36 (q, 3JH,H= 7.7 Hz, 1H, -NCH), 1.50 (d, 
3JH,H= 7.7 Hz, 3H, -CH3); 
13C-NMR 
(75MHz, CDCl3-d); δ= 179.0q, 162.4q, 161.6q, 134.6, 132.8, 130.6, 128.9, 128.8, 127.9, 
125.8q, 61.0, 16.9(CH3). 
 
4-Benzyl-2-phenyl-4H-oxazol-5-one 51  
51 was synthesised following the general procedure for the synthesis of oxazolones from 
42 (4 g, 14.9 mM) in  150 mL of DCM and 2.85 g (1 eq.) of DCC to afford 51 as an oil in 
good yield: 3.2 g (87 %): 1H-NMR (300 MHz CDCl3-d): δ= 8.07 (d, 
3JH,H =7.7, 1H, Ar-H), 
7.82 (d, 3JH,H =7.4, 2H, Ar-H), 7.60-7.06 (m, 7H, Ar-H), 4.59 (t, 
3JH,H =5.1 Hz, 1H, -
NCH), 3.23-3.04 (m, JH,H = 5.1 Hz, 2H,CH2); 
13C-NMR (75MHz, CDCl3-d): δ= 177.6q, 
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162.4q, 161.8q, 135.3q, 134.6, 133.5, 132.8, 130.6, 130.1, 129.8, 128.9, 128.8, 128.5, 
127.9, 127.2, 125.7q, 66.5, 37.3(CH2). 
 
4-(1H-Indol-2-ylmethyl)-2-phenyl-4H-oxazol-5-one 52  
52 was synthesised following the general procedure for the synthesis of oxazolones from 
43 (4 g, 12.97 mM) in  130 mL of DCM and 2.49 g (1 eq.) of DCC to afford 52 in good 
yield: 3.4 g (90 %): 1H-NMR (300 MHz, CDCl3-d): δ= 8.21-8.04 (m, 
3JH,H = 8.5, 4.7 Hz, 
1H, Ar-H), 7.88-6.93 (m, 3JH,H =8.5, 5.7 Hz, 9H, Ar-H), 4.65 (m, 
3JH,H =14.7, 5.7 Hz, 1H, 
-NCH), 3.47-3.24 (m, JH,H =14.7, 8.5, 4.7 Hz, 2H, CH2); 
13C-NMR (75MHz, CDCl3-d): δ= 
178.0q, 161.9q, 136.0q, 134.7, 132.7, 130.6, 129.0, 128.7, 127.9, 127.4q, 125.7q, 123.6, 
122.0, 119.6, 119.2, 111.1, 109.4q, 66.5, 27.3(CH2). 
 
2-Benzyl-4-methyl-4H-oxazol-5-one 53  
53 was synthesised following the general procedure for the synthesis of oxazolones from 
46 (2.77 g, 13.4 mM) in  145 mL of DCM and 2.75 g (1 eq.) of DCC to afford 53 as a oil 
in good yield: 2.0 g (79 %); 1H-NMR (300 MHz, CDCl3-d): δ= 7.29-7.11 (m, 5H, Ar-H), 
4.12 (q, 3JH,H =7.8 Hz, 1H, -NCH), 3.70 (s, 2H, -CH2), 1.37 (d,
 3JH,H =7.8, 3H, -CH3); 
13C-
NMR (75MHz CDCl3-d): δ= 178.87q, 164.5q, 132.8q, 129.2, 128.9, 127.7, 60.5, 35.8(CH2), 
16.6(CH3). 
 
2,4-Dibenzyl-4H-oxazol-5-one 54  
54 was synthesised following the general procedure for the synthesis of oxazolones from 
47 (2.2 g, 7.77 mM) in 82 mL of DCM and 1.58 g (1 eq.) of DCC to afford 54 as an oil in 
good yield: 1.9 g (93 %). 
 
2-Benzyl-4-(1H-indol-2-ylmethyl)-4H-oxazol-5-one 55  
  
55 was synthesised following the general procedure for the synthesis of oxazolones from 
48 (4.9 g, 15.2 mM) in 160 mL of DCM and 3.1 g (1 eq.) of DCC to afford 55 in good 
yield: 4.2 g (91 %). 
 
Synthesis of amino acid derived imidazolines, general procedure: 
A solution of 1 molar equivalent of aldehyde and benzylamine in dry DCM was refluxed 
under nitrogen atmosphere for 2 hours. To the solution was added the oxazolone and 1.3 
molar equivalents of chlorotrimethylsilane and refluxed for 6-10 hours then stirred over 
night at room temperature. The solvent was removed by rotatary evaporation and the 
product isolated by flash chromatography with 100 % ethyl acetate then 100% 
methanol. 
 
1-Benzyl-4-methyl-2,5-diphenyl-4,5-dihydro-1H-imidazole-4-carboxylic acid 56  
To a solution of benzaldehyde (580 μL) and benzylamine (620 μL) in dry DCM (84 mL) 
was added oxazolone 50 (1 g, 5.71 mM) and chlorotrimethylsilane (580 μL) and refluxed 
for 6-10 hrs. The product was isolated by flash chromatography to afford 56 in good 
yield: 0.97 g (46 %): mp 57-60 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 7.96-6.94 (m, 
15H, Ar-H), 5.42-4.43 (b, 1H, -OH), 4.87 (d, 2JHH =16.3 Hz, 1H, -CH2), 4.63 (s, 1H, -
CH), 4.14 (d, 2JHH =16.3 Hz, 1H, -CH2), 1.59 (s, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) 
δ = 173.6q, 164.1q, 134.5q, 133.2, 133.2q, 132.6, 129.8, 129.3, 129.2, 128.9, 128.6, 
128.5, 128.38q, 127.9, 123.1q, 73.3, 69.6q, 48.4(CH2), 26.5(CH3); ESI-MS: calcd m/z = 
371.45 (M+H)+, found m/z = 371.3 (M+H)+. 
 
1,4-Dibenzyl-2,5-diphenyl-4,5-dihydro-1H-imidazole-4-carboxylic acid 57  
To a solution of benzaldehyde (410 μL) and benzylamine (440 μL) in dry DCM (84 mL) 
was added oxazolone 51 (1 g, 0.00398 M) and chlorotrimethylsilane (410 μL) and 
refluxed for 6-10 hrs. The product was isolated by flash chromatography to afford 57 in 
good yield: 0.91 g (51 %): mp 65 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 7.81-6.97 (m, 
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19H, Ar-H), 6.22 (d, 3JHH = 7.4 Hz, 1H, Ar-H), 4.81 (s, 1H, -CH), 3.94 (m, 2H, -CH2), 
3.25 (m, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 166.1q, 161.9q, 138.7q, 135.3q, 
133.7q, 132.8, 131.4q, 130.2, 129.2, 129.1, 129.0, 128.9, 128.9, 128.6, 128.5, 128.3, 
128.2, 127.7, 127.5, 127.1, 127.0, 126.3, 123.3q, 74.1, 71.3q, 48.0(CH2), 43.4(CH2); ESI-
MS: calcd m/z = 447.55 (M+H)+, found m/z = 447.4 (M+H)+. 
 
1-Benzyl-4-(1H-indol-3-ylmethyl)-2,5-diphenyl-4,5-dihydro-1H-imidazole-4-carboxylic 
acid 58  
To a solution of benzaldehyde (350 μL) and benzylamine (380 μL) in dry DCM (84 mL) 
was added oxazolone 52 (1 g, 3.44 mM) and chlorotrimethylsilane (350 μL) and refluxed 
for 6-10 hrs. The product was isolated by flash chromatography to afford 58 in good 
yield: 1.1 g (63 %): mp 185 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 7.95-6.90 (m, 19H, 
Ar-H), 6.03 (d, 3JHH = 7.5 Hz, 1H, Ar-H), 4.76 (s, 1H, -CH), 4.26 (m, 2H, -CH2), 3.26 (m, 
2H, -CH2);
 13C-NMR (75 MHz, DMSO-d6) δ = 168.0q, 161.8q, 139.6, 136.0q, 131.2q, 
130.8q, 129.0, 128.7q, 128.5q, 128.4, 128.3, 128.2, 127.9, 127.9, 127.5, 127.3, 127.0, 
126.8, 118.7q, 110.2q, 70.5, 63.9q, 48.6(CH2), 47.9(CH2); ESI-MS: calcd m/z = 486.58 
(M+H)+, found m/z = 486.4 (M+H)+. 
 
1,2-Dibenzyl-4-methyl-5-phenyl-4,5-dihydro-1H-imidazole-4-carboxylic acid 59  
To a solution of benzaldehyde (810 μL) and benzylamine (850 μL) in dry DCM (100 μL) 
was added oxazolone 53 (1.2 g, 6.34 mM) and chlorotrimethylsilane (990 μL) and 
refluxed for 6-10 hrs. The product was isolated by flash chromatography to afford 59 in 
good yield: 2.37 g (97 %): mp 206-208 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 8.75 
(s,1H, -OH), 7.69–6.97 (m, 14H, Ar-H),  6.70 (d, 3JHH = 6.9 Hz, 1H, Ar-H), 5.15 (m,  1H, 
-CH), 5.04 (s, 1H, -CH), 4.49 (s, 2H, -CH2), 3.91-3.82 (m, 1H, -CH2), 1.63 (s, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 169.3q, 167.3q, 134.1q, 132.8q, 132.1q, 129.6, 129.3, 
129.2, 129.1, 129.0, 128.8, 128.6, 128.4, 128.3, 128.1, 128.0, 127.7, 70.0q, 69.4, 
47.7(CH2), 30.9(CH2), 25.4(CH3); ESI MS: calcd m/z = 385.48 (M+H
+), found m/z = 385.3 
(M+H+). 
  
 
1,2,4-Tribenzyl-5-phenyl-1H-imidazole-4-carboxylic acid 60  
To a solution of benzaldehyde (450 μL) and benzylamine (480 mL) in dry DCM (85 μL) 
was added oxazolone 54 (1.0 g, 3.77 mM) and chlorotrimethylsilane (410 μL) and 
refluxed for 6-10 hrs. The product was isolated by flash chromatography to afford 60 in 
good yield: 1.4 g (83 %): mp 136.139 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 8.67 (s, 1H, 
-OH), 8.53 (d, 3JHH  = 8.5 Hz, 1H, Ar-H), 7.62-7.05 (m, 18H), 6.57 (d, 
3JHH  = 7.2 Hz, 
1H, Ar-H), 4.57 (m, 1H, -CH), 4.28 (m, 2H, -CH2), 3.44 (m, 2H, -CH2), 2.95 (m, 2H, -
CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.2q, 169.9q, 133.7q, 132.4q, 132.2q, 131.0, 
130.7q, 130.0, 129.4, 129.2, 129.0, 128.6, 128.5, 128.3, 128.2, 128.0, 127.7, 127.0, 
126.6, 126.2, 126.1, 73.8q, 70.4, 47.6(CH2), 37.8(CH2), 30.9(CH2); ESI-MS: calcd m/z = 
461.57 (M+H)+, found m/z = 461.4 (M+H)+. 
 
1,2-Dibenzyl-4-(1H-indol-3-ylmethyl)-5-phenyl-1H-imidazole-4-carboxylic acid 61  
To a solution of benzaldehyde (410 μL) and benzylamine (430 μL) in dry DCM (75 μL) 
was added oxazolone 55 (1 g, 3.29 mM) and chlorotrimethylsilane (370 mL) and refluxed 
for 6-10 hrs. The product was isolated by flash chromatography to afford 61 in good 
yield: 1.6 g (96 %): mp 146-148 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 10.84 (s, 1H, -
OH), 8.53 (t, JHH = 5.9 Hz, 1H, Ar-H), 8.33 (d, 
3JHH = 8.2 Hz, 1H, Ar-H), 7.64 (d, 
3JHH = 
7.8 Hz, 1H, Ar-H), 7.37 (d, 3JHH = 8.0 Hz, 1H, Ar-H), 7.31 – 6.94 (m, 16H, Ar-H), 4.64 
(m, 1H, -CH), 4.29 (d, JHH = 5.9 Hz, 2H, -CH2), 3.41 (s, 2H, -CH2), 3.10 (m, 2H –CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.5q, 169.9q, 139.2q, 136.3q, 136.1q, 129.0, 128.2, 
128.1, 127.3q 127.0, 126.6, 126.2, 123.7, 120.8, 118.5, 118.2, 111.2, 110.0q, 74.5q, 
70.1, 42.1(CH2), 42.0(CH2), 28.1(CH2); ESI-MS: calcd m/z = 500.61 (M+H
+), found m/z = 
500.4 (M+H+). 
 
1,2-Dibenzyl-4-methyl-5-pyridin-4-yl-1H-imidazole-4-carboxylic acid 62  
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To a solution of pyridine-4-carboxaldehyde (550 μL) and benzylamine (550 μL) in dry 
DCM (60 μL) was added oxazolone 53 (0.8 g, 4.23 mM) and chlorotrimethylsilane (460 
μL) and refluxed for 6-10 hrs. The product was isolated by flash chromatography to 
afford 62 in good yield: 1.63 g (100 %): mp 76-80 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 
8.80-8.44 (m, 3H, Ar-H/-OH), 7.80-6.98 (m, 11H, Ar-H), 6.53 (d, 3JHH = 7.3 Hz, 1H, Ar-
H), 5.05 (s, 1H, -CH), 4.41 (s, 2H, -CH2), 3.85 (m, 2H, -CH2), 1.65 (s, 3H, -CH3); 
13C-
NMR (75 MHz, DMSO-d6) δ= 172.6q, 155.2, 155.0q, 154.7, 134.5, 134.4, 134.0, 133.8, 
133.6, 133.5, 133.2, 133.0, 132.8, 132.1, 131.7q, 131.4, 128.0q, 73.4, 72.8q, 47.6(CH2), 
36.7(CH2), 25.4(CH3); ESI-MS: calcd m/z = 386.47 (M+H
+). found m/z = 386.3 (M+H+). 
 
1,2,4-Tribenzyl-5-pyridin-4-yl-4,5-dihydro-1H-imidazole-4-carboxylic acid 63  
To a solution of pyridine-4-carboxaldehyde (420 μL) and benzylamine (480 μL) in dry 
DCM (60 μL) was added oxazolone 54 (1.0 g, 3.77 mM) and chlorotrimethylsilane (410 
μL) and refluxed for 6-10 hrs. The product was isolated by flash chromatography to 
afford 63 in good yield: 1.6 g (94 %): mp 92-96 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 
8.80-8.41 (m, 3H, Ar-H/ -OH), 7.82 (d, 3JHH = 5.9 Hz, 1H, Ar-H), 7.61-7.08 (m, 16H, Ar-
H), 6.55 (d, 3JHH = 7.2 Hz, 1H, Ar-H), 5.14 (s, 1H, -CH), 4.52 (s, 2H, -CH2), 3.42 (m, 2H, 
-CH2), 2.88 (m, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.2q, 166.3q, 150.5, 
150.1, 133.3q, 132.8, 132.2q, 130.8, 130.0, 129.1, 129.2, 129.1, 129.0, 128.6, 128.5q, 
128.5, 128.3, 128.1, 128.0, 127.9, 127.4, 127.0, 126.6, 126.3q, 126.1, 122.8, 71.6, 
69.2q, 48.0(CH2), 43.9(CH2), 31.0(CH2); ESI-MS: calcd m/z = 462.56 (M+H
+). found m/z = 
462.4 (M+H+). 
 
1,2-Dibenzyl-4-(1H-indol-3-ylmethyl)-5-pyridin-4-yl-1H-imidazole-4-carboxylic acid 64  
To a solution of pyridine-4-carboxaldehyde (374 μL) and benzylamine (430 μL) in dry 
DCM (60 μL) was added oxazolone 55 (1.0 g, 3.29 mM) and chlorotrimethylsilane (370 
μL) and refluxed for 6-10 hrs. The product was isolated by flash chromatography to 
afford 64 in good yield: 1.3 g (80 %): mp 156 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 
8.88-8.41 (m, 3H, Ar-H/ -OH), 7.84-6.94 (m, 14H, Ar-H), 6.59 (d, 3JHH = 7.2 Hz, 1H, Ar-
  
H), 6.40 (d, 3JHH = 7.1 Hz, 1H, Ar-H), 6.17 (d, 
3JHH = 7.3 Hz, 1H, Ar-H), 5.02 (s, 1H, -
CH), 4.52 (s, 2H, -CH2), 3.78 (m, 2H, -CH2), 2.73 (m, 1H, -CH2); 
13C-NMR (75 MHz, 
DMSO-d6) δ = 171.6q, 169.2q, 150.0, 149.6, 132.2q, 131.5q, 131.5q, 129.5, 129.1, 
129.0, 128.7, 128.5q, 128.5, 128.5q, 128.3, 127.8, 127.6q, 127.3, 126.3, 125.5, 121.3, 
120.8, 119.1, 118.2, 111.7, 111.4, 110.0q, 74.5, 68.7q, 47.6(CH2), 42.1(CH2), 27.8(CH2); 
ESI-MS: calcd m/z = 501.60 (M+H+), found m/z = 501.4 (M+H+). 
 
General N-alkylation procedure  
To a stirring solution of imidazoline in dry DMF under nitrogen was added an alkyl halide 
and heated for 6 hrs at 90 ˚C. The solvent was evaporated by heating at 70-80 ˚C under 
negative pressure. The remaining residues of DMF were removed by bulb-to-bulb 
distillation using a kugelrohr. Further purification was carried out by recrystalisation from 
ethyl acetate and hexane. 
 
3-Benzyl-5-carboxy-1-ethyl-5-methyl-2,4-diphenyl-4,5-dihydro-3H-imidazol-1-ium; 
iodide 65  
Ionic salt 65 was synthesised from 56 (0.15 g, 0.405 mM) and 240 μL of ethyl iodide in 
3 mL of DMF following the general N-alkylation procedure to afford 65 in good yield: 0.19 
g (93 %): mp 54-56 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ= 8.35 (b, 1H, OH), 7.89-6.91 
(m, 15H, Ar-H), 5.34 (s, 1H, -CH), 4.77 (dd, 2JHH = 21.5, 16.2 Hz, 1H, -CH2), 4.04 (dd, 
2JHH = 21.5, 10.7 Hz, 1H, -CH2), 3.56,-3.48 (dq, 
3JHH = 16.3, 7.1 Hz, 2H, -CH2-CH3), 0.70 
(t, 3JHH = 7.1 Hz, 3H, -CH2-CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 174.4q, 166.0q, 
133.9q, 133.5, 132.8, 132.6q, 129.8, 129.3, 129.2, 129.0, 128.7, 128.5, 128.3, 127.7, 
122.5q, 73.0, 69.0q, 61.3(CH2), 48.7(CH2), 25.6(CH3), 13.3(CH3); ESI-MS: calcd m/z = 399.50 
(M+), found m/z = 399.3 (M+). 
 
1,3-Dibenzyl-5-carboxy-5-methyl-2,4-diphenyl-4,5-dihydro-3H-imidazol-1-ium; chloride 
66 
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Ionic salt 66 was synthesised from 56 (0.15 g, 0.405 mM) and 90 μL of benzyl chloride 
in 3 mL of DMF following the general N-alkylation procedure to afford 66 in good yield: 
0.23g (97 %): mp 66-70 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 9.43, (s, 1H, OH), 7.94-
6.84 (m, 20H, Ar-H), 5.02-4.94 (m, 1H, -CH), 4.81 (d, 2JHH = 15.3 Hz, 1H, -CH2), 4.63 
(d, 2JHH =12.5 Hz, 1H, -CH2), 4.40 (d, 
2JHH =12.6 Hz, 1H, -CH2), 4.12 (d, 
2JHH = 15.3 Hz, 
1H, -CH2), 1.74 (s, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 168.5q, 164.7q, 135.2q, 
134.1q, 133.6, 133.2, 132.8, 132.3q, 129.4, 129.3, 129.2, 129.1, 128.8, 128.5, 128.3, 
127.6, 127.5, 126.4, 122.5q, 73.3, 68.7q, 66.8(CH2), 48.8(CH2), 24.8(CH3); ESI-MS: calcd 
m/z = 461.57 (M+), found m/z = 461.4 (M+). 
 
3,5-Dibenzyl-5-carboxy-1-ethyl-2,4-diphenyl-4,5-dihydro-3H-imidazol-1-ium; iodide 67  
Ionic salt 67 was synthesised from 57 (0.11g, 0.247 mM) and 41 μL of ethyl iodide in 3 
mL of DMF following the general N-alkylation procedure to afford 67 in good yield: 0.14 g 
(95 %): mp 102 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 8.24 (b, 1H, -OH), 7.74-6.93 (m, 
19H, Ar-H), 6.04 (d, 3JHH = 7.3 Hz, 1H, Ar-H) 5.09 (s, 1H, -CH), 3.33 (q, 
3JHH = 7.3 Hz, 
2H, -CH2CH3), 2.98 (m, 2H, -CH2), 2.73 (m, 2H, -CH2), 1.14 (t, 
3JHH = 7.3 Hz, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 170.2q, 165.3q, 136.2q, 133.5q, 131.8q, 129.9, 129.3, 
129.0, 128.8q, 128.7, 128.6, 128.4, 128.3, 126.7, 126.4, 118.8, 74.9, 70.4q, 58.0(CH2), 
49.5(CH2), 41.9(CH2), 11.0(CH3); ESI-MS: calcd m/z = 475.60 (M
+), found m/z = 475.4 (M+). 
 
1,3,5-Tribenzyl-5-carboxy-2,4-diphenyl-4,5-dihydro-3H-imidazol-1-ium; chloride 68  
Ionic salt 68 was synthesised from 57 (0.12 g, 0.269 mM) and 64 μL of benzyl chloride 
in 3 mL of DMF following the general N-alkylation procedure to afford 68 in good yield: 
0.14 g (91 %): mp 116-118 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 9.21 (b, 1H, -OH), 
8.01-6.61 (m, 24H, Ar-H), 6.07 (d, 3JHH = 7.8 Hz, 1H, Ar-H), 5.14 (s, 1H, -CH), 4.27 (s, 
1H, -CH2), 4.10 (s, 1H, -CH2), 3.18 (s, 1H, -CH2), 3.08 (s, 1H, -CH2), 2.71 (s, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 169.6q, 165.7q, 131.9q, 131.2, 131.0, 130.5q, 130.4, 
130.2, 129.5, 129.3, 129.2, 128.7q, 128.5, 128.5, 128.3, 128.2, 127.7, 127.5, 127.4, 
  
126.5, 125.6, 120.0, 75.3, 64.9q, 59.2(CH2), 58.6(CH2), 49.6(CH2).; ESI-MS: calcd m/z = 
537.67 (M+), found m/z = 537.5 (M+). 
 
3-Benzyl-5-carboxy-1-ethyl-5-(1H-indol-3-ylmethyl)-2,4-diphenyl-4,5-dihydro-3H-
imidazol-1-ium; iodide 69  
Ionic salt 69 was synthesised from 58 (0.15 g, 0.309 mM) and 50 μL of ethyl iodide in 3 
mL of DMF following the general N-alkylation procedure to afford 69 in good yield: 0.19 g 
(98 %): mp 48 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 7.72-6.89 (m, 19H, Ar-H), 6.28 (d, 
3JHH = 7.4 Hz, 1H, Ar-H), 4.90 (s, 1H, -CH), 4.44 (m, 1H, -CH2), 3.75 (m, 1H, -CH2), 
3.33 (q, 3JHH  = 7.1 Hz, 1H, -CH2CH3), 3.04 (q, 
3JHH  = 7.1 Hz, 1H, -CH2CH3), 2.98 (s, 2H, 
-CH2), 1.12 (t, 
3JHH  = 7.1 Hz, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 170.0q, 
164.9q, 138.7q, 134.6q, 133.4, 132.8q, 132.5q, 131.4q, 130.9, 130.7, 130.1, 129.9, 
129.5, 129.4, 129.1, 129.0, 128.8, 128.7q, 128.6, 128.5, 128.3, 128.3, 128.2, 128.0, 
127.6, 127.4, 127.2, 127.0, 126.9, 122.5q, 75.1q, 70.3, 51.7(CH2), 48.3(CH2), 41.7(CH2), 
9.5(CH3); ESI-MS: calcd m/z = 514.64 (M
+), found m/z = 514.4 (M+). 
 
1,3-Dibenzyl-5-carboxy-5-(1H-indol-3-ylmethyl)-2,4-diphenyl-4,5-dihydro-3H-imidazol-
1-ium; chloride 70  
Ionic salt 70 was synthesised from 58 (0.15 g, 0.309 mM) and 86 μL of benzyl chloride 
in 3 mL of DMF following the general N-alkylation procedure to afford 70 in good yield: 
0.18 g (96 %): mp 54-56 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 7.95-6.95 (m, 22H, Ar-
H), 6.68 (m, 2H, Ar-H), 6.33 (d, 3JHH = 7.1 Hz, 1H, Ar-H), 4.75 (m, 1H, -CH), 4.52 (s, 
2H, -CH2), 3.95 (d, 
2JHH = 15.8 Hz, 1H, -CH2), 3.52 (d, 
2JHH = 15.8 Hz, 1H, -CH2), 3.23 
(s, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 170.3q, 165.1q, 138.5q, 137.9q, 134.9q, 
133.9q, 133.6q, 132.9, 132.7, 132.5q, 132.4, 131.2, 131.0, 130.9, 130.2, 130.1, 129.9, 
129.5, 129.3, 129.2, 129.1, 129.0, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 128.2, 
128.0, 127.9, 127.9, 127.8, 127.6, 127.5, 127.3, 127.2, 127.1, 127.0, 126.9, 126.5, 
126.2, 124.0q, 121.3q, 70.1, 66.8q, 49.3(CH2), 48.3(CH2), 42.1(CH2); ESI-MS: calcd m/z = 
576.71 (M+), found m/z = 576.5 (M+). 
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2,3-Dibenzyl-5-carboxy-1-ethyl-5-methyl-4-phenyl-4,5-dihydro-3H-imidazol-1-ium; 
iodide 71  
Ionic salt 71 was synthesised from 59 (0.4 g, 1.04 mM) and 133 μL of ethyl iodide in 3 
mL of DMF following the general N-alkylation procedure to afford 71 in good yield: 0.50 g 
(89 %): RTIL: 1H-NMR (300 MHz, DMSO-d6) δ = 8.18 (s, 1H, -OH), 7.90-678 (m, 14H, 
Ar-H), 6.36 (d, 3JHH = 6.0 Hz, 1H, Ar-H), 5.16 (s, 1H, -CH), 4.96 (d, 
2JHH = 15.0 Hz, 1H, -
CH2), 4.12 (d, 
2JHH = 15.0 Hz, 1H, -CH2), 3.86 (q, 
3JHH = 7.1 Hz, 1H, -CH2), 1.60 (s, 3H, -
CH3), 0.95 (t, 
3JHH = 7.1 Hz, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 172.7q, 169.3q, 
133.2q, 132.3q, 129.5, 129.3, 129.2, 129.0, 128.9, 128.6, 128.6, 128.5, 128.5, 128.3, 
128.0, 127.8q, 127.7, 71.9q, 69.2, 49.4(CH2), 47.5(CH2), 42.3(CH2), 25.6(CH3), 19.1(CH3); ESI-
MS: calcd m/z = 413.53 (M+), found m/z = 413.3 (M+). 
 
1,2,3-Tribenzyl-5-carboxy-5-methyl-4-phenyl-4,5-dihydro-3H-imidazol-1-ium; chloride 
72  
Ionic salt 72 was synthesised from 59 (0.5 g, 1.43 mM) and 187 μL of benzyl chloride in 
3 mL of DMF following the general N-alkylation procedure to afford 72 in moderate yield: 
0.4 g (54 %): mp 176-178 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 8.64 (s, 1H, -OH), 
7.60-6.86 (m, 19H, Ar-H), 6.72 (d, 3JHH = 7.0 Hz, 1H, Ar-H), 5.16 (m, , 1H, -CH2), 5.05 
(s, 1H, -CH), 4.45 (s, 2H, -CH2), 3.92 - 3.83 (m, 1H, -CH2), 1.63 (s, 3H, -CH3); 
13C-NMR 
(75 MHz, DMSO-d6) δ = 172.7q, 167.3q, 132.8q, 132.3q, 132.0q, 131.0q, 129.6, 129.2, 
129.2, 128.9, 128.8, 128.6, 128.5, 128.3, 128.1, 127.9, 127.7, 72.4, 69.4q, 47.7(CH2), 
42.1(CH2), 31.0(CH2), 25.5(CH3), 19.7(CH3); ESI-MS: calcd m/z = 475.60 (M
+), found m/z = 
475.4 (M+). 
 
2,3,5-Tribenzyl-5-carboxy-1-ethyl-4-phenyl-4,5-dihydro-3H-imidazol-1-ium; iodide  73  
Ionic salt 73 was synthesised from 60 (0.4 g, 0.868 mM) and 120 μL of ethyl iodide in 3 
mL of DMF following the general N-alkylation procedure to afford 73 in good yield: 0.46 g 
(86 %): dark oil: 1H-NMR (300 MHz, DMSO-d6) δ = 8.27 (s, 1H, -OH), 7.90 (d, 
3JHH = 8.3 
  
Hz, 1H, Ar-H), 7.76 – 6.94 (m, 18H, Ar-H), 6.76 (m, 1H, Ar-H), 4.58 (m, 1H, -CH), 4.28 
(d, 1H, -CH2), 3.85 (d, 
2JHH = 14.9 Hz, 1H, -CH2), 3.43 (q, 
3JHH = 7.1 Hz, 2H, -CH2), 3.04 
(m, 2H, -CH2), 2.81 (m, 2H, -CH2), 1.06 (t, 
3JHH =7.1 Hz, 3H, -CH3); 
13C-NMR (75 MHz, 
DMSO-d6) δ = 171.1q, 170.1q, 161.1q, 139.0q, 138.8q, 137.7q, 136.1q, 136.1q, 134.6, 
134.2q, 134.1q, 133.7q, 133.4q, 133.2q, 130.6, 130.1, 129.9, 129.8, 129.5, 129.2, 129.2, 
128.9, 128.8, 128.7q, 128.6, 128.5, 128.3, 128.3, 128.2, 128.1, 127.9, 127.45, 127.2, 
127.1, 127.0, 126.9, 126.7, 126.3, 126.2, 76.1q, 73.7q, 69.8, 69.6, 49.2(CH2), 44.6(CH2), 
40.7(CH2), 37.7(CH2), 13.9(CH3), 13.8(CH3); ESI-MS: calcd m/z = 489.63 (M
+), found m/z = 
489.4 (M+). 
 
2,3-Dibenzyl-5-carboxy-1-ethyl-5-(1H-indol-3-ylmethyl)-4-phenyl-4,5-dihydro-3H-
imidazol-1-ium; iodide 74  
Ionic salt 74 was synthesised from 61 (0.5 g, 1.0 mM) and mL of ethyl iodide in 3 mL of 
DMF following the general N-alkylation procedure to afford 74 in moderate yield: 0.28 g 
(43 %): mp dark oil: 1H-NMR (300 MHz, DMSO-d6) δ = 10.89 (s, 1H, -OH), 8.56 (s, 1H, 
Ar-H), 8.37 (d, 3JHH = 8.2 Hz, 1H, Ar-H), 7.73 – 6.87 (m, 19H, Ar-H), 4.60 (dd, JHH = 
14.0, 8.3 Hz, 1H, -CH), 4.26 (m, 2H, -CH2), 3.45 (s, 2H, -CH2), 3.26 – 2.89 (m, 4H, -CH 
& -CH2), 0.98 (t, 
3JHH = 7.2 Hz, 3H); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.6q, 169.9q, 
139.2q, 136.3q, 136.1q, 134.1, 128.9, 128.9, 128.5, 128.4, 128.1, 128.0, 127.3q, 126.9, 
126.6, 126.1, 123.7, 120.8, 118.5, 118.2, 111.2, 110.0q, 74.1q, 71.6, 54.4(CH2), 42.1(CH2), 
42.0(CH2), 28.1(CH2), 15.6(CH3); ESI-MS: calcd m/z = 528.66 (M
+), found m/z = 528.5 (M+). 
 
1,2,3-Tribenzyl-5-carboxy-5-(1H-indol-3-ylmethyl)-4-phenyl-4,5-dihydro-3H-imidazol-1-
ium; chloride 75  
Ionic salt 75 was synthesised from 61 (0.5 g, 1.0 mM) and 155 μL of benzyl chloride in 3 
mL of DMF following the general N-alkylation procedure to afford 75 in good yield: 0.47 g 
(75 %): mp 132-136 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 11.03 (s, 1H, -OH), 8.67 (m, 
1H, Ar-H), 8.50 (d, 3JHH = 8.2 Hz, 1H, Ar-H), 7.66-6.95 (m, 23H, Ar-H), 4.64 (dd, JHH = 
13.9, 8.2 Hz, 1H, -CH), 4.29 (m, 2H, -CH2), 4.02 (s, 2H, -CH2), 3.49 (s, 2H, -CH2), 3.29 
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– 2.99 (m, 2H, -CH2); 
13C-NMR (75 MHz, DMSO-d6) δ = 171.7q, 170.1q, 139.2q, 136.3q, 
136.1q, 135.9q, 134.5q, 134.0q, 132.6q, 132.2q, 131.6, 130.2, 129.0, 128.8, 128.7, 
128.5, 128.3, 128.2, 128.1, 127.6, 127.3q, 127.0, 126.6, 126.2, 123.8, 120.8, 118.5, 
118.2, 111.3, 110.0q, 71.8, 70.0q, 54.4(CH2), 42.1(CH2), 42.0(CH2), 28.1(CH2), 25.1(CH2); ESI-
MS: calcd m/z = 590.73 (M+), found m/z = 590.5 (M+). 
 
Dicationic pyridinium IL 
2-Benzyl-5-carboxy-1-ethyl-4-(1-ethyl-pyridin-4-ium; iodide)-5-methyl-3-(2-methylene-
pent-3-enyl)-4,5-dihydro-3H-imidazol-1-ium; iodide 76  
Di-cationic salt 76 was synthesised from 62 (0.3 g, 0.779 mM) and 177 μL of ethyl 
iodide in 3 mL of DMF following the general N-alkylation procedure to afford 76 in good 
yield: 0.47 g (87 %): mp RTIL ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 8.27 (m, 3H, Ar-H/ 
-OH), 7.56-6.80 (m, 12H, Ar-H), 5.03 (s, 1H, -CH), 4.67 (s, 2H, -CH2), 4.24 (d, JHH  = 
6.1 Hz, 2H, -CH2), 3.46 (m, 2H, -CH2), 1.52 (m, 
3JHH = 7.2 Hz, 6H, -CH3), 1.24 (t, 
3JHH = 
7.1 Hz, 3H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 172.7q, 164.3q, 145.2, 139.2q, 
136.2q, 136.1q, 129.3, 129.0, 129.0, 128.2, 128.1, 127.1, 126.9, 126.7, 126.6, 126.3, 
72.3, 69.8q, 42.3(CH2), 42.1, 41.8(CH2), 40.3(CH2), 18.3(CH3), 17.2(CH3), 16.3(CH3); ESI-MS: 
calcd m/z = 221.79 (M2+), found m/z = 221.5 (M2+). 
 
1,2,3-Tribenzyl-4-(1-benzyl-pyridin-4-ium; chloride)-5-carboxy-5-methyl-4,5-dihydro- 
3H-imidazol-1-ium; chloride 77  
Di-cationic salt 77 was synthesised from 62 (0.3 g, 0.779 mM) and 150 μL of benzyl 
chloride in 3 mL of DMF following the general N-alkylation procedure to afford 77 in good 
yield: 0.4 g (81 %): mp 158-162 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 9.16 (b, 1H, -
OH), 8.60-8.52 (m, 2H, Ar-H), 7.59-7.04 (m, 21H, Ar-H), 6.67 (s, 1H, Ar-H), 5.20 (m, 
1H, -CH), 4.23 (s, 2H, -CH2), 4.10 (s, 2H, -CH2), 3.47 (m, 2H, -CH2), 1.20 (m, 3H, -
CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 172.5q, 170.0q, 139.3q, 136.3q, 129.1, 129.0, 
129.0, 128.6, 128.4, 128.1, 128.1, 127.1, 126.9, 126.6, 126.2, 72.2, 69.8q, 48.6(CH2), 
  
47.8(CH2), 41.9(CH2), 41.8(CH2), 18.3(CH3), 17.2(CH3); ESI-MS: calcd m/z = 283.86 (M
2+), 
found m/z = 283.7 (M2+). 
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2.4 Synthesis of cyclodextrin ionic liquids. 
 
2.4.1 Introduction 
Cyclodextrins (CDs) have been catapulted into prominence in the last few decades 
because of their catalytic,85 enzyme mimic,86 complexation,87,88 drug encapsulation,89 
asymmetric,90 and molecular recognition91 behaviour. They are also used in purification, 
stabilization of products, polymerization, food preservation, chemical treatment, and 
other industrial processes.92 Since structural and available functional group limitations 
have hindered their utility, these molecules have been subjected to exhaustive synthetic 
manipulations and a large number of practical methods have been developed for their 
modifications. 
 
As chiral entities, selectively modified CDs have the potential for utilization in asymmetric 
synthesis, molecular recognition, molecular switches, and chiral separations.93 Since they 
are expected to be nontoxic and form complexes with various flavours, perfumes, 
vitamins, and essential oils,94 they have a promising future in biodegradable materials95 
and health-related products. Synthesis of artificial receptors that recognize and bind with 
transition metals is an important field96 which could find application in waste treatment. 
Modified cyclodextrins show better complexing behaviour than native cyclodextrins and 
hold greater potential for the formulation of slow-releasing drugs.97 CDs are 
spectroscopically inert and can be converted to photosensitive molecules by attachment 
of chromophores to function as chemosensors.91 Theoretical studies of cyclodextrins98,99 
and their derivatives100 with computer-generated 3D modelling provided information 
about their lipophilic,101 hydrophobic, and complexation102 behaviour. This insight has led 
to a better understanding in devising new synthetic approaches and applications for CD 
molecules. 
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Figure 2.46: Structure of β-cyclodextrin. 
 
The native cyclodextrin (α, β and γ cyclodextrins) are cyclic oligosaccharides, consist of 
six, seven and eight 1-4 linked α-D-glucopyranose units, respectively. Interest in these 
compounds stems from the fact that they act as host molecules, forming inclusion 
complexes with a wide variety of guest molecules (Figure 2.47).103-105 These CDs 
naturally exist as a single enantiomer, consequently, when they act as host molecules to 
a racemic guest, they can form inclusion complexations which lead to the formation of 
diastereoisomeric complexes of differing thermodynamic stability resulting in chiral 
discrimination. This has been intensively studied, most notably through the work of 
Armstrong et al.106,107 in the development of CD based chromatographic systems. The 
extent of chiral discrimination displayed by CDs is typically quite modest, with efficient 
resolution of racemates predominantly being attributed to the repeated interactions with 
the cyclodextrin. This low enantioselectivity is associated with the inherent symmetry of 
these oligosaccharides. In addition, inclusion complex formation often occurs principally 
as a result of interaction between the hydrophobic portion of the cyclodextrin with the 
guest molecule within the hydrophobic annulus of the cyclodextrin, rather than 
interaction with the CDs chiral centers. Thus, chiral discrimination can be increased with 
modified CDs whereby, the degree of asymmetry of the cyclodextrin is increased and 
there is increased interaction between the chiral sites of the cyclodextrins with those of 
the guests. 
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Figure 2.47: Guest-host inclusion complexation between CD and a guest molecule. 
  
Modifying cyclodextrins and their complexing characteristics usually involves 
derivatisation of one or more of the C-2, C-3 and C-6 hydroxy groups. The modifications 
can be divided into two categories, symmetric and asymmetric substitution patterns. 
Symmetric modification can be accomplished by two methods; the symmetric 
substitution to give a single modified cyclodextrin product (eg, all the hydroxy groups 
may be substituted). Secondly, random substitution resulting in a complex mixture of 
cyclodextrins where by the over all effect is equivalent to that of symmetric substitution. 
Symmetric substitutions tend not to alter the symmetry of the cyclodextrin. Thus, 
symmetrically substituted cyclodextrins tend to show no better chiral discrimination than 
the naturally occurring CDs. With asymmetric modification patterns, a single or a specific 
combination/ or number of substituents is introduced. This tends to induce significant 
changes in the asymmetry of the cyclodextrin and results in additional and more specific 
interactions between the chiral area of the guest and the asymmetry of the host. As a 
result this may restrict the host binding geometry, leading to greater enantioselectivity. 
 
Although native CDs are able to resolve some enantiomers108 this ability can be enhanced 
in many cases by their derivatisation. Each glucose unit of the native CDs has two 
secondary hydroxy groups on C-2 and C-3 positions and one primary hydroxy group on 
the C-6 position which can be derivatized readily by a wide variety of substituents. 
Therefore, additional interactions, such as π–π interactions, dipole–dipole interactions, 
ion-paring, electrostatic and steric repulsive effects can be introduced between the 
  
guest-analytes and the appropriately derivatized CDs. In this way, the chromatographic 
properties and the chiral recognition as well as the solubility and complex-forming 
capacity of the CDs can be improved. Therefore, the range of enantiomeric compounds 
that can be resolved with CDs has been greatly expanded.109-111        
 
Selective functionalization of the primary and the secondary hydroxy groups is 
complicated by statistical and steric problems. Several strategies have been developed to 
selectively functionalise either all the primary hydroxy groups or all the secondary 
hydroxy groups, however the complexity of the problem is increased if control on the 
degree of functionalisation such as mono-, di- or tri-substitutions, is desired. The 
methods available to achieve such control are often tedious and produce low yields.112 
Among these methods, selective monotosylation at the C6 positions (Figure 2.48) is 
straight forward,113 however, the secondary side (inner rim) has been shown to be the 
most important for CD binding studies.114 Although functionalisation of the secondary 
hydroxy groups is the most difficult, they are more important in the design and synthesis 
of chiral discriminating cyclodextrins.  
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Figure 2.48: Selective β-CD monotosylation product. 
 
In order to apply various derivatization methods for the syntheses of new CDs, it is 
important to understand the statistical and steric problems, as well as, various chemical 
factors which complicate the selective modification of the primary and the secondary 
hydroxy groups. The rotation of the secondary hydroxy groups at the 2- and 3-positions 
of adjacent glucose units is restricted forming of a ‘belt’ of intramolecular hydrogen 
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bonds which gives the oligosaccharide structural rigidity and the wider rim on the 
secondary side of the CD cavity, while the rotation of the primary hydroxy groups is not 
restricted, which is attributes to the smaller cavity diameter observed on the primary 
side of the molecule.104 The presence of the polar primary and secondary hydroxy groups 
makes the upper and lower end of the molecule hydrophilic while the cavity of 
cyclodextrins is hydrophobic due to the presence of glycosidic oxygens and C-H groups. 
The internal diameter of the cavity on the secondary side varies in size from 5.7 to 9.5 Å 
as the number of glucose units increases from α-CD to γ-CD, respectively, with β-CD 
having an internal diameter of 7.8 Å.115 NMR analysis of native β-CD in DMSO-d6 
illustrates the symmetric nature of cyclodextrin structure. Figure 2.49 shows the 13C-NMR 
spectra (i) and DEPT experiments which allow the determination of CH from CH2 carbons. 
DEPT135 experiment (iii) shows the C6 CH2 carbons as an inverse peak at 59.9 ppm, 
while the DEPT90 (ii) shows only the CH peaks corresponding to C1-C5 carbons. 
Modification of cyclodextrin yields complex chemical shift patterns depending on the type 
of modification carried out and the substituents used in the modification.  
 
 
O
O
O
O
O
O
O
OH
OH
OH
HO
HO
HO
OH
O
O
O
O
O
HO
OH
OH
OH
HO
HO
HO
OH
O
HO
HO
HO
OH
OH
OH
  
Figure 2.49: Native β-CD; A) i) 13C-NMR with ii) DEPT90 and iii) DEPT135 experiments 
and iv) 1H-NMR in DMSO-d6. 
 
Two main factors need to be considered in the chemical modification of cyclodextrins, the 
nucleophilicity of the hydroxy groups and the ability of cyclodextrins to form complexes 
with the reagents used. All modifications of cyclodextrins take place at the hydroxy 
groups. Of the three different hydroxyl groups present in cyclodextrins, the C6 primary 
hydroxy units are the most basic, with C2 secondary hydroxy groups being the most 
acidic, while C3 secondary hydroxyl groups are the most sterically inaccessible.116,117 
Consequently, an electrophilic reagent is more inclined to react with the C6 primary 
hydroxy groups. However, a more reactive reagent will attack the hydroxy groups with 
less selectivity. Thus, the more reactive reagents will not only react with C6 hydroxy 
groups but also with those on the secondary side C2 and C3 positions, whereas, a less 
reactive reagent will react selectively with the C6 hydroxy groups. An example of this is 
the application of the derivatising agents tert-butyldimethylsilyl chloride (TBDMSCl) and 
trimethylsilyl chloride (TMSCl). The less reactive more bulky reagent TBDMSCl reacts 
selectively with hydroxy groups at the 6-positions,118 to give 90 % of the major product 
under optimal conditions and the derivative can be easily isolated by flash column 
chromatography or by recrystallization.119 The smaller, more reactive TMSCl reacts with 
all the hydroxy groups non-selectively (Figure 2.50).120 
 
O
HO
O
OH
O
7
O
O
O
O
7
O
Si
Si
Si
Si
A B  
Figure 2.50: TBDMSCl and TMSCl β-CD derivatives A and B, respectively. 
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The ability of cyclodextrins to form complexes introduces an additional factor in 
determining the substitution pattern.121 If the complex formed with the reagent is very 
strong, the predominant product formed is dictated by the orientation of the reagent 
within the complex. If the complex is weak, then the relative nucleophilicities of the 
hydroxy groups dictate the product formed. Solvents play an important role in 
determining the strength and the orientation of the complex formed between the reagent 
and cyclodextrin. This is evident when tosyl chloride reacts with α-cyclodextrin in pyridine 
to give the 6-tosylated product, whereas, in aqueous base, the 2-tosylated derivative is 
the product.122 The size of the cyclodextrin cavity also has a marked effect on the 
strength and the orientation of the reagent complex, thus, affects the product of the 
reaction. For example, reaction of tosyl chloride in aqueous solution with α-cyclodextrin 
gives the 2-substituted product; whereas with β-cyclodextrin, the 6-substituted product 
is formed (Figure 2.48).112 
 
for the synthesis of C2 and C3 derivatives, the per-6-iodo-cyclodextrins is a very useful 
intermediate product from which further functionalisation with imidazolium or pyridinium 
moieties at the C6 position is permitted to afford novel ionic cyclodextrins with improved 
solubilities in less polar organic solvents than native CDs. The synthesis of these new 
ionic cyclodextrins per-2,3-O-acetyl-6-imidazolinium-β-cyclodextrin iodide, per-2,3-O-
acetyl-6-pyridinium-β-cyclodextrin iodide,  per-2,3-O-acetyl-6-imidazolium-γ-
cyclodextrin iodide, and per-2,3-O-acetyl-6-pyridinium-γ-cyclodextrin iodide is discussed 
and their thermal stabilities assessed for applicability as GC stationary phases. 
 
2.4.2 Results and discussion 
Primary hydroxy groups are more nucleophilic than their secondary counterparts, they 
are easily transformed into other functionalities. Herefore our focus was directed toward 
the selective derivatisation of these primary hydroxyl groups. Ideally the best 
cyclodextrin candidates for application as GC chiral selectors are asymmetrically 
substituted CDs. Modification of one -OH functional group is the simplest way to produce 
  
an asymmetrical mono-substituted CD. A convenient and widely used intermediate for 
modifying of one of the C6 hydroxy group on the primary side of CD into other functional 
groups such as amino,113,123 thioalkyl,124 halo,113 and formyl125 is mono-6-(p-
tolylsulfonyl)-6-OH-β-CD 78 (Figure 2.51). Thus this mono-6-(p-tolylsulfonyl)-6-OH-β-
CD was synthesised with the aim to directly synthesise a mono-6-imidazolium-6-OH-β-
CD (Figure 2.52). 
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Figure 2.51: Structure of mono-6-(p-tolylsulfonyl)-6-OH-β-CD (78). 
 
Mono-6-(p-tolylsulfonyl)-6-OH-β-CDs are typically prepared by the reaction of CD with p-
toluenesulfonyl chloride in dry pyridine112,113 or in aqueous acetonitrile at alkaline 
pH.112,113,124,126 This method has produced very low yields of 6 %,126 11 %,123 or 17 %,124 
and forming multi-tosylated by-products from which 78 must be isolated by 
chromatography.112  However, in 1998 Zhong et al.127 reported an easy large-scale 
synthesis of 78 as a single product in reasonable yield, avoiding the production of the 
multitosylated byproducts generated by other methods. Following this method p-
toluenesulfonic anhydride (Ts2O) was added to an aqueous solution of β-CD, subsequent 
addition of 10 % aqueous NaOH solution induced the tosylation reaction, affording 78 as 
the sole product in 49 % yield without the need for further purification. After filtration to 
remove the unreacted Ts2O, the product was isolated by precipitation at 4 ˚C overnight 
in alkaline medium (pH 8 with aq. NH4Cl). 
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Figure 2.52: i) β-CD and Ts2O at r.t for 2 hrs, add 10 % (aq) NaOH, react for 10 mins, 
ii) heat 78 and imidazole or pyridine for 24 hrs at 90 ˚C in DMF, iii) Reflux 78 with KI in 
DMF for 1 hrs, iv) heat mono-6-iodo-6-OH-β-CD with an imidazole or pyridine in DMF at 
90 ˚C for 24 hrs. 
 
The tosylate substituent has been described by Muderawan et al. to be displaced by 3-
methylimidazole (as well as pyridine and alkylamines) upon heating of 6-monotosyl-β-CD 
with imidazole at 90 ˚C in DMF for 48 hrs to afford a mono-6-(3-methylimidazolium)-β-
CD iodide in 99 % yield.128 Replication of these experiments did not yield the imidazole 
substituted β-CD (only starting material 78). Comparison of the melting point of the 
isolated CD 78 (195-196 ˚C) with those reported in literature by Melton and Slessor 
(159-162 ˚C), suggesting that mono-6-(p-tolylsulfonyl)-6-OH-β-CD might not have been 
isolated. No melting point were reported by Zhong et al.127 so a comparison with their CD 
isolate was not possible. 
 
Unable to substitute the tosyl group with an imidazole or pyridine, our focus should have 
been directed towards substituting the CD-tosyl group with iodine. Sulphonate groups are 
described as being readily displaceable by nucleophilic substitution with a variety of 
nucleophiles including iodine to afford mono-6-iodo-6-OH-β-CD by Melton and Slessor, in 
hindsight we recommend the further pursuit to displace the tosylate group with an iodide 
following the method described by Melton and Slessor in which 78 is boiled in water or 
DMF with excess NaI to afford  mono-6-iodo-6-OH-β-CD.113 With mono-6-iodo-6-OH-β-
  
CD nucleophilic substitition with an imidazole would take place more readily to yield the 
desired ionic mono-6-imidazolium-6-OH-β-CD iodide. Using this ionic mono-6-substituted 
CD, a series of asymmetrical mono-ionic CDs with various derivatives at the remaining 
hydroxyl groups with improved solubilities could potentially be synthesised for application 
as GC chiral selecting agents. Such mono-ionic CDs would be novel and highly desirable 
for this application.  
 
Selective per-modification of all the primary hydroxyl groups is easier than mono-, di-, or 
trisubstitution because symmetrical substitution is achieved when the reaction is allowed 
to run for a longer time with appropriate amounts of reagents. The formation of 
regioisomeric products (Figure 2.53) further complicates this situation when selective di- 
or trisubstituted cyclodextrins are required to be prepared, so that the reaction products 
require chromatographic purification. 
 
 
Figure 2.53: An illustration of the possible regioisomers for di- and tri-substitution 
patterns of β-CD where by each circle represents one derivatized glucose subunit. 
 
Given the difficulty in synthesizing mono-6-iodo-6-OH-β-CD, our focus was directed 
towards the preparation of per-substituted 6-iodo-β-cyclodextrin 79 and 6-iodo-γ-
cyclodextrin 80 from which per-2,3-O-acetyl-6-iodo-β-cyclodextrin 81 and per-2,3-O-
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acetyl-6-iodo-γ-cyclodextrin 82 can be synthesised (see Figure 2.56). From these per-
2,3-acetyl-6-iodo-cyclodextrins it is possible to synthesise a large variety of highly 
charged ionic CDs with seven or eight ionic substituents, respectively, on the primary 
side in high yields. 
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Figure 2.54: Synthesis of per-6-deoxy-6-iodo-β-CD To a solution of triphenylphosphine 
and iodine in DMF was added cyclodextrin and reacted at 80 ˚C for 18 hrs. 
Per-6-deoxy-6-iodo-β-cyclodextrin was synthesised from native β-cyclodextrin and native 
γ-cyclodextrin by nucleophilic substitution of the C6 hydroxy substituents with iodine 
using triphenylphosphine (Ph3P) dissolved in anhydrous DMF (Figure 2.56).
129 The crude 
product was isolated by precipitation in ice-water and collected by filtration to afford an 
off-white product at 90 % (79) and 87 % (80) yield. The 13C-NMR spectrum of per-6-
iodo-β-cyclodextrin in DMSO-d6 is shown in Figure 2.55 (ii); in the sugar region it is 
similar to that of native β-cyclodextrin (Figure 2.55 (ii)) with the exception of C6, 
substitution of the C6 hydroxyl groups with iodine leads to an upfield shift of the α-
carbon (C6) from 59.9 to 9.5 ppm, proportional to the electronegativity of the 
substituent, resulting from iodine being less electronegative than oxygen, but a smaller 
upfield shift of the β-carbon (C5) typical of the electron-withdrawing inductive effect, 
while the γ-carbon (C4) experiences a downfield shift. This is illustrated in Figure 2.55 by 
13C-NMR and DEPT experiments.  
 
  
 
Figure 2.55: 13C-NMR spectra of (ii) Per-6-deoxy-6-iodo-β-cyclodextrin compared with 
(i) native β-cyclodextrin (DMSO-d6). 
 
Per-6-deoxy-6-halogenated cyclodextrins are an important class of compounds which can 
be used for the selective functionalization of the primary face because of their great 
stability. However, their use is limited because of their insolubility in less polar solvents. 
They are only soluble in polar high boiling solvents such as pyridine, DMF, DMSO, or 
HMPA. Their solubility in nonpolar solvents can be increased by methylation or 
esterification of the secondary hydroxyl groups. The secondary side of the halogenated 
cyclodextrins can be acetylated with acetic anhydride in pyridine in high yields for further 
selective functionalization.130,131  
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Figure 2.56: Reaction scheme for the synthesis of per-6-deoxy-6-iodo-cyclodextrins 79-
80 from native β-cyclodextrin, followed by the synthesis of C2- and C3-O-acetylated per-
6-deoxy-6-iodo-cyclodextrins 81-82 and their ionic cyclodextrin derivatives 83-88. 
 
Acetylation of per-6-deoxy-6-iodo-β-Cyclodextin 
Per-alkylation or per-acetylation of the cyclodextin hydroxy groups improves their 
solubility in organic solvents, rendering them more soluble in less polar solvents than 
unmodified cyclodextrins132 widening their potential for further exploitation. Not only 
does derivatisation improve their solubility, but, the secondary side is stated to be 
catalytically very important,114,133 and therefore, modifications of this face are believed to 
produce valuable derivatives for catalysis, enzyme mimics, etc. Both of these 
characteristics are desirable qualities to incorporate onto these novel CD selecting 
agents. 
 
In order to improve solubility of per-2,3-hydroxy-6-deoxy-iodo-cyclodextrins in DCM, a 
solvent commonly used as the medium for dissolving the stationary phase in the 
procedure for static coating of capillary columns, the C2  and C3 secondary hydroxy 
groups were derivatised by non-selective acetylation by dissolving CD 79 or 80 in 
anhydrous pyridine under a nitrogen atmosphere, followed by the slow addition of acetic 
anhydride. The mixture was stirred for 4 hrs at room temperature in the presence of a 
catalytic amount of 4-dimethylaminopyridine (DMAP) to afford 81 in 85 % yield and 82 
in 78 % yield. This procedure gives the per-2,3-O-acetyl-6-deoxy-6-iodo-cyclodextrins in 
good yield and the products were simple to isolate and purify.  
 
Following acetylation of the C2- and C3-positions there was significant improvement in 
the solubility of the iodo-CDs in the less polar solvents. In Figure 2.57 show the 13C-NMR 
spectra and DEPT experiments for per-2,3-acetyl-6-deoxy-6-iodo-β-CD. Here 13C-NMR 
spectra are used as the primary means of characterising the CD derivatives given that 
the 13C-NMR shifts are a much better indicator of the structure variations than 1H-NMR, 
  
due to the fact that substituent-induced proton shifts do not follow a regular pattern as 
do carbon shifts.  Figure 2.57 shows 13C-NMR spectra of the symmetrical substitution 
pattern as expected from per-substitution of the secondary hydroxyl groups of CD 81.  
 
Figure 2.57: Per-2,3-acetyl-6-deoxy-6-iodo-β-CD; i) 13C NMR, ii) DEPT 135, iii) DEPT 90 
spectra in CDCl3. 
 
The 13C-NMR spectrum of Per-2,3-O-acetyl-6-deoxy-6-iodo-β-cyclodextrin in DMSO-d6 is 
shown in Figure 2.57; 13C-NMR spectra of CD 81 is similar to that of per-6-deoxy-iodo-β-
cyclodextrin (79) in the sugar region with the presence of two acetyl quaternary at 170.6 
ppm and 169.4 ppm, as well as CH3 at 22.7 ppm which are confirmed by DEPT 
experiments in which the signals for the two quaternary carbons do not appear in the 
DEPT experiments (Figure 2.57) (ii) and (iii) while the methyl carbon is present in the 
DEPT 135 (which show all proton bound carbons in positive amplitude with the exception 
of CH2 in negative amplitude) but disappears from the DEPT 90 (iii) spectra (which only 
show CH carbons). Acetylation of C2 and C3 can be confirmed as having gone to 
completion owing to the observed symmetry in the sugar region on the carbon spectra. 
C1 to C6 of each of the 7 glucose subunits of CD 81 appear as single peaks as a result of 
the symmetrical substitution pattern. 
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Figure 2.58: Preparation of per-6-substitued ionic CDs 89-94 by refluxing per-6-deoxy-
6-iodo-CD 81-82 in DMF at 90 ˚C with either various i) pyridine or ii) imidazole 
derivatives. 
 
The ionic cyclodextrin compounds 89-94 per-2,3-O-acetyl-6-deoxy-6-(imidazolium or 
pyridinium) β or γ-CD were prepared from compound 81 and 82 (per-2,3-O-acetyl-6-
deoxy-6-iodo-β- or γ-CD) by nucleophilic displacement of iodine with either excess 
imidazole or pyridine in DMF (or neat if the pyridine or imidazole used is liquid) at 90-100 
˚C for 24 hrs, similar to the method described by Thatcher et al.126 DMF was removed 
under reduced pressure and per-6-deoxy-6-imidazolium or per-6-deoxy-6-pyridinium-β-
cyclodextrin ionic liquids were isolated.  The ionic CDs synthesised are listed in Table 2.6. 
 
 
 
 
 
 
 
  
Table 2.6: A table of the CD compounds synthesied. 
C6-substituents 2,3-OH-β-CD 2,3-Ac-β-CD 2,3-Ac-γ-CD 
Per-6-deoxy-6-iodo-β-CD 79 (80 is γ-CD) 81 82 
-6-Methylimidazolium I- 83 89 90 
-6-Benzylimidazolium I- 84   
-6-Butylimidazolium I- 85 91 92 
-6-(-2-(1-imidazolium)-1-
phenylethanol) I- 
86   
-6-Pyridinium I- 87 93 94 
-6-(4-dimethylamino 
pyridinium) I- 
88   
 
 
 
Figure 2.59: Preparation of per-2,3-OH-6-deoxy-6-(N-dimethylaminopyridinium)-β-CD 
iodide 88 by refluxing per-2,3-OH-6-deoxy-6-iodo-β-CD 79 in DMF at 90 ˚C with either 
various pyridines or imidazoles substituents (in this case pyridine). 13C-NMR spectra; i) 
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Native-β-CD, ii) per-6-deoxy-6-iodo-β-CD, and iii) per-6-deoxy-6-(N-dimethylamino 
pyridinium iodide)-β-CD in DMSO-d6. 
 
Figure 2.59 shows the sequential 13C-NMR spectral shift changes in the 2 step synthesis 
of β-CD IL 88 starting from native β-CD (i) undergoing nucleophilic substitution with 
iodine to afford per-6-deoxy-6-iodo-β-CD (ii) followed by the nucleophilic substitution 
with pyridine to give ionic β-CD 88 (iii) in 66 % yield. The 13C-NMR spectra of ionic CD 
88 (iii) is similar to that of per-6-deoxy-6-iodo-β-cyclodextrin (ii) in the sugar region with 
the exception of the downfield shifted C6, resulting from the substitution of the less 
electronegative iodine with the more electronegative nitrogen from pyridine having a 
greater electron attracting power resulting in the de-shielded effect on the C6 carbon 
atom.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.7: Properties of per-2,3-substituted-6-deoxy-6-substituted β-CD ILs. 
 
C6-substituents 
mp [˚C] 
2,3-OH-β-CD 
mp [˚C] 
2,3-Ac-β-CD 
mp [˚C] 
2,3-Ac-γ-CD 
Per-6-deoxy-6-iodo-β-CD 207-210 198-200 190-192 
NN
I  
234 RTIL RTIL 
NN
I
 
234   
NN
I  
218 RTIL RTIL 
NN
OH
I
 
141-145   
NI
 
215-216 220-224 198-202 
N
N
I
 
242-243   
 
Thermogravimetric Analysis  
It is of significant importance to determine the thermal stability of the synthesised 
cyclodextrins as this directly reflects the maximum allowable operating temperature of 
the GC column in which these compounds will be incorporated. For application as chiral 
selectors in GC stationary phases it is of significant importance to know the temperatures 
at which these ionic CD are stable and the temperature at which decomposition begins to 
take place. The thermostabilities of the derivatised cyclodextrins were determined and 
compared with the thermal stabilities of native β–cyclodextrin as well as per-2,3,6-O-
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methyl-β-CD and per-2,3,6-O-acetyl-β-CD. Thermogravimetric analysis scans were 
obtained on a Mettler thermogravimmeteric balance at a heating rate of 20 ˚C/min from 
50 to 800 ˚C under an inert nitrogen atmosphere flowing at 20 mL/min, switching to air 
at 600 ˚C.  
 
The thermogravometric analysis of β-CD in Figure 2.60 showed mass loss in two different 
temperature regions. The first mass loss at around 200-400 ˚C being due to the melting 
and decomposition of the glucose unit in β-CD, and the second mass loss around 600 ˚C 
due to the introduction of oxygen. The first mass loss is the region of interest as this is 
indicative of the decomposition of the glucose and imidazolium/ or pyridinium units. 
Following TGA analysis of per-2,3-OH-6-deoxy-6-iodo-β-CD decomposition took place at 
221 ˚C, that is 23 ˚C lower than native-β-cyclodextrin which decomposed at 244 ˚C.  
Derivatisation of native-β-CD by per-2,3,6-methylation and per-2,3,6-acetylation 
significantly increased their thermal stabilities by 50 ˚C and 76 ˚C decomposing at 294 
˚C and 320 ˚C, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
A) 
 
B) 
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Figure 2.60: A) TGA analysis of native β-CD CD, per-6-deoxy-6-iodo-β-CD, per-
2,3,6-methyl-β-CD, and per-2,3,6-acetyl-β-CD. B) TGA analysis of the per-2,3-
acetylated ionic β-CDs 89, 91, and 93, represented in blue, green and black, 
respectively, as well as per-2,3-O-acety-6-deoxy-6-iodo-β-CD (81).  
 
Following nucleophilic displacement of iodide with an imidazole or pyridine substituent 
thermal analysis showed per-6-deoxy-6-benzylimidazolium 84 and per-6-deoxy-6-
methylimidazolium 83 β-CDs to have slightly higher thermal stabilities compared to that 
of the native β-CD while a diminished thermostability was observed for CD 86 
decomposing at 160 ˚C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.8: Thermal decomposition temperatures of per-6-deoxy-6-substituted CDs. 
Per C6-substituents 
TD [°C] 
2,3-OH-β-CD 
TD [°C] 
2,3-Ac-β-CD 
TD [°C] 
2,3-Ac-γ-CD 
Per-6-deoxy-6-iodo- 222 243 232 
NN
I  
256 202 188 
NN
I
 
257   
NN
I  
293 204 204 
NN
OH
I
 
160   
NI
 
225 227  223 
N
N
I
 
250   
 
 
Similarly, the pyridinium IL CD derivative generally showed a diminished thermal stability 
(ranging from 180-215 ˚C) compared to native β-CD, with per-2,3-OH-6-deoxy-6-(4-
dimethylaminopyridinium)-β-CD having a slightly higher thermal stability compared to 
native β-CD decomposing at 250 ˚C.  
 
TGA analysis of per-2,3-acetyl-CD ILs  
Following the thermogravimetric analysis of per-2,3,6-O-methyl-β-CD  and  per-2,3,6-O-
acetyl-β-CD it was evident that derivatisation at C2 and C3 significantly increased the 
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thermal stability of the cyclodextrin products. Thus it was expected that acetylation at C2 
and C3 would in improved thermal stability our imidazolium and pyridinium ionic CDs. 
However, the thermals stabilities were significantly diminished by up to 17-42 ˚C for the 
2,3-O-acetyl ionic β-CDs when compared with native β-CD and diminished by 21-89 ˚C  
when compared with their 2,3-hydroxy ionic β-CD analogues. An interesting observation 
was that the pyridinium CDs 87, 93, and 94 maintained their thermal stabilities at 225 
˚C, 227 ˚C, and 223 ˚C, respectively, regardless of whether C2 and C3 substituent was 
an acetyl group or hydroxy groups. Whereas, the thermal stabilities of the imidazolium 
CDs were affected by the C2 and C3 substituents, with the C2 and C3 acetyl groups 
generally lowering the thermal stabilities. The size of the CD ring had a minor affect on 
the thermal stability of the iodo-CDs with per-2,3-acetyl-6-deoxy-iodo-β-CD 
decomposing at 243 ˚C while per-2,3-acetyl-6-deoxy-6-iodo-γ-CD decomposed at 232 
˚C a difference of 11 ˚C. However, the size of the CD ring had little to no effect on the 
thermal stabilities of the ionic CDs when comparing the ionic γ-CDs and β-CDs analogues 
(see Table 2.8).  
 
Selective secondary face modification 
The internal secondary side is more crowded than the primary side due to the presence 
of twice the number of hydroxy groups. The hydrogen bonding between hydroxy groups 
at the C2- and C3-positions makes them rigid and less flexible as compared to C-6 
hydroxy groups. The hydroxy groups at the C3-positions are the least reactive probably 
due to their involvement in hydrogen bonding with C-2 hydroxy groups. The C3-position 
is more sterically hindered and not easily available for further modification. All these 
factors make the secondary side less reactive and harder to selectively functionalize than 
the outer primary face.  
 
Ideally the best cyclodextrin derivative candidates for application as GC chiral selectors 
are asymmetrically substituted CDs. To reduce the symmetry of the ionic CDs the 
synthesis of mono-6-deoxy-6-iodo-6-OH-β-CD was attempted initially, from which mono-
  
ionic CDs could have potentially been synthesised by nucleophilic substitution of the 
iodide with imidazoles or pyridines. Given that per-2,3-O-acetylated ionic CDs that were 
synthesised in this work are highly symmetrical products, it was sought to reduce the 
symmetry of these CDs by selectively per-methylating at the C2 positions and acetylating 
at C3 positions as described by Bicchi et al.134 It has been shown that asymmetrically 
substituted per-2-O-methyl-3-O-acetyl- or per-2-O-methyl-3-O-ethyl-CDs can extend 
enantioselectivity in comparison to that of the corresponding per-2,3-O-methyl or per-
2,3-O-acetyl symmetrical derivatives, in terms of both enantiomer resolution and number 
of chiral compounds separated by GC.134,135  
 
And so work was directed towards the selective C2 per-methylation of the per-6-iodo-β-
cyclodextins 79 and 80 with the intentions of per-acetylating the C3 hydroxy groups. 
Using these selectively derivatised iodo-CDs one can synthesise imidazolium or 
pyridinium ionic CDs by nucleophilic substitution of the C6 iodo substituent. Selective 
per-methylation is carried out with BaO and Ba(OH)2 monohydrate, a weaker base than 
NaH and thus more selective in its action as described by Bicchi.134 The procedure for 
selective C2 methylation were applied to CDs 79 and 80 by stirred with excess BaO and 
Ba(OH)2 monohydrate in anhydrous DMF at room temperature for 3 hrs, then cooled to 0 
˚C. Following which methyl iodide was slowly added and the mixture allowed to react at 
40 ˚C for 24 hrs. The reaction mixture was worked up by diluting with a 10 % ammonia 
solution filtered through a pad of silica gel and washed with water. The C2-O-methyl-CD 
derivative was supposed to be eluted with ethyl acetate, followed by purification by 
washed with brine, and drying over MgSO4. The solvent would then have been 
evaporated under vacuum to afford the derivative as an oily residue which is then to be 
further purified by column chromatography. However, our reaction product did not elute 
with ethyl acetate and as a result the C2-O-methyl derivative products were not isolated. 
This is possibly due to the difference in polarity of the compound we were trying to 
synthesise (per-2-O-methyl-3-OH-6-deoxy-6-iodo-CD) in comparison to the compound 
synthesised by Bicchi (per-2-O-methyl-3-OH-6-O-THDMS-γ-CD). Preliminary attempts 
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were made to isolate the product, however, due to time constraints the method for 
isolating these C2 per-methylated iodo-CDs was not further developed. The isolation of 
per-2-O-methyl-3-OH-6-deoxy-6-iodo-CD was unsuccessful as we were not able to 
confirm the product by NMR. A significant change in the solubility of the reaction product 
in methanol compared to the starting material (per-2,3-OH-6-deoxy-6-iodo-CD) was 
found. Per-2,3-OH-6-deoxy-6-iodo-CD was insoluble in methanol while the reaction 
product readily dissolved in methanol. Analysis by TLC in 4:1 Ethyl acetate/methanol 
gaven an Rf value of 0 for both per-2,3-OH-6-deoxy-6-iodo-β-CD and per-2,3-OH-6-
deoxy-6-iodo-γ-CD compare to an Rf value of 0.54 for the reaction products per-2-
methyl-3-OH-6-deoxy-6-iodo-β-CD and per-2-methyl-3-OH-6-deoxy-6-iodo-γ-CD. 
Further effort to isolate these compounds is part of the planned future work. Synthesis of 
per-2-O-methyl-3-OH-6-deoxy-6-iodo-CD would pave the way for the synthesis of the 
desirable differentially substituted per-2-O-methyl-3-O-acetyl-6-deoxy-6-iodo-CD and 
allow for the synthesis of per-2-O-methyl-3-O-acetyl-6-deoxy-6-imidazolium-CD ionic 
salts (Figure 2.61), novel compounds which have not yet been synthesised and are 
highly desirable for study as chiral selecting agents.  
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Figure 2.61: Reaction scheme for the synthesis of asymmetrically substituted ionic CDs.  
 
  
2.4.3 Conclusion 
We have reported a simple route for the synthesis of a range of pre-2,3-OH-6-deoxy-6-
imidazolium and of per-2,3-OH-6-deoxy-6-pyridinium substituted ionic CDs as well as 
their per-2,3-O-acetylated derivatives in good yields, some of which possess improved 
thermal stabilities as well as improved solubility in less polar organic  solvents making 
their coating onto capillary columns via the static method possible, given that the 
insolubility of native β-cyclodextrin in organic solvents make them difficult to coat onto 
capillary columns. These new CDs possess ionic substitutents making them interesting 
candidates for future application as stationary phases in chromatographic separations for 
enantiomeric resolution of racemates. This study paves the way for these new ionic CDs 
to be employed as potential selecting agents with chiral molecular recognition abilities in 
GC separation.  
 
The synthesis of the asymmetrically derivatised per-2-O-methyl-3-O-acetyl-6-deoxy-6-
iodo-CDs from which ionic CDs with reduced symmetry is part of future studies to be 
undertaken. To reduce the symmetry of the charged CD salts via the synthesis of mono-
6-deoxy-6-iodo-CD will be further investigated. These CDs may lead to the synthesis of 
novel per-2-O-methyl-3-O-acetyl-6-deoxy-6-(imidazolium or pyridinium)-CD ionic salts 
with reduced symmetry, as well as various mono-6-(imidazolium or pyridinium) 
substituted ionic CDs which may possess enhanced enantioselective capabilities.  
 
 
 
 
 
 
 
 
 180 
 
  
 
2.4.4 Experimental 
2.4.4.1 Reagents 
β-Cyclodextrin, γ-cyclodextrin, DMF, triphenylphosphine, sodium, MeOH, NaH, acetic 
anhydride, pyridine, DCM, BaO, Ba(OH)2, 1-methylimidazole, 1-butylimidazole, 1-
benzylimidazole,  pyridine, pyridine-4-carboxaldehyde, 2-imidazoyl-1-phenylethanol, 4-
dimethylaminopyridine (DMAP), and 2,6-dihydroxypyridine. All chemicals were purchased 
from Sigma Aldrich. 
 
2.4.4.2 Instruments 
DMF was removed by bulb-bulb distillation using a Buchi Kugelrohr (manufactured in 
Germany). Melting points were measured with a Gillkhenhamp Melting Point apparatus 
(England). NMR spectral analysis was recorded on a Bruker 300 spectrometer and the 
chemical shift values were recorded in ppm. All NMR structure elucidation was done from 
1H-NMR, 13C-NMR, DEPT135, DEPT90, HSQC, and HH-COSY experiments. Mass 
spectroscopy data were obtained by Electro-spray ionization (model) in positive ion 
mode, (in 1:1 acetonitile/ H2O). Thermogravimetric analysis (TGA) was conducted on a 
Perkin-Elmer TGA-7 instrument. The scan was obtained on a Mettler thermogravimeteric 
balance at a heating rate of 20 ˚C/min under an inert nitrogen atmosphere flowing at 20 
mL/min from 50 to 600 ˚C switching to air from 600 ˚C to 800 ˚C.  
 
2.4.4.3 Synthesis 
Mono-6-(p-tolylsulfonyl)-6-OH-β-CD 78 
A suspension of β-CD hydrate (5.09 g, 4.48 mM) and p-Tolylsulfonylic anhydride (Ts2O) 
(2.17 g, 6.65 mM) in 110 mL of water was stirred at room temperature for 2 hrs. A 
solution of NaOH (2.2 g in 22.1 mL of dH2O) was added, and after 10 mins unreacted 
Ts2O was removed by filtration. The filtrate was brought to pH 8 by the addition of NH4Cl 
  
(5.9 g), and cooled to 4 ˚C overnight to affording 78 as a precipitate; 2.83 g (49 %) 
yield, mp 195-196 ˚C (Lit. 159-162 ˚C)113; 1H-NMR (300 MHz, DMSO-d6) δ = 7.48 (d, 
3JHH =8.1 Hz, 2H, Ar-H(TsO)), 7.12 (d, 
3JHH = 7.9 Hz, 2H, Ar-H(TsO)), 5.80-5.63 (m, 14H, 
OH2,3), 4.88’ (s, 1H, H1), 4.84 (s, 6H, H1) 4.53’ (s, 1H, OH6), 4.48 (s, 5H, OH6), 3.91-
3.85’ (m, 4H, H3,5,6), 3.63-3.54 (m, 24H, H3,5,6), 3.36 (m, 14H, H2,4), 2.29 (s, 3H, 
CH3(TsO)); 
13C-NMR (75 MHz, DMSO–d6)
 δ = 144.7(TsO), 138.2(TsO), 128.2(TsO), 125.4(TsO), 
102.1’, 101.8, 101.5’, 82.6’, 81.7’, 81.4, 73.0, 72.6’, 72.3, 72.1’, 71.9, 70.1’, 59.8(CH2), 
45.3’(CH2), 20.8(CH3). 
 
Synthesis of per-6-deoxy-6-iodo-β-cyclodextrin 79.129  
Triphenylphosphine Ph3P (21.0 g) was dissolved with stirring in dry DMF (80 mL). To this 
solution was added 20.51 g of iodine over 10 minutes with the evolution of heat (the 
solution reaches approximately 50 ˚C). Dry β-cyclodextrin (4.32 g, 3.81 mM) was then 
added to this dark brown reaction mixture and the temperature was raised to 70˚C and 
allowed to stir under N2 atmosphere for 18 hrs. After which heating was discontinued and 
the solution concentrated under reduced pressure by the removal of DMF. A 3N solution 
of NaOMe in MeOH was then prepared by adding 4.14 g sodium to 60 mL MeOH under 
inert atmosphere with cooling. This NaOMe solution was then added to the reaction 
mixture with cooling, the reaction mixture was stirred for 30 minutes. The reaction was 
worked up by pouring the reaction mixture into MeOH to form a precipitate. The 
precipitate was washed with MeOH and air dry to leave an off white solid. The product 
was further purified by Soxhlet extraction with MeOH until there was no discolouration of 
the solvent. The pure product was air dried and then further dried under vaccum; yield: 
6.53 g (90 %): mp 207-210 ˚C; 1H-NMR (300 MHz, DMSO-d6) δ = 6.02 (d, JHH=6.3 Hz, 
7H, -OH), 5.91 (s, 7H, OH3), 4.99 (s, 7H, H1), 3.82-3.78 (d, 7H, H3) , 3.73-3.52 (m, 7H, 
H5), 3.51-3.20 (m, 28H, H 2,4,6);
 13C-NMR (75 MHz, DMSO-d6) δ = 102.1, 85.91, 72.1, 
71.9, 70.9, 9.4(CH2). 
 
Per-6-deoxy-6-iodo-γ-cyclodextrin 80 
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80 was synthesised following the procedure described for the synthesis of 79 using 21.2 
g of Ph3P, in 80 mL of DMF, with 20.0 g of iodine and 5.0 g of γ-CD (3.85 mM). The 
reaction solution was treated with 3N solution of NaOMe and the mixture precipitated in 
MeOH to afford 80 as a solid in good yield: 8.21 g (87 %): mp 204 ˚C: 1H-NMR (300 
MHz, DMSO-d6) δ = 6.03-5.98 (m, 16H, OH2,3), 5.03-5.02 (d, 8H, H1), 3.83-3.8 (m, 
JHH=9.7 Hz, 8H, H3), 3.60-3.57 (m, 8H, H5) 3.45-3.25 (m, 32H, H2,4,6);
 13C-NMR (75 MHz, 
DMSO-d6) δ = 101.9, 85.2, 72.4, 71.8, 71.1, 9.3(CH2). 
 
Synthesis of per-6-deoxy-6-(N-alkylimidazolium or pyridinium iodide)-β-
cyclodextrin ILs 
Mix per-6-deoxy-6-iodo-β-cyclodextrin with excess imidazole or pyridine (28 mol eq.) in 
DMF and heat under nitrogen atmosphere at 90 ˚C for 48 hrs. Allow to cool to room 
temperature then remove half of the DMF by concentrating the reaction mixture under 
vacuo. Alternatively, when using a liquid imidazole or pyridine, the CD was refluxed neat 
in excess imidazole or pyridine without DMF. The crude product was precipitated from the 
reaction solution by addition of either acetone or ethyl acetate. Wash the product 
repeatedly with the precipitating solvent and further purify by soxhlet extraction. 
  
Per-6-deoxy-6-(N-methylimidazolinium iodide)-β-cyclodextrin 83 
β-Cyclodextrin 79 (0.3 g,  0.156 mM) was refluxed with N-methylimidazole in 3 mL of 
DMF to afford 83 in good yield: 0.28 g (73 %): mp 234 ˚C: 1H-NMR (300 MHz, DMSO-
d6) δ = 9.13 (s, 7H, HIm), 7.73 (s, 14H, HIm), 7.56’ (s, HIm), 7.10’ (s, HIm), 6.86’ (s, HIm), 
6.18 (d, 7H, OH2) 5.94 (s, 7H, OH3), 5.06 (s, 7H, H1), 4.47-3.33 (m, 63H, H2,3,4,5,6, -
CH3Im);
 13C-NMR (75 MHz, DMSO-d6) δ= 137.6, 123.8, 123.4, 101.9, 82.0, 72.2, 71.5, 
68.9, 49.5(CH2), 32.8(CH3); ESI-MS: calcd m/z = 354.05 (M
7+), found m/z = 353.9 (M7+). 
 
Per-6-(N-benzylimidazolinium iodide)-β-cyclodextrin 84 
β-Cyclodextrin 79 (0.3 g, 0.156 mM) was refluxed with N-benzylimidazole in 3 mL of 
DMF to afford 84 in good yield: 0.33 g (71 %): mp 234 ˚C: 1H-NMR (300 MHz, DMSO-
  
d6) δ = 9.35 (s, 7H, HIm), 7.83-7.78 (m, 14H, HIm), 7.47-7.30 (m, 35H, Ar-H), 6.18 (d, 
7H, OH2), 5.96 (s, 7H, OH3), 5.49 (m, 14H, -CH2-), 5.03 (s, 7H, H1), 4.52-3.67 (m, 28H, 
H2,3,4,5), 3.32 (m, 14H, H6); 
13C-NMR (75 MHz, DMSO-d6) δ = 137.2, 134.5q, 128.8, 
128.4, 124.0, 122.3, 102.0, 82.0, 72.2, 71.4, 68.8, 51.9(CH2), 49.7(CH2) ; ESI-MS: calcd 
m/z = 430.24 (M7+), found m/z = 430.0 (M7+). 
 
Per-6-(N-butylimidazolinium iodide)-β-cyclodextrin 85 
β-Cyclodextrin 79 (0.3 g,  0.156 mM) was refluxed with N-butylimidazole in 3 mL of DMF 
to afford 85 in good yield: 0.35 g (80 %): mp 218 ˚C : 1H-NMR (300 MHz, DMSO-d6) δ = 
9.24 (s, 7H, HIm), 7.84 (s, 7H, HIm), 7.77(s, 7H, HIm), 7.22’ (s, HIm), 6.95’ (s, HIm), 6.18 
(d, 7H, OH2), 5.95 (s, 7H, OH3), 5.06 (s, 7H, H1), 4.51-3.42 (m, 42, H2,3,4,5,6, [4.23 (t, 
14H,-CH2-Im]), 1.77 (qui, 14H, -CH2CH2CH3), 1.26 (sxt, 14H, CH2CH3), 0.89 (t, 21H, -
CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 137.2Im, 123.5Im, 122.7Im, 101.9, 82.1, 72.2, 
71.4, 68.8, 49.6(CH2), 48.8(CH2), 45.9(CH2), 32.5(CH2), 31.3(CH2), 19.1(CH2), 18.9(CH2), 
13.3(CH3).; ESI-MS: calcd m/z = 396.22 (M
7+), found m/z = 395.9 (M7+). 
 
Per-6-(N-1-hydroxy-1-phenylethylimidazolinium iodide)-β-cyclodextrin 86 
β-Cyclodextrin 79 (0.1 g,  0.0525 mM) was refluxed with (+/-)-2-(1-Imidazolyl)-1-
phenylethanol 6 in 3 mL of DMF to afford 86 in moderate yield: 0.11 g (63 %): mp 141-
145 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ = 9.11 (s, 7H, HIm), 7.76 (s, 14H, HIm), 7.54-
7.24 (m, 35H, Ar-H), 6.27 (s, OHIm), 6.02 (s, 14H, OH2,3), 5.03 (s, 7H, H1), 4.68-4.09 
(m, 14H, H3,5), 3.78-3.25 (m, 28H, H2,4,6); 
13C-NMR (75 MHz, DMSO-d6) δ = 141.0q, 
137.5Im, 128.4, 128.0, 126.1, 123.3 Im, 102.0, 82.0, 72.1, 71.4, 70.4Im, 68.8, 55.5(CH2), 
49.6(CH2); ESI-MS: calcd m/z = 460.27 (M
7+), found m/z = 460.1 (M7+). 
 
Per-6-(pyridinium iodide)-β-cyclodextrin 87 
β-Cyclodextrin 79 (0.3 g,  0.156 mM) was refluxed with excess pyridine (3 mL) to afford 
87 in good yield: 0.32 g (82 %): mp 215-216 ˚C: 1H-NMR (300 MHz, DMSO-d6) δ= 8.95 
(m, 7H, Ar-H), 8.64 (m, 7H, Ar-H), 8.23-8.13 (m, 7H, Ar-H), 6.32 (s, 7H, OH2), 6.08 (s, 
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7H, OH3), 5.97’ (s, OH), 5.20 (s, 7H, H1), 5.11’ (s, H1), 4.87-3.36 (m, 42H, H 2,3,4,5,6); 
13C-NMR (75 MHz, DMSO-d6) δ= 146.6, 145.9, 128.4, 101.6, 81.9, 72.1, 71.2, 68.9, 
60.5(CH2); ESI-MS: calcd m/z = 351.14 (M
7+), found m/z = 350.7 (M7+). 
 
Per-6-(4-dimethyaminopyridinium iodide)-β-cyclodextrin 88 
β-Cyclodextrin 79 (0.3 g,  0.156 mM) was refluxed with 4-dimethyaminopyridine in 3 mL 
of DMF to afford 88 in good yield: 0.32 g (74 %): mp 242-243 ˚C: 1H-NMR (300 MHz, 
DMSO-d6) δ = 8.09 (s, 14H, Ar-H), 7.04 (s, 14H, Ar-H), 6.36 (s, 7H, OH2), 6.13 (s, 7H, 
OH3), 5.07 (s, 7H, H1), 4.37-3.35 (m, 42H, H2,3,4,5,6), 3.10 (s, 42H, -CH3); 
13C-NMR (75 
MHz, DMSO) δ = 155.4q, 142.9, 107.8, 101.6, 82.5, 72.1, 71.56, 69.2, 56.8(CH2), 
40.0(CH3); ESI-MS: calcd m/z = 394.21 (M
7+), found m/z = 393.8 (M7+). 
 
Per-acetylation of secondary hydroxyl groups 
Per-2,3-O-acetyl-6-deoxy-6-iodo-β-cyclodextrin 81 
CD (79) (2.0 g, 1.05 mM) was dissolved in anhydrous pyridine (9 mL) and stirred under 
nitrogen. Acetic anhydride (7.5 mL) was slowly added, and the mixture was stirred for 4 
hrs at room temperature in the presence of a catalytic amount of 4-
dimethylaminopyridine (DMAP). The pyridine and acetic anhydride were removed by 
rotatary evaporation and the reaction mixture dissolved in CH2Cl2 (15 mL) and washed 
with H2O and the combined organic layers successively washed with 3N HCl, saturated 
aqueous NaHCO3, and brine. After drying over MgSO4 and removal of the solvent 
afforded 1.96 g of CD 81 (85 % yield): mp 200-203 ˚C: 1H-NMR (300 MHz, CDCl3) δ = 
5.36–5.25 (m, 3JHH = 9.8 Hz, 7H, H3), 5.13 (d, 
3JHH = 3.9 Hz, 1H, H1), 4.76 (dd, 
3JHH = 
9.9, 3.8 Hz, 7H, H2), 3.80–3.64 (m, 14H, H5,6), 3.63–3.50 (m, 14H, H4,6), 2.00 (d, 42H, -
CH3); 
13C-NMR (75 MHz, CDCl3) δ = 170.6q, 169.4q, 96.5C1, 80.5C4, 70.4C2, 70.2C5, 
70.1C3, 20.7(CH3), 8.0(CH2). 
 
Per-2,3-O-acetyl-6-deoxy-6-iodo-γ-cyclodextrin 82 
  
γ-Cyclodextrin 80 (2.0 g, 0.817 mM) reacted with pyridine (9 mL), acetic anhydride (7.5 
mL)  and a catalytic amount of DMAP following the procedure described in the synthesis 
of CD 81, to afford 82 in good yield: 1.77 g (78 %): mp 200-203 ˚C: 1H-NMR (300 MHz, 
CDCl3) δ = 5.30 (d, 
3JHH = 9.8 Hz, 8H, H3), 5.18 (d, 
3JHH = 3.8 Hz, 8H, H1), 4.70 (dd, 
3JHH 
= 10.0, 3.8 Hz, 8H, H2), 3.73-3.70 (m, 16H, H5,6), 3.59 – 3.41 (m, 16H, H4,6), 2.02 (d, 
48H, -CH3); 
13C-NMR (75 MHz, CDCl3) δ =170.6q, 169.3q, 96.1C1, 79.6C4, 70.8C2, 70.3C5, 
69.6C3, 20.8(CH3), 20.7(CH3), 7.8(CH2). 
 
per-2,3-O-acetyl-β-CD ILs 
Per-2,3-O-acetyl-6-deoxy-6-(N-methylimidazolinium iodide)-β-cyclodextrin 89 
β-Cyclodextrin 81 (0.2 g, 0.091 mM) was refluxed with excess N-methylimidazole to 
afford 89 in good yield: 0.22 g (86 %): RTIL: 1H-NMR (300 MHz, DMSO-d6) δ = 9.30 (s, 
7H,HIm), 7.87 (s, 14H, HIm), 5.33-3.91 (m, 49H, HCD1,2,3,4,5,6), 3.75 (s, 21H, -NCH3), 2.09 
(s, 21H, O=CCH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 175.2q, 174.4q, 143.27Im, 128.6Im, 
102.2C1, 83.0C4, 74.7(C2,3,5), 54.6(CH2), 41.6(CH3), 25.8(CH3); ESI-MS: calcd m/z = 396.17 
(M7+), found m/z = 395.8 (M7+). 
 
Per-2,3-O-acetyl-6-deoxy-6-(N-butylimidazolinium iodide)-β-cyclodextrin 91 
β-Cyclodextrin 81 (0.2 g, 0.091 mM) was refluxed with excess N-butylimidazole to afford 
91 in good yield: 0.26 g (94 %): RTIL: 1H-NMR (300 MHz, DMSO-d6) δ = 9.38 (s, 7H, 
HIm), 7.85 (s, 14H, HIm), 5.23-4.15 (m, 49H, HCD1,2,3,4,5,6), 4.17 (t, 
3JHH =7.4 Hz, 14H, -
NCH2), 2.01(m, 42H, O=CCH3), 1.77(qui, 
3JHH =14.8, 7.4 Hz, 14H, -NCH2CH2), 1.24 (sxt, 
3JHH =14.7, 7.3 Hz, 14H, -CH2CH3), 0.89 (t, 
3JHH = 7.3 Hz, 21H, -CH2CH3); 
13C-NMR (75 
MHz, DMSO-d6) δ = 169.9q, 137.5Im, 123.1Im, 122.2 Im, 97.1, 78.1, 69.3(C2,3,5), 48.7(CH2), 
47.9(CH2), 31.5(CH2), 20.6(CH3), 18.8(CH2), 13.3(CH3).; ESI-MS: calcd m/z = 438.25 (M
7+), 
Found m/z = 438.1 (M7+). 
 
Per-2,3-O-acetyl-6-deoxy-6-(N-pyridinium iodide)-β-cyclodextrin  93 
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β-Cyclodextrin 81 (0.2 g,  0.091 mM) was refluxed with excess pyridine to afford 93 in 
good yield: 0.24 g (95 %): mp 220-224 ˚C : 1H-NMR (300 MHz, CDCl3-d/DMSO-d6) δ = 
9.22 ( m, 7H, Ar-Hpyr), 8.69 (m, 7H, Ar-Hpyr), 8.17 (m, 7H, Ar-Hpyr), 5.30-3.60 (m, 49H, 
H1,2,3,4,5,6), 2.02 (m, 42H, O=CCH3);
 13C-NMR (75 MHz, CDCl3-d/DMSO-d6) δ = 169.6q, 
145.8, 144.6q, 128.7, 96.4 78.9, 68.0(CH2), 20.5(CH3); ESI-MS: calcd m/z = 393.17 (M
7+), 
found m/z = 393.0 (M7+). 
 
Per-2,3-O-acetyl-γ-CD ILs 
Per-2,3-O-acetyl-6-deoxy-6-(N-methylimidazolinium iodide)-γ-cyclodextrin 90 
γ-Cyclodextrin 82 (0.15 g, 0.0539 mM) was refluxed in excess N-methyimidazole to 
afford 90 in good yield: 0.17 g (92 %): RTIL: 1H-NMR (300 MHz, DMSO-d6) δ = 8.69 (s, 
8H, -CHIm), 7.54 (s, 8H, -CHIm), 7.43 (s, 8H, -CHIm), 5.14-3.47 (m, 56H, -CHCD1,2,3,4,5,6), 
3.81 (s, 24H, -CH3), 1.94 (s, 24H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 172.1q, 
169.9q, 169.4q, 137.0, 136.2, 124.2, 123.3, 122.4, 121.9, 97.0, 77.2, 69.6, 49.2, 
34.8(CH3), 21.1(CH3), 20.6(CH3): ESI-MS: calcd m/z = 430.18 (M
8+), found m/z = 429.8 
(M8+). 
 
Per-2,3-O-acetyl-6-deoxy-6-(N-butylimidazolinium iodide)-γ-cyclodextrin 92 
γ-Cyclodextrin 82 (0.15 g, 0.0539 mM) was refluxed with excess N-butylimidazole to 
afford 92 in good yield: 0.18 g (88 %): RTIL: 1H-NMR (300 MHz, DMSO-d6) δ = 9.75 (s, 
1H, -CHIm), 9.12 (s, 8H, -CHIm), 8.17 (s, 8H, -CHIm), 7.94 (s, 8H, -CHIm), 7.78 (s, 8H, -
CHIm), 7.63 (s, 8H, -CHIm), 5.19-3.63 (m, 56H, CH(CD)1,2,3,4,5,6), 4.23 – 4.16 (m, 16H, -
CH2), 2.00 (s, 24H, -CH3), 1.76 (qui, 
3JHH = 7.3 Hz, 16H, -CH2), 1.23 (sxt, 
3JHH = 7.4 Hz, 
16H, -CH2), 0.87 (t, 
3JHH = 7.3 Hz, 24H, -CH3); 
13C-NMR (75 MHz, DMSO-d6) δ = 172.0q, 
169.9q, 169.3q, 137.5, 135.2, 123.1, 122.1, 121.8, 120.34, 96.8, 77.4, 69.3, 58.0(CH2), 
49.1(CH2), 48.6(CH2), 48.0(CH2), 31.5(CH2), 31.3(CH2), 31.0(CH2), 21.1(CH3), 20.5(CH3), 18.8(CH2), 
18.7(CH2), 13.3(CH3), 13.2(CH3); ESI-MS: calcd m/z = 472.26 (M
8+), found m/z = 471.9 
(M8+). 
 
  
Per-2,3-O-acetyl-6-deoxy-6-(N-pyridinium iodide)-γ-cyclodextrin 94 
γ-Cyclodextrin 82 ( 0.15 g, 0.0539 mM) was refluxed with excess pyridine to afford 94 in 
good yield: 0.17 g (95 %): mp 198-202 ˚C: 1H-NMR (300 MHz, CDCl3-d/DMSO-d6) δ = 
9.26 (m, 8H, Ar-Hpyr), 8.53 (m, 8H, Ar-Hpyr), 8.18 (m, 8H, Ar-Hpyr), 5.41-3.47 (m, 56H, 
H(CD)1,2,3,4,5,6), 2.02 (m, 48H, O=CCH3); 
13C-NMR (75 MHz, CDCl3-d/DMSO-d6) δ = 169.5q, 
146.1, 145.5q, 128.0, 96.2, 78.0, 69.4(CH2), 20.7(CH3); ESI-MS: calcd m/z = 427.18 (M
8+), 
found m/z = 426.9 (M8+). 
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3 Chapter 3 
Chiral analysis by Gas Chromatographic  
 
 
 
 
 
 
 
 
 
 
 
 
 3.1 Introduction to Chapter 3 
There is evermore a need for the continual development of new chiral stationary phases 
(CSPs) as the production of new chiral products such as drugs continually increases and 
no guarantee that the currently available CSPs will provide adequate enantioseparation. 
With the increased demand from drug regulatory agencies for drug manufacturers to 
provide safety data by way of enantiomeric purity, there is a need for the development of 
more chiral selectors for application in GC/ or LC stationary phases for the analysis of 
chiral drug products. A single column cannot separate all chiral compounds, consequently 
analysts need to select (or introduce new) specific phases that permit separation and 
analysis of novel chiral drug products. Given that GC is one of the preferred methods of 
chiral analysis recommended by drug regulatory agencies, it is important to have a range 
of GC stationary phases which possess diverse physical and chemical properties to allow 
researchers to conduct not only routine chiral analysis but provide a selection of 
stationary phases with the appropriate properties required to conduct specialised 
enantioselective analysis experiments.    
 
An example of the need for a selection of chiral columns which possess a variety of 
chemical properties for specialized applications is the study of species that undergo 
interconversion or some other type of structural change during the chromatographic 
elution process, known as dynamic molecular interconversion, where each molecule 
undergoes a mechanism of structural change into their counterpart. The results of the 
evaluation for enantioselective capabilities of the novel chiral ionic liquid stationary 
phases are presented in chapter 3.2. While in chapter 3.3, the results of the study of the 
dynamic molecular interconversion of chiral oximes is presented. 
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3.2 An investigation into the potential application of novel chiral ionic salts 
as chiral selecting agents in gas chromatography stationary phases. 
 
3.2.1 Introduction 
The most common liquid stationary phases in GC columns are polysiloxanes and 
polyethylene glycol phases. Polysiloxane based stationary phases are primarily utilized 
for the routine analysis of the less polar analytes. The polysiloxane can be modified to 
contain various substituent groups to change the polarity of the phase. Dimethyl 
polysiloxane (such as OV1 and OV101 phases, see Figure 3.1) are classically nonpolar 
phases, and can be modified to be more polar by increasing the percentage of phenyl, 
cyanopropyl, fluoro groups, or other substituents on the polymer. For routine analysis of 
very polar analytes, polyethylene glycol (PEG), also known as Carbowax (Figure 3.2), is 
commonly used as the stationary phase.  
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Figure 3.1:  Structure of dimethylpolysiloxanes such as OV-1 and DB-1. 
 
For chiral analysis currently available columns consist primarily of the less polar 
polysiloxane stationary phases, impregnated with chiral selecting agents by either; 
chemically bonding the chiral selecting agent to siloxane pendent groups or by dissolving 
the chiral selecting agent in the liquid polymer.  
n
HO
O
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Figure 3.2: Structure of Carbowax 20M a polyethyleneglycol polymer with an average 
molecular weight of 20,000. 
 
Cyclodextrin derivatives (CDs) are the most common and widely used chiral selecting 
agent in chiral stationary phases (CSPs) for GC. This is due to their broad applicability to 
 enantioselective separation, ease of derivatisation, compatibility with column 
manufacture and ability to separate underivatized enantiomers of different volatilities. 
When used in enantioselective GC, CDs are dissolved in non-polar to moderately polar 
phases such as polysiloxanes in order to obtain highly efficient capillary GC columns.1-3 
 
IL bonded polysiloxane phase 
Derivatives of polysiloxane4 cover a majority of the commercially available and lab-made 
stationary phases due to their good film-forming ability, chemical stability and thermal 
stability. Since a complex sample is usually composed of various polar and nonpolar 
components, a given stationary phase cannot offer good separation for both polar and 
nonpolar components in one run. Fortunately, ionic liquid stationary phases possess the 
unique advantage of “dual nature” 5,6 characteristics over traditional stationary phases. It 
was noted that this unique characteristic may be beneficial to the analysis of a complex 
samples comprising of components with a wide polarity range. 
 
The earliest report on the GC stationary phase of organic molten salts was contributed by 
Barber et al. in 1959.7 Later, Poole and co-workers studied the stationary phases of 
organic molten salts, such as ethylammonium nitrate and ethylpyridinium bromide.8,9 
These stationary phases exhibited separation ability for many compounds, but their 
thermal stabilities were not favourable. Hence, little attention was paid to this kind of 
stationary phase in GC until the publication of IL stationary phase based on an imidazole 
cation 1-butyl-3-methylimidazolium coupled with hexafluorophosphate and chloride 
anions by Armstrong’s group.5 These stationary phases were able to separate a wide 
range of organic compounds and exhibited the special characteristic “dual nature”, 
reviving research into IL GC stationary phases. Subsequently, various imidazole bases 
ILs have been investigated as stationary phases, one example being the di-cationic 
vinylimidazole 1,9-di(3-vinyl-imidazolium)nonane bis(trifluoromethylsulfonyl) imidate IL, 
which is produced commercially as SLB IL-100 (Figure 3.3). Since the ionic liquids were 
primarily compounds of small molecular mass they did not possess high thermal 
stabilities and good coating stability simultaneously. As a result a method of in-column 
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polymerization was proposed to prepare polymeric stationary phases from IL monomers 
composed of vinylimidazole.10 This kind of IL polymer was shown to withstand higher 
temperatures of up to 350 ˚C,10 however, the reactions have been deemed to be 
complicated and time consuming.11,12  
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Figure 3.3: Structure of the ionic liquids 1,9-di(3-vinyl-imidazolium)nonane 
bis(trifluoromethylsulfonyl)imidate. 
 
Since various substituted polysiloxanes have been employed extensively as stationary 
phases in GC owing to their high thermal stability and wide variability in modification,13-18 
combining the characteristics of polysiloxane phases with the “dual nature” separation 
capabilities of ILs was seen to have the potential to improve the performance of IL 
stationary phase. Therefore, ILs were diluted in commercial stationary phases (e.g., OV-
1, OV-1701 and FFAP) and evaluated.19,20 Qi and Armstrong investigated the “dual 
nature” of the geminal dicationic IL, 1,9-di(3-vinylimidazolium)nonane 
bis(trifluoromethylsulfonyl)imidate, for the purpose of separating both nonpolar and polar 
compounds of complex samples such as essential oils that contain a great variety of 
compounds. The dicationic IL was utilised as a stationary phase for capillary GC either as 
a neat IL phase or as a mixed stationary phase with a polysiloxane as the diluent. 
Interestingly, it was found that the mixed stationary phase exhibited a much better 
selectivity for polar and nonpolar compounds than either the dicationic IL or the 
polysiloxane, suggesting that a kind of synergistic effect occurred when these stationary 
phases were combined.19 
 
Compared with neat IL stationary phases, the mixed stationary phases provided excellent 
wetting ability on the inner wall of the capillaries. However, the durability of the physical 
 mixtureseemed to be doubtful because of the significant difference between the ILs and 
commercial stationary phases. Subsequently, two different synthesis routes for ionic 
liquid bonded polysiloxanes stationary phases were reported.21,22 The method by Wei et 
al.21 was based on hydrosilylation between poly(methylhydrosiloxane) and 1-vinyl-3-
hexylimidazolium hexafluorophosphate [VHIm][PF6]. The column efficiency of this phase 
was relatively low (only 2500 plates/m) with conditioning temperature of 200 ˚C. Sun et 
al.22 proposed an alternative way via the quaterisation of γ-chloropropyl-polysiloxane 
with methylimidazolium. The content of the imidazolium moeity in ionic liquids was about 
10 %. This kind of IL stationary phase was more stable than the physical mixture and 
offered better wetting ability on inner wall of capillaries than neat IL stationary phases. 
Nevertheless, it could not be used over 220 ˚C. Thus, improving the thermal stability of 
IL bonded polysiloxanes and an increase in their separation efficiency is still crucial to the 
development of IL stationary phases. In that work, a novel methylimidazolium 
bistrifluoromethanesulfonylimide ionic liquid bonded to polysiloxane ([PSOMIM][NTf2]) 
was prepared.23 For the purpose of comparison, another ionic liquid methylimidazolium 
chloride ([PSOMIM][Cl]) was tested with an imidazolium ionic liquid unit content of 30 
%.23 The synthesized polymers were then used as GC stationary phases and their 
selectivity was compared to that of DB-1.23 The results suggested that the ionic liquid 
bonded polysiloxane [PSOMIM][NTf2] has great potential for practical application as 
stationary phases for high temperature and high selectivity GC analysis.23 
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Figure 3.4: Polysiloxane bonded methylimidazolium ionic liquids [PSOMIM][NTf2] and 
[PSOMIM][Cl]. 
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Methylimidazolium bis(trifluoromethanesulfonyl)imidate-polysiloxane exhibited good 
coating ability and durability. Moreover, the solvation parameter evaluation revealed that 
hydrogen bond basicity of [PSOMIM][NTf2] was expectedly lower than that of 
[PSOMIM][Cl] under the test conditions.23 It was shown that the anion had significant 
influence on the thermal stability, polarity and selectivity of the IL bonded 
polysiloxanes.23 The [PSOMIM][NTf2] column possessed higher separation efficiency than 
[PSOMIM][Cl] column, and was found to have good selectivity for analytes of a wide 
range of polarities including aromatic isomers, fatty acid methyl esters (FAMEs), 
polychlorinated biphenyls (PCBs) and aromatic amines.23 These new IL bonded 
polysiloxane [PSOMIM][NTf2] have  great potential in high temperature and highly 
selective GC analysis. 
 
Work has been undertaken to combine the unique attributes of polysiloxanes such as 
high thermal stability with the unique “dual nature” characteric of ILs which allows for the 
separation of both polar and nonpolar analytes on the same column. However, in our 
work the need to develop new enantioselective IL chiral selectors was addressed, striving 
to make a contribution toward the continual need for development of new chiral 
separation media for GC stationary phases. Highly enantioselective IL chiral selectors can 
be useful in the development of new stationary phases such as polysiloxane bonded ILs. 
Advancements in chromatography permit the separation and isolation of a larger variety 
of chiral synthetic compounds, thus, making available to research chemists and drug 
companies alternative chiral separation media for obtaining the data required by 
regulatory agencies. 
 
3.2.2 Results and Discussion 
Strategies to engineer CDs which possess and exploit the desired chromatographic 
properties of the desired stationary phases, such as increased enantioselectivity, is to 
either combine two chiral selectors into a single phase24-28 or create a hybrid selector.  
 
 A good example of a mixed CD phase was demonstrated by Ruderisch et al.,24 in which 
two stationary phases, Chirasil-Dex and Chiralsil-Calixval, where combined by chemically 
bonding the associated chiral selectors; mono-kis-O-octenyl-permethyl-β-cyclodextrin 
and octakis-O-[(L-valine-tert-butylamide)-N-acetyl]-C-decenyl-resorcinarene, to 
polysiloxane forming the Chiralsil-Calixval-Dex phase.  
 
An engineered hybrid stationary phase was investigated by Bicchi et al. whereby per-6-
O-THDMS-3-O-acetyl-2-O-methyl-γ-CD and 6-O-THDMS-2-O-acetyl-3-O-methyl-γ-CD 
hybrid chiral selectors were synthesised (Figure 3.5) and tested for enantioselectivity and 
their performance compared to their analogous phases 2,3-di-O-methyl- and 2,3-di-O-
acetyl-γ-CD, not with unequivocal results.29 A general conclusion was not made regarding 
the enantioselective behaviour of the hybrid phases given that some analytes showed 
improved separation while others did not and had better separation on the non-hybrid 
columns. However, it was found that all the analytes tested were separated by all the 
phases that had an acetyl substituent at C3. Other hybrid phases have been reported by 
Bicchi et al. more recently where the asymmetrically substituted 2-O-methyl-3-O-ethyl- 
and 2-O-ethyl-3-O-methyl-6-O-TBDMS-β-CD showed extended enantioselectivity 
compared to their symmetrical 2,3-O-methyl and 2,3-O-ethyl derivatised counter parts.30  
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Figure 3.5: per-6-O-THDMS-3-O-acetyl-2-O-methyl-γ-CD and 6-O-THDMS-2-O-acetyl-
3-O-methyl-γ-CD hybrid chiral selectors. 
 
The CD ring size and substituents at C-2, C-3 and C-6 positions of the sugar units 
strongly influence the CD's chemical and physical properties and enantioselectivity. We 
have chosen to use the intermediate size β-CDs. It has been shown that CD derivatives 
with the “small” substituents such as acetyl, methyl or ethyl groups on the secondary 
face, with a bulky group on the primary side produce good enantioselectivity by GC. 
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Keeping this concept in mind, CDs with bulky imidazolium or pyridinium groups on the 
primary face were prepared that complemented the design by substituting the secondary 
face with per-2,3-O-acetyl substitutuents. The influence of the substituents in positions 
2, 3, and 6 of the CD ring has been discussed extensively by Bicchi et al., and 
Shitangkoon et al.31-33 Amongst the most effective derivatives used as CSP for 
enantioselective GC are 6-TBDMS-β-CDs substituted with methyl, ethyl or acetyl groups 
at C-2 (OR1) and C-3 (OR2) positions (Figure 3.6).34,35 
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Figure 3.6: 6-TBDMS-β-CDs substituted with methyl, ethyl or acetyl groups at C-2 (OR1) 
and C-3 (OR2). 
There are many CD GC capillary columns currently commercially available for 
enantioseparation application. ASTEC produces Chiradex capillary GC column phases 
consisting of derivatives of α-, β-, or γ-cyclodextrin for the separation of enantiomers as 
illustrated in Table 3.1. These columns can routinely separate a variety of underivatised 
non-aromatic enantiomers and several aromatic enantiomers including compounds that 
are starting materials or intermediates for chiral synthesis, biochemical and 
pharmaceutical intermediates, metabolites, environmental contaminants, flavours, etc., 
permitting the resolution of small chiral compounds. The various compounds separated 
by the different Chiraldex columns are presented in Table 3.1. These cyclodextrin 
derivatives are stable, high boiling liquids, which makes them effective stationary phases 
for gas-liquid chromatography. Their maximum allowable operating temperatures (MAOT) 
both for isothermal and temperature programmed conditions range between 180-220 ˚C 
(Table 3.1).  
Column Derivatisation Compounds separated on column 
Interaction 
Mechanism
s 
MAOT  
(°C) 
Chiradex TA  
2,6-di-O-pentyl-3-
trifluoroacetyl 
α-TA Small epoxides, alcohols, amino alcohols, amino 
alkanes, and diols.  
β-TA Alkyl alcohols, halo acid esters, amino alkanes, amino 
acid derivatives, halocycloalkanes, certain lactones, diols, 
alkyl halides, and furan and pyran derivatives. 
γ-TA Chiral alcohols, diols, polyols, hydrocarbons, lactones, 
amino alcohols, halocarboxylic acid esters, furan and pyran 
derivatives, epoxides, glycidyl analogs, and haloepihydrins. 
Strong 
dipole-dipole 
interactions 
180 
 Chiradex DP  
2,3-di-O-propionyl-
6-t-butylsilyl 
α-DP Acid esters, amines, lactones, alcohols, and some 
diols. 
γ-DP Acid esters (long chain), fused ring/bulky amines, and 
lactones. 
Mostly 
surface 
interactions 
220 
Chiradex PN  
2,6-di-O-pentyl-3-
propionyl 
γ-PN Epoxides, secondary amines, alcohols, esters, 
lactones, and diols. 
There is little 
evidence of 
inclusion 
formation 
220 
Chiradex BP 
2,6-di-O-pentyl-3-
butyryl 
γ-BP Amino acids, certain primary amines, and furans. 
primary 
surface 
interactions 
220 
Chiradex DM 
2,3-di-O-methyl-6-t-
butylsilyl 
β-DM Aromatic alcohols, short chain alcohols, amines, 
amino alcohols, epoxides, cyclic ketones, diols, aromatic 
acids, and esters 
γ-DM Aromatic alcohols , polar amines, bulky amines, 
Size 
selectivity 
Fewer 
structural 
220 
  
aromatic amines, halogenated aliphatic acids, and 
derivatized long chain diols. 
requirements 
 
Chiradex PM 2,3,6-tri-O-methyl 
β-PM Acids, alcohols, barbitals, diols, epoxides, esters, 
hydrocarbons, ketones, lactones, and terpenes. 
Inclusion 
complexes  
220 
Chiradex DA  
2,6-di-O-pentyl-3-
methoxy 
α-DA Small cyclic and aromatic amines, alcohols, and 
epoxides. 
β-DA Heterocyclics, some multi-ring lactones, aromatic 
amines, sugars, certain amino acid derivatives, bicyclics, 
and epoxides. 
γ-DA Aromatic amines containing 2 or more rings, large 
cyclic diols, some heterocyclics, multi-ring compounds, or 
compounds with bulky substituents. 
Inclusion 
complexes 
220 
Chiradex PH  
(S)-2-hydroxy 
propylmethylether 
α-PH Small linear and saturated amines, alcohols, esters, 
and epoxides. 
β-PH Linear and cyclic amines and alcohols, lactones, 
amino alcohols, sugars, bicyclics, epoxides, haloalkanes, 
aromatic and cyclic hydrocarbons. 
Inclusion 
complexes 
220 
Table 3.1: A list of commercial ASTEC columns, the compounds they separate, the primary enantiorecognition mechanisms involved and 
their maximum operating temperatures.36,37 (data obtained from www.sigmaaldrich.com).  
There are currently a few ionic liquid stationary phase GC capillary columns available on 
the market (Table 3.2). These columns range from polar to highly polar with maximum 
allowable operating temperatures ranging from 270-300 ˚C comparable to polyethylene 
glycol (PEG) phases which have a MAOT of ~280 ˚C, with the exception of IL column 
SLB-IL 100 with a MAOT of 230 ˚C. The ionic liquid used in SLB-IL 100 is the di-cationic 
vinylimidazole 1,9-di(3-vinyl-imidazolium)nonane bis(trifluoromethylsulfonyl)imidate 
(Figure 3.3). Of the commercial ionic liquid GC capillary columns on the market there are 
no chiral IL based stationary phases available for application in enantiomer resolution 
application.  
Table 3.2: Commerial non-bonded IL stationary phases.37  
Column MAOT (°C) 
SLB-IL 59 300 
SLB-IL 76 270 
SLB-IL 82 270 
SLB-IL 100 230 
SLB-IL 111 270 
 
Consequently, we endeavoured to address the need for the development of new 
enantioselective IL chiral selectors for application in GC stationary phases. New chiral IL 
were diluted in the polysiloxane OV-1701 and incorporated into GC capillary columns for 
accessing enantioselectivity.  
 
Static coating method 
Film thickness 
All capillary columns were prepared by static coating, as outlined in Section 3.2.4.3, with 
a  chiral IL and polysiloxane OV-1701 at a proportion of 30 % chiral selector to 70 % OV-
1701 (w/w) (or Carbowax 20 where indicated). 
  
In general columns with a thinner film stationary phase have slightly higher efficiencies 
than a corresponding thicker film column. All the columns prepared were coated using a 
0.4 % (w/v) solution of DCM giving a stationary phase with a standard film thickness of 
0.25 µm calculated with Equation 1; 
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                                              m25.0                 Eqn. (1) 
where dc is the diameter of the capillary column (µm) and c is the percentage weight of 
stationary phase dissolved in the solvent (DCM). 
 
Percentage composition of ionic chiral selector in OV-1701 
The dilution of cyclodextrin derivatives in a polysiloxane stationary phase has proven to 
have several advantages enabling the operating temperature range of the column to be 
wider, and making it possible to conduct chiral analysis at temperatures below the 
melting points of the chiral selector (in this case the ionic salts). Finally, improved 
column efficiencies can be achieved due to the favourable coating properties of 
polysiloxanes. The amount of chiral selector in the polymeric stationary phase can have a 
large influence on enantioselectivity. As expected, Schmarr et al. reported that low 
cyclodextrin concentrations reduce enantioresolution.38 Hardt and König39 also reported a 
significant increase in selectivity as the amount of octakis(3-O-butyryl-2,6-di-O-pentyl)-
γ-cyclodextrin in OV-1701 increased, but the separation factor levelled off when the 
concentration of the chiral selector neared 50 % (w/w). Bicchi et al. achieved separation 
of 1,8-epoxy-9-(3-methyl-6-buten-1-yl)-p-methane using 30 % permethylated β-CD in 
OV-1701 but not when the permethylated β-CD was at a concentration of 10 % (w/w).40 
Jung et al. demonstrated both theoretically and experimentally that different solutes 
exhibited different behaviours; that is, the apparent enantioselectivity factor for each 
racemate reached a plateau at different amounts of chiral selector.41 In general, 
however, it is expected that the highest possible concentration of the CD derivative 
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compatible with its solubility in the polymeric solvent should be used to achieve the 
highest enantioselectivity factor for most solutes. As a general rule, less polar polymers 
lead to enhanced enantioselectivity. Therefore OV-1701 (a moderately polar phase) was 
chosen as the achiral diluent phase for the chiral selectors being tested for 
enantioselectivity.   
 
The main dilemma with using OV-1701 as our achiral phase is that the solubility of the 
most polar CD derivatives in nonpolar or moderately polar polysiloxanes is rather limited 
at relatively low temperatures, while low elution temperatures are required to enhance 
the molecular interactions that lead to enantioseparation. Ideally, conditions that favour 
low chromatographic temperatures should be selected to maximise the resolution of 
enantiomers. The maximum solubility that allows GC separations at low temperatures 
has to be critically studied for each mixture of the ionic salt and the achiral stationary 
phase in which it is diluted. However, given the number of chiral selectors being tested in 
this study, it was not practical to determine the optimum concentration that would 
produce the best chromatographic separations at low operating temperatures for each 
chiral selector. For practical consideration a medium concentration of 30 % chiral selector 
was chosen; and assumed to be high enough to permit enantioselectivity studies and low 
enough for the chiral selectors to be soluble at the lower operating temperature. 
 
All of the columns prepared by the static method consisted of 30 % (w/w) chiral selector 
dissolved in OV-1701 (with the exception of per-2,3,6-acetylated-β-CD which was also 
diluted in Carbowax 20 (designated PA-CD wax) as well as OV-1701). The chiral selectors 
tested are illustrated in Figure 3.7, the non-cyclodextrin IL CSPs are named according the 
compound number of the chiral ionic salt they are impregnated with, while the CD CSPs 
are designated with an acronym (see Figure 3.7). 
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Figure 3.7: Chemical structures of the ionic chiral selecting agents tested.  
 
Column conditioning 
Long term conditioning of newly coated columns at high temperatures is not necessary 
and column bleeding is negligible if pure ILs are used. However, all columns were 
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conditioned to remove any possible residual solvent from the coating process. The 
columns were conditioned from 40 ˚C to 180 ˚C at 10 ˚C/min and then held at 180 ˚C 
for 50 mins. The capillary columns were then installed into a GC followed by injection of 
the test mixtures. Stationary phase polarity was determined using the Rohrschneider-
McReynolds classification system, and column efficiencies determined with naphthalene 
at 100 ˚C isothermal with a constant column pressure of 2.5 psi. 
 
Evaluation of column polarities  
Rohrschneider–McReynolds classification system 
To characterize and categorize the solute selectivities of GC stationary phases, the 
Rohrschneider–McReynolds system42,43 is the most widely utilized stationary phase 
classification system, based on the retention of five probe molecules; benzene, butanol, 
2-pentanone, nitropropane, and pyridine. Each probe molecule has the ability to undergo 
distinct interactions with the stationary phase. Benzene (X) measures dispersive 
interactions with weak proton acceptor properties; butanol (Y) measures dipolar 
interactions with both proton donor and proton acceptor capabilities; 2-pentanone (Z) 
measures dipolar interactions with proton acceptor but not proton donor capabilities; 
nitropropane (U) measures weak dipolar interactions; and pyridine (S) measures weak 
dipolar interactions with strong proton acceptor but not proton donor capabilities. 
 
 
 
 
 
 
 
 
 
 
 
  
A) 
5 10 15 20 25
0
200000
400000
600000
MEGA
R
e
s
p
o
n
s
e
Time(mins)
 
B) 
5 10 15 20 25
0
200000
400000
600000
26
R
e
s
p
o
n
s
e
Time (mins)
 
Figure 3.8: Separation of the alkane series C7-C13 on the MEGA commercial chiral 
column (A) and on IL 26 column (B). 
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Kovats’ Retention Index 
To find the Kovats’ index (I) for the probe molecules on a given stationary phase, 
members of the alkane homologuous series were chromatographed. Then the probe 
molecules were run under the same conditions and the retention values of the probe 
molecules and the homologous series, were used to determine Kovats’ index using 
Equation (2). It is desirable that the alkanes chosen, bracket the retention value of the 
analyte. If the flow rate is kept constant during the analysis, then adjusted retention 
times can be used.  
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Figure 3.8 shows the analysis of the C7-C13 alkane series on (a) the commercial column 
(MEGA) and (b) the ionic phase 26. Comparison of the phases revealed a significant 
difference in the retention behaviour of alkanes despite both phases being of 
intermediate polarity (see Table 3.5 for a comparison of polarities). The C13 alkane eluted 
from the 23 m MEGA column in under 22 mins and eluted from the 10 m ionic 26 phase 
in just over 22 mins. The shorter ionic phase column with a slightly higher polarity 
tended to retain the nonpolar alkanes more strongly than the less polar commercial 
column.  
 
The value of each phase constant (i.e., X, Y, Z, U, and S) was determined by subtracting 
the retention index of the probe on a squalane stationary phase (ISQ) from the retention 
index of the probe on the stationary phase being characterized (ITP). For example, the 
phase constant of benzene (X) would be calculated as shown in Equation 3. 
 
ΔI(X) = ΔI(benzene) = ITP(benzene) - ISQ(benzene)   Eqn. (3) 
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Figure 3.9: Squalane a saturated highly branched C30 hydrocarbon 
 
The difference in these indices provides a measure of the increased relative polarity of 
the test phase relative to squalane (which is known as the universal nonpolar standard). 
All five probes were run on squalane and on the stationary phase whose polarity is to be 
determined, and a set of five ∆I values were determined. The sum of the five retention 
indices (∑∆I) then gave the relative phase polarity of the phase being evaluated relative 
to a squalene stationary phase, while the overall polarity of the stationary phase was 
determined by taking the average of all five phase constants. Table 3.5 and Table 3.6 
show the retention indices and phase polarities of some non-ionic liquid commercial 
columns and ionic liquid commercial columns, respectively. 
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Table 3.3: The Rohrschneider–McReynolds system applied to stationary phases of 
commercials columns.37 
McReynolds Constants 
Stationary 
phases 
 
X 
 
Y 
 
Z 
 
U 
 
S 
Av. 
 ΔI 
Squalane 0 0 0 0 0 0 
Apolane 87 21 10 3 12 25 14 
OV-1 or DB-1 16 55 44 65 42 44 
OV-101 17 57 45 67 43 46 
Dexsil 300 41 83 117 154 126 104 
Equity-1701* 82 131 150 233 136 146 
OV-17 119 158 62 243 202 157 
OV-225 228 369 338 492 386 363 
Carbowax 20M 322 536 368 572 510 462 
DEG 492 733 581 833 791 686 
OV-275 629 872 763 1106 849 844 
 (*data from www.sigmaaldrich.com), ® = Registered trademark 
 
Armstrong and coworkers determined the Rohrschneider–McReynolds constants for two 
imidazolium-based ILs: 1-butyl-3-methylimidazolium chloride [C4C1Im]Cl and 1-butyl-3-
methylimidazolium hexafluorophosphate [C4C1Im]PF6.
5 A comparison of the phase 
constants for [C4C1Im]PF6 and [C4C1Im]Cl to two common commercial GC stationary 
phases, DB-5 (phenylmethyl polysiloxane; 5 % phenyl) and OV-22 
(phenylmethyldiphenyl polysiloxane; 65 % phenyl) revealed the average polarity of the 
two ILs ([∑∆I]Av =216 and [∑∆I]Av =218, respectively) to be very similar to that of the 
OV-22 stationary phase ([∑∆I]Av=215).
5 Both the ILs exhibited significant proton 
accepting and dipolar interactions with solute molecules.5 It was also observed that 
different anions influenced the magnitude of the phase constants, but did not affect the 
  
overall polarity of the stationary phase.5 Although the overall polarities of the studied ILs 
were similar to each other and other polysiloxane stationary phases, their separation 
selectivities were very different.5  
 
The effect of the chiral ionic additive on the polarity of the OV-1701 phase was 
investigated using the Rohrschneider–McReynolds system. The retention indices of each 
of the polysiloxane-based chiral ionic phases are presented in Table 3.5 along with a 100 
% OV-1701 phase for comparison. The retention indices given for each phase was the 
average of 3 injections at either 60 ˚C or 70 ˚C normalised to squalane. Table 3.5 shows 
the phase polarities of the polysiloxane-based ionic phases to range from [∑∆I]Av 75 to 
187 compared to 100 % OV-1701 phase with an overall phase polarity of [∑∆I]Av 131.  It 
would be expected that the chiral additive would increase the overall polarity of OV-1701, 
however, this was not necessarily the case. 
 
Table 3.4: The Rohrschneider–McReynolds system applied to commercial IL phases.37 
McReynolds Constants 
Stationar
y phases 
 
X 
 
Y 
 
Z 
 
U 
 
S 
Av. 
ΔI 
Squalane 0 0 0 0 0 0 
SLB-IL59 338 505 549 649 583 525 
SLB-IL76 456 690 643 845 745 676 
SLB-IL82 532 676 701 921 808 728 
SLB-IL100 602 853 884 1017 1081 888 
SLB-IL111 766 930 957 1192 1093 988 
 
PM-CD (per-2,3,6-methyl-β-CD) and PA-CD (per-2,3,6-acetyl-β-CD) diluted in OV-1701 
both have a polarity of 98 which is significantly lower than that of pure OV1701, while 
PM-CD diluted in carbowax 20 (PM-CD wax) has a significantly higher polarity ([∑∆I]Av 
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220) as expected, (pure carbowax 20 has a polarity of 462). Derivatised cyclodextrins, 
either permethylated or peracetylated, lower the overall polarity of the stationary phase 
in which they are diluted. While carbowax 20 is a highly polar phase, the dilution of 30 % 
permethylated β-CD (PM-CD) lowered the overall polarity of the stationary phase from 
highly polar to one of intermediate polarity.  
 
Figure 3.10: Visual representation of the polarity scale of the tested phases in 
comparison to various commercial phases; the polarities of the phases tested range from 
75-220. 
 
When the polarities of PM-CD and PA-CD diluted in OV-1701 are compared with those of 
the ionic CD phases there is only a minor increase in the polarities for the ionic β-CD 
derivatives. The ionic substituent had little effect on the overall polarity of the phase 
while the size of the cyclodextrin had a more profound effect on the phase polarity. The 
ionic P23A6BuImγCD (92) has a phase polarity of [∑∆I]Av 89 (making it a nonpolar 
phase) which is significantly lower than its β-CD analogue (P23A6BuImβCD (91)) with a 
polarity of [∑∆I]Av 120 (intermediate polarity). All the ionic salts tested significantly 
reduced the polarity of the OV-1701 polysiloxane polymer in which they were diluted with 
the exception of phase 69 which increased the phase polarity and 4 which had no effect 
on the polarity of the phase resulting in a similar polarity to OV-1701. The ionic liquid 
stationary phases currently available on the market, shown in Table 3.4, have polarities 
ranging from highly polar to extremely polar ([∑∆I]Av 525 to 988). Whereas the polarity 
range of the polysiloxane-based ionic stationary phases do not differ greatly from pure 
OV-1701, yet the retention behaviours of the probe molecules analysed varied 
0 100 400 >888 
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significantly as a result of the differences in the chemical structures of the chiral ionic 
additives.  
 
Table 3.5: The Rohrschneider–McReynolds system applied to the chiral ionic phases. 
McReynolds Constants 
Stationary phases  
X 
 
Y 
 
Z 
 
U 
 
S Av. ΔI 
Squalane 0 0 0 0 0 0 
OV-1701 46 161 127 201 121 131 
MEGA 36 178 93 169 94 114 
4 46 171 129 214 125 137 
26 47 129 86 136 87 97 
39 33 130 97 166 98 105 
35 33 93 68 112 70 75 
65 36 174 118 190 -11 101 
69 46 158 220 172 338 187 
PM-CD wax 93 321 141 314 232 220 
PM-CD 8 144 77 165 94 98 
PA-CD 3 149 42 187 110 98 
P23Ac6BuβCD (91) 43 156 99 177 127 120 
P23Ac6MeβCD(89) 33 176 83 192 128 122 
P23Ac6BuγCD (92) 31 106 80 141 86 89 
 
The relative contributions of the chiral additives to the McReynolds constants of the OV-
1701 phase are shown in Table 3.6. These results were derived by subtracting the 
McReynolds constants for pure OV-1701 from the constants of the OV-1701 phases 
impregnated with a chiral compound. When normalised to OV-1701 we can see the 
contribution the additives make to the distinct interactions each probe molecule 
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undergoes with the stationary phase. P23A6BuImβCD (91) and P23A6MeβIm-CD (89) 
stationary with having similar overall polarities of 120 and 122, respectively, showed 
distinctly different molecular interaction with the probe molecules (see Table 3.6). 
P23A6BuImβCD (91) phase showed a decrease in dipolar interactions with proton 
acceptor but not proton donor capabilities (Z) as well as a decrease in weak dipolar 
interactions (U), while P23A6MeImβCD (89) phase not only showed a decrease in dipolar 
interactions with proton acceptor but not proton donor capabilities (Z), but a marked 
increase in dipolar interactions with both proton donor and proton acceptor capabilities 
(Y). These differences are most likely attributed to the differences in the chemical 
structure of the imidazolium cationic component of the ionic salt given that all the ionic 
CDs have the same counter anion (iodine).  
 
Not only does the chemical structure of the imidazolium substituent affect the strength of 
interaction, but the size of the CD ring itself has a marked effect on how the probe 
molecules interact with stationary phases. Comparison of P23A6BuImβCD (91) and 
P23A6BuImγCD (92) indicates their markedly different polarities, of 120 and 89 
respectively, one being of moderate polarity and the other non-polar on the polarity 
scale. Although both additives have the same butylimidazolium cation derivative bonded 
to the C6, the difference in the size of the cyclodextrin ring cavity exerts a significant 
effect on the strength of the molecular interactions between the probe molecules and the 
stationary phase (Table 3.6). The γ-CD ionic phase P23A6BuImγCD (92) showed a 
distinct reduction in all the molecular interactions represented by the phase constants, X, 
Y, Z, U, and S, in comparison to the β-CD ionic stationary phase P23A6BuImβCD (91).  
 
 
 
 
 
 
 
  
Table 3.6: The relative contribution of the additives to McReynolds constants derived 
from the Rohrschneider–McReynolds system and normalised to OV-1701.  
 
Relative contribution of the additives to McReynolds Constants 
Stationary phases  
X 
 
Y 
 
Z 
 
U 
 
S 
Av. 
OV-1701 0 0 0 0 0 0 
4 0 10 2 13 4 6 
26 1 -32 -41 -65 -34 -34 
39 -13 -31 -30 -35 -23 -26 
35 -13 -68 -59 -89 -51 -56 
65 -10 13 -9 -11 -132 -30 
69 0 -3 93 -29 217 56 
PM-CD -38 -17 -50 -36 -27 -34 
PA-CD -43 -12 -85 -14 -11 -33 
P23Ac6BuβCD (91) -3 -5 -28 -24 6 -11 
P23Ac6MeβCD (89) -13 15 -44 -9 7 -9 
P23Ac6BuγCD (92) -15 -55 -47 -60 -35 -42 
 
However, there are limitations with the application of the Rohrschneider–McReynolds 
method for characterising a stationary phase. The Rohrschneider–McReynolds approach 
is helpful in illustrating differences between ILs in terms of the types of interactions they 
exhibit with the probe molecules. Any one probe can indicate a particularly strong 
interaction, indicating that the phase interacts strongly with compounds of comparable 
characteristic to the probe molecule. However, the model has deficiencies that preclude it 
from fully characterizing individual solvation interactions. The method utilizes probe 
molecules that are too volatile (e.g., benzene, 2-pentanone, and nitropropane) having 
short retention times often eluting with the dead volume of the column. In addition, a 
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single parameter polarity scale has the disadvantage of describing a weighted average of 
all solute–solvent interactions.44 Ideally what is required is to ascertain the individual 
solvation interactions the ionic additive contributes to the properties of the OV-1701 
phase. Given that the additives vary significantly in their chemical structures, they may 
undergo variable solvation interactions. To determine the individual solvation interactions 
imparted by the cation and anion, the method must be capable of describing more than a 
single polarity, or phase constant. The solvation parameter model (linear solvation free 
energy relationship [LSFER] model) developed by Abraham,45,46 has been used to 
characterize liquid- or gas-phase interactions between solute molecules and liquid 
phases. It is highly recommended that such a model be applied to gain a better 
understanding of the individual solvation interactions contributed by the chiral ionic salt 
additives to the polysiloxane phase.  
 
Column efficiency 
Number of theoretical plates (N) 
The most common measure of the efficiency of a chromatographic system is the Number 
of theoretical plates or plate number, N.  For a chromatogram containing many peaks, 
the values of N for individual peaks may vary (increasing slightly with retention time). It 
is common practice, however, to assign a value to a particular column based on only one 
measurement even though an average value would be better. Here, naphthalene has 
been assigned as the analyte for assessing the column efficiencies. 
 
Column efficiency is the relationship between solute retention time and the amount of 
band broadening. Symmetrical peaks with small width are desired. Narrow peaks can be 
close together and still be resolved. Broader peaks of the same distance apart will not be 
resolved as well and may co-elute. Column efficiency is expressed as the number of 
theoretical plates (N), and is calculated from Equation 4; 
h
R
w
t
N 545.5    Eqn. (4) 
  
where tR is the peak retention time and wh is the peak width at half height expressed in 
units of time. The higher the number of theoretical plates, the higher the column 
efficiency and its potential to resolve two closely eluting solutes.  
 
Table 3.7: Column efficiencies; plate number and plate height of naphthalene on the 
ionic test phases compared with OV-1701 and the commercial column (MEGA). 
 
Columns tR’ N H 
OV-1701 6.99 20231 494 
MEGA 9.7 6153 2409 
4 3.04 2135 106797 
26 10.19 287 73173 
39* - - - 
35* - - - 
65 5.20 25324 1376 
69 6.85 1568 12296 
PM-CD OV1701 14.35 4798 11616 
PM-CD wax 9.83 2605 14242 
PA-CD 17.66 633 39962 
P23Ac6BuImβCD (91) 7.73 228 73156 
P23Ac6MeImβCD (89) 7.75 309 33914 
P23Ac6BuImγCD (92) 10.97 430 33781 
*Unable to determine N for 850 & 870 due to extreme peak broadening of Naphthalene. 
(The green number is the compound number of the chiral selector used in the phase). 
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Plate height (H) 
Another related parameter which expresses the efficiency of a column is the plate height 
(H), also called the Height Equivalent to One Theoretical Plate (HETP), where L is the 
length of the column (mm) and N is number of theoretical plates (Equation (5)).  Plate 
height is better than the number of theoretical plates for comparing efficiencies of 
columns of differing lengths. A good column will have a large N and a small H value. 
 
N
L
H      Eqn. (5) 
 
Table 3.7 compares the column efficiencies of the ionic stationary phases with 100 % 
OV-1701 and the commercial column (MEGA). The chiral ionic additives significantly 
reduced the efficiency of the stationary phase for naphthalene, with the exception of 
phase 65 with a plate height of 1376 which is better than the plate number produced by 
the commercial column (plate height 2409). 
 
Chiral analysis 
The capability of the chiral ionic stationary phases to chromatographically resolve 
enantiomeric mixtures was tested against the series of chiral analytes illustrated in 
Figure 3.11. Of the 54 racemic compounds tested only the most significant results will be 
reported here. No separation was observed for other terpenes, including limonene and α-
pinene, with any of the columns tested. The commercial column (MEGA) however, 
separated 19 out of the remaining 39 chiral analytes tested. Over all, the commercial 
column resolved 50 % of the chiral compounds analysed.  
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Figure 3.11: List of racemic analytes tested. 
 
Figure 3.12 shows chiral resolution of γ-valerolactone using the commercial column 
(MEGA) as well as with the PA-CD (per-2,3,6-acetyl-β-CD) phase. The enantiomeric 
resolution of γ-valerolactone with a stationary phase prepared and coated in our lab 
validated the effectiveness of the coating procedure.  
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Figure 3.12: Chromatographic spectra of ketones, lactones and alkanes separated on 
the MEGA, and PA-CD columns. 1) 3-methylpentanone 2) δ-decalactone 3) γ-
valerolactone 4) 3-methylhexane 5) 3-methylpentane. 
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Figure 3.13 shows a comparison of the separation of a test mixture of the aromatic and 
cyclic chiral analytes limonene, mentone, styrene oxide, and 1-chloro-2,3-epoxypropane 
(epichlorohydrin) on stationary phases OV-1701, MEGA, PA-CD, PM-CD, 39, 26, 
P23Ac6MeImβCD (89), and P23Ac6BuImβCD (91). The differences in retention time, 
peaking broadening, and peak symmetry show just how differently the analytes behave 
on the different phases. For example, 1-chloro-2,3-epoxypropane is not strongly retained 
and co-elutes with the solvent peak on phase 39 and the ionic CD phases, whereas the 
peak is present in the spectra of the remaining phases. Severe peak broadening was 
observed for styrene epoxide on both ionic CD phases to the extent where the analyte 
could not be seen in the spectra where as it was detected in the remaining stationary 
phases. Enantiomeric resolution of 1-chloro-2,3-epoxypropane was observed on PA-CD 
stationary phase while the MEGA column resolved limonene and styrene epoxide. 
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Figure 3.13: A comparison of the separation of a test mixture of aromatic and cyclic 
chiral analytes on the OV-1701, MEGA, PA-CD, PM-CD, 39, 26, P23Ac6MeImβCD (89), 
and P23Ac6BuImβCD (91) stationary phases. 1) Limonene, 2) Mentone and iso-methone, 
3) Styrene oxide, 4) 1-chloro-2,3-epoxypropane (epichlorohydrin). 
 
The chromatographic separation of aldehydes and oximes on OV-1701, MEGA, 39 and 
PA-CD stationary phases is illustrated in Figure 3.14. The commercial MEGA column was 
able to enantiomerically resolve 2-methylpentane aldehyde, and enantiomers of the E 
and Z isomers of the oximes. The remaining ionic phases did not resolve the enantiomers 
of either the aldehydes or oximes, but the E and Z isomers of the oximes were resolved 
on all the ionic phases tested. 
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Figure 3.14: Chromatographic separation of aldehydes and oximes on OV-1701, MEGA, 
39 and PA-CD stationary phases. 1) 2-methylbutyraldehyde, 2) 2-
methylpentanealdehyde, 3) 2-methylbutyraldehyde oxime, 4) 2-methylpentanealdehyde 
oxime. 
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The retention factor (k) is a measure of how much time a solute spends in the stationary 
phase relative to the time it spends in the mobile phase (carrier gas). All solutes spend 
the same amount of time in the mobile phase, thus the k value is directly related to the 
retention caused by the stationary phase. It has a unitless value calculated using 
Equation 6; 
M
MR
t
tt
k

    Eqn .(6) 
 
where tR is the solute retention time and tM the retention time of non-retained solute 
such as methane gas. Table 3.8 shows the partition ratios of selected compounds 
analysed on the ionic phases 26, 4, P23Ac6MeImβCD (89) and P23Ac6BuImγCD (92), 
compared with the 100 % OV-1701 phase, PA-CD phase and the MEGA (commercial 
column). The commercial column having a different stationary phase to OV-1701 and 
consisting of a different cyclodextrin is expected to show considerably different retention 
behaviours for each test analyte. However, a comparison of the differences in retention 
behaviour of the chiral analytes of the OV-1701 based ionic stationary phases verses the 
100 % OV-1701 stationary phase reveals the retention caused by the chiral ionic 
additives.  
 
A further comparison of the effect of the differences in the chemical structure of the 
cyclodextrin additive can be made by studying the difference in the retention behaviours 
of the chiral analytes on the PA-CD stationary phase consisting of 30 % per-2,3,6-acetyl-
β-CD additive in OV-1701, verses P23Ac6MeImβCD (89) ionic stationary phase 
composed of 30 % per-2,3-acetyl-6-(N-Methylimidazolium iodide)-β-CD in OV-1701. 
These β cyclodextrin derivatives have a similar chemical structure with an acetyl group at 
C2 and C3 but, differing at C6 with P23Ac6MeImβCD (89) having a methyimidazolium 
substituent instead of an acetyl group as per PA-CD. By comparing these two phases the 
effect of the C6 imidazolium substituent can be seen by comparing the k value in Table 
3.8. The effect of the size of the cyclodextrin ring on the retention of the analytes can be 
  
seen by comparing P23Ac6BuImβCD (91) and P23Ac6BuImγCD (92) stationary phases. 
Both CD derivatives have identical substituents at C2, C3 and C6, the only difference 
being that one is a β-CD derivative and the other a γ-CD derivative, respectively. 
 
Table 3.8: A comparison of the retention factors (k) of selected chiral analytes on the various stationary phases. 
Chiral Analytes MEGA 
OV-
1701 
PA-
CD 
PA23Ac 
6MeImβCD 
P23Ac 
6BuImγCD 
PA23Ac 
6BuImβCD 
4 26 
 k1 k2        
2-Butanol 3.9 4.0 1.3 3.1    0.9 1.7 
2-Pentanol 7.4 7.5 2.7 5.5  3.2  2.1 9.84 
2-Methyl-1-butanol 10.1  4.0 8.7   3.87 3.0 2.59 
1-Phenylethanol 23.1 23.3 20.3 47.4 61.30  38.30 27.7  
2-Octanol 16.3  31.1 24.2 24.87 20.9 17.64 16.9 13.08 
2,3-Butanediol(rr/ss) 13.4 14.0 12.9 31.0 54.71 17.1 30.96 7.9 12.08 
2,3-Butanediol  14.6  14.8     8.6  
2,3-Butanediol (meso)   12.7    32.27   
1,2-Propanediol 12.6 12.8 11.7 34.2 57.03 35.9 33.13 7.4 26.74 
1,3-Butanediol 18.4  23.4 43.4 68.05 43.7 41.21 29.4 31.77 
2,5-Hexanediol 22.2 22.3 37.9 49.7 68.27 45.4 44.35 19.6 31.77 
2-Methyl-2,4-pentanediol 17.6 18.2 23.6 36.9 27.39 21.4 19.98 2.6 13.74 
3-Methylpentanone 6.0 6.8 3.6 4.5 4.25 4.3 3.18 80.1 2.43 
δ-decalactone 33.9 33.9 75.2   66.1  20.9  
γ-Valerolactone 16.9 18.3 25.2 41.2   34.81 0.7 13.67 
  
3-Methylhexane 2.2  1.0      1.1 
4-Methyl-1-cyclohexene 4.6 4.7 2.1 2.8 3.27 3.4 2.19 1.4 2.08 
α-Pinene 9.7 9.8 8.7 11.2 13.53 13.2 9.16 6.3 8.39 
Menthol 23.0  37.9 41.0 43.96 37.3 32.46 33.8 24.34 
Menthol    42.4  38.5 33.73 35.5 25.12 
Carvone 24.3  46.3 46.6 52.27 43.3 38.79 42.0 28.29 
Limonene 14.4 15.0 16.5 20.4 23.97 21.9 16.49 12.6 14.24 
Mentone* 18.6  34.5 32.7 40.24 34.7 29.86 30.1 22.44 
Mentone*  19.1 36.0 33.8 41.36 35.5 30.82 31.6 22.95 
Strene oxide 18.0 18.6 26.2 36.4    22.1 16.94 
Epichlorhydrin 6.6  3.2 11.6   8.34 2.3 2.15 
Linalool 19.2   34.4 34.1 29.5 25.58 25.9 18.88 
sec Butylamine 2.0  4.6 1.0      
α-Methylbenzylamine 18.7 19.0 29.4 32.7    19.7 17.52 
Lactic acid 22.0 22.6     53.86   
2-Ethylhexanoic 25.3 25.4 41.1 56.4  36.3 33.17 41.7  
2-Methylbutyraldehyde 4.1  1.6 2.5  2.0 1.45 1.2 1.11 
2-Methylpentane aldehyde 7.5 7.8 3.6 4.4  4.5 3.30 2.6 2.55 
2-Methylbutyraldehyde oxime 16.2 16.5 10.0 26.5    8.2 6.58 
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2-Methylbutyraldehyde oxime 17.2 18.5 11.0 27.5    9.0 6.98 
2-Methyl pentanealdoxime 19.1  16.9 33.2  17.1 14.90 14.6 10.75 
2-Methyl pentanealdoxime 19.2 20.9 18.0 34.2  17.8 15.50 15.5 11.29 
Malic acid methyl ester 23.3 23.9 46.2 58.1   49.92   
Mandelic acid methyl ester 27.9 28.0 55.2       
2-Hydroxydecanoic acid methyl ester 30.7 30.9  60.9    60.2  
D/L Alanine methyl ester 11.5   13.8      
D/L Aspartic acid methyl ester 22.9 23.2  53.8    38.4  
D/L Asparagine methyl ester 23.2   53.9      
D/L Leucine methyl ester 16.5       18.4  
D/L methionine methyl ester 26.9 27.1  58.7    49.0  
D/L Phenylalanine methyl ester 31.0 31.3      63.5  
D/L Serine methyl ester 22.8 23.3  53.0      
D/L Threonine methyl ester 21.1 22.4  48.8    26.2  
D/L Valine methyl ester 13.8 14.1  20.8    11.3  
 
* Methone was present as two isomers (as methone and iso-menthone) in the test mixture, each isomer was present as a racemic 
mixture which were not resolved by the chiral ionic liquids. 
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Figure 3.15: Amino acid derivatisation into methyl esters. 
 
Amino acids and carboxylic acids were derivatised into their methyl esters, following a 
procedure by Li and Sha,47 by mixing the amino acid or carboxylic acids with an excess 
molar equivalent of freshly distilled chlorotrimethylsilane (TMSCl) in methanol and 
stirring at room temp for 24 hrs to afford the methyl ester hydrochlorides as a product 
(Figure 3.15). Methanol was removed by evaporation and the methyl esters dissolved in 
DCM for injection. 
 
Table 3.9: Derivatised D/L amino acid and R/S carboxylic acid methyl esters 
 
Alanine Aspartic acid Asparagine Leucine Methionine 
Phenylalanine Serine Tryptophan Threonine Valine 
Malic acid Mandelic acid Tartaric acid 
2-Hydroxydecanoic 
acid 
Citrulline 
 
Of the amino acid and carboxylic acid methyl esters analysed the commercial column 
separated 8 out of the 15 methyl esters. However, neither the ionic or, PM-CD and PA-CD 
selecting agents showed chromatographic resolution of the enantiomers of the methyl 
esters. The ionic phases 26, P23Ac6MeIm-BCD (89), as well as the 100 % OV-1701 
phase strongly retained the amino acid and carboxylic acid methyl esters, with the 
exception of the ionic phase 4 (derived from the alkylation of the amino acid N-
acetylhistidine) which eluted the majority of the amino acid methyl esters analysed. 
Despite having similar a polarity as 100 % OV-1701 (Av. ΔI =131) the IL additive 4 in 
stationary phase 4 (Av. ΔI=137) had a significant effect on the retention behaviour of 
this ionic stationary phase. Given that OV-1701 strongly retained the amino acid and 
  
carboxylic acid methyl esters it is recommended that an alternative phase be used to 
dilute the chiral ionic additives for application in amino acid and carboxylic acid analysis, 
one that will not strongly retain the analytes. 
 
Discussion of chiral analysis 
Permethylated-β-CD is one of the most extensively used chiral selectors. From the 
comprehensive work of Schurig and co-workers,48-50 it is evident that a wide range of 
chiral analytes can be enantioseparated with this selector. Usually, the selector is 
dissolved in the moderately polar polysiloxane OV-1701 or in SPB-35 (35 % diphenyl, 65 
% dimethylpolysiloxane); that are commercially available. However, the solubility of PM-
β -CD in the OV-1701 polymer is limited.1 According to Bicchi et al.,51  the minimum 
operating temperature for columns containing PM-β-CD were 110 ˚C for the column 
coated with undiluted PM-β-CD, 75 ˚C for the column coated with 30 % PM-β-CD in OV-
1701, 55 ˚C for the column coated with 10 % PM-β-CD in OV-1701, and 0 ˚C for the 
column coated with 5 % PM-β-CD in the same polysiloxane. Generally, permethylated 
cyclodextrin is only sparingly soluble in nonpolar dimethylpolysiloxanes and enantiomer 
separations below 80 ˚C have proven to be unsuccessful on this stationary phase.50 To 
overcome this problem Schürig et al.50 chemically bonded permethylated 5-Pent-1-enyl-
β-cyclodextrin derivative to a polysiloxane backbone. The resulting chiral stationary 
phase is known commercially as Chirasil-Dex.50  
 
Thus it is important to know/ or determine the solubility of the chiral selective agent in 
the polysiloxane in which it is to be diluted. Ideally the maximum percentage of chiral 
selective agent added to the polysiloxane should be determined based on the solubility of 
chiral selector in the phase, however, given that the chiral ionic salts are novel 
compounds for which such data is not yet available, a concentration of 30 % (w/w) was 
selected. It is unknown whether this quantity of ionic selective agent is optimal for 
chromatographic resolution of enantiomers to be observed. However, it is important to 
note that spectroscopic discrimination does not necessarily correlate with the 
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thermodynamic discrimination associated with the diastereomeric complexes involved in 
enantiomer resolution. 
 
It was reported by Bicchi et al. that increasing the amount of 2,6-dimethyl-3-pentyl-β-
cyclodextrin from 10 % to 30 % in OV-1701 increased enantioresolution of some 
racemates but caused complete loss of resolution for the menthol racemate.52 On the 
other hand, the separation of another group of analytes was not affected by increasing 
the concentration of the chiral selector in OV-1701.52  
 
Research has been carried out with several other commonly used polymers with the aim 
of obtaining a higher PM-β-CD solubility, and presumably better enantioseparations. More 
recently however, ionic liquids have been investigated as chiral stationary phases for 
application in chiral analysis by GC. To date there have only been three reported 
applications for chiral ILs as stationary phase solvents and chiral selectors in GC analysis. 
One method involved dissolving the chiral selector in an ionic liquid and coating the 
stationary phase on the capillary wall.53 Cyclodextrin derivatives (permethylated-β-
cyclodextrin and dimethylated-β-cyclodextrin) were dissolved in 1-butyl-3-
methylimidazolium chloride and the performance of these IL-based chiral stationary 
phases were compared with analogous polysiloxane based commercial columns 
(Chiraldex BPM and Chiraldex BDM) employing the same chiral selectors. Although the 
chiral IL phases did show enantioselectivity, the observed enantioselectivities of these IL-
based columns did not rival those of the commercial columns. 
 
The second application involved using chiral ILs directly as chiral stationary phases, as 
opposed to the method described above whereby an achiral IL was impregnated with a 
chiral selector. N,N-dimethylephedrinium bis(trifluoromethanesulfonyl)imidate-based ILs 
were the first class of 100 % chiral ionic liquid stationary phase used for the separation 
of enantiomers in GC.54 Enantiomers including alcohols, diols, sulfoxides, epoxides, and 
acetylated amines were resolved. The successful use of a pure ionic liquid phase in chiral 
resolution of a selective group of analytes suggests that perhaps in this study using 
  
higher concentrations of the chiral ionic salts may have possibly improved chiral 
resolution capability of the tested ionic stationary phases. It is possible that the 30 % 
ionic salt concentration used in polysiloxane may not have been sufficient to observe the 
chromatographic resolution.  
 
The third application involved the use of chiral ionic cyclodextrin derivatives as chiral 
selectors diluted in an ionic liquid phase. When compared with commercial polysiloxane 
based phases which possess analogous CD selectors to the ionic CD phases, the ionic CD 
phases were reported as having improved enantioselectivity for more than one third of 
the chiral analytes tested and also separated some compounds that were not separated 
on the commercial phases  tested.55 Achiral RTIL’s have been reported as being able to 
dissolve highly polar compounds including carbohydrates56 and appear to work well as a 
stationary phase matrix for dissolving cyclodextrin selecting agents. It is possible that the 
ionic CDs (and imidazolinium salts) synthesised are not highly soluble in OV-1701, and 
possibly raises the minimum operating temperatures of the stationary phase well above 
the temperature ranges in which enantioselectivity occurs for the individual chiral 
analytes tested in this study.  Perhaps if an achiral RTIL had been employed as the 
stationary phase matrix, instead of a polysiloxane for which the solubility of CDs (such as 
PM-CD) is known to be limited, the enantioselectivity of the chiral ionic phases may have 
been improved. The degree of miscibility of the chiral ionic salts studied in this work with 
OV-1701 (and polysiloxanes in general) has not been established and limited solubility 
cannot be eliminated a possible contributing factor toward the poor performance of the 
ionic salts as chiral resolving agents. 
 
Chiral diastereomeric complexation interaction mechanisms 
The cyclodextrins exist as a single enantiomer, with the consequence that as host 
molecules, their interaction with a racemic guest may lead to the formation of 
diastereoisomeric complexes of differing thermodynamic stabilities.  This chiral 
discrimination by unmodified cyclodextrins has been extensively studied, most notably 
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through the work of Armstrong et al.57,58 in the development of cyclodextrin based 
chromatographic systems.  
 
In GC the enantioselective separation of enantiomers by CD derivatives has been 
recognized to be the result of fast kinetics and is governed entirely by 
thermodynamics.49,59 As a consequence, enantioselective separation is strongly 
dependent on temperature. The discrimination of two enantiomers results from a small 
difference in the energy of association during complexation interactions, between each 
enantiomer and the CD selector.41,48 It has been noted previously that no correlation 
exists between the retention times of molecules on cyclodextrin-based chromatography 
phases and the thermodynamic stability of the inclusion complexes formed in solution 
between those molecules and cyclodextrins.48 Thus, spectroscopic discrimination does not 
necessarily correlate with thermodynamic discrimination.  
 
Chiral resolution on IL columns 
It was also observed by Ding et al. that the configuration of the chiral center of the N,N-
dimethylephedrinium bis(trifluoromethanesulfonyl)imidate IL CSPs played a significant 
role in the observed enatioselectivity.54 For example, (1S,2S) N,N-dimethylephedrinium 
bis(trifluoromethanesulfonyl)imidate IL CSP exhibited no enantioselective separation of 
chiral alcohols but exhibited similar enantioselectivity to its (1S,2R) IL analogue in the 
separation of chiral sulfoxides. It was found that prolonged exposure of these N,N-
dimethylephedrinium IL CSPs to oven temperatures ≥140 ˚C resulted in 
enantioselectivity losses for some classes of molecules such as alcohols, but not 
sulfoxides. These enantioselectivity losses were attributed to the formation of a 
dehydration product (Figure 3.16) via a thermally induced epimerization process that 
may also result in racemisation.54 It was concluded that a fixed configuration of the first 
stereogenic center was required for enantiorecognition and enantiomeric resolution of the 
sulfoxide analytes, but not the second stereogenic center.54 However, enantiomeric 
resolution of the alcohols not only requires the configuration of both stereogenic centers, 
but, that they have opposite absolute configuration, either (1S,2R) or (1R,2S).54 The 
  
N,N-dimethylephedrinium chiral hydroxyl group was found to be imperative in separating 
all the sulfoxide analytes tested, but not sufficient alone for the enantioseparation of 
chiral alcohols, epoxides, and acetylated amines.54 
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Figure 3.16: The dehydration and epimerisation product of (1S,2R)-N,N-
dimethylephedrinium cation.  
 
Given that the configuration of the chiral stereogenic center of the IL CSP has been 
demonstrated to be of significant importance to chiral recognition, it must be considered 
that the configuration of the stereogenic centers of the 2,4,5-triphenylimizolinium ILs 
(26, 35, and 39) tested in this study (all being of (4S,5S) configuration isolated from 
trans (+/-)-2,4,5-triphenylimizoline) may not have been the appropriate stereogenic 
configuration to produce enantiomeric resolution.  It would be of great value in future 
work to examine the enantioselectivities of the (4R,5R), (4R,5S), and (4S,5R) isomers of 
the 2,4,5-triphenylimizolinium IL chiral selecting agents tested in this study.  
 
The single report which appeared in 2001 on the use of achiral ILs as stationary phase 
solvents for derivatized cyclodextrins,53 in which permethylated-β-CDs (BPM) and 
dimethylated-β-CDs (BDM) were dissolved in 1-butyl-3-methylimidazolium chloride (at 
concentrations of 26.4 % and 27.7 % (w/w), respectively) and the column performances 
evaluated and compared with those of analogous polysiloxane-bases commercial columns 
(Chiraldex BPM and Chiraldex BDM), were found to have column efficiencies up to ten 
times higher than the commercial columns, but they separated only about a fifth to a 
third of the racemic analytes that could be separated on the commercial columns.53 The 
narrow range of enantioselectivity was attributed to the small BMIM-Cl ion pair being 
included in the CD cavity and consequently reducing the inclusion complexation 
interaction between the chiral selector and the analyte. The only enantiomers resolved 
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were separated by an external adsorption process rather than inclusion complexation, 
with excellent resolution as a result of the high efficiencies reported on these IL-based 
matrix columns. 
 
In order to reduce the accessibility of IL matrices in the CD cavity and combine the 
higher efficiency of the IL matrix based chiral stationary phases with the excellent 
enantioselectivity of the polysiloxane based chiral stationary phases, charged 
cyclodextrins, (permethylated mono-6-(butylimidazolium)-cyclodextrin (BIM-BPM) and 
permethylated mono-6-(tripropylphosphonium)-cyclodextrin (TPP-BPM)), were 
synthesised and dissolved in ionic liquid matrices and examined as GC chiral stationary 
phases. Although charged cyclodextrin derivatives have been widely employed as chiral 
selectors in capillary electrophoresis (CE),60-62 the use of charged cyclodextrins as chiral 
selectors in GC has only been reported once.55 
 
The first successful application of the ionic cyclodextrins to the enantiomeric separation 
of a variety of chiral molecules by GC was demonstrated by Huang et al in 2010.55 The 
synthesised ionic cyclodextrins (BIM-BPM and TPP-BPM) were dissolved in ionic liquid 
matrices rather than a polysiloxane matrix. The selectivity of these ionic CD phases were 
compared with the commercial stationary phase Chiraldex BPM. It was found that the 
cationic CD chiral selector made a significant contribution to the enhanced column 
efficiency while the type of ionic functional group on the CD had a major impact on the 
chiral recognition capability of the stationary phase.55 When compared with the 
commercial column, the IL-based stationary phases showed improved enantioseparation 
for more than one third of the analytes tested and separated some compounds that were 
not separated on the commercial column.55 This demonstrated the feasibility of using 
charged cyclodextrins as chiral selectors in GC stationary phases, opening a new avenue 
of research and development of potentially useful GC chiral stationary phases. 
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Figure 3.17: An illustration of column bleed during analysis on phase 35. 
 
Thermal stability of ionic Phases 
Ionic CDs were shown to be thermally stable at the maximum operating temperature of 
150 ˚C reached during analysis. Thermal gravimeteric analysis of the ionic CDs showed 
decomposition temperature ranging from 160 ˚C - 250 ˚C (see Section 2.4.2) by TGA 
analysis, far beyond the maximum operating temperatures reached during GC analysis. 
No significant column bleed was observed during analysis with the exception of phase 
35, which showed significant column bleed at high operating temperatures (Figure 3.17) 
while 65 showed a marked reduction in the selectivity of some compounds following 
exposure to high temperature ranges. Subsequent analysis of the same test mixture 
showed poor resolution for selected compound on phase 65 as illustrated in Figure 3.18. 
This could be a result of pooling of the stationary phase following operation at high 
temperature resulting in an unevenly coated phase in subsequent analyses, or the ionic 
chiral additive may be unstable at high temperatures. Given that the thermal stabilities of 
the imidazolinium ionic salts have not been determined by TGA analysis it cannot be 
discounted that the ionic salts may be unstable at the higher operating temperatures. 
Neither can the possibility of isomerisation or racemisation occurring during high 
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temperature analysis be discounted, particularly for trans-2,4,5-triphenylimidazoline 21 
derived ionic salts such as 26, 39, and 35. Because 21 can be synthesised from either 
cis-2,4,5-triphenylimidazoline 20 or hydrobenzamide 19 via an anionic intermediate, the 
possibility of isomerisation or racemisation occurring on the column cannot be 
overlooked.  
 
The stereospecific formation of 2,4,5-triphenylimidazolines occurs via an electrolytic 
pericyclic ring closure which involves the cyclisation of the conjugated polyene 
hydrobenzamide via a 2,4-diazpentadienyl anion. The anionic intermediate in Figure 2.14 
has been accounted for the interconversion between amarine 20 and iso-amarine 21.63 
Busacca et al.64 studied the racemisation of chiral imidazolines upon exposure to base 
and found that strong inorganic bases could induce racemisation, however, racemisation 
occurred only when nitrogen on the imidazoline was un-substituted, and they proposed a 
symmetry-allowed thermal disrotatory ring opening and closure via a diazapentadienyl 
anion as the mechanism by which racemisation occurred. Given that both nitrogens on 
the imidazolinium salts were substituted it was expected that racemisation or 
isomerisation were unlikely occurring during GC analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A) 
0 5 10 15 20
0
100000
200000
300000
400000
500000
600000
700000
IS
3
6
2
4
3
1
65
R
e
s
p
o
n
s
e
Time (mins)
 
B) 
0 5 10 15 20 25
0
50000
100000
150000
200000
65
R
e
s
p
o
n
s
e
Time (mins)
 
Figure 3.18: An illustration of the temperature effect on phase performance. A) First 
temperature programed run on phase 65, B) subsequent analysis of the same test 
mixture on phase 65 showing markedly reduced resolution.  
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3.2.3 Conclusion 
The design and synthesis of chiral selecting agents is difficult and unpredictable. 
Although enantiomer resolution was not observed for the series of chiral analytes tested 
in this study, their application as chiral ionic salts for enantioselective separation yielded 
stationary phases of similar polarities with significantly different retention patterns. 
However, the ionic stationary phases need be evaluated against a wider variety of chiral 
analytes to determine their full potential as chiral selecting agents, as well as conducting 
a comprehensive investigation into the optimum concentration of ionic salt necessary in 
polysiloxane to achieve optimal resolution. Perhaps different polysiloxanes also need to 
be investigated to determine how they affect chiral resolution.  
  
Given that per-2,3-O-acetylation yields a highly symmetrical product it’s recommended 
to reduce the symmetry of these CDs by selectively permethylating at the C2 positions 
and acetylation at C3 positions. The enantioselectivity of the symmetrically substituted 
novel per-2,3-acetylated ionic CDs was comparable to that of the known symmetrically 
substituted per-2,3,6-methyl-β-CD (PM-CD) where no enantioresolution was observed, 
while per-2,3,6-acetyl-β-CD only marginally performing better by enantiomerically 
resolving 2 chiral analytes out of the 69 tested. It has been shown that asymmetrically 
substituted methyl/acetyl CDs can extend enantioselectivity in comparison to that of the 
corresponding per-2,3,6-O-methyl or per-2,3,6-O-acetyl symmetrical CD derivatives, in 
terms of both enantiomer resolution and number of chiral compounds separated.29 It has 
also been reported that mono-substituted ionic CDs display superior enantioselectivity 
when compared with commercial columns with comparable non-ionic CD derivative 
analogues.55 Synthesis of per-substituted ionic CD analogues with a higher degree of 
asymmetry is recommended to improve the enantioselectivity of the novel ionic CD chiral 
selectors beyond that of the symmetrically substituted PM-CD and PA-CD chiral selectors 
tested in this study. This study opens the door for the development and application of 
new chiral imidazolinium ionic salts as well as imidazolium cyclodextrin ionic salts as 
potential chiral selecting agents in GC stationary phases.    
 
  
The growing need for new chiral selecting agents with better enantioseparation capacity 
to increase the number of chiral compounds separated with a single chiral selector, 
and/or improve their resolution, has not been resolved. New chiral selecting agents with 
better performances can actively contribute to increasing the adoption of the “one 
column for one problem” approach and, as a consequence, extend the use of 
enantioselective GC in routine analysis and specialised chiral analysis. 
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3.2.4 Experimental 
3.2.4.1 Sample preparation 
All stock test mixtures were diluted in 10 mL dichloromethane (DCM) except in the case 
of the probe molecules which were used neat. The alkane test mixture was made up with 
200 μL of each alkane for C7-C13 in 10 mL DCM. Naphthalene was made up to a 
concentration of 0.2 g in 10 mL of DCM. While the stock chiral test mixtures were made 
up in 10 mL DCM with 30 μL 1-Octanol as the internal standard. Samples were prepared 
for injection by diluting 500 μL of the stock test mixture (as prepared above) with 1500 
μL DCM in a sample. 
 
3.2.4.2 Methyl esterification47 
100-200 mg of amino acid or carboxylic acid were placed in sample vials with excess 
methanol (2-4 mL depending on the solubility of the starting material). Then excess 
TMSCl was added to the sample vials, the solution mixed manually and capped. The 
solutions were left to react at room temperature for 24 hrs with occasional mixing. The 
sample vials were placed under vacuum to remove the methanol and TMSCl, leaving the 
product as a methyl ester hydrochloride. 
 
3.2.4.3 Column preparation by static coating  
Into a 2 mL degassed solution of DCM was added 4 mg chiral IL to make a 0.4 % (w/v) 
stationary phase solution. Similarly, 4 mg of OV-1701 (or Carbowax 20M where 
polysiloxane was not used as the stationary phase) was added to a 2 mL degassed 
solution of DCM. These two 0.4 % (w/v) solutions where mixed together at a proportion 
consisting of 30 % IL solution to 70 % (v/v) OV-1701 solution. The capillary was filled 
with the 0.4 % mixed solution and the other end of the capillary column sealed with a 
viscous solution of sodium silicate. Air bubbles must be rigorously excluded during the 
  
coating process. After consolidation of the sodium silicate plug overnight, the capillary is 
mounted in a water bath at room temperature and a vacuum pump is connected on the 
open end. It is essential that the sodium silicate plug is sight and that the solvent is 
removed slowly and steadily. The presence of any air bubbles will cause the solution to 
be sucked out partially or totally. In this case the coating procedure has to be repeated. 
After the complete evaporation of the solvent a few centimetres of the column ends were 
cut off. The capillary then installed into a GC and conditioned prior to testing.  
 
All capillary columns were coated with ionic salts diluted in the polysiloxane OV-1701 at 
30 % IL to polysiloxane (w/w) unless otherwise stated. The ionic salts were coated onto 
deactivated inner column surface by static procedure on a 10m fused silica capillary 
column. Following the coating process, the column was conditioned from 40 ˚C to 150 ˚C 
at 10 ˚C/min. Column efficiency was determined with naphthalene at 100 ˚C at 2.9 psi. 
A Shimadzu GC-17A GC with FID, split injection (split ratio 50:1) and hydrogen as a 
carrier gas, injection temperature of 250 ˚C and detector temperature of 250 ˚C. All 
analytes were dissolved in DCM with the exception of the probe molecules which were 
used neat.  
 
Isothermal analysis of alkanes and probe molecules for calculating Kovats retention 
indices 
Isothermal analysis was conducted at 50 ˚C, 60 ˚C, 70 ˚C, 80 ˚C, 90 ˚C, and 100 ˚C at 
a column pressure of 2.5 psi, with a split ratio of 50 (for the alkane series) and 100 (for 
the probe molecules. 
 
Temperature programming for chiral analysis. 
Chiral analytes were analysed by temperature program starting at 40 ˚C (0mins) with a 
ramp rate of 3 ˚C/min to 100 ˚C followed by a ramp rate of 4 ˚C/min to 150 ˚C which 
was held for 5 mins. 
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3.3 Dynamic interconversion of chiral oxime compounds in gas 
chromatography. 
 
Published in: 
Journal of Chromatography A, 1217 (2010) 1114-1125 
 
3.3.1 Introduction 
The study of species that undergo interconversion or some other type of structural 
change during chromatographic elution is a small but interesting topic area, which can be 
subdivided into two distinct or different processes. One is a structural change that is 
irreversible, such as in decomposition processes, a good example is the decomposition of  
dicyclopentadiene to cyclopentadiene.65 The other process is that of dynamic molecular 
interconversion, a process where each molecule undergoes a mechanism of a reversible 
structural change into their counterpart (Figure 3.20). The most important features of 
dynamic interconversion being that (i) the two molecules should be resolvable on the 
phase and under the conditions applied, and (ii) the physical conditions applied allow the 
observation of the interconversion process (i.e. the temperature and/or time of analysis 
is adequate to permit interconversion). The general scheme of the dynamic 
interconversion process is shown in Figure 3.19, a chromatogram of an interconverting 
system A  B, with sketched hypothetical distributions of each of the isomers underlying 
the overall response. The interconversion region corresponds to compounds that undergo 
an isomerisation step, and therefore are largely resolved from each of the original 
isomers A and B. Thus the total band of the compound comprises the original narrow 
peaks of A and B, and the broad zone of interconversion.  
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Figure 3.19: Chromatogram of interconversion process between two isomers A and B, 
with the net effect shown in bold, and sketched outlines showing the A isomer 
distribution dotted, and B isomer dashed. 
 
A number of researchers have been prominent in this area, in particular Schurig’s group 
which has investigated a wide range of molecular processes, including chiral molecules in 
a variety of enantioselective separation methods, including HPLC and GC. 66-72 Schurig 
has reviewed this general area.49,73,74 Rotational energy barriers for chiral cyclophanes 
determined by using GC were reported by Hochmuth and König.75 The dynamic effect of 
the secondary equilibria of prolines in reversed-phase HPLC were discussed by Melander 
et al.76 While the theoretical interpretation of the interconversion  process and a 
computer program to derive physical constants were developed by Trapp,77-79 Krupcik 
compared the experimental data and the simulated results of various examples of 
interconversion.80   
  
The observation of sterically hindered rotation of phenanthrene and anthracene 
molecules, organometallics and inorganic complexes was reported in a series of papers 
by Marriott et al., who also studied the oxime system using one-dimensional gas 
chromatography systematically.81-83 
The enantiomerization (inversion) barriers for 1-chloro-2,2-dimethylaziridine in the gas 
phase, with a range of ΔG# values from 70 kJ mol-1 to 200 kJ mol-1 was determined using 
enantioselective stopped-flow multidimensional gas chromatography (MDGC). Gas phase 
enantiomerization of the heart-cut fraction of one single enantiomer was performed in 
the second (reactor) column at increased temperature after GC separation of the 
enantiomers in the first column. This fraction was subsequently separated into the 
enantiomers in the third column.84 This process was recently reviewed.85 
More recently, Marriott et al. applied comprehensive two-dimensional gas 
chromatography (GC×GC) to the study of the interconversion processes of oximes.86,87 
Oximes can exist in 2 discrete geometrically isomeric forms: the E isomer and the Z 
isomer, owing to the relative rigidity of the carbon-nitrogen double bond. In solid state, 
both oximes show high configurational stability and discrete existence. However, in 
solution, equilibrium between both isomers is rapidly established, favouring the most 
thermodynamically stable isomer. In these GC×GC experiments a modulator 
programmed to collect effluent from the first dimension (1D) column every 2-8s and 
pulsing it rapidly to a 2D short, fast elution column. With the proper choice of 2D column 
phase, it was possible to resolve the different isomer forms of the compound produced 
during the interconversion process, providing an instantaneous distribution of species at 
any given point over the chromatographic profile.86,87 Trapp et al. interpreted the GC×GC 
experiment based on theoretical treatment and derived kinetic data for the isomerisation 
process.88 The separation of two pairs of diastereoisomers for chalcogran under 
conditions of dynamic interconversion were proposed in a review of molecular structure – 
retention relationships in GC×GC,89 with the assumption of adequate resolution of all 
species on the two columns, however this system had not been experimentally verified. 
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Based on this background, the present study extended the oxime study to chiral 
molecular species, and incorporated enantioselective GC column phases as the separation 
medium.  
R H
N
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Figure 3.20: E and Z isomers of chiral aldoximes 
 
3.3.2 Results & Discussion 
3.3.2.1 Relative elution and interconversion on single column systems.  
Initial analysis on the chiral column was found to not generate the characteristic 
isomerisation profile shown in Figure 3.1, but rather only separated the compounds. The 
chiral column resolved both E and Z isomers, and did so more effectively than the SolGel 
wax or the BP20 wax phases. For the chiral oximes, it was generally found that the E 
isomers were resolved into their (R) and (S) enantiomers better than the Z isomers. For 
instance, for 2-methylbutraldehyde oxime  on the chiral phase at 90 ˚C and 20 kPa H2 
pressure, the  Rs of E isomers was found to be about 8.5, whereas for the Z isomers Rs 
was only approximately 1.2-1.5. The Z isomer normally eluted earlier than the earliest 
eluting E enantiomer. In contrast, for 2-methylpentanaldehyde oxime the Z isomers often 
elute after the first E enantiomer. The Z isomers exhibited a much greater change in 
retention factor as temperatures were varied, such that it could elute earlier than the 
first E enantiomer, and then co-elute with this isomer, and eventually could co-elute with 
the later of the E enantiomers as the temperature was increased (see Figure 3.21). This 
was more pronounced for the 2-methylpentanaldoxime compound than for the 2-
methylbutanaldoxime.  
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Figure 3.21: Isobaric 20 psi, 2-methylbutanaldoxime analysis on a wax-chiral column 
configuration. (A) 90 ˚C, (B) 100 ˚C, (C) 110 ˚C, (D) 120 ˚C, (E) 130 ˚C, (F) 140 ˚C. 
 
An additional observation was that the low polarity phase produced less isomerisation. 
Thus the BPX5 phase was able to resolve the E and Z isomers but little interconversion 
was observed. While the wax-type (polyethylene glycol) phases, SolGel Wax and BP20, 
led to much greater interconversion. The chiral phases tested produced to negligible 
isomerisation, presumably due to the low polarity of polymer phase in which the chiral 
selector is dissolved. Only the Mega phase gave effective resolution of the enantiomers of 
both the E and Z isomers and so was chosen for further study. Unfortunately, there 
currently does not seem to be a phase that is able to simultaneously resolve the 
geometrical isomers and enantiomers, and also strongly generate isomerisation. These 
characteristic would be expected from a phase with a cyclodextrin chiral selector 
embedded in a polar wax-type phase, and columns with this characteristic do not seem 
to be widely available. This is surprising, given that wax-type phases are compatible with 
essential oil components, which often exhibit chirality, and often require determination of 
the chiral composition of those compounds. Thus to circumvent the unavailablility of 
columns which permit the simultaneous study of the isomerisation process and 
enantiomer resolution, the approach reported here was to join a chiral to a wax phase 
column, so that both chiral resolution and interconversion can be observed, though this is 
a sequential process rather than simultaneous.  
 
On an achiral column, the chiral molecules lead to only two peaks, E and Z, with almost 
negligible interconversion barrier under conditions which promote this process. For 2-
methylbutyraldehyde oxime the Z isomer elutes rather later than the E isomer, so the 
relative retentions of Z and E were reversed on the chiral and achiral columns.  
The effect of increased oven temperature (T) on extent of interconversion, for the chiral 
2-methylbutanaldoxime compound on the wax column, can be seen in Figure 3.22. Even 
at 80 ˚C there was evident interconversion, and at 150 ˚C, the distribution resembled a 
smooth but broad band, with no evidence of the E and Z antipodes. This corresponds to 
  
rapid interconversion, but not so rapid that the band then becomes a narrow peak of 
similar magnitude to a non-interchanging internal standard, which would imply tRE ~ tRZ.  
 
 
 
Figure 3.22: Isobaric (20 kPa) 2-methylbutyraldehyde oxime analysis on a wax column. 
Isothermal oven temperatures are (A) 80 ˚C; (B) 110 ˚C; (C) 130 ˚C; (D) 150 ˚C. 
 
3.3.2.2 The dual column system 
There are three approaches which can be taken to interpretation of the results of the dual 
column system. 
(i) decide what happens to the Z isomer 
(ii) decide what happens to the E isomer 
(iii) decide how to treat the interconversion region on the first column, as it enters 
then is eluted from the second column. 
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In this case it was informative to study the effect of each column separately. The various 
studies below report such observations, denoted as detector-1 (DET-1), and detector-2 
(DET-2). 
 
The two columns perform different functions; the chiral column gives enantiomer 
separation and E/Z separation, but little isomerisation; the wax phase produces a much 
larger extent of isomerisation, but also gives E/Z separation. The assumption here is that 
E/Z isomerisation occurs only within the particular enantiomer (R) or (S), i.e. E(S)  
Z(S) or E(R)  Z(R), and E/Z isomerisation is not accompanied by enantiomerisation. 
The dual column arrangement used here comprised a chiral column and a wax column, 
coupled in either order. The dual column arrangement was first used to analyse achiral 
oximes in order to facilitate understanding of the processes that occur without the 
complexity that comes with chiral separation, then the chiral oxime compounds were 
studied. The need for both wax-chiral and chiral-wax column arrangements to be tested 
was due to the different types of processes that can be observed on each column. A 
detector was provided between the columns in some experiments and the dual FID 
system was employed when a separate evaluation of the effect of each column was 
required. For the GC × GC experiments (see Section 3.3.4.5) the most appropriate 
column order was selected based on the analysis results obtained from the Dual FID 
system. 
 
Achiral compounds 
Wax-chiral arrangement. The wax column separated the E/Z isomers, and depending 
on conditions (temperature (T), and time (t) spent in the column), promoted 
interconversion to varying extents. 
The chiral column will then; 
(i) separate the individual E and Z enantiomers according to the retention factor 
of each; and 
(ii) cause the interconversion region to move apart as specific bands . Here it 
cannot be stated that the chiral column will ‘resolve’ the interconversion 
  
region, because this is a broad overlapping band, and it is possible that the 
broad E and Z bands that comprise the interconversion zone will not be fully 
resolved. 
 
Figure 3.23 is an example of the achiral compound heptanaldoxime progressively 
undergoing an increasing extent of isomerisation as the carrier flow (as indicated by the 
pressure setting) is decreased from 50psi to 10psi. The first column (wax) reveals a 
smooth distribution comprising the interconversion zone, which reflects the type of 
‘plateau’ conventionally found for this system and as seen in Figure 1. The trace at the 
end of the second column (chiral) is no longer a smooth plateau shape, but is distorted 
by the separation that the chiral column generates for the interconversion zone (see 
Figure 3.23 (C)(ii)). The distortion results from the specific retentions of the E and Z 
isomers comprising the interconversion zone, on the chiral column. Note that even 
though there is considerable interconversion on the wax column, there is little additional 
interconversion on the chiral column, as indicated by comparison of Figure 3.23 C(i) and 
C(ii); the E and Z isomers change very little in respect of their areas, compared to the 
total area of the band. The relative retentions of the E and Z isomers do not appear to 
have varied greatly on the chiral phase, but Z elutes slightly closer to E. For the wax 
column, kE ~ 1.65, and kZ ~ 1.98; for the chiral column, kE ~ 1.6, and kZ ~ 1.7. Figure 
3.25 D(i) generates a single peak, although its width (~ 1 min) implies that there is still 
considerable influence of the E and Z isomers in defining the total width. Figure 3.25 D(ii) 
shows the E and Z isomers delivered to the chiral column, but some separation occurs 
(without additional interconversion). Peak width now being about 2.5 min. 
 
 Figure 3.23: Isothermal (130 ˚C) heptanaldoxime analysis. Dual detector wax–chiral column system, respectively. (i) FID1 detector (DET-1); 
(ii) FID2 detector (DET-2), carrier gas pressures are (A) 50 psi; (B) 40 psi; (C) 30 psi; (D) 10 psi. As an indication of the linear carrier 
velocities in each case, these were estimated to be 191, 97, 74 and 25 cm/s, respectively. 
 Chiral-wax arrangement. The chiral column causes E/Z separation, but little 
interconversion. Then on the wax column the individual E and Z isomers undergo an 
isomerisation process, but essentially now on physically resolved isomers from the first 
(chiral) column (see Figure 3.24). Thus, an observation somewhat like a decomposition 
process 65 might be expected rather than the more familiar reversible interconversion 
process of the oximes due to the prior resolution on the wax column. The extent of 
resolution of the E and Z isomers on the wax column will most likely be different to that 
of the input distribution from the chiral column. This will be determined by the individual 
retention factors on each column.  
This means it should be possible to consider this to be a sum of the effect of the wax 
column on the E isomer, and the effect of the wax column on the Z isomer. The actual 
distribution will therefore not be the same as that for the analysis of E and Z on a single 
wax column but will more likely be a complex linear combination of the two effects. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Isothermal (130 ˚C) heptanaldoxime analysis. Dual detector chiral-wax column system, respectively. (i) FID1 detector 
(DET-1); (ii) FID2 detector (DET-2), carrier gas pressures are (A) 50 psi; (B) 40 psi; (C) 30 psi; (D) 10 psi. 
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Chiral compounds: 
Wax-chiral arrangement. The process on the wax column is the same as for the 
achiral compound above (E/Z isomer separation, with isomerisation).  However, when 
the chiral compound reaches the chiral column, each of the E enantiomers ((R)E and 
(S)E) and Z enantiomers will commence to resolve. This is shown in Figure 3.25. The 
swapping of positions is clear in this figure. The chiral 2-methylbutanaldoxime molecule 
exhibits a small extent of interconversion on the wax column at 100 ˚C (Figure 3.25 A(i) 
and B(i)) and only a minor plateau is given even at 20 psi. The chiral column selectivity 
towards the E and Z isomers is readily seen to vary greatly from that of the SolGel 
column, as the isomers swap positions with the Z isomer showing a large reduction in 
relative retention on the chiral phase. The relative resolution of the two enantiomers for 
E are also very much greater than that for the Z enantiomers. Thus for Figure 3.25 A(i) 
and B(i) Rs is from 3 to 4, whilst for A(ii) and B(ii) Rs of the (R,S) E enantiomers is from 7 
to 8, and for the Z enantiomers, Rs is < 1.0. 
There appears to be a small shoulder (marked with the arrow (a) Figure 3.25 A(ii)) 
preceding the Z isomers, which is taken to arise from the Z isomer zone at the 
interconversion region marked (a) in Figure. 3.25 A(i), eluting earlier than the Z 
enantiomers of the unconverted compounds.  Likewise the small shoulder after the E 
enantiomers are the E enantiomers of the interconversion region moving to a later 
retention than the non-converted E enantiomers, which is more clearly visible in Figure. 
3.25 B(ii).  
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Figure 3.25: Isothermal (100 ˚C) 2-methylbutyraldehyde oxime analysis. Dual detector 
wax–chiral column system. (i) FID1 detector; (ii) FID2 detector. Carrier gas pressures 
are (A) 50 psi and (B) 20 psi. (a) Indicates the interconversion region which for data in 
(ii) shows this region moves earlier than the Z isomer peaks. 
 
Chiral-wax arrangement. The chiral compounds are resolved into (R) and (S) species 
(here, each of E and Z are racemic) so two pairs of peaks (R,S)E and (R,S)Z were 
obtained. Note that E and Z show markedly different chiral resolutions, and often (R,S)Z 
may partially overlap one enantiomer of E. Then on the wax column, (R)Z and (R)E will 
interconvert, and also (S)Z and (S)E, but again from a starting basis of an input 
distribution that has already resolved the E and Z isomers. Thus, it is necessary to 
identify and interpret (i) the peaks that interconvert, and (ii) the extent of 
interconversion and how it is displayed in the final chromatogram. 
  
Following the use of the system shown in Figure 3.34 (System A) for the non-modulated 
dual column – dual FID system, the Figure 3.34 (System B) arrangement was tested, but 
with only a single detector at the outlet of the triple column arrangement.  
To some extent, the experience with the achiral compound will inform the understanding 
of interpretation of such a process. It is important to note that the interconversion could 
lead to a product that has either a greater or lesser retention on the second column, and 
this will lead to different presentation of the overall distribution. Since often the Z 
isomers are not well resolved from one of the E isomers, this makes the interconversion 
process difficult to distinguish with certainty when using 1D GC. But only one E isomer is 
affected by overlap with the Z isomers. The Z isomers also exhibit small resolution on the 
chiral column, making it difficult to recognize the individual (R)Z and (S)Z isomers 
(Figure 3.26 shows this). The Z isomers overlap the earlier E enantiomer after passage 
through the wax column. Under 20psi isobaric conditions, at T = 90 ˚C, the Z peaks elute 
just before the E peak, while at 110 ˚C, one of the Z peaks elutes just after the E 
enantiomer (see Figure 3.27). 
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Figure 3.26: Isothermal (100 ˚C) 2-methylbutyraldehyde oxime analysis. Dual detector 
chiral–wax column system. (i) FID1 detector; (ii) FID2 detector. Carrier gas pressure at 
(A) 50 psi and (B) 20 psi. 
 
 Figure 3.27: Isobaric (100 ˚C) 2-methylbutyraldehyde oxime analysis. Dual detector chiral–wax column system. (i) FID1 detector; (ii) 
FID2 detector. Carrier gas pressure at (A) 50 psi and (B) 20 psi. 
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3.3.2.2 Comprehensive 2D GC 
Previous reports have revealed interesting chromatographic data from the use of GC×GC 
for interconverting species. 86-88 Based on the prior experimental data, it was decided to 
adopt the wax-chiral column arrangement for GC×GC experimentation, which results in 
separation of the E/Z isomers with interconversion, followed by chiral resolution, where 
applicable. 
 
Achiral compound:  
In the present case, only a wax-chiral column set was employed for (1D1+
1D2), with a 
wax column as the 2D column. Figure 3.28 is the GC×GC result for the achiral 
heptanaldoxime compound, with the 1D insert shown in Figure 3.28 (B) being similar to 
the chromatographic result shown in Figure 3.23 D(ii). Given that a slightly higher oven 
temperature was used here, and that there is no chiral separation for the achiral 
compound, only a broad peak was obtained. Figure 3.28(A) shows that at 140 ˚C, the 
heptanaldoxime isomers show considerable interconversion having a broadened 
distribution on the 1D column set. There is almost baseline resolution of E and Z on the 
2D column, with the first peak being the E isomer. The Z isomer elutes just after the E, as 
reported in Figure 3.28(C); their retention difference on the 2D column is about 0.4 s. 
This clearly demonstrates the ability of GC×GC to provide detailed chromatographic 
information on each compound compared with the apparent single broad ‘hump’ in Figure 
3.28(B). The broadened bands for both E and Z are indicative of peak broadening 
(coalescence) of the forth kind (according to Schurig)74 which is a result of extensive 
interconversion between the isomers, but not so extensive that the peaks become rapidly 
interconverting on the GC time scale. Rapid interconversion would generate a peak of 
conventional peak width (as indicated by comparision with an internal standard). This will 
only happen if the rate of interconversion is extremely fast and leads to the two 
compounds effectively having the same chromatographic distribution constant. Whilst 
Schurig referred to 4 types of coalescence for enantioselective complexation GC, type 4 
would appear to be generally applicable to any rapidly interconverting case. 
  
 
 
Figure 3.28: Isothermal (140 ˚C) GC×GC heptanaldoxime analysis. PM = 3 s; 5.0 
mL/min flow rate. (A) Modulated GC result; (B) equivalent 1D GC analysis on the same 
column set; (C) 2D representation of data in A. 
 
Chiral compounds:  
Figure 3.29 is the modulated (GC×GC) case for 2-methylbutyraldoxime at 100 ˚C. Figure 
3.29(A) is the linear presentation of chromatographic data i.e. the non-transformed 
detector response.  The (R) and (S) enantiomers of E isomer are located at about 3.3 s 
on the second dimension, whilst the Z enantiomer is well resolved from E on the second 
column, and is located at about 3.6 s (Figure 3.29(C)).  Compared with the rather 
difficult to interpret 1D GC result in Figure 3.29(B), the GC×GC reveals the individual 
 278 
 
  
overlapping compounds and the ‘tails’ that exist for each compound which should permit 
a rational model to be developed to describe the chromatographic result. Here it is easy 
to note the different effect on the E isomers and Z isomer. There appears to be a tail 
before the Z isomer, but the tail is after the E isomers. The tails appear to be of about 
the same magnitude in these two cases. The two isomers of (R,S)Z are not well resolved, 
and this is reflected in the apparent single peak for Z. Inset B shows the non-modulated 
result for the same compounds and conditions. The small preceding tail for Z (and the 
tail after the E isomer) is also seen in this inset. The 2D GC×GC plot indicates this 
preceding tail for Z to in fact due to the presence of the Z isomer. This result is 
interpreted as due to the Z isomer in the interconversion zone on the wax column eluting 
earlier than the unconverted Z isomer, on the chiral phase column.  
 
  
Figure 3.29: Isothermal (100 ˚C) GC×GC 2-methylbutanaldoxime analysis. PM = 4 s. 
Chiral–wax column system. 1.5 mL/min flow rate. (A) Modulated GC result; (B) 
equivalent 1D GC analysis on the same column set; (C) 2D representation of data in (A). 
 
Injection of 2-methylpentanaldoxime at 110 ˚C under GC×GC operation leads to the 
result shown in Figure 3.30. In contrast to 2-methylbutanaldoxime, the Z isomer elutes 
after the earlier E enantiomer. At this temperature, retention is relatively long. The Z 
isomer also appears to show partial resolution into its enantiomers (see inset, Figure 
3.30(B)) although the transformed data in Figure 3.30(C) does not seem to show this so 
clearly for isomer Z. However, this is confirmed by the pattern of modulation of the Z 
peak in Figure 3.30(A) at 18.5 min, which does not exhibit the classical in-phase, 180˚ 
out-of-phase nor intermediate phase peak shape, but rather has a broader distribution 
that can be interpreted as emerging peak separation. The Z isomer elutes close to, but 
just after, the first eluting E isomer. The tailing on the peaks (earlier for Z, later for E) is 
still seen. There is now considerable resolution between the E enantiomers, and there is 
a wide baseline region between the Z isomers and later E enantiomer. 
 
The above 2-methylpentanaldoxime compound exhibits considerable shift in relative 
retentions of the Z and E isomers in 2D space with change in T.  
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Figure 3.30: Isothermal (110 ˚C) 2-methylpentanaldehyde oxime analysis. PM = 4 s; 
1.5 mL/min flow rate. (A) Modulated GC result; (B) equivalent 1D GC analysis on the 
same column set; (C) 2D representation of data in (A). 
At 10 ˚C higher oven temperature, (120 ˚C; Figure 3.31) the Z enantiomers (now not 
well resolved on the chiral column) elute closer to the later eluting E enantiomer.  The 
tails reported for Figure 3.29 and Figure 3.30 are now extended somewhat in Figure 
3.31. The vertical alignment of the tails (E and Z) in the 2D plot would classically be 
interpreted as an interconversion region between the first E enantiomer and the Z peak 
as shown in Figure 3.31(B). The resolution provided by GC×GC operation clarifies the 
contribution of the E and Z isomers to this overlap region. The Z isomer here almost 
obeys 180˚ out-of-phase modulation (Figure 3.31(A)), which suggests practically 
  
unresolved R and S enantiomers. Between the Z and later eluting E isomers, the 
response almost returns to baseline (Figure 3.31(B)).  
 
Figure 3.31: Isothermal (120 ˚C) 2-methylpentanaldehyde oxime analysis. PM = 2 s; 
1.5 mL/min flow rate. (A) modulated GC result; (B) equivalent 1D GC analysis on the 
same column set; (C) 2D representation of data in (A). 
 
At 130 ˚C, (Figure 3.32) the (R,S)Z enantiomers, which are still unresolved, elute very 
close to the later E enantiomer. Now, there is no baseline resolution between the isomers 
on the 1D column. The tails referred to above are still seen. Overall resolution of the E 
enantiomers has decreased significantly, as expected for higher temperature operation 
on a chiral column.  
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Figure 3.32: Isothermal (130 ˚C) 2-methylpentanaldehyde oxime analysis. PM = 2 s; 
1.5 mL/min flow rate. (A) Modulated GC result; (B) Equivalent 1D GC analysis on the 
same column set; (C) 2D representation of data in (A). 
3.3.2.3 Development of a model for chiral interconversion in GC×GC  
Based on the observations above, a schematic model of the process of wax-chiral 
sequential column separation of the chiral compound is proposed in Figure 3.33 
Considering the separation on the wax column on 1D1 in Figure 3.33(A), the effect of 
chiral resolution on 1D2 of each compound in turn (here taking the E and Z isomers 
separately) is shown in Figure 3.33 (B)(i) and Figure 3.33(B)(ii). The interconversion 
zone is separately illustrated in Figure 3.33 (B)(iii), and this interconversion zone 
comprising (R,S)Z and (R,S)E now can be considered to move apart on the chiral phase 
(with Z isomers not so well resolved as stated earlier). The tailing of the Z isomer to 
  
earlier retention arises due to interconversion zone of the Z isomer (Figure 3.19), and is 
caused by this zone eluting earlier on the chiral phase than the original Z isomers. The 
tailing to longer retention of the E isomer arises from the interconversion zone of the E 
isomers eluting later on the chiral column. The two E enantiomers of this zone will move 
to locate just after their respective enantiomers. Here, the (R) enantiomer is shown to 
elute earlier than the (S), but this has not yet been confirmed. It is shown for 
demonstrating purposes only.  The overall distribution is then given by the summation of 
(B)(i) – (B)(iii), as given in Figure 3.33(C). Figure 3.33(C) bears close resemblance to 
Figure 3.33(B), and so represents but one chromatographic condition of relative 
retentions of E and Z isomers with respective chiral resolution and extent of 
interconversion. Note that at this stage, development of a more rigorous model must 
await further experimentation and interpretation, and the present proposal is offered as a 
means to inform consideration of future, more complete description of the 
chromatographic results for the behaviour reported in this study. 
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Figure 3.33: Model of analysis of a chiral compound on a wax–chiral column set, in the 
case where there is interconversion of the compound. The two processes of what is 
believed to occur for the E and the Z enantiomers are isolated. (A) is the initial 
separation into E and Z forms on the wax phase; (B)(i) and (B)(ii) are the individual 
(R,S)E and (R,S)Z enantiomer separations, whilst (B)(iii) is the chiral resolution of the 
interconversion zone from the wax column. (C) is the net effect shown as a summation of 
each of the parts given in B(i)-(iii). Here, the (R) enantiomer is shown to elute before the 
(S) enantiomer, however this has not been proven at this stage. 
 
3.3.3 Conclusion 
A study of chiral oxime compounds which undergo E/Z isomerisation on polar (wax-type) 
columns is described. Since the wax column does not lead to enantioseparation, a chiral 
(cyclodextrin) column was used to provide enantiomer separation. The chiral compounds 
  
undergo classical isomerisation on the wax column as has been seen in previous achiral 
studies, however the chiral column does not appear to provide isomerisation. The relative 
retentions and hence isomer separation of E and Z can swap on the two phases 
depending on the compound and conditions employed. In order to examine the effect of 
chiral resolution, and provide some measure of isomerisation, a dual column 
arrangement with either a wax-chiral or chiral-wax arrangement was implemented. In 
one method, an FID was located between the two columns to assist in understanding of 
the separate effect of the two columns. The resulting distribution exhibited a complex 
overlap of enantiomer separation and interconversion. The use of comprehensive 2D GC 
with a wax-chiral arrangement chosen, assisted in resolving the different effects that 
these compounds undergo.  
A model is proposed to aid interpretation of the results of the process observed. At this 
stage, kinetic data for interconversion have not been derived for this system, however 
this should be possible. Since interconversion does not appear to arise on the chiral 
column, only kinetic data on the wax column will be obtainable. The use of a single 
column that simultaneously provides both chiral and E/Z resolution, along with E/Z 
interconversion, would be an interesting system to investigate.  
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3.3.4 Experimental 
3.3.4.1 Reagents and chemicals 
The aldehydes 2-methylbutyraldehyde and 2-methylpenatanaldehyde used to synthesise 
the oximes were purchased from Aldrich, and used without further distillation. Absolute 
ethanol (Ajax), hexane (Ajax), hydroxylammonium chloride (BDH) and sodium hydroxide 
(BDH), all of analytical reagent grade, were also used in the synthesis of oximes. 
 
3.3.4.2 Synthesis 
2-methylbutyraldehyde oxime, and 2-methylpentanealdehyde oxime, were synthesised 
from their aldehydes, 2-methylbutyraldehyde, and 2-methylbutyraldehyde, respectively, 
following a modified procedure from Boucher et al. 90 in which an 80 mmol solution of 
hydroxylammonium chloride in 20 mL of ethanol was stirred at room temperature. To 
this solution was added 20 mL of an 80 mmol aqueous solution in sodium hydroxide, 
followed by a 40 mmol solution of aldehyde dissolved in ethanol. The reaction mixture 
was stirred at room temperature for 4 hrs. After 4 hrs the solution was filtered to remove 
the sodium chloride precipitate, and ethanol was removed by rotary evaporation at 50 ˚C 
under reduced pressure. The oxime was extracted with either hexane or petroleum ether, 
dried with anhydrous MgSO4 and the solution filtered. Solvent was removed by rotary 
evaporation under reduced pressure at 50 ˚C to afford the crude product. The crude 
product was purified by bulb-to-bulb distillation in a kugelrohr and charactacterised by 
NMR and GC-MS 
 
H
N
HO
H
N
OH
Z E  
2-methylbutyraldehyde oxime 95 
  
1H-NMR (300MHz CDCl3): δ = 8.97(Z) (s, 1H, -OH), 8.76(E) (s, 1H, -OH), 7.23(E 60%) (d, 
3JH,H=7.0 Hz, 1H, -NCH), 6.44(Z 40%) (d, 
3JH,H=7.7 Hz, 1H, -NCH), 3.10-2.98(Z) (m, 
3JH,H= 
,1H, -NCHCH-), 2.34-2.10(E) (m, 1H, -NCHCH-), 1.49-1.28(E+Z) (m,
 3JH,H=14.7, 7.5 Hz, 
2H, -CH2CH3), 1.01(E) (d, 
3JH,H= 6.0 Hz, 3H, -CHCH3), 0.97(Z) (d, 
3JH,H= 6.9 Hz, 3H, -
CHCH3), 0.84(E+Z) (t, 
3JH,H= 7.4 Hz, 3H, -CH2CH3); 
13C-NMR (75MHz CDCl3): δ=157.3(Z) 
(CH), 156.4(E) (CH), 36.0(E) (CH), 31.1(Z) (CH), 27.5(E+Z, CH2), 17.5(E, CH3), 17.1(Z, CH3), 
11.6(Z, CH3), 11.4(E, CH3).  
H
N
HO
H
N
OH
Z E  
2-methylpentanealdehyde oxime 96 
1H-NMR (300MHz CDCl3): δ= 9.41 (s, 1H, -OH), 9.19 (s, 1H, -OH), 7.04 (d, 
3JH,H= 7.2 
Hz, 1H, -NCH), 6.26 (d, 3JH,H= 7.7 Hz, 1H, -NCH), 2.90 (m, 1H, -NCHCH-), 2.14 (m, 1H, 
-NCHCH), 1.17-1.02 (m, 4H, -CH2CH2-), 0.83-0.78 (dd, 3H, -CHCH3), 0.67-0.56 (m, -
CH2CH3); 
13C-NMR (75MHz CDCl3): δ = 157.3(Z), 156.5(E), 36.8(E+Z, CH2), 34.1(E), 29.3(Z), 
20.4(Z, CH2), 20.2(E, CH2), 18.0(E, CH3), 17.4(Z, CH3), 14.1(Z, CH3), 14.0(E, CH3). 
 
3.3.4.3 Sample preparation: 
Following synthesis samples of 2-methylbutyraldehyde oxime and 2-
methylpentanaldehyde oxime were prepared for GC analysis in dichloromethane (B&J 
ACS; HPLC grade) with N,N-dimethylformamide (Ajax; AR grade) used as an internal 
standard, heptanaldoxime was prepared in absolute ethanol (Scharlau;  HPLC grade) and 
1-octanol (Ajax; LR grade) as an internal standards. 
 
3.3.4.4 Instrumentation: 
NMR 
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All oximes were prepared in CDCl3-d solvent (Merck) and characterised by NMR on either 
a Brucker Avance 300 or Bruker 500 instrument. 2-methylbutyraldehyde oxime and 2-
methylpentanaldoxime were characterised using the Brucker Avance 300 NMR.  
 
GC-MS  
A quadrupole mass spectrometry system (GC-qMS) was used for characterisation of the 
synthesised oximes. The system consisted of an Agilent model 6890 GC fitted with an 
Agilent model 7683 autoinjector, coupled to a model 5973 MS detector with fast 
electronics upgrade (Agilent Technologies, Burwood, Australia). A BPX5 column (SGE 
International, Ringwood Australia) of dimensions 30 m × 0.25 mm i.d × 0.25 µm film 
thickness (df) was used. Data acquisition and processing was afforded by Agilent 
ChemStation software.     
 
GC-FID 
Once the oximes were characterised, preliminary single dimension GC experiments were 
conducted on an Agilent model 5890 GC system, subsequently, a Shimadzu model GC-
17A with autosampler model AOC-17 (Shimadzu, Rydalmere, Australia) was used for 
single dimension GC experiments. Both systems were fitted with a flame ionisation 
detector (FID).  
Single dimension GC experiments were conducted to find the most suitable wax and 
chiral columns to employ for our experiments. The column found to be the most suitable 
for chiral analysis was a MEGA column (diethyl-t-butyl-β-cyclodextrin phase) capillary 
column, of dimensions 23 m × 0.25 mm ID × 0.25 µm df.    
For interconversion experiments, a polyethylene glycol (wax) phase was found to be 
most suitable, and so a SolGel Wax phase (SGE International; 30 m x 0.25 mm ID x 0.25 
df) column was used. In order to combine the chiral separation properties and the 
molecular interconversion properties of the respective columns, the two columns were 
coupled together to form one long column (dual column). 
 
  
For coupled column analysis (dual 1D columns), the above MEGA and SolGel wax columns 
were joined in either chiral-wax or wax-chiral order. To investigate the contribution of 
each column on the overall chromatogram a FID was positioned at the interface of the 
coupled columns.  Whilst other chiral columns were tested (Rt-BDex cst-TM from Restek 
Corp, Bellefonte, PA) they were not successful in resolving both of the enantiomers of the 
E and Z isomers, of the chiral compounds of interest.  
A range of GC conditions were employed, according to the needs of the analysis, to either 
limit or promote interconversion. This was accomplished by a combination of temperature 
and pressure (flow rate) settings. Generally isothermal conditions were used, but on 
occasions temperature programmed analyses were conducted. Hydrogen carrier gas was 
used throughout. The injector and detector temperatures were both 230 ˚C. Shimadzu 
Class GC-10 software was used for data acquisition. 
 
GC×GC-FID 
The gas chromatograph, equipped with a flame ionisation detector (GC×GC-FID), used in 
the study was an Agilent 6890 system with a Longitudinal Modulation Cryogenic System 
(LMCS, Chromatographic Concepts Pty Ltd, Doncaster, Australia). The dual 1D (wax-
chiral) column arrangement was used for GC×GC studies. Since the 2D column should be 
of wax type to ensure adequate 2D separation, either a Stabilwax (1.1 m × 0.1 mm i.d × 
0.1 µm df, Restek) or a BP20 (3.1 m × 0.1 mm i.d × 0.1 µm df; SGE) column was used, 
the latter providing better resolution. 
The injector and detector temperatures were 230 ˚C and 250 ˚C, respectively. A 
sampling frequency of 100 Hz was used for GC×GC analysis. A high sampling frequency 
of 100 Hz was used for GC×GC analysis. A high sampling frequency is required to 
monitor very fast GC peaks at the end of the 2D column. Hydrogen was used as a carrier 
gas at various flow rates as indicated on the figures, and the temperature was usually 
isothermal, at various temperatures as indicated on figure captions. A range of 
modulation periods between 2-5 s were used, according to the retention time on the 2D 
column and the duration of the overall peak distribution on the 1D column.  The 
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temperature of the modulator system (TM) was held at 0 ˚C. CO2 was used as a coolant 
in the LMCS and nitrogen as a flush gas at a pressure of 15 psi. The modulator in GC×GC 
operation was commenced at a time usually 2 min prior to the elution of the first peak of 
interest. Agilent ChemStation software was used for modulation control, data acquisition 
and processing.  
3.3.4.5 Description of instrument arrangements and conditions: 
For analyses which employed a dual column set-up, a FID was positioned at the interface 
and/or at the end of the dual column arrangement. Figure 3.34 is a schematic diagram 
describing the different geometries of the column arrangements developed in this study. 
Collectively, the system can be operated as:  
(i) a single GC column (1D1), with a single FID (FID1); 
(ii) a dual GC column (1D1 + 
1D2), with a single FID (FID2); 
(iii) a dual GC column (1D1 + 
1D2), with a  dual FID (FID1 + FID2); 
(iv) a dual GC column as first dimension (1D1 + 
1D2), with a single column second 
dimension (2D) and a single FID (FID2), for GC×GC operation 
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Figure 3.34: Dual column arrangement. (System A) Single dimension coupled column 
with an FID detector (FID1) between column 1D1 and 
1D2, and FID detection (FID2) after 
1D2. The two columns can be either a wax–chiral set, or a chiral–wax set. The single 
column arrangement is trivial. (System B) Two-dimensional coupled column with a single 
FID detector (FID2) after the 2D column, as shown by the dotted line. Only a wax–chiral 
column arrangement for 1D1 + 
1D2 was employed in this case, with a wax 2D column. A 
modulator M is located between the 1D columns and the 2D column. 
 
Figure 3.34 (System A) describes a one-dimensional system even when comprising two 
columns, since the columns are essentially directly connected and there is no heart-
cutting or other process at their interface. Figure 3.34 (System B) describes a 
comprehensive 2D system, since the modulator performs the classical function of sub-
sampling the first dimension effluent into the 2D column for rapid separation.   
 
For 1D analysis, a variety of single chiral columns, and two different wax-type columns 
were used. For dual column operation, the wax and chiral columns were swapped around 
as required with either wax-chiral or chiral-wax arrangement. For GC×GC operation, it 
was decided to choose the chiral-wax column arrangement for (1D1 + 
1D2), with both 
short (1.1 m) Stabilwax and longer (3.1 m) SolGel wax columns as 2D, each of 0.1 mm 
ID and 0.1 μm df. The longer column provided improved separation in the second 
dimension. Table 3.10 presents an overview of different experiments that were 
conducted for the different columns and system arrangements. The most important 
variables are temperature setting and retention times, and these can generally be found 
on the Figure legends and from the chromatographic traces. Thus either pressure or 
linear carrier flow rates are only of value as a means to change overall retention.  
3.3.4.6 Data conversion 
Data were converted to .csv format, and exported in ascii format for processing using 
Origin (Microcal Software, Northampton, MA, USA). Contour plots were displayed using 
Transform software (Fortner Research, VA, USA).  
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Table 3.10: Details of experimental arrangements investigated, and conditions 
employed. 
Experiment Compounds 
1D GC; 5890 GC; BP5 and 
wax columns 
Heptanaldoxime, 2-methylbutyraldehyde oxime, 2-
methylpentanaldehyde oxime, and phenylacetaldoxime 
1D GC; GC-17 GC; single 
column; chiral columns and 
wax columns 
Heptanaldoxime, 2-methylbutyraldehyde oxime, 2-
methylpentanaldehyde oxime, and phenylacetaldoxime 
1D GC; GC-17 GC; dual 
columns; wax-chiral & chiral-
wax columns 
Heptanaldoxime, 2-methylbutyraldehyde oxime, 2-
methylpentanaldehyde oxime 
1D GC; dual FID GC-17 GC; 
dual columns; wax-chiral & 
chiral-wax columns 
Heptanaldoxime, 2-methylbutyraldehyde oxime, 2-
methylpentanaldehyde oxime 
GC × GC; 6890 GC; dual 1D 
columns (wax-chiral) and 2D 
wax column;   
Heptanaldoxime, 2-methylbutyraldehyde oxime, 2-
methylpentanaldehyde oxime 
Conditions: Generally conditions were varied over a range of temperatures from 70 ˚C 
to 150 ˚C, and pressure settings were generally varied over the range from 10 psi to 50 
psi. Resulting flow rates depended upon pressure, column lengths and i.d., and the 
temperature. In general, neither the linear carrier flow rate nor pressure setting are 
critical in determining the extent of reaction, but rather the temperature setting and the 
time on the column (as given by the retention time of the species) are the critical 
parameters. Hence for ease of presentation, the pressure settings are generally 
provided.  
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